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ABSTRACT 
 
Post partum haemorrhage is one of the leading causes of maternal mortality in both the 
developed and developing world [1,2]. Post partum haemorrhage is caused by the loss of 
blood from the uterus following labour because of decreased uterine tone, retained placenta or 
placental fragments as well as lower genital tract trauma [3]. Routine management of post 
partum haemorrhage involves the use of parenteral oxytocin (OT) that is administered via the 
intramuscular or intravenous route to increase uterine tone and reduce bleeding. However, OT 
is rapidly metabolised in the liver and cleared from the body via the kidney [4]. The use of a 
long acting parenteral preparation of OT to maintain uterine tone is therefore proposed as a 
means of reducing maternal mortality by preventing post partum haemorrhage. 
 
A variety of alternatives were investigated for the development of an appropriate dosage form 
for OT delivery. The use of Pluronic® F127 (PF-127) as a thermo-sensitive gel that exists as a 
viscous flowing liquid at low temperatures but forms a stiff gel on warming to body 
temperature is proposed. The properties of PF-127 allow for the administration of a cold 
liquid preparation via a syringe and needle into muscle tissue followed by the formation of a 
depot gel that has the potential for sustained delivery of OT in vivo. 
 
Aqueous solutions of PF-127 were prepared using the cold method. PF-127 solutions were 
characterised with respect to critical micelle concentration and gelation temperature for 
different concentrations of gel. The temperature at which gelation occurs was found to be 
concentration dependent. The rheological properties of solutions of PF-127 were also 
investigated and a dramatic change in viscosity was found to occur simultaneously with the 
visual onset of gelation. 
 
Due to the lack of compendial guidelines for in vitro release testing of controlled release 
parenteral preparations, different dissolution methods were evaluated for their potential to 
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discriminate between formulations of different compositions. Tests that were used to assess 
discriminatory behaviour were ANOVA analysis, the f1 and f2 difference and similarity 
factors, and Gohel’s Similarity factor, Sd. The discriminatory behaviour was assessed by 
comparing the in vitro release of OT from 20%, 25%, and 30% w/w PF-127 containing 
preparations and it was observed that the USP Apparatus 3 showed the greatest potential to 
discriminate between all formulation compositions tested, compared to other test methods that 
were evaluated. The method was further optimised for OT per dose unit and to establish 
whether pH changes affected drug release from these systems. 
 
The Korsmeyer-Peppas power law was used to assess the primary mechanism of drug release 
from the extemporaneously prepared dosage forms tested using different dissolution methods. 
The values of the release exponent, n, revealed that the mechanism of release of OT from PF-
127 gels is generally a combination of diffusion and swelling controlled release or anomalous 
release. The extent to which diffusion or swelling impacts on the in vitro release of OT was 
dependent on the specific dissolution test that was used to evaluate the in vitro release of OT. 
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STUDY OBJECTIVES 
 
Post partum haemorrhage is one the primary causes of maternal morbidity and mortality [1,2]. 
The consequences of excessive haemorrhage following the delivery of a baby include hypo-
volaemic shock and anaemia, which reduce the quality of life and care for both the mother 
and neonate. The incidence of post partum haemorrhage may be reduced by routine 
administration of oxytocin (OT) which maintains uterine tone and prevents bleeding. 
However, due to the short half-life of OT in vivo, the primary objective of the project was to 
develop and assess an alternate delivery system that would provide sustained and prolonged 
release of OT in vitro. 
 
The objectives of this study were: 
 
i. To develop and validate a suitable and sensitive High Performance Liquid 
Chromatographic (HPLC) method to accurately and precisely quantitate OT in 
pharmaceutical dosage forms and OT release from dosage forms during in vitro 
release testing, 
ii. To review current trends of protein and peptide delivery and objectively evaluate and 
propose an alternative sustained release OT dosage form, 
iii. To characterise a potential matrix for an OT dosage form for sustained delivery in 
order to understand factors that are likely to impact on the performance and integrity 
of the dosage form, 
iv. To develop a discriminatory in vitro dissolution method for assessing the release of 
OT from sustained release dosage forms of different formulation compositions and, 
v. To determine the mechanism/kinetics of OT release from the delivery matrix using 
model dependent approaches. 
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CHAPTER 1 
 
OXYTOCIN 
 
1.1 INTRODUCTION 
 
Oxytocin (OT) is synthesised in the cell bodies of the paraventricular and supraoptic nuclei in the 
hypothalamus from precursor proteins [5-7]. OT is attached to the carrier protein, 
neurohypophysin and is transported via axonal processes to the posterior lobe of the pituitary 
gland where it is stored and subsequently released when required [5,7]. 
 
OT possesses uterogenic and galactogenic activity in mammals resulting in uterine contractions 
and milk letdown following secretion, respectively [8-11], which can be considered the classical 
actions of OT. OT also possesses diverse peripheral and central effects due to the extensive 
expression of OT receptors (OTR) in several organs and tissues other than the uterus and 
mammary glands. Studies have shown that the activity of OT extends to stimulation of 
endometrial prostaglandin production, T-cell function, bone and muscle formation and secretion 
of prolactin in the pituitary gland, luteolysis and sperm transport [12,13]. 
 
OT is available commercially as parenteral and nasal solutions of the acetate salt [10]. Ampoules 
of OT containing 5 and 10 IU/ml are available on the South African market [14], whereas the 
nasal spray is not. The nasal spray is formulated to contain OT in a concentration of 40 IU/ml 
[15]. 
 
The commercial or brand names of OT products are Alpha-hypophamine®, Ocytocin®, 
Endopituitrina®, Pitocin®, Syntocinon®, Nobitocin S®, Orasthin®, Oxystin®, Partocon®, Synpitan®, 
Piton-S®, Uteracon® [16]. 
  
1.2 PHYSICO-CHEMICAL PROPERTIES 
 
1.2.1 Description  
 
OT comprises of nine (9) amino acids. The amino acid sequence of OT is shown in Figure 1.1 
[8,11]. 
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H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
 
Figure 1.1 The primary structure of OT [8,11] 
 
The amino acid moieties in the endogenous peptide exist in the L-configuration and a disulphide 
bridge links the two (2) cysteine residues resulting in a six (6)-membered ring linked to a 
tripeptide residue that is amidated at the carboxy terminal [8]. Figure 1.2 shows the complete 
chemical structure of OT [8]. 
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Figure 1.2 The chemical structure of OT (C43H66N12O12S2) MW = 1007.23 [8] 
 
The amino acid sequence of OT may define its chemical name. OT is L-cysteinyl-L-tyrosyl-L-
isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucyl-glycinamide cyclic (1 → 6) 
disulphide or L-Hemi-cystinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-hemi-
cystinyl-L-prolyl-L-leucyl-glycinamide [8]. 
 
The free base of OT has not yet been isolated in its crystalline form, but OT is available as the 
freeze-dried acetate salt. The acetate salt occurs as a white or almost white fluffy hygroscopic 
powder with a faint odour of acetic acid [8,11]. 
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1.2.2 Biological Activity 
 
OT can be manufactured using different synthetic pathways that may in turn, result in grades of 
OT with slightly different biological activity. The potency of synthetically produced OT samples 
may be standardised according to the contractility of the rat uterus, vasopressor activity in 
chickens and rats, as well as ejection of milk in lactating rats following administration [8]. The 
resultant activity is expressed in posterior pituitary units and a unit is equivalent to 2.0 – 2.2 µg of 
the pure hormone [15]. It has been reported that 12.5 IU of OT are contained in 21.4 µg of the 
synthetic peptide (584 IU/mg) [9] in one (1) ampoule of the Fourth International Standard (1978). 
The National Institute of Standards and Control (London, UK) indicates an activity of 595 IU/mg 
for the Fourth International Standard of OT [8]. The United States Pharmacopeia (USP) [10] 
recommends that the activity of OT must not be less than 400 IU/mg and the British 
Pharmacopoeia (BP) [11] by convention labels 1 mg of OT to be equivalent to 600 IU. The 
variability noted with regard to the standardisation of OT in the different compendia implies that 
the characterisation of OT samples may be mandatory. Characterisation may be achieved by 
determining the actual biological activity of OT using the biological assays described or by means 
of analytical assays and/or comparing a synthetic OT sample with an international reference 
standard [8]. 
 
1.2.3 Synthesis 
 
In general, OT is produced on a commercial scale synthetically, but can be obtained from the 
pituitary glands of healthy domesticated animals [10]. However, the extraction of OT from 
pituitary glands is of no practical significance and therefore no longer used for the commercial 
preparation of OT [8]. 
 
OT and vasopressin (VP) were the first two (2) hormones for which the chemical structures were 
fully elucidated and chemical synthesis was successfully completed [17]. The first chemical 
synthesis of OT was reported by du Vigneaud et al. in 1953 [18,19]. In this early work, a highly 
purified form of OT was obtained, and isolated as a crystalline flavianate salt. 
 
In the large-scale production of OT, protective species are necessary to hinder access to reactive 
amino and sulphydryl groups. Tosyl and carbobenzoxy groups are used for the protection of 
amino functionalities and a benzyl residue can be useful for the protection of the sulphydryl group 
in the cysteine residue [19]. The synthetic procedure used by du Vigneaud et al. [19] is shown in 
Figure 1.3. 
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Figure 1.3 The du Vigneaud synthetic pathway for OT (adapted from [19]) 
 
The initial step in the synthesis of OT is the coupling of tosyl-L-isoleucyl-L-glutaminyl-L-
asparagine (I) with S-benzyl-L-cysteinyl-L-prolyl-L-leucylglycinamide (II) via a condensation 
reaction using tetraethyl pyrophosphite by a procedure known as the amide procedure. The 
heptapeptide (III), containing tosyl and benzyl protective groups, is formed and the protective 
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groups are removed in the presence of sodium in liquid ammonia. The reduced compound is re-
benzylated with benzyl chloride to re-protect the sulphydryl group, forming L-isoleucyl-L-
glutaminyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-L-leucylglycinamide (IV). 
 
Condensation of this heptapeptide with a dipeptide, N-carbobenzoxy-S-benzyl-L-cysteinyl-L-
tyrosine (V), is achieved in the presence of tetraethyl pyrophosphite to produce an open chain 
nonapeptide derivative, N-carbobenzoxy-S-benzyl-L-cysteinyl-L-tyrosinyl-L-isoleucyl-L-
glutami-nyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-L-leucyl-glycinamide (VI). The 
resultant nonapeptide is further treated with sodium in liquid ammonia to remove both the 
protective benzyl and carbobenzoxy groups forming an open chain nonapeptide, L-cysteinyl-L-
tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucyl-glycinamide (VII). 
Air oxidation in a dilute aqueous solution at pH = 6.5 results in cyclisation of the nonapeptide by 
the formation of a disulphide bridge between the two cysteinyl residues to form OT (VIII) [19]. 
 
Subsequently OT has been produced by methods that have differed slightly in the chemistry of the 
synthetic process, use of different protective groups, methods used to make peptide linkages, and 
manufacturing plans used to synthesise the entire peptide [8]. 
 
Protective groups that have been used in the synthetic procedure include an S-acetamidomethyl 
group for protection of the cysteine residue [20]. p-methylbenzyl and p-methoxybenzyl, which 
were found to be better cysteine-protecting groups compared to benzyl [21], and S-
benzamidomethyl [22] have also been used for this purpose. New protective groups for cysteine 
residue protection, 2,2,5,7,8-pentamethyl-3,4-dihydro-6-benzopyranylmethyl, 2,2,4,6,7-
pentamethyl-2,3-dihydro-5-benzofuranylmethyl and 4,5,6-trimethoxy-2,3-dihydro-7-
benzofuranylmethyl have been synthesised and tested in the OT synthetic procedure [23]. 
 
N-tert-butoxycarbamate (N-Boc) has been used successfully to protect amino groups in the 
synthesis of OT [24,25] and the use of an o-nitrophenylsulphenyl group has also been reported 
[24]. 
 
Mixed anhydrides, active esters, and azide methods have been used to make peptide linkages in 
OT [8]. In a stepwise addition, polychlorophenyl esters of three (3) equivalents of the 
butoxycarbonylamino acids were reacted in the presence of 1-hydroxybenzotriazole. This 
procedure was followed by aminolysis and deprotection of the reactive groups [26]. Furthermore, 
intermediates with pre-formed disulphide bridges have been used to synthesise OT [27]. 
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Recently, biologically active OT has been synthesised using a 13C and 15N-labelled proline residue 
using Oppolzer’s method. Sultam was used as the chiral auxiliary for the synthesis of the 
tripeptide fragment. N-Boc and 9-Fluorenylmethyloxy carbamate (N-Fmoc) were used for the 
protection of the amino groups in tocinoic acid, which is the twenty (20)-membered disulphide 
ring of OT. These were later removed using either trifluoroacetic acid or piperidine [28]. 
 
1.2.4 Solubility 
 
The solubility of OT acetate in different solvents is summarised in Table 1.1. 
 
Table 1.1 The solubility of OT acetate in different solvents [8] 
Solvent Concentration (IU/ml) Concentration (mg/ml) 
Water  37 800 63 
Methanol 86 400 144 
Dichloromethane 2.9 0.005 
 
1.2.5 Isoelectric Point 
 
OT has a free amino group on the cysteine1 residue and a free acidic phenol group on the tyrosine2 
residue and is thus an amphoteric molecule. The isoelectric point is reported to occur at pH = 7.7 
[8]. 
 
1.2.6 Ultraviolet Spectrum 
 
The ultraviolet (UV) spectrum of OT in an aqueous solution of concentration 200 IU/ml over the 
range 200 – 600 nm at a scan speed of 600 nm/min and data interval of 0.800 nm is depicted in 
Figure 1.4. The UV spectrum was generated using a GBC UV/VIS 916 Spectrophotometer (GBC 
Scientific Equipment, Pty Ltd, Dandenong, Australia). 
 
The UV spectrum depicted in Figure 1.4 is similar to that obtained by Nachtmann et al. [8]. The 
UV spectrum for OT shows two distinct wavelengths at which maximal absorbency occurs. OT 
has a λmax at approximately 275 nm, with a shoulder at approximately 280 nm and shows another 
region of increased absorbency between 200 – 240 nm. 
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Figure 1.4 UV absorption spectrum of OT acetate in aqueous solution 
 
1.2.7 Infrared Spectrum 
 
The infrared (IR) spectrum of each compound is unique and serves as a useful tool to identify the 
chemical structure of an organic compound. Although the spectrum is characteristic of a 
compound, certain groups of atoms in organic molecules give characteristic absorption bands in 
the IR region, irrespective of the structure of the molecule. However, the precise interaction of the 
atoms in a molecule generates the unique spectrum for that molecule [29]. The IR spectrum of OT 
(470 IU/mg) is shown in Figure 1.5 and was generated from 4000 to 400 cm-1 using a Spectrum 
2000 FTIR Spectrophotometer (Perkin Elmer Instruments LLC, Shelton, CT, USA) using a Mull 
technique with Nujol® or heavy liquid paraffin (UniLab, Redmont WA, USA). 
 
The IR spectrum of OT shows characteristic absorption bands in the region of about 3500 – 3200 
cm-1 that can be attributed to the presence of both primary amide bonds and the amine 
functionality, which show medium absorption bands in this region [29]. Alkanes give rise to 
medium intensity absorption bands around 3000 cm-1 and a sharp band can be observed in the IR 
spectrum at this region. In addition, bands in this region are also due to the presence of liquid 
paraffin, which has C-H bonds resulting in resonance at this frequency. 
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Figure 1.5 Infrared spectrum of OT acetate 
 
The OT molecule has a disulphide linkage, and mercaptans result in weak absorption bands at 
about 2500 cm-1 and a weak absorption band is observed in this region in the spectrum of OT. 
Several functional groups absorb IR light in the 1700 – 600 cm-1 region. The tertiary amine in the 
proline residue produces a medium strength band at a wavenumber of approximately 1700 cm-1. 
Primary amides in the peptide linkages give rise to an absorption band that is observed at about 
1650 cm-1. 
 
The absorption observed for the rest of the region is primarily due to alkanes that are also present 
in liquid paraffin, primary amines, and amide groups which absorb IR light in this range, although 
only a weak absorption band is noted in the region between 1000 – 800 cm-1. The IR spectrum 
obtained differs with one published in the literature [8] due to the use of a different method to 
obtain the IR spectrum. The IR spectrum reported in the literature [8] was generated using 
potassium bromide and this does not produce intense absorption bands due to the frequencies 
produced by C-H bonds present in the liquid paraffin that are observed in Figure 1.5. 
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1.3 STABILITY 
 
1.3.1 Temperature 
 
Freeze-dried OT acetate may be kept in a refrigerator for several years without significant loss of 
oxytocic activity. However, inactivation of the peptide stored under these conditions may occur as 
a result of disulphide interchange in which intramolecular disulphide linkages convert to form 
intermolecular bridges [8], and it may therefore be necessary to test the biological activity of 
samples following long-term storage. 
 
OT sample concentrates that were stored in a refrigerator at 5 °C showed no significant loss of 
activity after twelve (12) [8] or eighteen (18) months [30]. Whereas samples that had been kept at 
21 °C, showed only a slight loss of activity of 1.5% per annum, and samples maintained at 30 °C 
showed an increased loss of activity of approximately 10% per annum [8]. 
 
The compendial and pharmacopoeial guidelines for OT storage concur with the stability 
characteristics of commercial OT preparations described above. The USP [10] and BP [11] 
recommend that OT must be stored in airtight containers in a refrigerator set between 2 and 8 °C 
and must be discarded after 30 days if OT ampoules have been stored between 15 and 25 °C [31]. 
 
The thermal stability of OT in aqueous media has been reported previously [32]. Only 38% of the 
original OT that was added to the solution remained after evaporating an aqueous solution of OT 
to dryness by maintaining the solution at 35 °C in a water bath. Heating at 100 °C for 30 min 
resulted in a 39% loss of OT, whereas heating for 15 min at 120 °C resulted in no loss of activity 
[32]. After heating an aqueous solution of OT (10 IU/ml) at 50 °C for 10 min, as described in § 
2.5.6.3, only 3.55 + 1.07% of the OT degraded. This experiment was conducted in triplicate (n = 
3) and was analysed using a validated HPLC method (Chapter 2, vide infra). 
 
1.3.2 pH 
 
The stability of OT is pH dependent and pH therefore affects the shelf life of OT in formulations. 
At low pH, OT undergoes hydrolysis of the peptide linkages [8]. However OT has been found to 
be stable between pH = 5 and pH = 8.5 and has a pH of maximal stability at pH = 3. As the pH 
increases towards a neutral value and proceeds to a more alkaline range, the formation of dimers 
and other polymeric forms of OT occurs as a result of the conversion of intramolecular disulphide 
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linkages to form intermolecular links between the cysteine residues in two (2) different OT chains 
[8]. 
 
Approximately 10.58, + 0.51%, of OT degrades in 0.1 M solutions of hydrochloric acid and 
70.33, + 0.25%, of OT degrades in 0.1 M sodium hydroxide solutions in 2 hours as described in 
detail in § 2.5.6.1 and 2.5.6.2, respectively. The degradation studies were performed in triplicate 
(n = 3) and analysed using a validated HPLC method (Chapter 2, vide infra). 
 
OT parenteral preparations are formulated with acetate buffer at a pH of approximately 3.9 using 
a sodium acetate buffer and acetic acid to adjust the pH to the required value, to ensure maximal 
stability of the peptide formulation [33]. 
 
1.3.3 Oxidation 
 
OT is susceptible to oxidation and 21.67, + 0.49%, of OT degrades in twenty (20) volume 
hydrogen peroxide solutions, as described in § 2.5.6.5, and analysed using HPLC, as described in 
detail in Chapter 2, vide infra. 
 
1.4 CLINICAL PHARMACOLOGY 
 
1.4.1 Physiological Role of OT in the Uterus 
 
The primary role of OT is to cause uterine smooth muscle tissue contraction during parturition 
[5,12,15,34,35,36]. In the pregnant and puerperal uterus, OT causes a dose dependent increase in 
the frequency and amplitude of uterine contractions and at high doses causes an increase in the 
uterine resting tone [15]. 
 
Successful parturition depends on coordinated changes in the uterine contractility and sensitivity 
of the uterine smooth muscle tissue to OT because of increased OTR and changes in the 
connective tissue that allows cervical ripening and dilation [34]. In mammals, the changes in the 
uterus are a result of an increase in the levels of circulating oestrogen and a corresponding decline 
in circulating progesterone levels [5,34]. 
 
There is an almost thirty (30) fold increase in the number of OTR in the uterus in early labour 
compared to their expression in early pregnancy [5,37]. Consequently, there is an increased 
sensitivity and responsiveness of the uterus to OT. This sensitivity may increase up to eight (8) 
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fold in the last nine (9) weeks of pregnancy, with an associated increase in contractility of the 
uterine smooth muscle tissue [5,13]. This is associated with the up-regulation of OTR messenger, 
ribonucleic acid (mRNA), and the density of the myometrial OTR, which reaches a peak in early 
labour [13,38]. In addition, there is an increase in myometrial weight and actinomycin content, 
which also promote uterine muscle tissue contraction [15,34]. Furthermore, an increase in 
spontaneous motor activity of the uterus in the third trimester, as compared to the first and second 
trimesters of pregnancy can be considered to parallel the increase in the responsiveness of uterine 
tissues to OT stimulation [5]. The synergistic effects result in contraction of the uterus at full term 
pregnancy at the commencement of labour [5,8,9,15]. 
 
Progesterone has been shown to antagonise the effects of OT in vitro and therefore may have an 
effect on the responsiveness of the uterus to OT. The decline in the progesterone levels prior to 
birth may therefore also play a role in the activity of OT and initiation of labour [5,37]. 
 
1.4.2 Physiological Role of OT in the Mammary Glands 
 
Milk ejection from the mammary glands is triggered by the suckling action of an infant on the 
nipple. Suckling stimulates the mammary tactile receptors that generate sensory impulses and 
directs them to the paraventricular and supraoptic nuclei via the spinal cord [5,8,9,13,15]. The 
oxytocinergic neurons in the hypothalamus display a high frequency-bursting activity with each 
burst resulting in a massive release of OT into the systemic circulation, which is carried to the 
breasts of lactating mothers. In the mammary gland, OT causes a contraction of the myoepithelial 
cells in the walls of lactiferous ducts, sinuses, and breast tissue alveoli. In humans, milk ejection 
occurs within 30 – 60 seconds following the commencement of suckling [13]. OT is considered 
essential for infant nursing and a deficiency of OT in mice has been shown to result in failure of 
test animals to effectively nurse their offspring [39]. 
 
1.4.3 Additional Physiological Roles of OT 
 
OTR are expressed in several other issues, thereby revealing the diverse nature of the 
physiological roles of this nonapeptide in the human body [13]. 
 
In the peripheral tissues, OTR are expressed in the ovary [40] and corpus lutetium [41] and OTR 
expression has been observed in males [42] including in the testes [43] and prostate gland [44]. 
OT synthesis has also been recently observed in the breast [45] and lung tissues [46], where it 
may be involved in the proliferation of cancerous cells.   
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OTR are also expressed in the kidney [47], heart [48], thymus [49], and pancreas [50] among 
other peripheral organs, indicating a diversity of physiological roles for OT. In the brain, OT 
plays a role in sexual and maternal behaviour [51,52], stress related behaviour [53] and eating 
disorders [54], amongst other diverse functions and roles. 
 
1.4.4 Mechanism of Action 
 
OTR is a G-protein coupled receptor (GPCR) and is functionally coupled to Gq/11α class of 
guanidine triphosphate (GTP) binding proteins [13]. The GTP binding protein, coupled with Gβγ 
stimulates the activity of phospholipase C-β forms, which results in the hydrolysis of 
phosphoinositide, generating two entities, specifically, inositol 1,4,5-triphosphate and 1,2-diacyl 
glycerol. Inositol 1,4,5-triphosphate triggers the release of calcium ions from intracellular stores 
and 1,2-diacyl glycerol causes the stimulation of protein kinase C, which phosphorylates, as yet 
unidentified, target proteins [55-57]. The increase in intracellular calcium ions results in a variety 
of intracellular events including the formation of calcium-calmodulin complexes. In smooth 
muscle tissues of the uterus, the increase in calcium ions triggers the activation of myosin light-
chain kinase activity, which results in contraction of the myometrial tissue resulting in uterine 
contraction [13,58,59]. 
 
1.4.5 Structure-Activity Relationships 
 
The conformation of a drug at a receptor is important for eliciting a biological response in vivo. 
For OT a myriad of possible conformations exist and therefore understanding the elements of the 
molecule necessary to stimulate biological activity is imperative to comprehend the subsequent 
biological events. In addition, understanding the structure-activity relationships (SAR) of OT 
facilitates the design of stable agonists and antagonists that can be used in clinical practice 
[7,60,61]. 
 
Hormone-receptor interactions actually involve three different states for the hormone-receptor 
complex. At the outset, hormone-receptor binding interaction occurs and is considered to be the 
recognition step between the hormone and the receptor. The recognition step is necessary for 
binding but is not adequate to elicit a biological response. The transduction state follows and 
involves hormone-receptor interactions with a regulatory protein, and leads to activation of a 
second messenger compound such as cyclic adenosine monophosphate (cAMP) and/or calcium 
ions. The third step in the process is the dissociation of the hormone-receptor complex and return 
 13 
of the cell to a basal state. The recognition and transduction states are known to involve structural 
and conformational properties of hormones and research has shown that the two steps for peptide 
hormone-receptor systems can actually involve two different conformations of the same hormone 
[62]. 
 
In order to understand the agonist activity of OT, the structure of OT must be separated into the 
20-membered backbone and a tripeptide side chain. Early SAR studies of the activity of OT 
showed that the 20-membered ring was essential for the activity of OT. In support of this theory it 
was noted that a synthetic ring-opened form of OT was found to have significantly reduced 
potency as compared to the closed form. The ring-opened structure however had a slower onset of 
activity that was attributed to the slow oxidation of the linear form of the compound prior to 
transformation into a cyclic peptide form [63]. 
 
The tripeptide tail has no known activity but plays a critical key role in the potency of the 
molecule and binding affinity of the OT molecule to receptors. The replacement of the C-terminal 
amide group with a carboxylic acid group forming oxytocinoic acid, results in a molecule that has 
only 1/400th the activity of OT [64]. 
 
It is generally believed that the tripeptide side chain and the disulphide ring work cooperatively in 
the interaction of OT with OTR or in transducing the receptor, thereby eliciting a biological 
response [7]. 
 
The SAR of OT at the uterus receptor have been summarised by Hruby et al. [62] as follows: 
i. The 20 membered disulphide ring system is sufficient for activity at the uterine receptor, 
ii. There is cooperativity that occurs between the disulphide ring and the tripeptide tail, 
which is important for the full binding interaction of OT with OTR, 
iii. The tripeptide tail of OT is essential for binding of OT to the receptor but is not important 
in the transduction of the uterine OTR, 
iv. Important residues for both binding and transduction are cysteine residues (1 and 6), the 
tyrosine2 and asparagine5 residues, which appear to be involved in a cooperative manner 
in the transduction process and,  
v. The OTR in the uterus appears to have three (3) separate topological binding sites for OT. 
There is a lipophilic site associated with first and third residues in OT, a hydrophilic site 
with hydrogen bond accepting properties for the fourth and fifth residues and a more 
lipophilic site that encompasses the tripeptide tail of the hormone. 
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1.4.6 Clinical Use, Indications and Dosage 
 
OT may be used for the induction of labour or augmentation of labour when medically indicated 
[5,9,36,65,66]. For this purpose OT may be given by a slow intravenous infusion in which 5 IU of 
OT are placed in 500 ml of a physiological compatible fluid such as normal saline, although 
higher doses may be used [5,9,15,67]. Initially, 0.5 – 2 mU/min may be administered 
intravenously and the dose may be increased every 15 – 60 min as is necessary [68]. There is 
general debate about the correct dosage for labour induction, although the consensus is that a 10 
mU/ml of OT administered at an initial dose level of 1 mU/min [5] is sufficient to promote labour. 
Guidelines [69] recommend 10 or 20 IU in 1000 ml normal saline and that the infusion is initiated 
at a rate of 1 – 2 mU/min, gradually increasing every 30 min, until a maximum of 3 – 4 
contractions per 10 minute interval is observed [9,31,69]. It has been recommended that 
increments be implemented at 40 minute intervals [65] or even 60 minute intervals in order to 
prevent excessive uterine contractions and foetal distress [70,71] based on the pharmacodynamic 
profile of OT [70]. 
 
An administration rate of 12 mU/min is the maximum that is usually required for labour 
induction, although a rate of 6 mU/min is sufficient to produce physiological levels of OT usually 
present at the commencement of natural labour [9]. Foetal heart rate and uterine contractions 
should be monitored in the process once labour has commenced and is progressing and at that 
stage, the OT infusion may be gradually withdrawn [9]. 
 
OT has also proved useful for the prevention of postpartum haemorrhage and management of 
postpartum or postabortal uterine atony in the third stage of labour [5,9,15,72,73]. In order to 
promote routine third stage prophylaxis, a recommended dose of 5 – 10 IU as an intravenous 
bolus [68,74] or intramuscular [69] dose of OT may be used. This may be followed by a slow 
intravenous infusion in severe cases, where 5 – 20 IU [9] or 10 – 40 IU of OT in 1000 ml of a 
compatible and non-hydrating diluent are administered following a normal vaginal delivery [69], 
or a high dose of OT, 2667 mU/min, administered over 30 min for caesarean delivery [69,75]. A 
dose of 10 IU is recommended at a rate between 20 – 40 mU/min [9]. Initially, the infusion is 
given at a rate of 10 ml/min for a few minutes until the uterus has contracted and then is reduced 
to 1 – 2 ml/min until the mother is ready to be transferred to the postpartum unit [5]. OT may also 
be administered as an intramuscular injection (10 IU) for the treatment of uterine atony [5]. 
Furthermore, as a prophylactic measure OT may be administered intramuscularly (5 IU) in 
combination with ergometrine maleate (500 µg) to non-hypertensive patients with or after the 
delivery of the shoulders of the baby, or if OT administration alone fails to produce adequate 
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uterine tone [5,9]. In the case of a missed abortion, 5 IU of OT is administered via slow 
intravenous injection or as an infusion at a rate of 20 – 40 mU/min or higher [3,5,9,15,76]. 
 
OT may also be used to stimulate lactation and may be recommended for nursing mothers 
following the premature delivery of infants [77]. A double-blind randomised controlled clinical 
study showed the effectiveness and safety of nasal OT for the promotion of lactation [78]. 
However, a recent double blind randomised clinical trial [79] comparing the effectiveness of nasal 
OT to a placebo preparation for the promotion of lactation in mothers of pre-term infants, showed 
that the administration of nasal OT resulted in faster initial milk production compared to the 
placebo formulation. However, there was no significant difference between the use of the OT 
nasal spray and the placebo, suggesting the presence of a significant placebo effect. A 
recommendation for promotion of lactation has been that the encouragement and support of 
mothers, with unrestricted feeding, may diminish the need for OT use to stimulate lactation [80]. 
In order to stimulate lactation, OT is administered as a nasal spray and one (1) puff is sprayed into 
one (1) or both nostrils 3 min before suckling is initiated [9,15]. There is a risk of dependence and 
therefore OT use for lactation stimulation is not always recommended [9]. 
 
1.4.7 Overdose 
 
An overdose of OT results in uterine hyperactivity, hypertone or tetany, which are potentially 
detrimental to both mother and baby, causing severe adverse reactions as described in § 1.4.8. OT 
administration must be discontinued immediately and symptomatic and supportive treatment is 
advised in cases of overdosing [31]. 
 
1.4.8 Adverse Drug Reactions 
 
OT is an endogenous hormone and has not been reported to have any adverse effects following 
administration on its own. However, administration of OT in high doses may result in 
uncontrolled and violent uterine contractions or uterine tetany that may result in uterine rupture 
and decreased utero-placental blood flow, resulting in foetal bradycardia, foetal arrhythmia, 
asphyxia and even maternal and foetal death [9,15]. Nausea, vomiting, and cardiac arrhythmias 
may also occur [81]. 
 
OT is structurally similar to VP and possesses weak anti-diuretic properties due to interaction 
with VP receptors [35,82]. Prolonged infusions over 120 min and high doses of OT may result in 
water retention with associated water intoxication and hypo-natraemia, resulting in pulmonary 
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oedema, convulsions, coma or even death, in serious cases [81]. The vasopressor effect of OT is 
more likely with OT of natural origin, but may occur when synthetic OT is administered 
[9,15,83]. 
 
Rapid administration of commercial OT may also result in hypotension and reflex tachycardia 
[9,15]. Some studies have shown that the impact of commercial OT preparations is not due to the 
OT itself, but the combination of OT and chlorbutol, the preservative in commercial formulations. 
The combination results in cardio-depressive and negative inotropic effects, which are similar in 
magnitude to those caused by chlorbutol when administered alone, resulting in vasodilation, 
precipitating hypotension, and consequent tachycardia in patients receiving such commercial 
preparations [82,84-87]. 
 
A rare case of water intoxication and hypo-natraemic encephalopathy has been reported [88] 
following excessive use of OT administered via the nasal route. Following administration of 
intravenous fluids, water intoxication resulted, probably due to the anti-diuretic properties of OT 
with a result of hypo-natraemic encephalopathy and convulsion. It is therefore recommended that 
the use of nasal OT for promotion of lactation be monitored to prevent such deleterious effects 
[88]. 
 
The use of OT to induce labour has been associated with an increase in the incidence of neonatal 
jaundice [89,90]. OT may cause neonatal jaundice by inhibiting hepatic glucoronyl transferase 
[91] and by increasing erythrocyte deformation and haemolysis at high doses [89]. 
 
Anaphylactic and hypersensitivity reactions to OT, although rare [81], include cardiac arrhythmia, 
pelvic haematomas in addition to nausea and vomiting [9,15]. Following administration of OT via 
the nasal route, insulin and glucagon secretion is increased [92], which may result in low plasma 
glucose levels. 
 
1.4.9 Contraindications 
 
OT should not be administered in cases where its action is likely to harm the mother or the foetus 
i.e., where there is a poor risk: benefit ratio for the patient [9,15]. OT use is contraindicated for 
obstetrical conditions such as cephalopelvic disproportion, foetal malpresentation, foetal distress, 
placenta praevia, and in cases of mechanical obstruction to delivery. Moreover, OT is 
contraindicated in cases where there is a predisposition to uterine rupture as in the case of 
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multiple pregnancy or when there has been previous entry into the uterine cavity, for example a 
previous caesarean section, myelectomy or any other genital tract related surgery [9,15,36,81]. 
 
A rare contraindication to the use of OT for induction of abortion has been reported, where sepsis 
as a result of ligamentary ectopic pregnancy occurred and abortion was indicated at over twenty 
four (24) weeks of pregnancy [93]. The administration of OT failed to induce labour resulting in 
persistent bleeding and OT is therefore contraindicated in such gynaecological complications 
[93]. 
 
OT should not be administered in cases of uterine hyperactivity and in patients in which there is 
an increase in the basal tone of the uterus, as this may result in uterine rupture [9,15,81]. 
 
OT is contraindicated in patients that have hypersensitivity to OT [15]. Hypersensitivity usually 
occurs as a result of administration of very high doses of OT and may be reduced by 
administration of OT with small increments in the infusion rate thereby preventing hyper-
stimulation of the uterine smooth muscle and hypersensitivity [15]. OT must also be used with 
caution in patients with cardiac disorders [81]. 
 
1.4.10 Drug Interactions 
 
Drug interactions with OT are not common; however, OT may increase the vasopressor 
effect of sympathomimetic drugs [9]. This is the consequence of administration of high 
doses of OT resulting in high circulatory levels of the hormone, and therefore OT acting 
on the VP receptors due to the similarity in their primary amino acid sequence and 
structure. Therefore, there is an associated drop in blood pressure following this 
interaction [35]. Prostaglandins must be used with caution if administered concomitantly 
with OT as this may result in uterine hyperactivity [81].  
 
1.5 PHARMACOKINETICS 
 
1.5.1 Absorption 
 
OT is a labile peptide that is not susceptible to trypsin-mediated degradation in the gastro-
intestinal tract (GIT). The degradation of OT in the GIT is due to metabolism by chymotrypsin, 
which digests the tyrosine2 – isoleucine3 and leucine8 – glycine9 bonds [94]. OT was found to 
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degrade rapidly within 60 min in intestinal fluid contents, but the degradation of OT in the gastric, 
colonic and rectal membranes and in the intestinal microvilli membranes is thought to relatively 
slow and could be a result of membrane-bound proteins such as endopeptidase 24,11 and amino 
peptidase, which digest proteins [94]. Due to extensive metabolism in the GIT, OT is not active 
orally. It is however rapidly absorbed across mucous membranes and OT has been formulated as a 
sublingual dosage form, although this has been discontinued due to erratic and unpredictable 
absorption of OT from the buccal mucosa when this dosage form was administered [95]. 
 
1.5.2 Distribution 
 
OT distributes into the extracellular fluid space, occupying approximately one third of the total 
volume of the extracellular fluid [96] and has a volume of distribution of approximately 0.3 l/kg 
[97] indicating that OT has little or no apparent protein binding characteristics [96]. 
 
Administration of OT by different routes, viz., nasal, intramuscular, intravenous, and buccal 
routes, results in different plasma concentrations. Basal levels of OT are reported to be < 10 
pg/ml. Following nasal administration of between 65 – 100 µg OT, the plasma concentration of 
OT increased to between 36 – 85 pg/ml. Administration of an intramuscular dose of OT (25 µg) 
produced resultant plasma concentrations that were markedly higher that those attained following 
nasal administration, reaching between 360 – 480 pg/ml. However, the administration of buccal 
OT (70 µg) was ineffective as the plasma concentrations observed were lower than 10 pg/ml [98]. 
 
1.5.3 Metabolism 
 
OT is rapidly cleared from the systemic circulation by metabolism in the liver and is excreted via 
the kidneys [4,8,99]. OT has a plasma half-life of only a few minutes, reported to be 3.2 min 
following a single intravenous bolus injection and 4.8 min following an intravenous infusion at 
0.5 IU/min for 25 min [96,100]. 
 
OT is metabolised primarily by two (2) enzyme systems that are responsible for the removal of 
glycinamide from the C-terminal of the polypeptide and removal of the Leu-Gly-NH2 sequence 
[8]. 
 
Glutathione plays an important role in the metabolic fate of OT in the kidney, increasing the rate 
of degradation observed in the renal microvilli by membrane-bound enzymes [4]. In vivo, 
glutathione may be involved in the metabolism of OT by cleavage of the disulphide link between 
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the cysteine moieties [101]. An alternate mechanism by which OT may degrade in the kidney in 
the absence of glutathione may be a result of the presence of a membrane bound enzyme, 
endopeptidase 24.11, which attacks lipophilic bonds i.e. proline7 – leucine8 [4]. 
 
Degradation of OT in the liver does not occur as a result of membrane-bound enzymes, but occurs 
in the hepatocytes [4] and OT has been found to be susceptible to enzymatic attack by peptidases 
in the liver in vitro. Peptidase enzymes are located mainly in the lysosomes and microsomes 
[102]. In addition, OT undergoes receptor-mediated endocytosis into the hepatocytes and 
undergoes intracellular metabolism in these regions, as has been observed for VP [103]. The rate 
and extent of degradation in the kidney in the presence of glutathione is higher than in the liver 
[4]. 
 
Furthermore, pregnant women produce plasma oxytocinase [104-107], which is an 
aminopeptidase enzyme that cleaves OT at the cysteine1 – tyrosine2 bond resulting in the 
formation of an inactive acyclic compound [8]. An enzyme present in the placenta identical to 
plasma oxytocinase also hydrolyses OT [107-109]. Figure 1.6 shows a summary of this 
degradation reaction.  
 
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys
Plasma oxytocinase
 
Figure 1.6 Metabolic degradation of OT by plasma oxytocinase (Redrawn from [8]) 
 
Reported half-life and mean metabolic clearance rates of OT vary according to the route of 
administration and the dose delivered. The plasma half-life of OT in males is reported to be 
between 3.2 – 10.3 min [97] and in non-pregnant females is between 3.3 – 4.5 min, whereas in 
pregnant females the range is 1.8 – 4.9 min [110]. The mean metabolic clearance of OT has been 
reported to be 21.5 + 3.3 ml/kg/min [97] and 16.4 ml/kg/min [111]. Following the use of OT for 
labour induction, the metabolic clearance rate has been reported to be 7.97 ml/min [112]. There 
are no significant differences in the mean metabolic clearance rate of OT between men, non-
pregnant and pregnant women. Reported values of mean metabolic clearance are 27 + 1.8 
ml/kg/min in men, 20.6 + 2.8 ml/kg/min in non-pregnant women and 23.1 + 2.6 ml/kg/min in 
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pregnant women, using the corrected weight pre-pregnancy weight for pregnant women to give a 
metabolic clearance rate of 25.4 + 2.0 ml/kg/min [113].  
 
The administration of an intravenous dose of OT results in a rapid onset of action that occurs 
within 1 minute, with a duration between 30 and 60 min and with a half-life less than 5 min 
[31,69]. The onset of action following intramuscular administration is within 3 – 5 min and lasts 2 
– 3 hours [31]. 
 
1.5.4 Elimination 
 
OT is eliminated primarily via the renal route [31,110]. Less than 1% of the administered dose is 
excreted unchanged in the urine of pregnant women as compared to 20% recovery in the urine of 
non-pregnant women [110]. 
 
1.6 CONCLUSION 
 
OT is a powerful uterotonic agent, useful for the induction and augmentation of labour, 
prevention of postpartum haemorrhage and promotion of lactation. The instability of OT in the 
GIT is primarily due to the high acidity of the stomach, the alkaline pH of the small intestine and 
the presence of enzymes in the GIT. The compound is therefore unsuitable for formulation for 
delivery via the oral route.  
 
The short half-life of OT makes it a suitable agent for formulation into a sustained release 
parenteral formulation. However, the use of a sustained release formulation is limited for labour 
induction, as careful monitoring of the patient for this indication is required to prevent 
complications to mother and/or baby and the use of an implanted sustained release parenteral 
preparation would be unsuitable. However, after the delivery of the shoulders of a baby, in the 
third stage of labour, the routine use of a sustained release OT preparation could be advocated to 
prevent postpartum haemorrhage and incidences of hypo-volaemic shock [114], which is one of 
the leading causes of maternal morbidity and mortality. A sustained release OT product would 
assist in maintaining uterine tone and prevent excessive bleeding.  
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CHAPTER 2 
 
HPLC METHOD DEVELOPMENT AND VALIDATION 
 
2.1 INTRODUCTION 
 
2.1.1 Overview 
 
The analysis of OT has traditionally been based on biological assays that measure uterine 
contractions in the rat or a drop in the blood pressure of chickens [8]. The BP 1993 [115] and USP 
1990 [116] recommended the use of these assays to quantitate OT activity. However, biological 
assays are time consuming and the applicability of high performance liquid chromatography 
(HPLC) in comparison to biological assay methods has ensured that this analytical tool has 
become a method of choice for the quantitation of OT in biological samples [117,118], 
pharmaceutical formulations [119-124] and for quality control purposes [125,126]. Furthermore, 
there is a good correlation that exists between the activity of OT measured using biological assays 
and the use of HPLC as a quantitative analytical tool [8,121,124]. In addition, current compendial 
methods recommend the use of HPLC for the assay of OT containing formulations [10,11].  
 
The objective of these studies was to develop and optimise an HPLC method for the quantitation 
of OT in pharmaceutical dosage forms. Furthermore, the development of a stability-indicating 
analytical method for the assessment of OT was desired. The method for OT analysis was further 
optimised by increasing the sensitivity in order to allow for the use of the method in the 
assessment of OT release from extemporaneously prepared OT gel formulations for parenteral 
delivery of the peptide. 
  
2.1.2 Principles of HPLC  
 
HPLC has become one of the most versatile tools in a wide variety of fields, finding application in 
the pharmaceutical sciences [127-129], chemical [130-132], cosmetic [133-135], biotechnological 
[136-138], biomedical and clinical fields [139-141].  
 
The term HPLC encompasses numerous forms of the technique including liquid-liquid, liquid-
solid, ion exchange, and size-exclusion chromatography [142-144]. Modification of liquid-liquid 
chromatography gave rise to bonded phase chromatography and the original form of bonded 
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phase chromatography is referred to as normal phase HPLC. Normal phase chromatography uses 
a polar stationary phase and a non-polar solvent or mobile phase is used to ensure elution of the 
analyte of interest. However, a more commonly used form of HPLC is reversed-phase HPLC (RP-
HPLC) where the stationary phase is non-polar and the mobile phase is comprised of polar 
materials. RP-HPLC is a more useful technique for the analysis of pharmaceuticals as the majority 
of compounds of interest are polar in nature, being either weak acids or bases and are ionisable, 
necessitating the use of polar solvents to effect rapid elution from hydrophobic stationary phases 
[143-145]. 
 
The stationary phase is usually retained in a column made of stainless steel and is primarily made 
up of a silica backbone, chemically bonded to different functional groups, such as for example, 
alkyl chains. The mobile phase is pumped through the stationary phase in the column and carries 
the analyte(s) of interest to the detection system for analysis. Usually the detector system is 
coupled to a computer system, integrator, or chart recorder for data capture and integration of the 
detector response. The components of a mixture undergoing analysis interact differently with the 
stationary and mobile phases, resulting in differential migration or varying rates of movement and 
consequently, different retention times of the compounds of interest thus effecting a separation 
[143-145]. 
 
The separation of compounds in HPLC is a poorly understood complex process, despite numerous 
efforts to elucidate the precise nature of the interaction between an analyte and the stationary and 
mobile phases. Several mechanisms for the retention of analytes in RP-HPLC have been 
proposed, each having distinct advantages and/or shortcomings. The failure to reach consensus for 
the mechanisms of retention is probably due to the complexity of interactions that occur in RP-
HPLC systems, which change with the nature of the mobile phase composition, type of stationary 
phase and the analyte in question [146-148]. The understanding of mechanisms of retention in 
RP-HPLC is useful for the prediction of performance of a specific separation in chromatographic 
systems and the logical optimisation of that separation, especially in complex systems that contain 
a wide range of solutes or analytes to be separated [147,149,150]. 
 
The retention of an analyte in RP-HPLC is a function of its distribution between a liquid polar 
mobile phase and a non-polar stationary phase. The equilibrium existing in a system is not strictly 
liquid-solid equilibrium, as the chemically modified hydrophobic layer is made up of mobile 
chains and therefore there is no sharp interface between the stationary and mobile phases. 
Furthermore, the equilibrium cannot be considered as a liquid-liquid equilibrium as the stationary 
phase, although it contains mobile chains, is chemically bonded to a stationary silica backbone 
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[146]. When the layer of bonded alkyl chains is exposed to the contents of a mobile phase, it 
adsorbs some of the contents of the mobile phase and swells to a degree, forming a complex, thick 
solid-liquid interface [146]. 
 
Analyte retention was initially proposed to be due to interactions between a solute and the mobile 
phase [151,152]. Karger et al. [151] proposed that hydrophobic molecules tend to cluster in 
aqueous media and result in the formation of a cavity, of which the surface area is directly 
proportional to the molecular connectivity providing a topological index. The retention of solutes 
increases with an increase in molecular connectivity of a molecule and therefore, more 
hydrophobic entities, which occupy larger surface areas, have longer retention times. The 
solvophobic theory [152] also describes the importance of the aqueous medium in reducing the 
surface area of non-polar solutes forming a cavity in the media to accommodate the solute. The 
solvophobic tendency results in the interaction of solutes with the stationary phase and 
hydrophobic molecules therefore tend to interact more with the stationary phase compared to 
more hydrophilic compounds. The size of the molecule and the surface tension of the mobile 
phase are therefore important factors in determining the mechanism of retention [152]. 
 
Later studies have provided evidence of the importance of the stationary phase in the retention 
process [153-156] and models that include both the characteristics of the stationary and mobile 
phases have been developed. Experimental data reveal that the density and length of the alkyl 
chains in a stationary phase are important components in determining the retention mechanism for 
small non-polar solutes [157]. Tan and Carr [155] investigated the role of cavity formation, 
dispersion interaction, polarity, hydrogen bond acidity and basicity on the retention behaviour of 
analytes. The stationary phase was found to be an important determinant in the retention 
mechanism. 
 
The mechanism of retention can be described by essentially three mechanisms [158]: 
i. Partitioning of an analyte between a stationary and mobile phase [149,154],  
ii. Adsorption of an analyte onto the surface of a non-polar adsorbent [159] and,  
iii. The combined effects of adsorption and partitioning [160].  
 
Partitioning implies that a solute becomes fully embedded in a stationary phase, whereas in 
adsorption, a solute interacts with a stationary phase only on the surface of that phase [158]. 
 
In the partitioning model [158], the stationary phase can be considered an amorphous bulk fluid 
medium and the transfer of solutes between the stationary medium is driven by the relative 
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chemical affinity of a solute for the mobile and stationary phases. The solvophobic theory [152] is 
an example of the early partitioning models, although it fails to provide a complete picture for the 
partitioning process as it neglects to describe the impact of a stationary phase on solute retention 
[149]. Equation 2.1 depicts the analyte distribution/partition coefficient used to describe the 
partitioning theory [143,148]. 
 
m
s
C
C
K =       Equation 2.1 
Where, 
  Cs = Concentration of analyte in the stationary phase 
  Cm = Concentration of analyte in the mobile phase   
 
In this model, the migration of a solute may be assumed to occur only when the molecules are in 
the mobile phase and a greater distribution of the solute in the stationary phase results in a higher 
partition coefficient. As a result, the rate of migration of a solute is inversely proportional to the 
partition coefficient and in cases where there is a larger amount of analyte in the stationary phase, 
longer retention times result [143]. A correlation exists between the partition coefficient of a 
solute in water and n-octane and the retention factors for RP-HPLC [146]. Relationships to 
determine and predict the migration of analytes within RP-HPLC columns can be derived from 
the partition coefficient [148]. The partitioning of solutes in RP-HPLC can be considered to occur 
in three steps viz., the creation of a solute-sized cavity in the stationary phase, which is followed 
by the transfer of the solute from the mobile phase leaving a cavity and is finally closed by the 
mobile phase in the subsequent step [158]. 
 
The contribution of adsorption to the retention process was initially underestimated, but 
adsorption is now recognised to play a vital role in the retention of analytes in RP-HPLC 
[154,158,159]. Adsorption describes an accumulation of one component in close proximity to an 
adsorbent surface, under the influence of surface forces. When a liquid binary solution is used, the 
accumulation of an analyte onto a stationary phase surface occurs with the simultaneous 
displacement of solvent from the surface region near the adsorbent, into the bulk solution. At 
equilibrium, a certain amount of analyte will remain accumulated on the adsorbent surface at a 
higher concentration than that present in the bulk solution [148]. This model has been considered 
more logical in explaining retention mechanisms of solutes as compared to the partitioning model. 
This is because column-packing material is porous, with a large surface area that is impermeable 
to analytes, allowing the adsorption process to occur primarily in the liquid phase [148]. The 
retention mechanism for proteins can be considered as adsorption of the analyte at the 
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hydrophobic stationary surface described above, although the mechanism of retention for proteins 
may be altered as a result of changes in protein conformation during RP-HPLC analysis [161]. 
 
The partitioning and the adsorption models are extremes in a spectrum of all possible mechanisms 
of retention and the overall retention of analytes is due to a complicated process of different 
interactions occurring simultaneously in RP-HPLC [146,148]. 
 
The organic modifier used in a mobile phase can also be adsorbed at the stationary phase interface 
thereby forming a thick layer suggesting that a modified model may be necessary to explain the 
retention process. In the first stage of the process, an analyte partitions between an adsorbed 
organic layer and the bulk mobile phase and subsequently, the analyte is adsorbed onto the 
surface of the stationary phase [148]. Jaroniec [156] proposed a partition-displacement model in 
which the formation of the solvent-surface stationary phase occurs via a displacement mechanism 
and the distribution of the solute between the mobile and stationary phases follows partitioning of 
an analyte between the stationary and mobile phases of a system. 
 
Differential migration of analyte(s) is influenced by variables that affect the interaction(s) 
between the analyte of interest and either the stationary and/or mobile phase. The retention 
process is a complex system that is affected by several factors, including mobile phase 
composition and the nature of the organic modifier in the mobile phase [146,162,163], flow rate 
and temperature [163,164], pressure [146], presence of salts, buffer molarity and pH [146,165]. 
 
Several methods and relationships have been used to add clarity on the mechanism of retention in 
RP-HPLC systems. A semi-logarithmic relationship shown in Equation 2.2 has been applied to 
describe analyte retention in binary RP-HPLC systems where the relationship shows a linear 
dependence of the logarithm of the retention factor, k’, (log k’) and the composition of the mobile 
phase, Φb [166,167]. 
 
bw Skk Φ−= log'log             Equation 2.2 
Where, 
k’ = isocratic capacity factor 
Φb = volume fraction of organic modifier 
kw = extrapolated value of k’ when Φb = 0 
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The limitation of this method is that the relationship that exists often deviates from linearity as the 
aqueous component exceeds 90% (Φb < 0.1) and is only linear when the volume fraction of the 
organic modifier is between 0.2 – 0.8. However, this limitation is overcome by use of a quadratic 
function that is shown in Equation 2.3, of the mobile phase composition to represent log k 
[168,169].  
 
wbbb kEBAk 'log'log
2 +Φ+Φ+Φ=           Equation 2.3       
Where, 
k’ = isocratic capacity factor 
Φb
2
 = volume fraction of organic modifier at high volume fractions (>0.8) 
Φb
 
= volume fraction of organic modifier (between 0.2 – 0.8)  
√ Φb = volume fraction of organic modifier at low volume fractions (<0.2) 
kw = extrapolated value of k’ when Φb = 0 
 
Linear free energy relationships have also been used [170-173] to describe retention mechanisms, 
although the major limitation of this method of description is that a large amount of retention data 
is necessary for the calibration of a chromatographic system and some solutes deviate from the 
model [174].  
 
Quantitative structure-retention relationships (QSSR) have played an important role in predicting 
the retention characteristics of solutes in RP-HPLC and explaining the retention mechanism in 
these systems [150,175,176]. This has improved the understanding of retention mechanisms and 
the selectivity in RP-HPLC. QSSR are useful in predicting the retention characteristics of a new 
solute, identifying the most informative descriptors and gaining insight into the mechanism 
operating in RP-HPLC, evaluation of physicochemical properties of analytes, and the prediction 
of relative biological activities within a set of test drugs [150]. 
 
2.2 LITERATURE REVIEW 
 
Prior to the development of a specific HPLC method for the analysis of OT, a literature review 
was conducted and the published conditions used for the analysis of OT are summarised in Table 
2.1. The initial conditions used for the development of the HPLC method for use in these studies 
were based on the data presented in Table 2.1. 
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Table 2.1 HPLC methods for OT analysis 
Column Mobile phase Flow rate Detector Retention 
time 
Reference 
Nucleosil® C18, 5 µm, 100 X 4.6 mm  35% v/v ACN in 0.83 mM phosphate buffer, pH = 
5 containing 0.05 % sodium tetradecyl sulphate.  
2.5 ml/min UV 8 min [124] 
 
Partisil® SCX, 10 µm,  
250 X 4.6 mm  
10% v/v MeOH in 20 mM in phosphate buffer, pH 
= 5  
0.5 ml/min UV 209 nm 18 min [177] 
Column RP 18, 10 µm, 250 X 4.6 mm 18% v/v ACN in 67 mM phosphate buffer, pH = 7 2.0 ml/min UV 210 nm 8 min [8] 
Nucleosil® C8, 5 µm,  
150 X 4 mm  
20% v/v ACN in phosphate buffer, pH = 7 2.0 ml/min UV 210 nm 5 min [178] 
Spherisorb® S5 ODS, 5 µm, 75 X 3 mm  17.5% v/v ACN in borate buffer, pH = 10 1.0 ml/min UV 220 nm 2.5 min [178] 
Nucleosil® C18, 10 µm,  
150 X 4 mm 
20% v/v ACN in 67 mM phosphate buffer, pH = 7 4.0 ml/min UV 210 nm 
 
4 min [122] 
 
Zorbax® TMS, 5 µm, 250 X 4.6 mm 18% v/v ACN in 50 mM phosphate buffer, pH = 5, 
internal standard ethyl hydroxyl benzoate 
1.0 ml/min UV 210 nm 15 min [123] 
 
LiChrosopher® 60 RP-select, 5 µm 18% v/v ACN in phosphate buffer pH = 2.1 1.0 ml/min UV 220 nm 10 min [121] 
Partisphere® C18, 5 µm, 125 X 4.6 mm 21% v/v ACN in 0.1 % phosphoric acid 1.3 ml/min Fluorescence ex 250 
em 
12 min [179] 
 
RP 8® (Merck) 10 µm, 250 X 3 mm  
 
20% v/v ACN in phosphate buffer pH = 7 1.47 ml/min Fluorescence ex 390 
em 
6 min [180] 
RP-C18 (e.g. Shandon Hypersil®), 5 µm, 
125 X 4.6 mm 
A: 50% v/v ACN  
B: 100 mM sodium dihydrogen phosphate 
Gradient: 30% A to 60% A in 30 min 
1.0 ml/min UV 220 nm 8 min [125] 
 
Alltech Hypersil® ODS, 5 µm,  
120 X 4.6 mm 
Beckman Ultrasphere® ODS, 5 µm,  
150 X 4.6 mm 
A: 100mM sodium phosphate monobasic with pH 
varied from pH = 3.1 to pH = 4.5  
B: 50% v/v ACN 
Gradient elution  
1.5 ml/min UV 220 nm 10 min [120] 
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The analysis of OT in both biological samples and pharmaceutical dosage forms has been 
performed on silica support columns, with C8 and C18 columns being used most frequently, 
although ion exchange columns such as Partisil® SCX columns [177] have also been used. 
 
The most commonly used organic modifier that has been used is acetonitrile (ACN) [119-
123,125,178], although methanol (MeOH) has also been used [177]. The content of organic 
modifier content is usually relatively low and ranged from between 10 – 35% v/v ACN [124].    
 
The use of ion-pairing reagents in RP-HPLC for analysis of peptide containing samples has 
been recommended as they result in improved peak shapes [181]. The use of an ion-pairing 
reagent, sodium tetradecyl sulphate, has been reported for the analysis of OT in dosage forms 
[124], but the use of ion-pairing reagents has a drawback of producing long equilibration times 
and the need for removal of salts from a column, thereby also reducing the column life span 
[182]. The majority of published methods summarised in Table 2.1 did not support the need for 
use of an ion-pairing reagent in analysis of OT samples. 
 
OT is an amphoteric molecule (§ 1.2.5) and buffered systems are used for the successful 
analysis of OT using RP-HPLC systems. Phosphate buffer at pH of between pH = 5 and pH = 7 
have most commonly been reported [122-124,177,178,180] due to the stability of OT in this pH 
range (§ 1.3.2), although a borate buffer at pH = 10 has also been successfully used [178]. 
 
HPLC with UV detection is the preferred method of analysis for many assays as its use is well 
documented in the scientific literature [119-122,178] and official compendia [10,11]. In 
addition, the use of fluorescence [179,180] and coulometric detection [117] has also been 
reported. 
 
2.3 EXPERIMENTAL 
 
2.3.1 Reagents and Materials 
 
OT was obtained from PolyPeptide Laboratories s.r.o. (Prague, Hostivar-Czech Republic) and 
Inter-Chemical Hongkong Ltd (Shenzhen, China). The potencies of OT used in these studies 
were 541 IU/mg and 470 IU/mg, respectively. Methyl hydroxybenzoate (MHB) and propyl 
hydroxybenzoate (PHB) were obtained from Sigma Aldrich (St Louis, MO, USA). Acetonitrile 
(ACN) (HPLC grade, far UV) was purchased from Romil Ltd, (Cambridge, United Kingdom). 
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Sodium hydroxide pellets and ortho-phosphoric acid (85% w/w) were obtained from Merck 
Chemicals Ltd, (Modderfontein, South Africa). HPLC grade water was purified using a Milli-
Ro® -15 Water purification system (Millipore, Bedford, MA, USA), which is made up of a 
Super-C® carbon cartridge, two Ion-X® ion-exchange cartridges and an Organex-Q® cartridge. 
The water was filtered through a 0.22 µm Millipak® stack filter prior to use (Millipore, 
Bedford, MA, USA). Syntocinon® (Batch Number S0042, Novartis, Johannesburg, South 
Africa), a locally available dosage form of OT at a concentration of 10 IU/ml was purchased 
from a local pharmacy. All reagents were used without further preparation and were at least of 
analytical reagent grade. 
 
2.3.2 Preparation of Stock Solutions 
 
Approximately 10 mg of OT (541 IU/mg) was accurately weighed, transferred into a 100 ml A-
grade volumetric flask, and made up to volume with HPLC grade water to produce a final 
concentration, in solution of 54.1 IU/ml. The standard stock solution was used to prepare 
calibration standards in the concentration range 0 – 12 IU/ml by serial dilution using A-grade 
glassware. Standards were prepared by serial dilution of the standard stock solution to produce 
solutions of 1, 2, 4, 6, 8, 10, and 12 IU/ml for use when assessing OT content in pharmaceutical 
dosage forms. Standards for the optimised method were prepared from a 1 IU/ml stock solution 
of OT to produce solutions of 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 IU/ml. 
 
A stock solution of internal standard was prepared as follows; approximately 5 mg of MHB was 
accurately weighed and dissolved in 200 ml of HPLC grade water using a 200 ml A-grade 
volumetric flask, to produce a concentration of 25 µg/ml. Then, 6 ml was pipetted using an A-
grade pipette, into a 20 ml A-grade volumetric flask and made up to volume with water to 
produce a solution of a concentration, approximately 7.25 µg/ml. 
 
2.3.3 Preparation of Buffer Solutions 
 
80 mM buffer solutions were prepared by pipetting 5.460 ml of 85 % w/w ortho-phosphoric 
acid into a 1000 ml A-grade volumetric flask. Approximately 500 ml of HPLC grade water was 
added and the pH was titrated to pH = 5 with sodium hydroxide pellets using a Crison Model 
GLP 21 pH meter (Crison Instruments, SA, Barcelona, Spain) to monitor the pH. The volume 
was made up to 1000 ml using HPLC grade water.   
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2.3.4 Preparation of Mobile Phase 
 
Appropriate volumes of buffer and ACN were measured separately using A-grade measuring 
cylinders. The individual components were then mixed in a 1000 ml Schott® Duran bottle 
(Schott Duran GmbH, Wertheim, Germany). The mobile phase was filtered and degassed under 
vacuum, after mixing, using an Eyela Aspirator A-2S vacuum pump (Rikakikai Co., Ltd, 
Tokyo, Japan) and a Millipore® HVLP 0.45µm filter (Millipore, Bedford, MA, USA). 
 
2.3.5 HPLC System A 
 
The method for OT analysis in pharmaceutical dosage forms was developed and validated on 
HPLC System A. The modular isocratic HPLC system consisted of a Spectra-Physics Isochrom 
LC pump (Spectra-Physics Inc., San Jose, CA, USA), Waters WISP 712 autosampler 
(Millipore, Waters Chromatography Division, Milford, MA, USA), Linear UV/VIS-500 Model 
6200-9060 detector (Linear Instrument Co., CA, USA) and a Perkin Elmer 561 strip chart 
recorder (Perkin Elmer Instruments LLC, Shelton, CT, USA). A Phenomenex Hypersil® 
column, 5 µm, 4.6 x 150 mm (Phenomenex, Torrance, CA, USA) was used at ambient 
temperature (22 °C). The separation was conducted under isocratic conditions with UV 
detection at 220 nm. The volume of injection was 20 µl and a flow rate of 1.5 ml/min was used. 
 
2.3.6 HPLC System B 
 
HPLC system B was used for the optimisation of the analytical method for use in the 
subsequent development of an in vitro release test method for OT and the in vitro assessment of 
OT dosage forms. HPLC System B differed from System A. It consisted of, a Model P100 dual 
piston solvent delivery module (Thermo Separation Products, San Jose, CA, USA), a Model 
AS100 autosampler (Thermo Separation Products, San Jose, CA, USA) fitted with a 
Rheodyne® Model 7010 injector (Rheodyne, Reno, Nevada, USA) and a fixed volume 20 µl 
loop and a GASTIGHT® 250 µl Model 1725 syringe (Hamilton Co., Reno, NV, USA). Data 
was collected using a Spectra Physics SP 4600 integrator (Thermo Separation Products, San 
Jose, CA, USA). The detector and column used for the analysis was the same as that used in 
HPLC System A (§ 2.3.5). 
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2.4 METHOD DEVELOPMENT AND OPTIMISATION 
 
2.4.1 Introduction 
 
The initial step in the development of an analytical method is to consider the nature of the 
sample that is to be analysed, including the chemical structure and acidic/basic nature of the 
analyte, the presence of impurities, degradation products and any compounds that may interfere 
with the analytical procedure [183-186]. In addition, the intended purpose or use of the HPLC 
method has also been considered in the development stages [185,187-189] as this is directly 
related to the desired sensitivity and range of the analytical method that must be developed. 
 
Traditional means of method development and optimisation have focused on selecting the initial 
conditions based on the literature or by assessing the nature of the molecule to be analysed and 
predicting the most appropriate initial conditions for an analysis. The method is then optimised 
by determining the effect of operating variables such as organic modifier content, type of 
organic modifier, column type, and temperature on the resultant separation [183].  
 
Current trends in the development of analytical methods depend on the application of automated 
column selection systems that can be used to compare a series of HPLC columns varying in 
hydrophobicity and silanol activity, in combination with computer software such as DryLab® 
software [190-192] and ChromSword® optimisation software [193]. The basic strategy involves 
automated screening of various columns and mobile phase combinations initially, and then 
selection of the best starting conditions for the separation and finally, the optimisation of that 
separation [193]. Another example of current trends in method development is a three-step 
method development/optimisation strategy for pharmaceuticals including a multiple-
column/mobile phase screening test, which uses a column-switching device and allows further 
optimisation of the separation by using multiple organic modifiers in a mobile phase. Multiple-
factor method optimisation, where several aspects are changed simultaneously, is also possible 
with automated systems [194]. Intelligent software such as LabExpert®, which operates in real-
time for analytical method development has also been described [195].  
  
Analytical procedures for use in quality control and formulation development studies should 
have relatively short run times in order to allow multiple analyses to be conducted in as short a 
time as possible. A run time for each sample should generally be less than 20 min although run 
times between 5 – 10 min are preferable for these purposes to expedite analyses [183]. 
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2.4.2 Challenges in RP- HPLC Analysis of Proteins and Peptides 
 
RP-HPLC analysis of biomolecules such as proteins and peptides can be a challenge as there are 
often problems associated with analytical systems such as excessive band broadening, peak 
tailing or mis-shaped bands, low recovery, ghost peaks and the appearance of one protein in two 
or more distinct bands [196]. Understanding the impact of process variables in RP-HPLC can 
help minimise or eliminate these undesirable effects.  
 
The analysis of biochemical entities such as peptides, proteins, and oligonucleotides by RP-
HPLC pose different challenges as compared to the analysis of small chemical molecules since 
they have larger hydrodynamic radii and different functionalities in the molecules that may 
result in different interactions with RP-HPLC stationary and mobile phases. These factors must 
be considered in the development of an analytical method for proteins and peptides [183,197]  
 
2.4.3 Column Selection 
 
A description of the relevant physicochemical properties of OT was reported in Chapter 1 and 
reveals that the molecule is a peptide, with a molecular weight of 1007.23. OT has free amino 
and acidic phenol groups, making it an amphoteric molecule with an isoelectric point at pH = 
7.7. This fact is important since the separation of OT is dependent on the pH of the mobile 
phase and elution in RP-HPLC can be modulated by the presence of buffers.  
 
2.4.3.1 Column Packing and Stationary Phases 
Stationary phases used in RP-HPLC are primarily made of a silica backbone that is chemically 
bonded to various aliphatic functional groups such as methyl, butyl, octyl and octadecyl, 
although other functional groups such as –phenyl, cyano, amino, diol and hydroxyl have also 
been used [142,143,145]. The stationary phases are typically prepared by covalently bonding an 
organosilane with the relevant functional group onto a support surface producing siloxane 
linkages (Si – O – Si – R) between the silica support and organosilane [183]. 
 
Silica based bonded phases dominate the separation of proteins and peptides [198-202]. Peptide 
separations are frequently achieved on C18 columns, but protein separations are carried out on 
C3 and C4 columns [203]. Different types of stationary phases that may be used in RP-HPLC for 
protein and peptide separations include micropellicular stationary phases and gigaporous 
packings, which increase the efficiency of biomolecular separations [197]. 
 33 
There are several advantages of a silica backbone for stationary phases that have made it the 
most widely accepted and used stationary phase support [183]. Advantages include the fact that 
the support consists of porous silica particles that can be prepared in a wide range of pore and 
particle sizes, thereby increasing the variety of columns that can be produced. This allows for 
the separation of a wide variety of molecules with diverse molecular weights, increasing the 
utility of RP-HPLC columns. In addition, the silica backbone can be attached to a wide variety 
of functionalities, thereby further enhancing the applicability of RP-HPLC in a wide range of 
analytical applications [183]. 
 
One of the primary advantages of silica as a support in RP-HPLC is its mechanical strength that 
enables tight packing of stationary phase beds, thereby increasing the surface area for 
interaction of analytes and subsequent retention. In addition, tightly packed beds allow the 
column to withstand the high-pressure conditions that are usually encountered in RP-HPLC 
[204]. Furthermore, silica does not swell or shrink when exposed to organic solvents making it 
inert under these conditions. Importantly, the production and bonding chemistry for silica 
supports is also reproducible, well understood and can be performed with different 
morphologies to give a wide variety of stationary phases, increasing the applicability and the 
diversity of molecules that can be separated using RP-HPLC [183,204]. 
 
Column failure in RP-HPLC may occur because of the vulnerability of silica-based stationary 
phases to deterioration effects. One of the major disadvantages of silica support materials is the 
instability of silica and chemically modified silica as a function of pH. The typical operating 
range of such stationary phases is between pH = 2 and pH = 8, where only slight dissolution of 
the stationary phase occurs [205]. The organic ligands of most of the currently manufactured 
stationary phases are covalently bonded to the silica surface by mono- or polyfunctional 
siloxane bond(s) (Si – O – Si) [183,206]. In acidic media, siloxane bonds in silica support 
stationary phases undergo hydrolysis and release bound organo-silane from the stationary phase 
surface, resulting in elution of this organic moiety. Kirkland et al. [207] showed that the main 
mechanism resulting in the degradation of silica support stationary phases at low pH is due to 
the hydrolysis of the covalently bonded Si – O – Si organic ligands. This loss of bound silane in 
the stationary phase increases the population of surface silanols and results in a decrease of the 
retention of neutral and/or low polarity solutes, which would otherwise be retained on the 
hydrophobic stationary phase. With the increase in surface silanols, organic cations usually elute 
with increased peak widths and greater peak asymmetry [131]. The mechanism of deterioration 
changes above a pH of approximately 7, where the dissolution of silica is substantially 
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accelerated causing an impairment of the silica backbone. The resultant effect is a reduction of 
theoretical plate numbers and column efficiency and finally column clogging [207]. 
 
Another disadvantage of silica support columns for use in RP-HPLC is the strong affinity of 
such phases for strongly basic compounds, which often results in unsatisfactory separations, 
with poor resolution, peak asymmetry, and substantial peak tailing [205]. 
 
Despite the major disadvantages of silica, a silica-based column was found to be appropriate for 
the development of an analytical method for OT. This decision followed considering the 
properties of this type of packing and reviewing published analytical methods of OT, which 
have used silica columns for the analysis of OT. In addition, the pH range within which the 
separation of OT was to be undertaken would not cause the degradation of the column and 
therefore the life span of the column is unlikely to be negatively affected. 
 
2.4.3.2 Internal Diameter and Length 
The internal diameter (i.d.) of a column plays an important role in the performance of that 
column. Separations for proteins and peptides have been mostly achieved on columns of i.d. of 
between 3 – 5 mm, although narrow bore columns with diameters of between 0.5 – 2 mm are 
gaining significance and even microbore columns with diameters less than 0.5 mm are 
considered useful [197]. Microbore columns of 1.0 mm i.d. have been used [208,209] and found 
to have greater efficiency allowing for the detection of low concentrations of analyte. However, 
the primary disadvantage to smaller i.d. columns is that for the same column length, a microbore 
column will require a larger inlet pressure than that required by a wider column [143] and this 
has detrimental effects on both the column and the solvent delivery module reducing their life 
span [145]. 
 
Peptide and protein separation is normally carried out under gradient elution conditions using 
short columns with high velocity flow rates. However, protein separations have been achieved 
using columns as short as 3 – 5 cm in length and peptide separations can be achieved on 
columns between 10 – 25 cm in length [197]. 
 
An appropriate column diameter that allows for adequate separation efficiency and a reduced 
column backpressure, with reduced deleterious effects to the column and the HPLC system that 
is regularly used is usually of 4.6 mm i.d. and 15.0 cm in length. A column with these 
dimensions was selected for the analysis of OT as a compromise on the factors discussed above. 
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2.4.3.3 Particle Size 
The particle size of a stationary phase affects the efficiency of a separation for protein and 
peptide samples. Smaller particle sizes have greater separation efficiency as compared to larger 
particles due to the associated increased surface area for adsorption and interaction. Moreover, 
the separation of bio-molecules results in smaller plate numbers and smaller particles are 
usually required to ensure a good separation is achieved [197]. A decrease in the particle size of 
the packing material results in an increase in the efficiency of separation and a decrease in 
analysis time, with a consequent increase in column backpressure [210]. Particle sizes of 5 µm 
are routinely used for biochemical sample analysis [183] and therefore a column with these 
dimensions was selected for use in these studies. 
 
2.4.3.4 Pore Size 
In RP-HPLC, the interaction between an analyte and the stationary and mobile phases governs 
the retention mechanism of that solute as discussed in § 2.1.2. The pore size of the stationary 
phase material dictates the extent to which analyte molecules penetrate/interact with the interior 
of that phase. Large molecular weight molecules require larger pore sizes to prevent restricted 
diffusion, which is likely to occur if the column porosity is of the wrong dimensions [183]. For 
peptides that contain more than 50 amino acid residues, column packings with pore sizes of 
between 250-350 Å are essential. For a molecule with a molecular weight of less than 2000 Da, 
a pore size of 100 Å is acceptable [183]. OT has a molecular weight of 1007.23 Da, with only 
nine (9) amino acids and therefore a column with a pore size of 100 Å is appropriate for the 
analysis of this nonapeptide. 
 
2.4.3.5 Column Selection 
The column selected for use in the development of an analytical method for the analysis of OT 
was a bonded phase silica column. The column that was selected was a Phenomenex® Hypersil 
150 X 4.6 mm i.d. (Phenomenex, Torrance, CA, USA) with a 5 µm particle size stationary 
phase and 100 Å pore size. 
 
2.4.4 Method of Detection 
 
Following the separation of analytes from a column, specific and sensitive detector systems are 
required for the quantitation of an analyte of interest. An electronic signal generated as a result 
of changes in a detector response due to the presence of analytes is produced and this is 
recorded as a peak on a chromatogram [211]. 
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Detector systems that have found application in RP-HPLC include UV/VIS, 
spectrofluorometric, diode array, electrochemical, and refractometer detectors and more recently 
mass spectrometers have been used [183,212]. Hyphenated systems such as HPLC-MS and 
HPLC-NMR, which couple other analytical techniques to HPLC are also gaining recognition 
and increase the sensitivity and utility of RP-HPLC analyses allowing for complete peak 
identification and characterisation [212,213]. 
 
The UV/VIS detector is the most versatile detector used in HPLC for analysis of proteins and 
peptides at wavelengths of 210, 220, and/or 280 where absorption maxima are observed [183]. 
In addition, a large number of compounds are capable of detection by UV absorption in the 
wavelength range of 200 – 400 nm further extending the applicability of this type of detector in 
HPLC analysis [183]. UV/VIS detection is not always ideal as it lacks specificity but the 
method is extensively used since it produces a linear response, allows for accurate calibration 
and the use of a single standard to calibrate the detection system following validation [212]. 
Another challenge in the use of UV detection for protein and peptide analysis is that UV 
spectroscopy can only be applied to a small range of protein concentrations if no other 
absorbing components that may interfere with detection are present in the solution being 
analysed. The use of diode array detection in the UV range overcomes the lack of selectivity of 
this method, but is less sensitive in comparison to conventional UV/VIS detection [214]. 
 
The detection of OT has mainly been achieved using UV/VIS detectors set at a wavelength of 
220 nm as shown in Table 2.1. The selection of the wavelength for the detection of OT in this 
system was 220 nm since the UV absorption spectrum shown in Figure 1.4 shows a region of 
increased absorbance at this wavelength, which is greater than the λmax of approximately 280 nm 
that was observed in the spectrum. 
 
2.4.5 Temperature 
 
Temperature is also an important variable for protein and peptide sample separations [215-217] 
ultimately affecting the selectivity, column efficiency and sample run times in RP-HPLC. 
Temperature ranges for effective separations of proteins and peptides can vary from 20 °C to 60 
°C [216,217] or even 90 °C [196], where higher temperatures were found to increase the 
recovery of an analyte. In addition, increasing the temperature also decreases bandwidths and 
lowers column backpressures. However, elevated temperatures result in a decrease in the life 
span of alkyl silica-based columns such as C8 and C18. The instability of silica columns to high 
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temperatures that may be used in RP-HPLC separations has been overcome by the availability 
of modified columns, resistant to the detrimental effects of high operational temperatures [196]. 
 
Temperature has been found to impact on the conformation of proteins and affecting the quality 
of the chromatogram produced. Cohen et al. [218] demonstrated these effects for ribonuclease, 
which shows asymmetric peaks when analysed at low temperatures and shows a significant 
improvement in peak shape with increased temperatures. This was due to a change in the 
conformation of the protein during HPLC separation and the denaturation at higher 
temperatures. At lower temperatures, a dynamic equilibrium between the different 
conformations of the molecule results in poorly shaped peaks. 
 
The use of elevated temperatures may offer advantages for the separation of proteins and 
peptides due to an increase in the kinetic and transport properties of the analytical procedures 
for biomolecules [197]. There is also a decrease in the viscosity of the mobile phase at higher 
temperatures, which increases the diffusivity of large macromolecules such as proteins and 
increases the efficiency of the separation [197]. 
 
The analytical methods for OT, reported in Table 2.1, do not indicate the use of elevated 
temperatures. OT is a small peptide and is unlikely to suffer from a change in conformation as 
described for the ribonuclease assay [218]. Small peptides respond in a similar manner to 
individual amino acids and with an increasing number of amino acid residues, the secondary, 
tertiary, and quaternary structures become increasingly important and affect the retention 
behaviour of the compounds in RP-HPLC analysis [219]. OT has only nine (9) amino acids, 
therefore conformational changes are unlikely to impact on the retention mechanism and 
characteristics of the molecule, and therefore there is no need for use of elevated temperatures to 
improve separations during OT analysis. 
 
The use of a constant temperature increases the robustness of an analytical method and it is 
therefore important that a column oven be used in order to ensure that the separation is achieved 
under constant temperature. However, the use of an air-conditioned laboratory with a constant 
temperature is acceptable and ensures the reproducibility of retention times and quality of 
separation [220]. The method for OT analysis was developed under ambient conditions of 22 
ºC. 
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2.4.6 Quantitative Measurement 
 
Calibration curves of detector responses to standards are used to quantitate samples in analytical 
procedures, where the concentration or amount of unknown analyte can be extrapolated from an 
appropriately constructed calibration curve [183]. 
 
Either peak area and/or peak height responses can be monitored in quantitative analysis by RP-
HPLC. The peak area is determined by the sum of all individual responses of sample molecules 
over a given period from the start to the end of the peak, but the peak height is determined by 
the maximal concentration of a sample that passes through the flow cell [183]. The maximum 
concentration that can be monitored is dependant on the amount of band spreading that may 
occur on a column during chromatography while the peak area is independent of the amount of 
band spreading, as it measures all the components present in a system. However, peak area is 
influenced by the time that it takes the molecules to pass through the detector flow cell and 
varies if there are changes in the flow rate as the flow cell transit time changes [145,183]. 
Fluctuations in mobile phase flow rates result in the components of a sample moving along a 
column and into the detector flow cell at different speeds and this is reflected on a recorder that 
traces a chromatogram reflecting sample concentration versus time. The peak remains 
approximately the same height, but becomes broader as there is an increase in the number of 
particles passing through the flow cell as a function of time [183]. 
 
The extinction coefficient can be used to quantitate analytes in RP-HPLC with UV detection. 
Once the extinction coefficient of an analyte is determined with an appropriate standard, future 
measurements can be related to the extinction coefficient, negating the need for the preparation 
of calibration standards [214]. The use of a response factor calculated from different parameters 
including the extinction coefficient, detector response in millivolts (mV), and the absorbance for 
protein and peptide analysis has been proposed by Erberlein [214]. This method was found to be 
at least as accurate as using a peak area calibration curve for sample quantitation.  
 
Due to the possible variability of flow rate and the overall constant response of peak height as 
opposed to peak area, peak height was selected as the preferred parameter for all quantitative 
analyses of OT in these studies. 
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2.4.7 Mobile Phase Selection and Flow Rate 
 
The efficiency of a RP-HPLC separation depends on several factors, including the use of an 
appropriate mobile phase, since the interactions between an analyte and a stationary phase also 
depend on the interaction of the analyte with the mobile phase as described § 2.1.2. 
Intermolecular interactions between these three interacting variables in RP-HPLC are of 
paramount importance in order to achieve a successful and possibly rapid separation in an 
analytical method. Polarity is important in the interaction, for example, if the sample 
components and the mobile phase have polarities that are similar, there is likely to be poor 
retention and the components will be eluted rapidly. In RP-HPLC, the most polar component(s) 
will be eluted first as there is little or no interaction with the stationary phase and an increase in 
the polarity of the solvent will result in an increase in the elution time for non-polar analytes 
[221]. 
 
Mobile phases for protein and peptide samples usually contain ACN in gradient elution systems, 
with the use of low concentrations of trifluoroacetic acid to maintain mobile phase pH at < 2 
[196,203,216,217]. 
 
Ion-pairing reagents such as the alkylsulphonates, trifluoroacetic acid and triethylammonium 
phosphate (pH = 4) may be used as mobile phase additives for protein and peptide separation 
[222]. These additives increase the hydrophobicity of peptides and proteins by forming 
uncharged entities through ionic interactions, thereby increasing the interaction of otherwise 
polar molecules with a stationary phase resulting in sharper and more symmetrical peaks 
[181,196]. The use of ion-pairing reagents for OT analysis is not widely advocated as reported 
in Table 2.1 and discussed in § 2.2 and therefore their use was not considered since successful 
separations have been achieved without the use of these agents. 
 
2.4.7.1 Choice of Organic Modifier and Appropriate Buffer 
The mobile phase selection process for RP-HPLC usually involves an assessment of various 
solutions of MeOH and/or ACN that may or may not be buffered. It is important that the mobile 
phase of choice does not absorb UV radiation at the wavelengths used in analytical procedures, 
and that the minimum wavelength that can be used or the cut-off wavelength of the solvent of 
choice is known. This is because the use of wavelengths below the cut-off wavelength will 
result in the mobile phase absorbing UV light thereby preventing accurate detection of the 
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analytes of interest. The UV cut-off wavelength of ACN and MeOH are 190 nm and 205 nm, 
respectively [183]. 
 
ACN is a less viscous solvent than MeOH and therefore results in comparatively lower column 
backpressures that arise due to the difficulty in pumping viscous liquids through the analytical 
column [183,220]. The differences in retention behaviour of molecules when using ACN or 
MeOH is a function of their different properties in aqueous media, more specifically, their 
ability to form hydrogen bonds with water. MeOH is able to form hydrogen bonds by accepting 
or donating protons but ACN is unable to do so and the difference in the ability to form 
hydrogen bonds with water affects the efficiency of a separation and the retention mechanisms 
of analytes of interest [155]. Differences in the interaction of ACN and MeOH with water result 
in the production of sharper peaks with ACN containing mobile phases and lower percentages 
of ACN are required in RP-HPLC separations due to its comparatively higher elution strength 
[220]. Other benefits when using ACN include lower solvent consumption in comparison to the 
use of MeOH and better resistance of silica stationary phase gels to dissolution in an ACN-
based mobile phase as compared to MeOH-based mobile phases [220]. ACN appears to be the 
organic modifier of choice for OT separations (Table 2.1) and the benefits of using ACN as an 
organic modifier resulted in its selection as the organic solvent of choice for the mobile phase 
for OT chromatographic analysis. 
 
In some cases, it is important to use a buffer as a means of controlling the pH when the 
separation of acidic and basic compounds is undertaken. In general, buffer concentrations in the 
region of 25 mM are considered as suitable for RP-HPLC analyses. The UV cut-off wavelength 
of phosphate buffers is < 200 nm, which makes it an ideal buffer system as it does not absorb 
light at the longer wavelengths that are normally used for the analysis of drug molecules [183]. 
 
Column stability is also of importance for the analysis of peptides since mobile phases of low 
pH are commonly used to effect the separation of peptides. The use of a low pH may result in 
the instability of the silica based stationary phase [145,183] (§ 2.4.3.1). The stability of the 
stationary phase was not of major concern for the analysis of OT since the pH range of the 
mobile phases that have been reported for the analysis of OT were between pH = 5 and pH = 7 
(Table 2.1, § 2.2). 
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2.4.7.2 Mobile Phase Composition 
The initial mobile phase composition that was selected for use was based on literature data 
[122,178] and was comprised of 20% v/v ACN in 67 mM Phosphate buffer, pH = 7. The 
influence of changing ACN content on the retention time and the peak shape of OT was then 
monitored. In addition, the impact of flow rates of 1 ml/min and 1.5 ml/min on these parameters 
was also assessed. Figure 2.1 shows the impact of the changes in mobile phase composition on 
retention time. 
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Figure 2.1 The effect of changing ACN content and flow rate on the retention time of OT 
 
It is clear from the data shown in Figure 2.1 that as the percentage v/v of ACN increases there is 
a decrease in the retention time of OT. The decrease in polarity of the mobile phase as ACN 
content increases results in the preferential partitioning/adsorption of the drug into the mobile 
phase as compared to compositions with lower amounts of organic modifier, favouring elution 
of the molecule. This is despite the polar nature of the drug, since OT has a carbon backbone 
that provides non-polar characteristics to the molecule. The retardation of elution of proteins 
and peptides in RP-HPLC has been explained based on the solvophobic theory [152]. The 
interaction of the non-polar portion of the molecule with the hydrophobic stationary phase is 
promoted by the forces of attraction between the stationary phase and the molecule compared to 
those between the solvent and the molecule [161]. The increase in the content of organic 
modifier decreases the attractive forces between the peptide and the stationary phase and 
promotes the elution of OT in RP-HPLC [161]. Figure 2.2 shows the effect of changing the flow 
rate on the peak shape and height of OT using mobile phases containing 18% w/v ACN and 
23%w/v ACN as examples.  
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Figure 2.2 The impact of changing flow rate on the peak shape and height of OT using 18 % v/v ACN (A) 
from 1 ml/min (A1) to 1.5 ml/min (A2) and using  23 % v/v ACN (B) from 1 ml/min (B1) to 1.5 ml/min (B2)  
 
 
 
A1 
 
A2 
 
B1 
 
 
B2 
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It can be seen that the faster the flow rate of the mobile phase, the faster the elution of OT from 
the chromatographic system. The peaks produced from the slower flow rate were broader than 
those from 1.5 ml/min, as shown in Figure 2.2, in which the peak shapes obtained for mobile 
phase compositions containing 18% v/v ACN and 23% v/v ACN for the different flow rates, 
respectively, can be compared. 
 
Peak symmetry for the different mobile phase compositions and different flow rates was 
compared using the peak asymmetry factor As, measured at 10% of full peak height and the 
peak-tailing factor (PTF) measured at 5% of full peak height. Excellent columns give an As 
value of between 0.95 and 1.1 although values of < 1.5 are acceptable. PTF values of between 
1.0 and 1.4 are also acceptable [183]. The relationships of PTF and As are schematically 
illustrated in Figure 2.3. 
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Figure 2.3 Peak asymmetry and peak tailing factors (adapted from [183]) 
 
The As and PTF values for the mobile phase compositions and the flow rates that were used to 
assess the peak symmetry are reported in Table 2.2 and therefore allowed for the selection of a 
mobile phase composition for further optimisation. 
 
Table 2.2 Peak asymmetry and tailing factors for OT for different mobile phase compositions 
ACN content (% v/v) 1 ml/min 1.5 ml/min 
 As PTF  As   PTF 
18.0 1.17 1.28 1.11 1.17 
20.0 0.97 1.17 1.05 1.10 
21.5 0.93 1.21 0.97 1.08 
23.0 1.10 1.38 0.96 1.15 
25.0 1.18 1.29 0.91 1.27 
30.0 1.27 1.33 0.89 1.44 
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The mobile phase flow rate affected peak shape and the retention time of OT. As the flow rate is 
reduced, the analyte of interest takes longer to pass through the detector cell and the peaks that 
were observed are broader than peaks observed when using faster flow rates (Figure 2.2) [145]. 
OT peaks that were observed at the higher flow rate also indicated improved symmetry, 
compared to the lower flow rate. However, the use of higher flow rates resulted in higher 
column backpressures, which may be deleterious to the solvent delivery module and column and 
thereby may reduce the working lifetime of these system components. The column backpressure 
resulting when flow rates of 1 ml/min and 1.5 ml/min were used, was monitored, and compared 
over a period of 3 days. A flow rate of 1.0 ml/min resulted in a column backpressure of 958 + 
42 psi and at the higher flow rate, a pressure of 1246 + 56 psi was observed. Although this 
pressure was higher, the backpressure was not considered to be excessive and would more than 
likely not result in excessive damage to the column and/or pump and therefore a flow rate of 1.5 
ml/min was deemed acceptable for use. 
 
For the separation of complex peptide and protein mixtures, lower flow rates are often desirable 
as this results in better resolution of the peaks of interest [183]. However since the separation of 
OT in these studies is not complex, low mobile phase flow rates are not necessarily desirable or 
required. The decision for the selection of the most favourable mobile phase was based on an 
appropriate retention time and the peak shape produced following introduction of the sample 
onto the HPLC system. Shorter retention times and peaks of better shape were produced using a 
flow rate of 1.5 ml/min as shown in Figures 2.1 and 2.2, respectively and summarised in Table 
2.2. The most favourable retention times were obtained for mobile-phase compositions of 20% 
v/v and 21.5% v/v ACN at flow rates of 1.5 ml/min, (6.8 min and 4.6 min respectively) and for 
21.5% v/v ACN at a flow rate of 1 ml/min (7.2 min). The mobile phase selected for further 
studies was therefore 20% v/v ACN in 67 mM phosphate buffer at pH = 7 as this composition 
was easy to produce with suitable reproducibility.  
 
2.4.7.3 pH 
Acidic mobile phases are preferred for the separation of proteins and peptides, as acidified 
media provide for the optimal interaction between peptide residues and stationary phases used 
for analysis. Acidic conditions result in the suppression of silanophilic interactions between the 
analyte of interest and the stationary phase. In addition, adjusting the eluent pH allows for 
optimisation of the chromatographic selectivity of a specific method [131]. The pH of the buffer 
used to produce a mobile phase in addition to the ultimate pH of the mobile phase mixture has 
an effect on retention times and peak shape in RP- HPLC. pH is particularly relevant for the 
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elution of compounds that have ionisable functional groups, such as weak acids and bases and 
amphoteric compounds that have both acidic and basic functional groups. Changing the pH of a 
mobile phase changes the ionisation state of the molecules of a mixture, thereby altering their 
polarity and hence their retention times. The effect of pH on the retention time and the peak 
shape of OT were investigated using a mobile phase composition of 20% v/v ACN in 67 mM 
phosphate buffer. The results of pH effects on retention time are depicted in Figure 2.4. 
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Figure 2.4 The effect of changing pH on the retention time of OT 
 
An increase in buffer pH resulted in an increase in the retention time of OT, which is more than 
likely due to a decrease in the polarity of the OT molecule. The ionisable functional groups of 
OT are ionised at low pH values and as the pH approaches 7.7, the isoelectric point at which OT 
is neutral is reached and the polarity of the molecule is reduced and is therefore better retained 
on a non-polar stationary phase. The pH chosen for further optimisation was pH = 5 as at this 
pH, OT peaks were sharp and representative chromatograms of OT under these conditions is 
shown in Figure 2.5 with a retention time of approximately 5 min, which also shows OT peaks 
at pH values, 6 and 7. 
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Figure 2.5 The effect of pH on the peak shape for pH = 5 (A), pH = 6 (B) and pH = 7 (C), 
 using a mobile phase comprised of 20% v/v ACN in 67 mM phosphate buffer 
 
2.4.7.4 Buffer Molarity 
The molarity of a buffer in a mobile phase also has an effect on peak shape and retention time 
and buffers of 50 mM, 67 mM, 80 mM and 100 mM strength were compared to determine the 
optimal buffer concentration to be used for HPLC analysis. The effect of buffer molarity on 
retention time is depicted in Figure 2.6. 
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Figure 2.6 The effect of buffer molarity on the retention time of OT 
 
As the buffer molarity was increased, there was a corresponding decrease in the retention time 
of OT. This is in agreement with previously reported results obtained following the analysis of 
proteins, OT, and other nonapeptides [178,183] where this is attributed to a corresponding 
increase in the solubility of OT and other peptides as the concentration of buffer salts in the 
mobile phase increases. The increase occurs up to a maximum, after which the solubility of OT 
and other peptides in the mobile phase will decrease. Therefore, the increase in the solubility of 
OT in the mobile phase with increasing buffer concentration resulted in a corresponding 
decrease in the retention time of OT as the peptide fraction/distribution in the mobile phase 
increased. Buffer strength affects the number of ions in a mobile phase that are available to 
interact with the eluent and as the buffer ionic strength is increased, there is increased number of 
ions in the mobile phase and therefore an increased interaction of the mobile phase with OT and 
a resultant decrease in the retention time. 
 
The selection of appropriate buffer strength was based on the number of theoretical plates 
calculated from the chromatograms following the injection of samples onto the chromatographic 
system and eluted with mobile phases containing buffers of different molarities. The number of 
theoretical plates may be useful in evaluating the performance of an analytical column and 
describes the ability of a column to produce sharp narrow peaks with adequate resolution 
between those peaks [183]. The theoretical plate number of a column is affected by the 
diffusivity of a molecule in that column, which increases with an increased plate number [197]. 
A column with a length of 150 mm and a particle size diameter of 5 µm, should have a 
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theoretical plate number between 10000 – 12000 for small molecules [183], although the Center 
for Drug Evaluation and Research recommends that a theoretical plate number of at least 2000 
is acceptable [223]. The theoretical plate number for OT under the specified conditions was 
calculated using Equation 2.4 [183]. 
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54.5
W
tN R              Equation 2.4 
Where, 
N = the number of theoretical plates 
tR = the retention time of the drug 
  W½ = the width of the peak at half the peak height [183] 
 
The results of calculation of the theoretical plate count for the column used in these studies and 
obtained following the analysis of OT are shown in Table 2.3. 
 
Table 2.3 The effect of buffer strength on the theoretical plate number using a Hypersil® column for OT 
Buffer strength (mM) Plate number 
50 3745 
67 4522 
80 4766 
100 2443 
 
It can be seen from the data summarised in Table 2.2 that as the buffer strength increases, there 
is an increase in the theoretical plate number of the column, which was greatest when a buffer of 
an ionic strength of 80 mM was used. Thereafter there is a decrease in the plate number. The 
buffer strength that was chosen for further development and optimisation was 80 mM at which 
OT had a retention time of approximately 4.4 min. 
 
The theoretical plate numbers obtained for the column used for the analysis of OT in these 
studies indicated that the column is operating well below the recommended efficiency level. It 
should however be noted that the separation of bio-molecules on such columns results in smaller 
theoretical plate numbers. This is because of the low diffusivity of the larger molecules in the 
column, which affects the velocity at which the molecules move along the column resulting in a 
smaller plate number count [183,197]. The column was however, found to be useful in 
achieving the intended purpose since the column theoretical plate number affects the resolution 
of compounds and the resolution obtained for this separation when an internal standard was 
used (§ 2.4.8) was found to be acceptable. 
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2.4.8 Selection of an Internal Standard 
 
Calibration in chromatographic test methods can be achieved by use of an external or internal 
standard. In external standard methods, a standard is analysed on a separate chromatogram from 
a sample and quantitation is based on comparison of the peak height/area of a sample to that of a 
reference standard. This method may be more appropriate in analytical procedures with 
single/narrow concentration ranges and simple sample preparation procedures [183,223]. 
 
Alternatively, an internal standard may be used in a calibration method and in such cases, a 
different compound with similar structural and physicochemical properties to the analyte is 
added in known concentrations to the sample to be analysed. The compound must be well 
resolved from the peak(s) of interest and the ratio of response i.e. either the peak height or peak 
area, of the analyte of interest to that of the internal standard is used for the calibration plot and 
all subsequent quantitative measurements [183,223]. 
 
The use of an internal standard is particularly valuable in quantitative analyses for 
pharmaceutical [224-226] and pharmacokinetic studies [227-229] and especially for the analysis 
of samples that require significant pre-treatment that may undergo significant loss during the 
preparation procedure, such as the case when analysing biological samples. Furthermore, where 
the expected concentration ranges are wide and/or low concentrations of the analyte of interest 
are likely to occur, the use of an internal standard is recommended. Where variability of 
instrument responses is prevalent, the use of an internal standard is also recommended to 
enhance the precision of such methods. Instrumental variation in HPLC analyses can be a 
consequence of flow rate variability that in turn results in variability in the detector response to 
analytes of the same concentration. The use of an internal standard compensates for the 
variability in a method, thereby increasing the accuracy and precision of an analytical method 
[230]. The relative responses of two compounds, viz., a drug, and internal standard will remain 
constant despite differences in instrumental operation and use of an internal standard ensures 
that the response that is measured is constant irrespective of equipment operation [183,223]. 
 
In addition, to achieve adequate resolution between an analyte of interest and an internal 
standard, the standard must have similar retention characteristics and times to the compound of 
interest. An internal standard should also be absent from the original sample matrix, available as 
a high purity sample commercially, chemically stable and no reactivity with the analyte of 
interest, the mobile and/or stationary phases used for the separation [183]. Furthermore, an 
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internal standard must also exhibit similar ultraviolet absorbance patterns to the compound of 
interest but need not necessarily be chemically similar to the analyte [183]. 
 
The selection of an internal standard was based on the data published in the available literature. 
Although most reported analyses of OT did not include the use of an internal standard, Ohta et 
al. [123] used ethyl parahydroxybenzoate as an internal standard for the quantitative analysis of 
OT in pharmaceutical preparations. Methyl hydroxybenzoate (MHB) and propyl 
hydroxybenzoate (PHB) were tested as potential internal standards using analytical conditions 
of 20% v/v ACN in 80 mM phosphate buffer, pH = 5 and the retention times of the MHB and 
PHB were approximately 7 min and more than 20 min, respectively. The internal standard that 
was therefore deemed appropriate and selected for use for the analysis of OT was MHB. The 
MHB peak was well resolved from that of OT, which eluted at 4.4 min under the specified 
conditions and its use resulted in a total analytical run time of < 10 min for each sample. 
 
The response of the internal standard should be approximately half that of the maximum 
expected concentration of the analyte of interest. Therefore, the concentration MHB that was 
used was approximately 7.25 µg/ml and was quantitatively added to each of the samples to be 
analysed prior to the analysis. 
 
2.4.9 Chromatographic Conditions Selected 
 
The optimal chromatographic conditions that were established for the quantitative determination 
of OT are summarised in Table 2.4 and a typical chromatogram of the optimised conditions is 
shown in Figure 2.7.  
 
Table 2.4 Optmised chromatographic conditions for quantitation of OT in pharmaceutical dosage forms 
Column  Phenomenex® Hypersil C18, 5 µm, 150 X 4.6 mm  
Mobile phase  20% v/v ACN in 80 mM phosphate buffer at pH = 5 
Detection wavelength  220 nm  
Detection sensitivity  0.005 AUFS  
Injection volume  20 µl  
Chart speed  5 mm/min  
Temperature  22 °C 
OT retention time  4.4 min  
MHB retention time  7 min  
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Figure 2.7 Typical chromatogram of the separation of OT (4.4 min) and MHB (7.0 min) 
 52 
2.5 METHOD VALIDATION 
 
2.5.1 Introduction 
 
The USP [10] states that the validation of an analytical method is a process that establishes the 
performance characteristics of a developed analytical method and ensures that it meets its 
intended purpose and analytical application. Method validation includes an assessment of the 
adequacy of the analytical procedure by means of statistical testing, including linear regression 
analysis, and relative standard deviation determination in order to demonstrate the validity of 
the method [231]. During validation, an analytical method is tested for reliability, accuracy, and 
preciseness of the intended purpose of that method [223]. The International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) [232] recognises accuracy, precision, repeatability, intermediate precision, specificity, 
limits of quantitation and detection, linearity, and the range of a method as important validation 
parameters. The guidance for the methodology and statistical tests and associated limits for the 
validation procedure is provided in the ICH Q2B document [233]. 
 
2.5.2 Linearity  
 
The ICH [232] defines the linearity of an analytical procedure as its ability, within a given range 
to obtain test results that are directly proportional to the concentration or amount of an analyte 
in a sample. The linearity of response to the concentration is in agreement with the Beer-
Lambert Law [234] where it was established that the absorbance of a solute in dilute solutions is 
directly proportional to the concentration of that solute or analyte in that solution [183,223]. 
 
To demonstrate linearity across a given concentration range, dilution of a standard stock 
solution and/or separate weighings of synthetic mixtures of a drug product and its components 
can be used. A minimum of five concentrations is required to demonstrate/establish linearity 
[233]. Linearity was assessed by analysis of seven (7) concentrations in the range of 0 – 12 
IU/ml (n = 5) of OT. Calibration solutions of the required concentrations were prepared, 
including a solution that contained 0 IU/ml of OT with the internal standard as previously 
described in § 2.3.2. 
 
To evaluate linearity, the ICH [233] recommends that a visual inspection of a plot of response 
signal as a function of analyte concentration or content initially, and if there is a linear 
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relationship then statistical testing should be conducted. Testing can be achieved by means of 
calculation of a regression line by a least squares linear regression method to determine the 
degree/extent of linearity of the analytical method. The correlation coefficient, y-intercept, slope 
of the regression line, and residual sum of squares and a plot of the data should be included. In 
addition, an analysis of the deviation of the actual data points from the regression line may also 
be helpful for evaluating linearity and the precision of a method. Figure 2.8 depicts a typical 
calibration curve for the analytical procedure developed and validated for analysis of OT. 
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Figure 2.8 Typical calibration curve for OT in the concentration range 0 – 12 IU/ml 
y = 0.1667x + 0.0008, r2 = 0.9995 
 
The equation for the best-fit linear regression line was y = 0.1667x + 0.0008 with a coefficient 
of determination of 0.9995 indicating that the calibration curve is linear over the calibration 
range studied. Under most circumstances a regression coefficient of 0.999 [183,223,235] is 
considered sufficient to deem the relationship between two variables linear. Furthermore, the y-
intercept should be < 2% of the response or near zero [235] and the intercept obtained (0.0008) 
satisfies this criterion. 
 
The use of the correlation coefficient as a means of determining the degree of linearity of a 
curve may have shortcomings, in particular if the responses are measured over one order of 
magnitude or deviate from linearity at the extremes of the calibration range [235]. In this case, 
the parameters of a linear regression equation may be affected by skewed data at the low and/or 
high concentration samples. A plot of the response factor versus concentration in order to 
ascertain the impact these data may have on the linearity of a method can be plotted and 
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evaluated. The response factor is determined by the detector response or peak height ratio 
divided by the concentration of the standard producing that response. If the response obtained at 
each concentration is equal or is similar then the points should form a straight line with a slope 
of zero [183,235]. The response factor graph obtained for these studies is depicted in Figure 2.9. 
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Figure 2.9 The response factor curve for OT in the concentration range 0 – 12 IU/ml, 
 showing the upper and lower limits of the standard deviation 
 
The average response factor was determined to be 0.1557 + 0.0238 and the response obtained 
for most concentrations are all within one (1) standard deviation. The equation of the line is y = 
0.0029x + 0.1429. The slope of the response factor slope has a near zero slope and shows that 
the relationship can indeed, be considered linear. 
 
2.5.3 Precision  
 
The precision of an analytical method is a measure of the degree of scatter or agreement among 
individual data values, when the method is applied to multiple samples. In addition, precision is 
a means of evaluation of how close the data values are to each other for a number of 
measurements taken using the same analytical conditions [10,223,232]. The ICH guidelines 
define precision on three levels, viz., repeatability, intermediate precision, and reproducibility. 
The ICH [233] recommends that the standard deviation, relative standard deviation or 
coefficient of variation and a confidence interval be reported for each type of precision that is 
investigated. 
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2.5.3.1 Intra-assay Precision (Repeatability) 
Repeatability refers to the precision of an analytical method used under the same operating 
conditions by the same analyst and measured over a short period of time [10,145,223,232,235]. 
The percent relative standard deviation (% RSD) of a group of samples is used to assess the 
precision of a method and the permitted % RSD depends on the intended use of the method and 
the matrix from which the active pharmaceutical ingredient (API) of interest is isolated. For an 
assay method, the limit of the % RSD would be 2%, whereas that for determining impurities at 
trace levels is 10% [235]. Repeatability of the method was determined by interpolation of data 
from the calibration curve at three levels covering the specified range viz., 3 IU/ml, 7 IU/ml and 
11 IU/ml. The samples were analysed with five samples (n = 5) at each concentration and the 
results are summarised in Table 2.5. In addition the precision of the calibration curve data (n = 
5) shown in Figure 2.8 are summarised in Table 2.6. 
 
Table 2.5 Intra-assay precision for OT in the concentration range 0 – 12 IU/ml 
Concentration (IU/ml) Peak height ratio 
(OT/MHB), (n = 5) 
Standard 
deviation 
% RSD 
3.0 0.492 0.00210 0.43 
7.0 1.165 0.00305 0.26 
11.0 1.788 0.00376 0.21 
 
Table 2.6 Intra-assay precision for the calibration curve of OT (0 – 12 IU/ml) shown in Figure 2.8 
Concentration 
(IU/ml) 
Peak height ratio 
(OT/MHB), (n = 5) 
Standard 
deviation 
% RSD 
0.0 0.000 0.00000 0.00 
1.0 0.172 0.00280 1.63 
2.0 0.345 0.00300 0.87 
4.0 0.715 0.00170 0.24 
6.0 1.021 0.00256 0.25 
8.0 1.335 0.00686 0.51 
10.0 1.667 0.00503 0.30 
12.0 1.974 0.00404 0.20 
 
The results shown for repeatability of the assay reveal % RSD values of less than 2% for all 
concentrations of OT studied thereby indicating that the method is repeatable. 
 
2.5.3.2 Inter-day Precision (Intermediate Precision) 
The intermediate precision of an analytical method evaluates the reliability of the method in a 
different environment other than that used during development of the method to ensure that the 
method will provide the same results once method development has been completed [223]. The 
ICH [232] defines intermediate precision as the long-term variability of a measurement process, 
expressing within laboratory variation, analysis on different days, different analysts, and/or 
equipment. The extent to which inter-day precision is determined is dependant on the 
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circumstances in which the analytical method is to be used and therefore the expected variation 
[233]. Intermediate precision can be determined by comparing the results of an analytical 
procedure run over a period of days to weeks. Intermediate precision was determined for three 
(3) concentrations, injected in triplicate (n = 3) on three (3) consecutive days. The results for 
intermediate precision studies are summarised in Table 2.7 and all % RSD values were less than 
2% indicating that the method has day-to-day precision. 
 
Table 2.7 Inter-day precision for OT in the concentration range 0 – 12 IU/ml 
Day 1 Day 2 Day 3 Concentration 
(IU/ml) Peak 
height 
ratio 
% RSD  
(n = 3) 
Peak 
height 
ratio 
% RSD  
(n = 3) 
Peak 
height 
ratio 
% RSD  
(n = 3) 
3.0 0.49 0.39 0.50 0.26 0.49 1.45 
7.0 1.16 0.25 1.18 0.24 1.16 0.24 
11.0 1.78 0.44 1.83 0.40 1.79 0.10 
 
2.5.3.3 Reproducibility 
The reproducibility of an analytical method is a measurement of the precision of a method that 
is used in more than one laboratory, i.e. precision between laboratories. The assessment of 
reproducibility serves to show that a method that has been developed can be transferred between 
laboratories. Inter-laboratory trials must be considered in the standardisation of a procedure 
such as those intended for inclusion in an official compendial publication [233]. Reproducibility 
may be determined by analysing samples from homogenous lots in different laboratories using 
different analysts. Reproducibility of this method was not established as it was to be used in one 
laboratory by the same analyst for the duration of these studies. 
 
2.5.4 Accuracy 
 
The accuracy of an analytical method is defined as the closeness of a measured value to the true 
value for that sample [10,183,223,232,235]. There are several ways of determining the accuracy 
of an analytical method including comparison to a reference standard, recovery of spiked 
analyte, and the standard addition of an analyte to a sample [233]. For drug products, it is 
recommended that accuracy be performed at 80, 100, and 120% of the label claim [223]. 
Accuracy should be assessed using a minimum of nine (9) determinations over a minimum of 
three (3) concentration levels covering the specified range, for example, three (3) concentrations 
analysed in triplicate (n = 3) [233]. 
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The accuracy of a method may be determined by recovery which is expressed as the 
amount/weight of a compound of interest reported as a percentage of the theoretical amount 
present in a medium and where full recovery of the analytes is desirable [223,233]. Percent bias 
(% Bias) can also be used to determine the extent of deviation of a result for a sample from the 
true value for that sample. The closer the recovery is to 100% and the lower the % Bias, the 
more accurate an analytical method can be considered and in general, a % Bias of less than 5% 
is desirable. 
 
Accuracy was determined at three (3) concentrations and each solution was analysed in 
replicates of five (n = 5) and the % Bias was calculated by interpolation of the data from a 
calibration curve. The resultant concentration was compared to the theoretical concentration for 
each of the samples and it was observed that the resultant % Bias for this method was low, and 
the results are summarised in Table 2.8. 
 
Table 2.8 Accuracy for OT in concentration range 0 – 12 IU/ml 
Concentration of OT 
(IU/ml) 
Determined concentration 
(IU/ml) 
% RSD  % Bias 
3.0 2.89 0.43 3.83 
7.0 6.96 0.26 0.54 
11.0 10.80 0.21 1.81 
 
2.5.5 Specificity 
 
Specificity is defined as the ability of an analytical procedure to accurately and quantitatively 
measure the concentration of an analyte in the presence of all sample materials, including 
extraneous components from which it must be well resolved [10,183,223,232]. The 
determination of the specificity of an analytical method is considered one of the most important 
steps in the development and validation of that method. 
 
The chromatographic procedure that is developed must resolve the peak of the compound(s) of 
interest from any possible excipients or contaminants that may be present in a dosage form, 
during analysis of that dosage form. Commercially available OT preparations include chlorbutol 
(CB) as a preservative at a concentration of 5 mg/ml [31]. A solution containing OT (10 IU/ml) 
and the preservative was prepared and on analysis no interference was observed between the OT 
and CB peaks, which was eluted at 4.4 min and 15.2 min respectively was observed. A typical 
chromatogram showing the separation of OT and CB is shown in Figure 2.10. 
 
 58 
 
OT 
CB
0 2 4 6 8 10 12 14 16 18 20
In
jec
tio
n
Time (min)
 
Figure 2.10 Typical chromatogram showing OT (4.4 min) and CB (15.2 min) 
 
2.5.6 Stress studies 
 
A stability-indicating assay can be defined as a validated quantitative analytical procedure that 
is able to detect changes in the pertinent properties of the drug substance and/or drug product 
[231]. A stability-indicating assay must also be capable of accurately measuring the specific 
analyte without interference from degradation products, process impurities, excipients, or other 
potential impurities. It is recommended that assay procedures used in stability studies should be 
stability-indicating, unless otherwise scientifically justified [231]. 
 
To demonstrate specificity in stability-indicating assays the quantitation of an analyte is 
attempted in the presence of degradation information obtained from stress studies in which the 
analyte(s) of interested are exposed to acid and base, heat, light and oxidation conditions to 
assess the impact of these conditions on the hydrolytic, thermal, photolytic and oxidative 
properties of the molecule. It is important that impurities and degradation products from the 
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analyte do not interfere with the quantitation of the active ingredient in an analytical method 
[231]. Specificity is vitally important in the development of stability-indicating assays and stress 
studies may be used to demonstrate of specificity of a developed method. Stress studies entailed 
exposing OT to acid, alkali, hydrogen peroxide, light, and heat conditions [10,183,223,233]. OT 
solutions (10 IU/ml) were prepared as described in § 2.3.2 and by Chaibva and Walker [119] 
and exposed to acidic, alkali, oxidative, light and heat conditions. 
 
2.5.6.1 Acidic Conditions 
Two millilitres (2 ml) of 0.1 M hydrochloric acid was added to eight millilitres (8 ml) of 
a 10 IU/ml solution of OT to produce a solution of OT that was 8 IU/ml. The solution 
was allowed to stand for one hour at 22 ºC [119]. The resultant chromatogram generated 
following injection of a sample that was allowed to stand in acidic conditions for one 
hour is shown in Figure 2.11. 
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Figure 2.11 Typical chromatogram showing degradation of OT  
after exposure to 0.1 M hydrochloric acid for 1 hour 
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OT underwent degradation, under acidic conditions, and the resultant degradation product peaks 
were well resolved from that of the OT peak. An assay of the sample using the validated HPLC 
method, to determine the extent of OT degradation revealed that 10.58 + 0.51% of OT had 
degraded under these conditions. 
 
2.5.6.2 Alkali Conditions 
Two millilitres (2 ml) of a 0.1 M sodium hydroxide solution was added to eight millilitres (8 
ml) of a 10 IU/ml solution of OT to produce a solution of 8 IU/ml. The solution was allowed to 
stand for one (1) hour at 22 ºC [119]. The resultant chromatogram generated following injection 
of a sample that was allowed to stand for 1 hour is shown in Figure 2.12. It is clearly evident 
that OT is highly unstable in alkali conditions [8] and that after exposure as described, almost 
all of the OT in solution had degraded and only a small peak corresponding to OT was observed 
on the chromatogram. The extent of degradation of OT under these conditions was determined 
and showed that 70.33 + 0.25% of OT had degraded. 
 
0 2 4 6 8 10 12 14 16 18 20
Time (min)
OT
In
jec
tio
n
 
Figure 2.12 Typical chromatogram showing degradation of OT  
after exposure to 0.1 M sodium hydroxide for 1 hour 
 
2.5.6.3 Heat 
Twenty millilitres (20 ml) of a 10 IU/ml solution of OT was heated and maintained at 50 °C for 
10 min [119]. The solution was allowed to cool to room temperature prior to injection onto the 
RP-HPLC system. The resultant chromatogram generated following injection of a sample 
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heated at 50 °C for 10 min is shown in Figure 2.13. The extent of degradation under these 
conditions was determined and it was observed that 3.55 + 1.07% of OT had undergone 
degradation. 
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Figure 2.13 Typical chromatogram showing degradation of OT  
after exposure to 50 °C for 10 min 
 
2.5.6.4 Light 
A 10 ml OT solution at a concentration of 10 IU/ml in a clear volumetric flask was exposed to 
natural sunlight for 8 hours, by placing the solution on a windowsill in the laboratory for the 
duration of the experiment [119]. No degradation was observed as a single OT peak was 
obtained on the chromatogram as shown in Figure 2.14, indicating that OT is stable in light after 
exposure for a period of 8 hours. 
 
2.5.6.5 Oxidation 
Two millilitres (2 ml) of a 3% hydrogen peroxide solution was added to eight millilitres (8 ml) 
of a 10 IU/ml solution of OT to produce a solution of 8 IU/ml. The solution was allowed to 
stand for 2 hours at 22 ºC in a dark cupboard [119]. The resultant chromatogram generated 
following injection of a sample that was allowed to stand for two hours under the specified 
conditions is shown in Figure 2.15. An assay of the resultant solution showed that 21.67 + 
0.49% of OT had degraded under these conditions. 
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Figure 2.14 Typical chromatogram showing degradation of OT 
after exposure light for 8 hours 
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Figure 2.15 Typical chromatogram showing degradation of OT  
after exposure to 3% hydrogen peroxide for 2 hours 
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2.5.6.6 Conclusion 
The specificity of the assay was clearly demonstrated by the ability of the analytical test to 
discriminate between OT peaks and those of degradation products that resulted after exposure of 
OT to stress conditions. Stability-indicating assays are essential for quality control purposes and 
give an indication of process or storage conditions that are likely to impact on the amount of 
drug that is present in a dosage form. 
 
The method developed for the analysis of OT in dosage forms is able to detect changes in the 
quantity of drug present in solution. The limitation of the stability-indicating method is however 
that the presence of degradation products of different retention times, limits the use of the 
internal standard (MHB) in the quantitation of the residual amount of OT. This is because the 
MHB peak would not be not resolved from thermal and oxidative degradation products peaks 
that are shown in Figures 2.13 and 2.15, respectively and that elute at approximately 7 min. 
Despite this limitation, the ability of the method to resolve OT and degradation products makes 
it invaluable for quality control purposes in pharmaceutical dosage forms. 
 
2.5.7 Limits of Quantitation (LOQ) and Detection (LOD) 
 
2.5.7.1 Introduction 
The limit of quantitation (LOQ) of an individual analytical procedure is defined as the lowest 
amount of analyte in a sample that can be quantitatively determined with suitable precision and 
accuracy [223,232]. The limit of detection (LOD) is defined as the lowest amount of analyte in a 
sample that can be detected but not necessarily quantitated as an exact value, under the defined 
experimental conditions [223,232]. UV detectors may result in diminished precision at low 
concentrations of an analyte because of a potential and/or gradual loss of sensitivity of detector 
lamps as they age or due to noise level variation of detector because of different manufacturers 
or even model number of that detector [223]. 
 
The ICH [233] recommends three different techniques that can be used to determine the LOQ 
and LOD of a given method. The LOQ and LOD can be determined based on visual evaluation 
of analytical data. The quantitation and detection limits can determined by the analysis of 
samples with known concentrations of analyte and by establishing the minimum level at which 
the analyte can reliably be quantified with acceptable accuracy and precision or detected, 
respectively. 
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The signal-to-noise ratio can be used to determine the LOQ and LOD of a method [10,233]. 
However, this approach can only be applied to analytical procedures that exhibit substantial 
baseline noise. To determine the signal-to-noise ratio, measured signals from samples with 
known low concentrations of analyte and of blank samples are compared establishing the 
minimum concentration that is required to give a signal-to-noise ratio of 10:1 for the LOQ and 
between 3 and 2:1 for the LOD. Even though this is recommended by the USP [10], this 
approach is not considered very practical, as the noise level on the detector may be different 
when the samples are assayed on different detectors [223]. The Center for Drug Evaluation and 
Research (CDER) [223] therefore recommends the use of an additional standard in the test 
method at the LOQ and a repeatability assessment of samples at the LOQ level. 
 
Another method that can also be used for determination of the LOQ and LOD is based on the 
standard deviation of the response and the slope of the line [233]. These relationships are shown 
in Equation 2.5 and Equation 2.6 respectively. 
 
S
LOQ σ10=           Equation 2.5 
 
S
LOD σ3.3=            Equation 2.6 
Where, 
σ = standard deviation of the response 
S = slope of the calibration curve 
 
The calibration curve may be used to estimate the requisite slope and the standard deviation 
may be determined by analysing the standard deviation of several blank samples or by the 
construction of a calibration curve in the range of the LOQ or LOD, as appropriate. The residual 
standard deviation of the y-intercept may be used as the standard deviation in these equations 
[233]. 
 
The ICH [233] recommends that if the LOQ or LOD are determined from visual evaluation of 
chromatograms or are based on the signal-to-noise ratio method then the presentation of the 
relevant chromatograms is required if the LOQ and LOD are obtained by calculation or 
extrapolation. This estimate may subsequently be validated by the independent analysis of a 
suitable number of samples known to be near or prepared at the detection limit. 
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2.5.7.2 LOQ 
The analytical method did not have any baseline noise and therefore the use of methods 
incorporating the signal to noise ratio were not deemed appropriate. The LOQ was determined 
using Equation 2.5 and a calibration curve in this region gave an equation, y = 0.1184x + 
0.0008, R2 = 0.9942. The LOQ was determined to be approximately 0.3 IU/ml with an average 
peak height ratio of 0.04 and a % RSD = 5.71 (n = 6). 
 
2.5.7.3 LOD 
As noted in § 2.5.7.2, the absence of baseline noise hindered the use of the signal-noise-ratio. 
LOD was determined using Equation 2.6 and the linearity curve described in § 2.5.7.2 and this 
was found to be approximately 0.1 IU/ml. 
 
2.5.8 Range  
 
The range of an analytical procedure is defined as the interval between the upper and lower 
concentration/amount of an analyte in the samples being analysed and include the upper and 
lower concentrations for which it has been demonstrated that the analytical procedure has a 
suitable level of precision, accuracy and linearity [232]. The range of a method depends on the 
purpose of the analytical procedure that has been developed. For assay procedures, the range 
would fall between 80 – 120% of the target concentration, but for combination analytical 
methods for assay and determination of impurities the range would be the limit of quantitation 
to 20% above the target concentration [223,233]. The range is derived from linearity and the 
LOQ studies and the range of this analytical method was found to be 0.3 – 12 IU/ml. 
 
2.5.9 Stability of the Analyte in the Mobile Phase 
 
During validation, additional data deemed necessary include the stability of all analytical 
sample preparations that will be used for the duration of the analysis [231]. The test method 
must be used to analyse sample stability, especially where samples are analysed overnight or 
following long storage periods after collection or preparation. This is especially a concern for 
drugs that undergo hydrolysis, photolysis, or that are adsorbed onto glassware [223]. Data to 
support sample stability in solution under normal operating laboratory conditions for the test 
procedure are therefore required. 
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The stability of the analyte in the mobile phase was investigated. A solution of concentration of 
10 IU/ml of OT was prepared as described in § 2.3.2 and the stability in the mobile phase was 
tested over a 3-day period, after storage of the samples in a refrigerator at 5 °C. No additional 
degradation products were observed during chromatographic analysis and the OT content over 
three consecutive days was determined to be 10.012 + 0.016 IU/ml with 0.16 % RSD. It was 
therefore established that OT was stable in the mobile phase, and the method developed for the 
quantitative analysis was suitable for analytical procedures that run over at least three days. 
 
2.6 ASSAY OF SYNTOCINON® 
 
An assay of the commercially available form of OT in South Africa was undertaken using the 
analytical method that had been developed and Syntocinon® 10 IU/ml was purchased from a 
local pharmacy. The analysis was performed in triplicate using three (3) individual ampoules 
and a 1.0 ml aliquot of the parenteral formulation was diluted to 5.0 ml with HPLC grade water 
in an A-grade volumetric flask and then subjected to analysis using the validated procedure 
described in this Chapter. A typical chromatogram obtained during analysis of the commercially 
available product is shown in Figure 2.16 and the results of these analyses are summarised in 
Table 2.9.  
 
Table 2.9 Result of the analysis of an assay of commercially available Syntocinon® 
Sample 
number 
Peak height ratio  
(OT/MHB) 
% RSD 
 (n=3) 
Determined  
concentration (IU/ml) 
1 0.35 1.75 10.08 
2 0.35 0.76 10.05 
3 0.33 0.62 9.55 
 
 67 
0 2 4 6 8 10 12 14 16 18 20
Time (min)
unknown 1
MHB
CB
OT
In
jec
tio
n
 
Figure 2.16 Typical chromatogram obtained following the assay of Syntocinon®  
showing an unknown peak (2.2 min), OT (4.4 min), MHB (7.0 min), and CB (15.2 min) 
 
2.7 CONCLUSION 
 
The method that was developed is linear, accurate, precise, sensitive, and selective and is 
appropriate for the analysis of the current pharmaceutical dosage form of OT that is available on 
the market. 
 
2.8 OPTIMISATION OF THE ANALYTICAL METHOD FOR IN VITRO USE 
 
The analytical method that was developed and validated was further optimised for use in the 
analysis of in vitro release of OT from hydrogel systems that were developed in subsequent 
studies (See Chapter 5, vide infra). The sensitivity of the method was increased in order to 
ensure that the lower concentrations expected during assessment of in vitro release could be 
quantitated. HPLC system B (§ 2.3.6) was used for the optimisation of the previously validated 
method. The method was optimised in terms of wavelength of detection and volume of injection 
by monitoring the change of response of OT. The method was thereafter revalidated to ensure 
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that the method would meet the necessary criteria to ensure that reliable and valid data were 
obtained. 
 
2.8.1 Wavelength 
 
A sample solution of OT of concentration of 0.3 IU/ml was injected under the same conditions 
that had been established using HPLC system A (§ 2.4.9) except that the wavelength was varied 
within the range of 200 – 230 nm. Samples were injected in triplicate (n = 3) and a plot of the 
effects of wavelength change on response are depicted in Figure 2.17.  
 
As the wavelength was increased, there was a corresponding decrease in the peak height 
response of OT. The greatest response was observed at a wavelength of 200 nm. However, since 
there is a decrease in the selectivity and excessive baseline noise when using this wavelength, 
210 nm was selected as the optimal wavelength for the detection of OT. This is because using a 
wavelength 210 nm provides an adequate analyte response and limited baseline noise, making it 
a suitable wavelength for detection of the peptide. 
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Figure 2.17 The effect of changing wavelength on the peak height of OT 
 
2.8.2 Volume of Injection  
 
Two volumes of injection were compared, viz., 20 µL and 50 µL and testing was performed in 
triplicate (n = 3). The results of these studies are depicted in Figure 2.18. 
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Figure 2.18 The effect of changing injection volume on the peak height of OT 
 
As the volume of injection is increased, there is a corresponding increase in the amount of 
analyte that passes through the column to the detector and an increase in detector response 
[122]. This is important as it permits very small concentrations of analyte to be detected because 
of the increase in response and higher peaks that are observed. However, when the volume of 
injection is increased excessively column overload may occur and this phenomenon must be 
evaluated prior to selecting a suitable volume for injection. Column overloading was not a 
major concern for this particular application as the maximum possible concentration that would 
be expected to be observed during in vitro testing was calculated to be no more than 0.50 IU/ml 
and therefore the maximum possible column load following an injection of 50 µl would be 
0.025 IU.  
 
No internal standard was used for the optimised analytical method for use in the assessment of 
OT release from Pluronic® gels (See Chapter 5, vide infra) because of the potential for the 
hydroxybenzoate preservatives to be solubilised by micelles [236]. The formation of micelles by 
Pluronic® F127 (PF-127) in aqueous solution (§ 4.5.4) may cause an interaction with the 
internal standard and result in interference with in vitro release studies of OT from PF-127 
dosage forms.   
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2.8.3 Optimised HPLC Conditions 
 
The optimised conditions for the separation of OT for in vitro release testing are summarised in 
Table 2.10 and Figure 2.19 summarise the optimised conditions for OT analysis and show a 
typical chromatogram of OT that was obtained using the optimised method, respectively.  
 
Table 2.10 Optimised conditions for in vitro analysis of OT release from hydrogel dosage forms 
Column  Phenomenex® Hypersil C18, 5 µm, 150 X 4.6 mm  
Mobile phase  20% v/v ACN in 80 mM phosphate buffer at pH = 5 
Detection wavelength  210 nm  
Detection sensitivity  0.005 AUFS  
Injection volume  50 µl  
Chart speed  2.5 mm/min  
Temperature  22 °C 
OT retention time  4.38 min  
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Figure 2.19 Typical chromatogram of OT under the optimised  
conditions for assessing the in vitro release of OT 
Retention time (min) 
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2.9 REVALIDATION OF THE ANALYTICAL METHOD 
 
The revalidation of analytical procedures is necessary if process variables, that may affect the 
results obtained using that method, are introduced. In the pharmaceutical industry, such 
variables may include changes in the source of raw material or drug substance, manufacture of 
the raw material by a different synthetic route or a change in composition of the drug product. 
Revalidation should be performed to ensure that the analytical procedure maintains its 
characteristics and specificity and to demonstrate that the analytical procedure continues to 
identify the strength, quality, purity, and potency of the drug substance and/or drug product. The 
degree of revalidation of an analytical method depends on the nature of the change(s) made to 
the method [231]. A change in the range, wavelength of detection and the volume of injection 
and HPLC system used and the absence of internal standard in these studies required 
revalidation of the analytical procedure.  
 
2.9.1 Linearity 
 
The linearity of the method was tested within the concentration range that was expected to occur 
during in vitro dissolution testing of OT in hydrophilic hydrogel systems that were to be 
developed. The calibration standards were prepared as described previously in § 2.3.2 and 
linearity was assessed in the same manner as described in § 2.5.2. The calibration curve shown 
in Figure 2.20 was produced by injecting OT samples in the range 0 – 0.50 IU/ml (n = 5).  
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Figure 2.20 Calibration curve for OT in the concentration range 0 – 0.50 IU/ml 
y = 5044x + 13.52, r2 = 0.9993 
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The calibration curve following revalidation was y = 5044x + 13.53, with a linear regression 
coefficient of 0.9993, indicating that the method is linear.  
 
2.9.2 Precision  
Intra-assay and inter-day precision of the analytical method were tested during revalidation as 
previously described in § 2.5.3. 
 
2.9.2.1 Intra-assay Precision (Repeatability) 
The repeatability of the methods was determined as described previously in § 2.5.3.1 and this 
was determined at three different levels, viz., 0.15 IU/ml, 0.25 IU/ml and 0.35 IU/ml and 
analysis was performed in triplicate (n = 3). The results of these studies are shown in Table 
2.11. Intra-assay Precision (Repeatability)  
 
Table 2.11 Intra-assay precision for OT in  the concentration range 0 – 0.50 IU/ml  
Concentration of OT 
(IU/ml) 
OT Peak height  Standard deviation  % RSD  
0.15 798.4 6.3008 0.79 
0.25 1327.8 8.5264 0.64 
0.35 1893.2 12.3369 0.65 
 
Table 2.12 summarises the precision of the calibration curve data depicted in Figure 2.20. 
 
Table 2.12 Intra-assay precision data for the calibration curve (0 – 0.50 IU/ml) shown in Figure 2.20 
Concentration of OT 
(IU/ml) 
OT Peak height  Standard deviation  % RSD  
0.00 0.0 0.0000 0.00 
0.05 291.6 7.7974 2.67 
0.10 528.6 17.6153 3.33 
0.20 1059.4 7.9875 0.75 
0.30 1610.6 17.9527 1.11 
0.40 2083.4 25.7740 1.23 
0.50 2666.8 12.0291 0.45 
 
The low % RSD values of < 5% that were obtained in precision studies indicate the repeatability 
of measurements made using this analytical method. It was however noted that as the 
concentration decreased, there was a decrease in the precision of the method, indicated by 
higher % RSD values. The resultant % RSD values were slightly higher than those that were 
obtained during the validation of the analytical method for dosage forms described in § 2.5.3.1 
because of the absence of an internal standard in the analysis. In addition, lower concentrations 
of OT were used in the optimised method compared to the analytical method for dosage forms, 
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viz., 0 – 0.50 IU/ml compared to 0 – 12.0 IU/ml, respectively and therefore the precision 
obtained was higher.  
 
2.9.2.2 Inter-day Precision (Intermediate Precision) 
Intermediate precision was assessed as previously described in § 2.5.3.2, and was determined at 
three (3) levels, viz., 0.15 IU/ml, 0.25 IU/ml and 0.35 IU/ml, in triplicate (n = 3) for three (3) 
days. The results of inter-day studies are summarised in Table 2.13. The method was found to 
be reproducible over several days as indicated by the low % RSD values that were obtained.  
 
Table 2.13 Inter-day precision for OT in the concentration range 0 – 0.50 IU/ml 
Day1  Day 2  Day 3  Concentration 
OT (IU/ml) Peak 
height  
% RSD  
(n = 3) 
Peak 
height  
% RSD  
(n = 3) 
Peak 
height  
% RSD  
(n = 3) 
0.15 798.4 0.79 805.8 0.89 788.4 1.09 
0.25 1327.8 0.64 1352.5 0.87 1308.8 0.98 
0.35 1893.2 0.65 1907.4 0.52 1882.5 0.53 
 
2.9.3 Accuracy  
The accuracy of the method was determined as described previously in § 2,5.4 and this was 
determined at three (3) different levels, viz., 0.15 IU/ml, 0.25 IU/ml and 0.35 IU/ml. Each 
sample was analyzed in triplicate (n = 3) and the results are summarised in Table 2.14, which 
shows a % Bias of less than 5% for the concentrations studied. 
 
Table 2.14 Accuracy  for OT in the concentration range 0 – 0.50 UI/ml 
Concentration of OT (IU/ml) Determined concentration (IU/ml) % RSD  % Bias 
0.15 0.1521 0.79 3.11 
0.25 0.2614 0.64 0.15 
0.35 0.3781 0.64 3.59 
 
2.9.4 Limits of Quantitation and Detection 
Different methods can be used to determine the LOQ and LOD as previously described in § 
2.5.7 and in this case, the LOQ and LOD were determined using the signal to noise ratio 
method. The LOQ which gave a signal to noise ratio of 10:1 was determined to be 0.03 IU/ml 
with a % RSD = 6.01 (n = 6). The concentration that gave a signal to noise ratio of 3:1 was 
found to be 0.01 IU/ml with a % RSD = 10.89 (n = 6) and this was considered to be the LOD.  
 
2.9.5 Range  
The ICH [233] recommends that the range for dissolution testing must be ±20 percent over the 
specified range. The method was found to linear in the concentration range 0.03 – 0.5 IU/ml.  
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2.10 CONCLUSION 
 
The successful application of analytical methods in the pharmaceutical sciences for different 
purposes including the quantitation of drugs in dosage forms for quality control purposes, 
determination of drug plasma for pharmacokinetic studies or generating in vitro release profiles, 
primarily depend on the use of an optimised and validated analytical method. The success of a 
separation in RP-HPLC is important in ensuring that the method is optimised for the detection 
of all relevant compounds. 
 
Different analytical columns have different properties because of the variation in stationary 
phases and the careful selection of a column for an analytical procedure is important to ensure 
that the interaction between an analyte and a stationary phase is optimal. The use of silica 
columns with a C18 support backbone for the separation of molecules is well documented in the 
literature. For peptide separations, the hydrophobic interior of such stationary phases allows for 
the successful retention of these entities with acceptable retention times.  
 
The use of ACN as an organic modifier is appropriate in comparison to the use of MeOH. With 
a polar molecule such as OT, the retention of OT decreased with an increase in ACN content 
and a concentration of 20% v/v ACN in a phosphate buffer was found to be optimal. Although 
the use of ion-pairing reagents to improve the separation in peptide mixtures has been 
advocated, this was not considered essential for OT, as the resultant chromatogram obtained 
without the use of these modifiers was acceptable. Buffered systems are important in the 
separation of ionisable and amphoteric molecules such as OT. The pH of a mobile phase affects 
the distribution between charged entities and therefore impacts on the interaction of the drug 
with both the mobile and stationary phases, thereby affecting the success/failure of the 
separation. A pH of 5 was found to result in the best-shaped peaks, with reasonable retention 
times. The molarity of the buffer affects the retention time of an analyte and molarity was 
optimised to produce sharp peaks for OT. The careful selection of an internal standard is 
advocated and resolution between the analyte of interest and the internal standard is important in 
order to allow accurate quantitation of the two compounds. MHB was selected as an appropriate 
internal standard thatg was well resolved from the OT peak. 
 
The validation of a method is essential in the pharmaceutical sciences. The linearity of a method 
allows for the successful generation of a calibration curve to allow for accurate quantitation of a 
molecule of interest. The coefficient of determination obtained for this method (R2 = 0.999) 
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ensured that interpolation of data within the range specified is reliable and accurate. The range 
used for a calibration curves must be relevant to the application of the method. For the 
determination of OT in dosage forms the most relevant range was found to be between 0.3 –12 
IU/ml.  
 
Much lower concentrations are expected when in vitro release tests are conducted and therefore 
the range was modified accordingly. The precision of the optimised method ranged between 
0.45 – 3.33% RSD therefore indicating that the method is reproducible and that day-to-day 
variations that would affect the response of the detection of analyte are minimal. The accuracy 
was appropriate and ranged between 0.54 – 3.83% Bias and 0.15 – 3.11% Bias for the dosage 
form analysis and in vitro release methods, respectively. In early formulation studies it is critical 
to ensure that changes in formulations that are reflected in the in vitro release profile are 
depicted accurately, and therefore appropriate decisions with regard to optimisation of dosage 
forms are made, as and when is necessary or required. 
 
The method that was optimised was sensitive, accurate, and precise. It was found to give a 
linear response in the desired concentration range. The method is therefore suitable for its 
intended use and therefore applicable in the analysis of OT from in pharmaceutical dosage 
forms and can be applied to the assessment of in vitro release of drug from hydrogel systems.  
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CHAPTER 3 
 
PROTEIN AND PEPTIDE FORMULATION 
 
3.1 INTRODUCTION 
 
3.1.1 Advances in Protein and Peptide Therapeutics 
 
The full sequencing of the human genome [237,238] has increased understanding and provided 
insight into the causes of genetic disease and possible drug therapies, including the use of 
endogenous proteins and peptides to cure or alleviate genetic disorders. High-throughput 
expression of recombinant proteins is required to ensure that proteins and peptides are produced 
rapidly and efficiently for therapeutic and research purposes [239]. 
 
The use of proteins and peptides in therapeutics is gaining recognition and acceptability, as 
these agents appear to offer therapeutic advantages compared to small conventional molecules. 
The selectivity, affinity, and specificity to target proteins and lower toxicity profiles of proteins 
and peptides compared to chemical entities, as well as the ability to produce effective and potent 
activity, are some of the major reasons for research advances in the development of protein and 
peptide drug delivery systems [240-242]. In addition, proteins and peptides have the ability to 
cure disease as they elicit biochemical changes in vivo by interacting with receptors and 
enzymes [242]. Bioactive peptides play an important role in the control of genetically linked 
diseases such as for example glucagon-like peptide-1 (GLP-1) which is important in the control 
of diabetes mellitus [243,244] and ghrelin, which is vital in the control of obesity [245,246]. 
Furthermore, the involvement of proteins and peptides in enzymatic catalysis, immuno-
protection, control of growth and differentiation processes, enhances the applicability of 
proteins and peptides in therapeutics [242]. Despite advances in production and the potential 
utility of peptides and proteins in clinical therapeutics, there are many formulation challenges 
that must be overcome in order to ensure safe and effective delivery of these entities. 
 
Initially, proteins used for therapeutic indications, including human insulin and human growth 
hormone were ‘simple replacement proteins’ with identical amino acid sequences to specific 
endogenous proteins and were administered clinically to mimic endogenous levels in vivo [247]. 
However, current trends in biotechnology indicate that modifications in protein sequences have 
been made in order to produce therapeutically superior molecules that are tailored to achieve 
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therapeutic goals. Modifications that have been made include mutations in primary sequences of 
the molecules, alteration of the molecule by covalent bonding to chemical groups or in the 
glycocomponent of proteins [247]. 
 
There are numerous protein and peptide agents currently available on the market for therapeutic 
indications and many others currently undergoing clinical trails [248]. There have been exciting 
developments in the approval of biopharmaceutical agents, including recombinant proteins, 
monoclonal antibodies, and nucleic acid-based drugs, with over 165 agents currently registered 
on the European and North American markets [248]. Of particular interest is the approval of the 
first non-parenteral protein formulations, viz., Exubera® (Nektar Therapeutics, San Carlos, CA, 
USA), an inhalable form of recombinant insulin and Fortical® (Fairfield, NJ, USA), an oral form 
of recombinant calcitonin [248]. Table 3.1 lists some of the protein therapeutic agents that have 
been approved for human use and indicates the manufacturer and therapeutic indication. 
 
Table 3.1 Some examples of proteins and peptide formulations registered [248] 
Product Company Indication  
Advate® (octocog-α 
recombinant human factor VIII) 
Baxter (Leverkusen, Germany) Haemophilia A 
Exubera® recombinant human 
insulin)  
Pfizer (New York, NY, USA) 
and Aventis (Kent, UK) 
Diabetes mellitus 
Serostim® (recombinant human 
growth hormone)  
Serono Laboratories (Geneva) AIDS-associated catabolism and 
wasting 
Viraferon® (recombinant 
interferon-α-2b) 
Schering-Plough (Kenilworth, 
NJ, USA) 
Hepatitis B, C 
Procrit® (recombinant human 
erythropoietin) 
Ortho Biotech (Bridgewater, NJ, 
USA) 
Anaemia 
Follistim® (follitropin-β, 
recombinant human follicle 
stimulating hormone) 
NV Organon (West Orange, NJ, 
USA) 
Infertility 
 
Commercial production of proteins and peptides must be highly efficient and economical, 
producing purified macromolecules relatively quickly and in acceptable quantities. A variety of 
techniques may be used for production of proteins and peptides, each with their own advantages 
and disadvantages. High-throughput cloning is one means of protein and peptide production, 
where the gene for a therapeutic protein/peptide to be cloned is transferred to appropriate 
vectors to allow expression of the gene in that vector, resulting in the production of the protein 
of choice [239]. Expression systems for the production of recombinant proteins using for 
example Escherichia coli, are the simplest means of producing proteins. It is therefore used 
extensively for high-throughput production of therapeutic proteins and peptides [239,248], with 
nine (9) of the thirty-one (31) therapeutic proteins approved since 2003 being produced using 
this method [248]. Mammalian cell lines are also used for production of recombinant proteins 
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and although this method is technically complex and more expensive compared to the use of 
Escherichia coli in expression systems and seventeen (17) of the therapeutic proteins approved 
for use since 2003 are produced in this way [248]. Cell-free expression systems using cellular 
lysates containing the necessary biochemical components for transcription and translation of 
DNA templates in vitro [239] may also be used for production of therapeutic peptides and 
proteins. Synthetic procedures are more applicable to the production of smaller peptides such as 
OT as described in § 1.2.3. 
 
3.1.2 Challenges in Protein and Peptide Delivery 
 
3.1.2.1 Introduction 
The success of protein and peptide formulations depends on the understanding by the 
formulation scientist of various manufacturing and process factors that affect the physico-
chemical stability of proteins/peptides and the biological processes that affect the in vivo 
performance of these molecules [240]. The large molecular size, low permeation rates through 
biological membranes and surface activity of proteins are some of the primary causes of 
instability of proteins in formulations [242]. Important considerations are the physical and 
chemical instability, immunogenicity, and pharmacokinetic profiles of proteins and peptides. 
Production and manufacturing strategies to overcome the inherent instability of these entities in 
vitro and in vivo are necessary to ensure the success of protein and peptide formulation 
development and production and for the achievement of desired therapeutic outcomes. 
 
Universal challenges in protein and peptide formulation include stability of the preparation and 
potential impact of the drug delivery system on protein conformation in formulation 
development, manufacturing, and the post-application processes [249]. Furthermore, the 
secondary and tertiary structures of proteins are important in eliciting biological responses and 
these must be conserved in pharmaceutical dosage forms, during the manufacturing processes, 
transportation, and long-term storage [250]. 
 
3.1.2.2 Physical and Chemical Instability of Proteins and Peptides 
Physical instability of proteins and peptides refers to non-covalent modification of the molecule 
and involves changes in the secondary, tertiary, and quaternary structures of the molecule, 
including denaturation, adsorption to surfaces, aggregation, and precipitation [251]. Chemical 
instability of proteins involves processes where chemical modification by formation or 
destruction of covalent bonds occur, resulting in modified molecular entities being formed 
[251].  
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The sensitivity of protein structure and conformation to external conditions causes many 
formulation challenges, with respect to handling, formulation aspects, manufacturing, and 
storage issues. Conformational changes in protein structure may arise because of the 
aforementioned processes affecting protein and peptide stability in vitro, causing aggregation 
and ultimately precipitation and therefore impact negatively on the integrity and success of 
protein formulations [240,250,252,253]. 
 
The specific conformation of a protein is a result of protein folding, which is dominated by 
hydrophobic and electrostatic interactions, hydrogen bonding, intrinsic propensities, and van der 
Waal’s forces [250]. Protein conformations are unstable and pharmaceutical processes are likely 
to impact on protein conformations. Such processes include shear forces, shaking, temperature, 
pH, and protein concentration [250,253]. The conformation of a protein is also dependent on the 
size of a protein and number of domains in the structure. Multi-domain large proteins are more 
susceptible to small changes in environmental conditions compared to their smaller molecular 
weight counterparts, resulting in aggregation [240]. 
 
Aggregation can be considered a physical process where protein monomers become coupled 
forming larger units, which may be insoluble and are often bio-inactive as they are unable to 
cross biological membranes to facilitate intracellular action or interact with membrane receptors 
[250,251]. Although aggregation is a predominantly physical process, it may also occur via 
covalent bond formation forming cross-links between protein molecules or altering the tendency 
to cause aggregation of proteins in solution [252]. Aggregation may result in formation of 
soluble or insoluble aggregates and the nature of the specific protein and conditions to which the 
protein is exposed will affect the type of aggregate formed. It is therefore important that the 
formulation scientist is aware of the specific conditions that cause aggregation for a particular 
protein, and whether they are prevalent during the formulation and manufacturing process and 
procedures [253]. The primary structure of a protein may play an important role in aggregation, 
with more hydrophobic proteins having a greater tendency to aggregate than their hydrophilic 
counterparts [254]. The secondary structure is also an important determinant of aggregation, 
where β-strands have a greater propensity to result in aggregation compared to α-helices, by 
forming coiled-coil contacts [255]. 
 
Shear induced by vortexing results in partitioning of proteins to the air/water interface, 
encouraging partial unfolding of the protein structure on exposure to air [256]. The use of non-
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aqueous solvents [250] and the concentration of protein [257] may also promote aggregation of 
proteins in solution. 
 
Other factors that affect the stability of protein formulations include drying processes [258], 
medium for reconstitution of freeze-dried formulations [259] and pharmaceutically relevant 
conditions, which mimic in vivo conditions to which the protein is exposed, such as temperature 
(37 °C) and humidity [260], as well as the storage conditions [261].  
 
Proteins tend to be stable within specific temperature ranges and generally, protein stability 
decreases with increasing temperature either by denaturation or by catalysis of chemical 
reactions [253,262]. 
 
The pH of the solution to which the protein is exposed is another factor that alters protein 
conformation by affecting the aggregation behaviour of proteins, or catalysis of chemical 
reactions that may result in denaturation [253,262]. Most proteins tend to be stable within a 
narrow pH range and it is therefore imperative that in formulation development, protein stability 
is adequately monitored and/or controlled. 
 
Proteins have the potential to adsorb onto surfaces, thereby reducing in vitro concentrations. 
The exposure of proteins to materials to which they can adsorb in formulation manufacture and 
to packaging and filters must be avoided as adsorption impacts negatively on biopharmaceutical 
formulation stability [250,251]. Salts, metal ions and chelating agents that may be used in 
formulations are also important considerations as they have the potential to affect the overall 
conformation and stability of protein molecules [263]. 
 
Proteins are susceptible to chemical instability that often results in degradation of the molecules 
by hydrolysis, deamidation, isomerisation or racemisation, oxidation, and formation or breakage 
of disulphide linkages, thereby resulting in the formation of degradation products [250,251]. 
Chemical instability does not always result in the biological inactivity of proteins, since the site 
of chemical change may not be crucial for the interaction of the molecule with the target 
receptor(s) and therefore a biological response may still be observed [264]. 
 
The use of appropriate analytical techniques is essential to monitor changes in protein stability. 
Capillary electrophoresis [265] and HPLC [266] have been used to monitor protein degradation, 
while differential scanning calorimetry (DSC) [267], fluorescence [268] and nuclear magnetic 
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resonance (NMR) [269] have been used to detect changes in protein folding. The aggregation 
behaviour of proteins has been monitored using light scattering mass spectroscopy [270]. 
 
Biopharmaceutical molecules such as proteins and peptides may be contaminated with 
biological substances such as viruses [240]. However, the inactivation of viral contaminants 
requires heat treatment at 60 °C, which causes denaturation of many biological proteins [253]. It 
is therefore imperative that protein formulations be protected against denaturation by controlling 
ionic strength and pH using buffer systems, or by addition of stabilisers such as Tween 20 [271] 
to limit aggregation. 
 
The stability of protein formulations in vitro can be improved through modification of the 
protein, addition of pharmaceutical adjuvants and the control of environmental conditions [253]. 
To prevent protein folding, formation of disulphide bonds and salt bridges, mutations in regions 
involved in local folding, have been introduced to stabilise and cause rigidity in these regions, 
thereby stabilising proteins [251,272]. 
 
Additives such as salts of ionic compounds may be included in protein formulations to improve 
stability, as salts are able to bind to specific ionic sites and prevent denaturation of proteins in 
formulations [251]. Polyalcohol materials such sugars and glycerol, stabilise proteins and 
reduce denaturation through selective solvation of protein surfaces at low additive 
concentrations. Water particles surround the protein surface in order to exclude hydrophobic 
additives and prevent exposure of the hydrophobic interior of proteins to the additives, thereby 
stabilising a formulation [251]. 
 
Detergents and amphiphiles such as polysorbate 20 [273], Pluronic® F68 and Brij 35 [274] 
reduced the aggregation of proteins due to shear forces by competing with proteins at the 
air/water interface, thereby stabilising protein formulations. However, the effects of the 
detergents may not be adequate in preventing aggregation in long-term stationary storage of 
protein formulations [275]. Cyclodextrins have also been found to be effective in controlling 
protein aggregation in pharmaceutical preparations for pharmaceutically relevant proteins such 
as insulin [276,277]. Cyclodextrins prevent folding of proteins by binding to aromatic residues 
in the protein chain, stabilising the protein in an unfolded state and reducing the rate of protein 
folding [278]. Lyophilisation or freeze-drying of proteins and peptides removes water from the 
protein, leaving the protein in an unreactive anhydrous or almost anhydrous state [240] and 
increases the stability of protein and peptide formulations [279,280]. To improve the shelf life 
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of protein pharmaceuticals, a formulation must be at the right pH and ionic strength and a 
stabiliser (e.g. sugars, polyethylene glycol) must be selected to ensure an acceptable shelf-life is 
obtained [253]. 
 
3.1.2.3 Biological Instability of Proteins and Peptides  
Proteins and peptides often have short half-lives in vivo because of degradation by protease 
enzymes in the systemic circulation, liver metabolism and rapid renal clearance especially for 
lower molecular weight (< 5 kDa) proteins [241]. In addition, proteins and peptides are unable 
to enter intracellular spaces, as they cannot penetrate lipophilic cell membranes, limiting their 
use in controlling intracellular processes in vivo [241]. 
 
A further complication with regards the use of therapeutic proteins, is their ability to induce 
immunogenic effects in vivo [240,281] by inducing T and B-lymphocyte activity resulting in 
antibody production and the consequent rapid elimination of therapeutically administered 
proteins and peptides. Factors that influence antibody formation in vivo include protein 
structure, immuno-modulatory effects of the protein, formulation composition, presence of 
contaminants and impurities, route, dose, frequency and duration of administration [281]. Prior 
to the advent of recombinant biotechnology allowing the use of human proteins in therapy, 
animal proteins were used which often resulted in activation of an immune response against 
therapeutic proteins thereby limiting in vivo use of the molecules [281]. Conversely, the use of 
recombinant human proteins has resulted in a reduced incidence and severity of immunogenic 
effects as patients are expected to be more tolerant of endogenous proteins as opposed to 
exogenous molecules. However, there have been reports of immunogenic effects and reduced 
clinical efficacy with long-term recombinant interferon therapy for multiple sclerosis [282,283] 
and pure red-cell aplasia following recombinant erythropoietin therapy [284]. The consequences 
of immunogenic effects in therapy include interference with the pharmacokinetic parameters of 
the molecule of interest and may result in a diminished therapeutic response and consequent 
therapeutic failure, or precipitation of an immune response, resulting in an attack on related 
endogenous proteins with a potential fatal outcome [281]. 
 
Strategies to improve the in vivo pharmacological and pharmacokinetic profiles of proteins and 
peptides have been proposed, and include PEGylation, acylation, or mutation of the amino acids 
of a primary sequence in a protein. However, it is important that biological efficacy be retained 
and that there is no induction of immunogenicity because of modifications made to proteins 
and/or peptides [240]. 
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Chemical modification by covalent binding of proteins and/or peptides to polyethylene glycol 
(PEG), known as PEGylation [285-289] is a strategy to increase the circulating half-life of the 
molecule and to reduce the immunogenicity of proteins and/or peptides. The conjugation of 
proteins and peptides with PEG occurs by reacting functional groups such as amino, cysteine or 
carboxyl groups of proteins and peptides with modified PEG molecules. Either a single large 
molecular weight PEG molecule (30 – 40 kDa) or several smaller molecular weight entities (5 
kDa) can be attached to the protein or peptide molecule [241]. PEG modification is 
advantageous and modifies protein and peptide pharmacokinetic profiles and biodistribution of 
the molecules in vivo [285]. The increment in size following conjugation results in lower renal 
clearance and a resultant increase in circulating half-life, reducing the need for frequent dosing 
of protein and peptide formulations that would otherwise be rapidly cleared [285]. Attachment 
of PEG molecules to proteins or peptides also masks charged and glycosylated sites on protein 
surfaces and shields antigenic and immunogenic epitopes of proteins, reducing immunogenic 
responses [290,291]. Furthermore, PEGylation results in reduced phagocytosis by the reticulo-
endothelial system and liver cells and reduction of protein degradation [290]. However, the 
attachment of a PEG moiety to proteins and peptides may result in diminished biological 
responses in vivo as the PEG molecule may interfere with protein/peptide and receptor 
interaction, thereby warranting the need for extensive testing of several PEG-protein/peptide 
derivatives [241]. PEGylated protein products approved for human use include Pegasys 
(Hoffman-La Roche, Nutley, NJ, USA) and PegIntron (Schering-Plough (Kenilworth, NJ, 
USA), which are PEGylated interferon N-2α and PEGylated interferon N-2β, respectively. 
 
Alternatively, N-terminal modification by acetylation or glycosylation or C-terminal amidation 
[292] may be performed in an attempt to improve the biopharmaceutical profile of proteins and 
peptides. The introduction of unnatural amino acids into primary protein or peptide sequences  
at vulnerable sites reduces proteolytic degradation of proteins and peptides, thereby potentially 
increasing the therapeutic efficacy of the molecules [290,292]. 
 
Acylation is the chemical attachment of fatty acids to exposed residues on protein surfaces and 
increases the affinity of proteins for serum albumin, thereby increasing protein binding, and 
prolonging circulation half-life of the molecule [293,294]. This has been successfully used to 
produce a long acting insulin analogue, insulin determir (Novo Nordisk, Bagsværd, Denmark) 
which is available on the market. Another strategy that can be used to increase the molecular 
weight of peptides is by genetic fusion of a protein to the Fc domain of human gamma 
immunoglobulin (IgG), thereby reducing the renal clearance of the protein [295]. 
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The hydrophilic nature of peptides hinders penetration of these entities into cells and therefore 
one strategy to improve cellular permeability has been to develop cell-penetrating peptides 
[296,297]. Peptides are attached to synthetic molecules or naturally occurring cationic peptides 
or amino acid sequences containing basic amino acids that are proline rich and are able to cross 
lipophilic cell membranes, thereby shuttling the desired peptides into intracellular spaces 
[296,297]. 
 
An analogue approach has been proposed to enhance the bioavailability of insulin following 
subcutaneous administration [298,299]. Insulin exists as individual monomers in the human 
body, but in pharmaceutical dosage forms, insulin tends to associate into dimers and hexamers 
resulting in low penetration of the insulin through biological membranes because of the large 
molecular weight and size of the dimers and hexamers. These polymeric units must dissociate 
before absorption from the site of injection, causing a delay in absorption and ultimately, a 
delayed onset of biological action. Mutation of amino acid residues important in the self-
association of insulin molecules results in a reduction in the tendency of insulin to self-associate 
promoting the prevalence of insulin monomers or dimers that are capable of penetrating 
biological membranes easily [300]. The onset of action is therefore accelerated and insulin 
lispro (Eli Lilly, Indianapolis, IN, USA) and insulin aspart (NovoRapid®) (Novo Nordisk, 
Bagsværd, Denmark) with rapid time-action profiles are available on the market. 
 
3.2 MECHANISMS AND OBJECTIVES OF CONTROLLED DRUG DELIVERY IN 
PROTEIN FORMULATIONS 
 
3.2.1 Introduction 
 
Controlled drug delivery defines methods that can be used to modulate the release of a molecule 
from a dosage form in order to obtain a desired release pattern that is specific to an indication or 
for the clinical use of a molecule [301]. 
 
There are two types of controlled release that can be achieved viz., temporal and distribution 
control [302]. Briefly, the aim of temporal control systems is to deliver a drug molecule over an 
extended or for a specific period during treatment, into the systemic circulation. The benefits of 
temporal release are exemplified in Figure 3.1, which shows plasma drug concentrations 
following use of frequent injections, administered every six (6) hours compared to the use of a 
controlled release injection formulation that is only administered once. 
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Figure 3.1 The drug concentrations following the administration of multiple injections  
compared to a controlled release temporal formulation, (redrawn from [302]) 
 
The therapeutic window of a drug defines the drug plasma concentration range in which 
therapeutic efficacy is achieved. Concentrations that are above and below the maximum and 
minimum therapeutic levels result in side effects and toxicity, or no therapeutic benefits, 
respectively [303]. The advantages of using temporal delivery systems are that plasma 
concentration levels are maintained within the therapeutic range and there are reduced 
incidences of toxicity or therapeutic failure [301]. 
 
Distribution control systems aim to localise drug action by restricting absorption of a 
therapeutic agent or drug into the general systemic circulation, with the primary advantage of 
decreasing adverse effects in systemic regions, whilst maintaining high drug concentrations at 
the site of action [302]. Distribution systems can be particularly useful for the administration of 
toxic drugs such as cytotoxic agents for cancer chemotherapy, thereby reducing systemic 
adverse effects. A diagrammatic illustration of a distribution control system, with plasma 
concentrations for both the systemic region and the localised site is depicted in Figure 3.2. 
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Figure 3.2 Drug plasma concentrations from a distribution control system showing plasma 
concentrations in the systemic circulation and at the site of action, (redrawn from [302]) 
 
The advantages of controlled release systems in drug delivery include improved efficacy and 
reduced toxicity as the level of drug/therapeutic molecule is maintained within the therapeutic 
range. Furthermore, improved patient compliance is likely due to reduced dosing frequencies 
and eventually culminates in a better chance of therapeutic success [302]. 
 
3.2.2 Objectives in Controlled Protein Delivery 
 
The objective of current and innovative drug delivery developments is to deliver drugs that 
facilitate maximum therapeutic performance, decrease undesirable or untoward side effects, as 
well as increase patient compliance. Innovative drug delivery systems for proteins and peptides 
focus on drug delivery that is both controlled and safe, in order to maximise the therapeutic 
potential of biopharmaceutical molecules. 
 
Therapeutic proteins and peptides often have short half-lives resulting in rapid elimination of a 
molecule from the body. In order to achieve therapeutic success, it is desirable to obtain 
continuous drug release over extended periods to maximise the therapeutic potential of the 
protein or peptide [249,304]. This is particularly important when using proteins that require 
frequent administration and where the use of a sustained release formulation would reduce the 
frequency of administration that is required to maintain the blood protein levels at therapeutic 
levels. 
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The use of controlled release systems for the delivery of proteins and peptides may also be 
beneficial where the molecule must be released in pulses as opposed to continuous release. An 
example of this requirement is in the treatment of diabetes, where the continual release of 
insulin from a delivery device would result in severe hypoglycaemic effects. Therefore, the 
development of an insulin delivery system that only releases the protein when required would be 
beneficial for the management of insulin-dependent diabetes. Furthermore, the inherent 
instability of proteins and peptides to enzymatic degradation and the possible production of 
antibodies in vivo, has been noted and therefore the formulation of proteins and peptides as 
distribution controlled delivery systems would be valuable to reduce the incidence of adverse 
effects [301]. 
 
3.3 ROUTES OF PROTEIN DELIVERY 
 
3.3.1 Introduction 
 
Different routes of administration for peptides and proteins have been described and reported in 
the literature. These vary according to the specific protein in a delivery system and the 
therapeutic indication of that protein. The desired therapeutic goal is important to consider in 
the formulation development stages, depending on the desired release rate, be it controlled, 
sustained, pulsatile, or immediate release. The required duration of action to achieve a 
therapeutic goal must also be considered in the formulation development process. Approaches 
to solving protein delivery issues include the use of oral, transdermal, nasal and ocular routes of 
delivery as well as the parenteral route.   
 
3.3.2 Oral Delivery 
 
3.3.2.1 Introduction 
The oral route of drug delivery is the most favoured route for the administration of medicinal 
agents and is the most widely used method for drug delivery [240,242]. However, the primary 
challenge with respect to oral delivery of proteins and peptides is the inherent instability of 
these agents to digestive enzymes and pH in the gastro-intestinal tract (GIT) which result in 
protein degradation. Moreover, the low permeability of proteins and peptides across the gastric 
and intestinal mucosa limits the feasibility of the use of this route for protein delivery [242]. 
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Barriers to the oral absorption of proteins and peptides may be described as physical, chemical 
and enzymatic [305]. The physical barriers to absorption of proteins and peptides include the 
large molecular size and hydrophilic nature of these macromolecules, which renders them 
unable to traverse aqueous channels and tight junctions between epithelial cells and cross 
lipophilic epithelial cell membranes in the GIT, respectively [305]. 
 
pH induced degradation in the GIT refers to acid induced degradation in the stomach, where 
larger protein and peptide molecules are broken down to their constituent amino acids and 
smaller peptide units such as dipeptides and tripeptides. In addition, the stability and 
conformation of proteins and peptides is dependent on environmental pH and changes in pH in 
the GIT from acidic pH values in the stomach to less acidic and more alkaline pH values in the 
lower GIT, results in changes in conformation and folding of proteins and aggregation. These 
factors reduce the therapeutic potential of orally administered proteins and peptides [305]. 
 
The GIT is rich in enzymes that degrade proteins and peptides by hydrolysis of peptide linkages 
or by chemical modification of the molecules by oxidation, reduction, or phosphorylation [305]. 
The small intestine contains the largest surface area for drug absorption, but also contains the 
largest number of hydrolytic enzymes secreted from the pancreas, mucosal cells and from the 
brush border of epithelial cells [305], to which proteins and peptides are susceptible. 
 
Advances in formulation technology, stabilisation of proteins and peptides in the GIT and the 
possibility in increasing permeability across the gastric mucosa have resulted in a corresponding 
increase in the oral bioavailability of these molecules from as low as 1% to between 30 – 50% 
for some proteins [242]. 
 
However, it is important to note that technologies used in oral delivery systems must not affect 
the overall integrity of the intestinal lumen or other endogenous biological systems since this 
may result in serious interactions with other drugs that may be concomitantly administered 
[306].  
 
Whilst the improvement in the bioavailability of therapeutic proteins and peptides may offer 
obvious advantages to improving therapeutic outcomes, an increase in the absorption of drugs 
may also have detrimental effects for agents with a narrow therapeutic range. Variability in 
absorption of drugs from the GIT may be a result of age or genomic factors and concurrent 
pathophysiological conditions that may compromise the structure of the intestinal mucosa. As a 
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result, increased absorption may cause high plasma levels of a therapeutic agent and result in 
fatal effects, such as for example high plasma levels of insulin resulting in excessive 
hypoglycaemia causing coma and death [306,307]. It is therefore important that the safety and 
efficacy of oral biopharmaceutical dosage forms, in addition to pharmacokinetic parameters of 
proteins, such as bioavailability and distribution be well established [306]. The effects of long-
term administration of excipients such as permeation enhancers or enzyme inhibitors on the 
integrity of the GIT and systemic physiology must also be evaluated if any formulation is to be 
used chronically [307]. 
 
3.3.2.2 Chemical Modification 
Absorption of a molecule across the intestinal mucosa is a function of the lipophilicity of that 
molecule. The degree of lipophilicity allows a molecule to partition into the lipid epithelial cell 
membranes and be transported into and through intracellular spaces [308]. However, the 
hydrophilic nature of the majority of proteins and peptides limits their GIT absorption and 
therefore some formulation strategies have focused on increasing the lipophilicity of protein and 
peptide molecules. 
 
Lipidisation of molecules describes the covalent conjugation of a hydrophobic 
moiety/compound to proteins and peptides which results in an increase in the lipophilicity of the 
proteins and peptides [307]. An example of lipidisation is the synthesis of palmitoyl derivatives 
of insulin that have increased the absorption of insulin in the GIT as compared to unmodified 
insulin [309]. However, there is also a likelihood of reduced bioactivity of molecules that is 
associated with such chemical modifications and therefore, the synthesis of reversible modified 
molecules has been investigated. In such cases, lipidisation is reversed in vivo but results in 
improved epithelial absorption and stability [310]. 
 
PEGylation results in the increased stability of proteins because of protection of the molecules 
from proteolytic degradation and has been investigated for improving the bioavailability of 
orally administered insulin [311]. 
 
The addition of novel functional groups to protein and peptides molecules that allow for 
receptor recognition or use of a delivery carrier system may also be undertaken in an attempt to 
improve the biopharmaceutical profiles of orally delivered peptides and proteins [242,306]. The 
main purpose for the addition of novel functionalities to proteins and peptides is to improve 
absorption by manipulation of endogenous transport-carrier molecules recognised in the GIT 
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and therefore allow for the shuttling of therapeutic proteins and peptides across GIT mucosa. 
Examples of associated protein transport mechanisms include membrane transporters and 
receptor-mediated endocytosis that recognise and internalise their specific ligands attached to 
macromolecules, and therefore ferry them across the intestinal lumen [306]. 
 
Conjugation of insulin with transferrin increases insulin permeability across the GIT mucosa 
through receptor mediated transcytosis, which normally results in the absorption of transferrin 
[312,313]. In addition, it has been proposed that the conjugation of insulin with transferrin also 
protects insulin from enzymatic degradation in the GIT [313]. Transferrin has also been 
conjugated to recombinant granulocyte colony-stimulating factor, where efficacy of the 
conjugate was found to last for up to three (3) days as compared to only one (1) day, following 
subcutaneous administration of the macromolecule in its native form [314]. 
 
3.3.2.3 Formulation Strategies 
Addition of protease inhibitors to protein formulations has been investigated with some success 
for improving the oral bioavailability of proteins and peptides, although the success of protease 
inhibitor use requires a full understanding of enzyme specificity for a particular protease 
inhibitor [315]. Examples of protease inhibitors include aprotinin for trypsin and chymotrypsin 
inhibition and amastatin, bestatin and boroleucine with inhibitory effects for aminopeptidases 
[315]. To improve the oral bioavailability of insulin, sodium glycocholate, camostat mesilate 
and bacitracin are effective in the large intestine, although it has been reported that the activity 
of these molecules was limited when used in the small intestine due to numerous enzymes 
present in that region of the GIT [316]. Soybean extract contains proteolytic enzyme inhibitors 
and has been used to improve insulin bioavailability [317]. In vitro studies have indicated that 
soybean extract reduces the degradation of insulin when exposed to simulated intestinal and 
gastric fluid, thereby making soybean extracts potentially useful in formulations for the oral 
administration of insulin and other proteins [317]. 
 
Absorption enhancers may also be used to improve the oral bioavailability of proteins and 
peptides from the GIT [305]. Absorption enhancers may function in different ways and include 
agents that disrupt the integrity of the epithelial mucosa by opening tight junctions, decrease 
mucus viscosity, and promote leakage of proteins through membranes or are able to shuttle 
proteins and peptides via specific membrane protein transporters [305]. Examples of permeation 
enhancers include chelators, surfactants, bile salts, fatty acids, and their derivatives [305]. 
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In addition, practical approaches to enhancing peptide and protein bioavailability include the 
use of enteric coating for protection of biopharmaceutical molecules from pepsin digestion in 
the stomach. The coating prevents the release of a protein/peptide in the stomach, but allows for 
the rapid release of drug in duodenum thereby providing a higher concentration of therapeutic 
proteins and peptides at the epithelial surface and promoting faster absorption of the molecule 
into the systemic circulation [306]. Other strategies for absorption enhancement include a 
temporary decrease of the local pH in the small intestine, adhesion to mucous membranes 
allowing longer contact times with the mucosa, as well as colon targeting where there are 
minimal proteolytic enzymes [306]. In most cases, a combination of different approaches to oral 
delivery often results in the successful development of a formulation for oral use. 
 
3.3.2.4 Particulate Delivery Systems 
The primary advantage of particulate delivery systems is their ability to protect protein 
molecules against enzymatic degradation and to provide a pathway for the transfer of 
macromolecules across epithelial cell walls. Examples of particulate delivery systems include 
hydrogels, microparticles, nanoparticles and lipid based systems such as liposomes and solid 
lipid nanoparticles [306]. 
 
Solid lipid nanoparticles are prepared from solid lipids, have a mean photon-correlation 
spectroscopy diameter ranging between 50 – 1000 nm, and are enclosed in a surfactant layer 
[318]. Solid lipid nanoparticles may be likened to emulsions that contain oil droplets, but 
instead a solid lipid phase as opposed to a liquid is used in their manufacture [318]. The 
advantage of lipid-based particles is their inability to entrap hydrophilic proteins and peptides 
efficiently and therefore promote drug stability and rapid release [306]. Colloidal lipid 
nanoparticles coated with chitosan have been recommended for the oral delivery of peptides, 
using salmon calcitonin as a model drug [319]. Lipid nanoparticles improved the bioavailability 
of molecules by increasing permeability across the GIT mucosa and potentially increasing blood 
residence time through modification of the biodistribution of drug in vivo. A combination of 
lipid nanoparticles with chitosan, a bioadhesive polymer that also increases transmucosal 
absorption of compounds and the stability of nanoparticles in simulated gastric and intestinal 
contents, is likely to result in an increased bioavailability as reported for salmon calcitonin 
[319]. In addition, chitosan coated nanoparticles have been shown to increase the permeability 
in Caco-2 cell monolayers by reducing the transepithelial electric resistance of the cell layer. 
This effect results in sustained release of calcitonin following the administration of calcitonin 
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containing chitosan coated nanoparticles [319]. A similar technology using chitosan to coat 
liposomes was also used for an oral calcitonin delivery system [320]. 
 
Lectins are a structurally diverse class of proteins with the ability to bind carbohydrates and 
glycosylated sites in epithelial cell membranes of the GIT mucosa, facilitating drug transport 
across cellular membranes [321]. Lectin-modified solid lipid nanoparticles have been 
investigated as carriers for oral administration of insulin [321,322]. Lectin-modified solid lipid 
nanoparticles were able to protect insulin from degradation by digestive enzymes in vitro and in 
vivo results indicated an improved oral absorption of insulin from these delivery systems [322]. 
 
The formulation of insulin-transferrin conjugates with pH sensitive complexation hydrogels 
prepared from UV initiated free radical polymerisation of methacrylic acid (MAA) and 
methoxy-terminated poly(ethylene glycol) monomethacrylate (PEGMA) consisting of cross-
linked polyMAA grafted with PEG chains was found to increase insulin-transferrin 
bioavailability [323]. The enhanced bioavailability of insulin is a result of an increased GIT 
residence time by adherence of the formulation to the GIT mucosa and inhibition of insulin 
degradation in the GIT [323]. pH sensitive complexation hydrogels may be considered suitable 
for oral delivery of proteins or peptides, as they are able to respond to changes in pH in the GIT 
thereby protecting biopharmaceutical agents from degradation. Reversible formation and 
dissociation of polymer chains in pH responsive systems is the principal mechanism by which 
drugs are protected in these systems. At acidic pH values, such as those that occur in the 
stomach, polymer chains interact strongly, entrapping proteins and peptides within the network, 
thus protecting them from acid induced degradation. However, at higher pH values (pH > 5.2) 
the polymer networks dissociate because of ionisation of the acidic functional groups, causing 
repulsion of the polymeric chains and subsequent release of the entrapped macromolecules 
[324]. Furthermore, complexation hydrogels are able to enhance the transport of 
macromolecules, including insulin [324,325], across the intestinal mucosa increasing their 
potential applicability as oral protein and peptide delivery systems. 
 
Multiple water-in-oil-in-water (w/o/w) emulsions are more complex systems than simple oil-in-
water (o/w) or water-in-oil (w/o) emulsions and in these systems, drops of the dispersed oil 
phase contain smaller dispersed water droplets that consist of the same phase as the continuous 
water phase [326]. These systems are intrinsically thermodynamically unstable systems and the 
inherent instability limits their use as drug delivery systems, which must be stabilised using 
appropriate combinations of surfactants. Cole et al. [326] reported using complexes of 
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poly(acrylic acid) and hydrophilic poloxamers, such as PF-127 in the aqueous phase in 
combination with lipophilic surfactants to prepare stable emulsions for oral protein delivery. 
The described method was used for the delivery of insulin and was shown to be suitable for 
either rapid onset or sustained action preparations depending on the type of complex formed 
between poly (acrylic acid) and PF-127 [326]. 
 
3.3.2.5 Site Specific Delivery in the GIT 
The ileum is an attractive site for macromolecular absorption since it has the capability and 
mechanism that allows for the absorption of large molecular entities. The uptake systems 
include the ileal uptake pathway suitable for cobalamin absorption that uses a receptor mediated 
transcytosis mechanism, which allows the absorption of cobalamin bound to an intrinsic-factor, 
by the intrinsic-factor receptor [305]. Conjugation of peptides to cobalamin is a possible 
mechanism of increasing the oral absorption of peptides and proteins and has been reported to 
effectively bind conjugates to the intrinsic-factor receptor, thereby allowing absorption of 
peptide entities [327]. 
 
The colon has markedly reduced enzymatic activity as compared to other regions of the GIT, 
resulting in reduced degradation, in addition to a prolonged residence time, making the colon an 
attractive site for targeting protein and peptide absorption [305]. The drawbacks of the large 
intestine for targeted delivery are that it has a smaller surface area/volume ratio compared to the 
small intestine and has fluctuating pH that is dependent on the type of food that is consumed 
[305]. An example of colon specific delivery systems include the use of pH responsive systems 
that respond to varying pH values in the GIT, allowing for the release of a drug in the alkaline 
environment of the colon [324,328] as described in § 3.3.2.4. 
 
3.3.3 Nasal Delivery 
 
3.3.3.1 Introduction  
The nasal route of delivery has been investigated as an alternative non-invasive route for the 
administration of proteins [329] as this route permits painless self-administration of drugs 
thereby potentially improving patient compliance and acceptability. Due to the impracticality 
and challenges associated with achieving success for oral protein delivery and the unpopularity 
of parenteral delivery due to the pain associated with injections, the nasal route is a potentially 
feasible and attractive avenue for protein delivery. The primary advantages of nasal delivery are 
that absorption can be highly efficient because of the large surface area for absorption, a thin 
 94 
diffusion pathway to the blood stream exists, and there is less proteolytic activity in the nasal 
mucosa as compared to the GIT [330]. In addition, there is no hepatic first-pass metabolism as 
therapeutic agents are absorbed directly into the systemic circulation [331]. Furthermore, rapid 
absorption and onset of action that occurs following nasal delivery is comparable to that 
obtained following the intravenous administration of drugs, because of the rapid absorption and 
rich vasculature of the nasal tissues [332]. 
 
The main challenges to success of intranasal administration of proteins and peptides are the low 
bioavailability of these agents due to a low mucosal permeability because of the hydrophilic 
nature of proteins and peptides and enzymatic degradation in the nasal tract [333]. Additionally, 
the large molecular weight of proteins render delivery through this route a pharmaceutical 
challenge [334] and the efficient physiological elimination mechanism and nasal mucociliary 
clearance of proteins and peptides from the nasal tract further reduce bioavailability of agents 
delivered using the nasal route [335,336]. The volumes used in nasal delivery systems are 
limited to between 25 – 150 µl per nostril [332] and it is therefore important that in formulation 
development, dosage strength is considered, with particular regard to the volume of formulation 
to be administered. In addition, pharmacokinetic parameters including bioavailability from the 
nasal tract must be evaluated. Formulation developments in nasal delivery systems have 
therefore focused on a means to increase the bioavailability of proteins and peptides by a variety 
of techniques. 
 
3.3.3.2 Formulation Strategies 
Strategies to improve the bioavailability of peptides and proteins in the nasal cavity have 
included the use of a combination of a surfactant (laureth-25) and a mucolytic agent (N-acetyl-
L-cysteine), which was used in a delivery system for salmon calcitonin [337]. The mucolytic 
agent decreases the viscosity of mucus in the nasal tract, allowing for rapid surfactant diffusion 
into the epithelial membrane, where it increases membrane fluidity and permeability to proteins 
and peptides [337]. The use of the mucolytic agent (N-acetyl-L-cysteine) in a powder 
formulation using ethylcellulose as a water insoluble inert excipient was reported to increase the 
nasal bioavailability of calcitonin in rats and dogs [337] and a faster absorption rate for the 
molecule was observed as compared to subcutaneously administered calcitonin. In addition, the 
combination did not result in irritation of the nasal mucosa therefore suggesting the potential 
utility of N-acetyl-L-cysteine in combination with ethylcellulose for protein and peptide 
delivery. 
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Absorption enhancers have been investigated as a means of improving the nasal bioavailability 
of drugs from nasal formulations. One such example is sodium glycocholate, a bile salt, which 
may act by interaction with membrane lipids and enzymatic inhibition and opening the tight 
junctions between epithelial cells, thereby increasing the transport of macromolecules across the 
epithelium [331]. The use of sodium glycocholate in combination with glycofurol resulted in 
increased nasal absorption of a model peptide, Peptide T in rabbits [331]. Additional absorption 
enhancers that have been investigated include chitosan [338,339], which may increase the 
permeation of proteins due to its bioadhesive effects, causing a reduction in mucociliary 
clearance of nasally administered proteins. In addition, chitosan is reported to have the ability to 
temporarily widen tight epithelial junctions in vivo [338,339]. Furthermore, cationic chitosan 
molecules are able to interact with the negatively charged mucosal surface and this interaction is 
enhanced by the use of large molecular weight chitosans, which bind to membranes for 
extended periods [339]. The use of dimethyl-β-cyclodextrin has been proposed as a permeation 
enhancer for protein/peptide powder formulations [340]. The use of absorption enhancers in 
nasal formulations has a major drawback of causing local irritation and toxicity that is 
undesirable in therapy and therefore absorption enhancers that are investigated for nasal use 
must be rigorously tested for in vivo toxicity and for short and long-term effects on the 
mucociliary system. 
 
Sucrose cocoate, an emulsifier has been investigated as a means for improving the nasal 
bioavailability of insulin and calcitonin in rats [341] and it was reported that preparations of 
insulin and calcitonin containing 0.5% sucrose cocoate resulted in a rapid decline in plasma 
glucose and calcium levels, respectively due to the increased circulatory hormone levels. 
 
Liquid and/or powder formulations may be used for nasal delivery and some studies 
[335,340,342] have shown that powder formulations are more stable and allow for better 
absorption and hence higher bioavailability compared to liquid dosage forms. This is primarily a 
result of the longer duration of contact of the formulation at the epithelial cell surface when 
powdered formulations are used compared to liquid dosage forms [335]. Dry powders for 
inhalation containing human parathyroid hormone were prepared by spray drying a blend of 
parathyroid hormone, lactose, and dipalmitoylphosphatidylcholine and were assessed for in vivo 
bioavailability and safety in rats [343]. A spinhaler device was used to administer the 
formulation and no acute inflammation was observed for up to 48 hours following a single dose 
administration, indicating the non-toxic or non-irritancy behaviour of the formulation [343]. 
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Protein and peptide formulations for nasal delivery may also be formulated as jet or ultrasonic 
nebulisers, metered dose inhalers, and dry powder inhalers [344]. 
 
3.3.3.3 Particulate Delivery Systems 
The use of colloidal carriers has been investigated as a mechanism for improving the 
permeability of proteins and peptides across nasal epithelial tissue cells [345]. The potential for 
use of chitosan as a colloidal carrier for nasal delivery has been investigated, whereby chitosan 
forms colloidal particles that entrap proteins and peptides and improve their permeation in the 
lungs [345]. 
 
Nanoparticles made of conjugates of poly(DL-lactic acid) with ethylenediamino or 
diethylenetriamino bridged bis(β-cyclodextrin) have been investigated for use in protein 
delivery systems [346], where bovine serum albumin (BSA) was encapsulated within 
nanoparticles and have an improved pharmacokinetic profile. Poly(lactic acid) poly(ethylene 
glycol) nanoparticles [347] and N-trimethyl chitosan nanoparticles [348] have also been 
investigated as protein and peptide delivery modules that show high loading efficiencies and 
low cytotoxicity. 
 
3.3.4 Transdermal 
 
3.3.4.1 Introduction 
The transdermal route of administration has the potential for use as a non-invasive delivery 
route for therapeutic agents to the systemic circulation via the skin [349,350]. The primary 
advantages of this route of delivery, besides the non-invasiveness nature of the route, include a 
large surface area that is accessible for absorption and avoidance of GIT degradation and 
hepatic first-pass metabolism, which may lead to an increased bioavailability of therapeutic 
agents administered via this route [349,350]. However, the skin’s outermost layer, the stratum 
corneum, is lipophilic and impenetrable to many therapeutic agents [349,350] and therefore 
limits the applicability of transdermal delivery for hydrophilic compounds such as proteins and 
peptides. 
 
To improve the potential of this route of delivery for agents, including proteins and peptides 
several techniques that compromise skin structure to increase permeability but do not cause 
significant clinical damage to the skin, have been investigated [351]. Techniques such as 
iontophoresis [352], electroporation [353,354], laser treatment [355], and microneedles [351] 
 97 
have been reported to improve the permeability of the skin to macromolecules such as proteins 
and peptides. Non-invasive methods offer a less painful way of drug delivery compared to the 
conventional parenteral route and therefore would have the advantage of better patient 
acceptability [351]. 
 
3.3.4.2 Transdermal Patches 
Transdermal patches are one of the primary means of delivering molecules systemically via the 
skin, although their use is limited to low molecular weight (< 500 Da), highly lipophilic 
molecules that are able to permeate the stratum corneum and for potent drugs that are able to 
produce biological effects at low doses [350]. These factors affect the utility of transdermal 
patches for the delivery of peptides and proteins, which have larger molecular weights, and are 
usually hydrophilic in nature. 
 
An interesting example of a transdermal protein and peptide delivery system is the Macroflux® 
transdermal patch that is able to deliver biopharmaceutical agents to a patient with minimal 
discomfort, in a controlled and reproducible manner [356,357]. Macroflux® transdermal patches 
have a titanium micro-projection array that is affixed to a polymeric adhesive platform. The 
total array may take up an area of up to 8 cm2 and the density of micro-projections may be up to 
300 micro-projections/cm2, with each micro-projection being < 200 µm in length [356]. Each of 
the micro-projections is coated with drug and when the patch is applied to the skin, the micro-
projections penetrate through the stratum corneum into the epidermis, from where the drug is 
absorbed into the systemic circulation. The advantage of this system is that it can produce a high 
rate of absorption promoted by high local concentrations of drug around the micro-projections 
and the large surface area provided by the array of micro-projections [356,357]. 
 
3.3.4.3 Iontophoresis 
Iontophoresis refers to the application of a small constant electrical potential or field across the 
skin to allow for permeation of both charged and uncharged molecules across the skin into the 
systemic circulation [352]. The amount of drug carried across the skin barrier depends on the 
current, duration of application and surface area of skin exposed to the drug [352]. This method 
has been investigated for the delivery of insulin [358,359] and calcitonin [360]. 
 
The primary advantage of iontophoresis in protein and peptide delivery is the ability to control 
the kinetics of delivery of the therapeutic agent, by controlling rate of release into the skin. This 
approach permits the use of a personalised approach to achieving appropriate therapeutic 
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outcomes. The flexibility in drug delivery means that dosing can be altered as a function of 
deterioration or improvement of a condition. In cases in which bolus inputs are required 
following basal delivery, tight control of drug delivery and optimised therapy can be achieved 
using iontophoresis [352]. Additionally, iontophoresis allows for an immediate onset and rapid 
offset of action once the applied current is terminated and iontophoresis is therefore suitable for 
emergency purposes [352]. Moreover, iontophoresis allows for the individualisation of therapy 
depending on the specific drug to be administered and the desired therapeutic profile in vivo. 
For example, iontophoresis can be used to deliver an agent using pulsatile and/or continuous 
release or by mimicking the endogenous peptide/protein cycles [352]. 
 
Iontophoresis has been demonstrated to deliver insulin in animals [361], but in humans, it is 
more difficult to administer insulin in appropriate therapeutic doses. The transport of large 
molecular weight proteins such as insulin is a challenge when using iontophoresis as large 
proteins are unable to permeate through the intact stratum corneum [352]. Iontophoresis has 
been successfully applied to the administration of smaller proteins and peptides such as 
calcitonin [360] resulting in pharmacological activity in vivo. 
 
Modifications to improve iontophoresis as a drug delivery technique include the use of 
poly(lactic-co-glycolic acid) (PLGA) nanospheres where the peptide/protein is encapsulated in 
nanospheres and then delivered across the skin using iontophoresis [362]. Triptorelin delivery 
was reported to have no burst effect in the release profile, allowing for sustained and predictable 
peptide delivery via this system. 
 
3.3.4.4 Microneedles 
The use of microneedles allows the creation of large transport pathways to permit the diffusion 
of molecules into the systemic circulation via the skin. The pathways that are created are larger 
than the dimensions of the molecule that is intended to be delivered and therefore this technique 
provides a possible alternate route for macromolecule delivery [351]. Studies to determine the 
utility of microneedles as a delivery system indicated an increased permeability of several 
orders of magnitude and the permeability of macromolecules such as insulin and BSA following 
use of microneedles was enhanced [363,364]. The use of microneedles therefore permits an 
alternate approach to the use of invasive parenteral delivery for proteins and peptides. 
 
An attractive feature for the use of microneedles in therapy is the painless manner by which 
macromolecules may be delivered to the systemic circulation. Microneedles penetrate only to 
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between 10 – 20 µm into the stratum corneum that contains no nerve endings, therefore offering 
the premise of painless drug delivery [351]. The painless nature of microneedles delivery has 
been investigated in a clinical trial [365] where subjects reported no pain following the insertion 
of microneedles. 
 
Microneedles can be either solid or hollow and each type has specific advantages. The use of 
solid microneedles allows different approaches to increase the efficiency of molecule delivery. 
The ‘poke with patch’ approach uses microneedles to produce openings in the skin structure to 
increase the permeability of a drug and subsequent application of a patch containing the drug 
results in an improved bioavailability. Iontophoresis can be applied to deliver the drug more 
efficiently, otherwise diffusion is the main mechanism by which drug passes into the skin [351]. 
In the ‘coat and poke’ approach, microneedles are coated with drug prior to insertion into the 
skin, thereby allowing drug to be delivered to the body during the insertion process, with no 
drug reservoir required to ensure delivery occurs [351]. Alternatively, the ‘dip and scrape’ 
method can be used, where microneedles are dipped into a drug solution and then scraped across 
the skin, leaving the drug-embedded in the microabrasions created by the microneedles [351]. 
Hollow microneedles permit the incorporation of drug into a hollow space within the needle, 
allowing for active fluid flow on application of microneedles, thereby permitting faster release 
rates compared to the use of solid microneedles [351]. 
 
Microneedles have been assessed for use as insulin delivery systems in hairless diabetic rats 
[366], where solid microneedles were injected into the skin using a high velocity injector. A 
solution of insulin was placed on top of the needles for a period of 4 hours, during which there 
was an observed steady decline in blood glucose levels in the rats. These results indicate the 
therapeutic potential of microneedles for insulin delivery and their ability to elicit a 
pharmacological response in vivo. Hollow microneedles have also been shown to be effective in 
reducing blood glucose levels following application into the skin of diabetic hairless rats [364]. 
 
3.3.5 Ocular Delivery 
 
3.3.5.1 Introduction 
The ocular route of delivery may be used for the systemic delivery of proteins and peptides, as 
this route allows for the rapid absorption of agents from the eye into the systemic circulation 
and permits the avoidance of hepatic first pass metabolism [332,367]. Instillation of 
formulations into the lower conjuctival sac can result in systemic absorption [368]. 
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The bioavailability of macromolecules via this route is expected to be lower than that for 
smaller drug molecules because of their molecular dimensions, hydrophilicity, and susceptibility 
to peptidase degradation in different tissues in the eye. One of the key disadvantages to the use 
of the ocular route for protein and peptide administration is that large sized molecules are likely 
to result in itching in the eye and lachrymation, causing a reduction in the bioavailability of 
therapeutic agents, which are washed out of the eye by tears [332,367]. Furthermore, there is an 
increased potential for irritation of the eye and the possible need for frequent instillation or 
application of the ophthalmic preparations [332]. The dynamics of the lachrymal drainage 
system limits the utility of this route of delivery of agents intended for systemic absorption as it 
rapidly drains lachrymal fluids and any other instilled solutions from the pre-corneal area into 
the nasal cavity and throat. Drainage of eye fluid results in rapid elimination and reduced 
bioavailability of therapeutic agents administered via the ocular route [368]. Examples of 
macromolecules for which absorption through the eye into the systemic circulation has been 
observed include enkephalinamide [369], inulin [369,370], and insulin [371,372]. 
 
3.3.5.2 Formulation Strategies 
The use of insulin solutions for ocular delivery has been investigated [373-375] but 
bioavailability of insulin was limited due to the rapid clearance of topically administered 
solutions from the eye. Failures in these formulations, indicates the need for use of permeation 
enhancers or alternate formulation optimisation strategies to increase absorption of ocularly 
administered proteins and peptides. The use of permeation enhancers is limited compared to the 
transdermal route because of the sensitivity of the eye to different chemical entities. An issue 
when using permeation enhancers for ocular delivery includes the potential toxicity to the 
ophthalmic tissues following repeated and long-term application of products [376]. 
 
Examples of agents that have been used include the sodium salts of bile acids such as 
taurodeoxycholate, taurocholate, glycocholate and deoxycholate salts which increase the 
permeability of insulin [372,377], showing the potential use of bile salts for application to the 
eye. Other examples of permeation enhancers include BL-9 [371,372], saponin [378,379], Brij 
78 [380]. 
 
Sucrose cocoate has been investigated as a means to improve the ocular absorption of insulin 
[341] in rats, where it was observed that an insulin preparation containing 0.5% sucrose cocoate 
resulted in increased insulin plasma levels with a corresponding decline in plasma glucose 
levels. Tetradecylmaltoside, a long chain alkyl glycoside was found to promote calcitonin 
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absorption, albeit to a lesser extent than that observed following the nasal administration of 
calcitonin [381]. 
 
Ocular formulations may also be prepared as viscous solutions, suspensions, and using 
liposomes, in an attempt to increase the bioavailability of ocularly administered drugs [368]. 
Increased bioavailability would be expected with increased viscosity of formulations because of 
the longer contact time and reduced clearance of the formulation in and from the eye. 
 
3.3.5.3 Particulate Delivery Systems and Intraocular Implants 
Liposomal delivery systems have been evaluated for the ocular administration of insulin 
[371,382] with the primary intention of sustaining and controlling the rate and extent of insulin 
release. The in vitro results indicate a sustained release could be achieved with these 
formulations and in vivo studies in rabbits resulted in a decrease in plasma glucose levels [382]. 
The comparison of therapeutic effectiveness of liposomal formulations and solution of insulin 
solution with or without permeation enhancers showed that the liposomal formulation produced 
a prolonged glucose lowering effect in vivo as compared to the solutions [371]. 
 
The utility of an ocular insert for sustained release of insulin using Gelfoam®, which is an 
absorbable gelatine sponge, as the insulin carrier, was investigated for sustained release of the 
protein [383]. One of the advantages of this technology for ophthalmic administration of drugs 
is that when Gelfoam® absorbs the aqueous components of tears, it becomes soft and pliable and 
is comfortable in the eye [383]. Brij-78 was used as an absorption enhancer and the result 
indicated that the use of an insert resulted in a duration of action of approximately 10 hours as 
compared to 0.9 hours for an insulin solution when 1 mg of insulin was administered, indicating 
the potential usefulness of the device for the controlled delivery of the insulin [383]. Brij-78 as a 
permeation enhancer was found to improve the therapeutic efficacy of insulin using Gelfoam® 
devices and prolongs the duration of action of ocular inserts compared to insulin solutions 
[380]. Gelfoam® has aslo been found to be effective for insulin delivery when formulated with 
acetic acid in the absence of a surfactant, with the primary advantage of reducing eye irritation 
that may occur because of inclusion of surfactants in ophthalmic preparations [384-386]. 
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3.3.6 Parenteral Delivery 
 
3.3.6.1 Introduction   
The parenteral route of drug delivery particularly via the intravenous, intramuscular, and 
subcutaneous routes, is currently the most accessible and viable means of protein delivery [367]. 
The major drawback of protein and peptide therapy administered in this manner is the rapid 
clearance of proteins and peptides from the systemic circulation as reported in § 3.1.2.1. 
Consequently, multiple injections that are often unacceptable to patients must be used to achieve 
the desired therapeutic outcomes. Strategies for parenteral formulation therefore focus on 
improving the pharmacokinetic parameters of proteins and peptides, thereby reducing the 
number of injections that must be administered to achieve the desired therapeutic outcomes 
[387]. Different dosage forms have been investigated for parenteral protein and peptides 
delivery with differing levels of success. 
 
3.3.6.2 Emulsions 
The use of water-in-oil (w/o) emulsions may result in pharmaceutical preparations with 
sustained release profiles for therapeutic agents, decreasing the need for frequent administration 
compared to conventional parenteral dosage forms [388]. In addition, increased stability of 
proteins and peptides is possible when using w/o emulsions since hydrophilic proteins and 
peptides are sequestered into the aqueous, dispersed phase and the oil phase protects the 
components of the aqueous phase from enzymatic degradation [388]. 
 
Oils and surfactants for use in emulsions for parenteral delivery systems must be non-toxic and 
should cause minimal muscle irritation or necrosis. Biocompatible emulsion systems include 
w/o emulsions prepared from a medium chain length triglyceride derived from fractionated 
coconut oil as the oil phase and polyglycerol polyricinoleate and sorbitan monooleate as 
surfactants located in the lipophilic phase [388]. Such systems have been reported to have a 
sustained release effect with an absorption half-life of up to at least 8 hours, with an associated 
high retention of the system at the intramuscular injection site. After 24 hours following 
injection of the preparation, 76 – 83% of the original amount in the dosage form was present at 
the site of injection, indicating the potential of w/o emulsions for use as sustained release 
delivery systems for proteins and peptides [389]. 
 
A w/o emulsion that has been investigated for use as a potential depot for the sustained release 
of a model polypeptide, aprotinin [390]. The system that was reported to be stable in vitro and 
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in vivo with resultant peak plasma concentrations occurring at 12 hours is comprised of 
fractionated coconut oil, triglycerol polyricinoleate-6, and Span 80 as the surfactants. 
 
A challenge in the use of emulsion systems for the controlled delivery of proteins and peptides 
is the possible discrepancy between the resultant in vitro and in vivo data that are derived from 
experiments. Inconsistencies may be a consequence of an interaction between surface-active 
proteins such as albumin and emulsion systems or the in vivo degradation of lipid phases of 
emulsions by lipase enzymes, which alters the composition of emulsions resulting in an 
unpredictable release profile of drug from these systems [390]. Furthermore, emulsions used as 
parenteral formulations are limited by the lack of long-term stability and as a result, may fail in 
controlling drug release over extended periods of time [367]. It has been reported that protein 
formulations made from w/o emulsions may result in changes in the protein conformation 
placed in that formulation and that changes in the distribution of secondary structure elements, 
viz., the α-helix and β-sheets in insulin and growth hormone for example [391]. 
 
3.3.6.3 Microparticles and Nanoparticles 
The classification of microparticles and nanoparticles is based on their respective colloidal 
sizes. Nanoparticles may be defined as submicron (< 1 µm), ranging in size from 10 – 1000 nm. 
These colloidal systems are often, but not always made of polymeric materials [392,393]. 
Nanoparticles may be distinguished into nanocapsules, which are vesicular systems, and in 
which a drug is confined within a cavity surrounded by a membrane or nanospheres into which 
a drug is dispersed in a monolithic system comprised of a porous or solid polymeric matrix 
[392,393]. Microparticles may be defined as polymeric entities that are sized between 1 – 1000 
µm [394] and may be separated into two (2) types, viz., microcapsules that are micrometric 
reservoir systems or microspheres which are micrometric matrix systems [394]. 
 
Microspheres developed for parenteral delivery of proteins and peptides can be biodegradable or 
non-biodegradable although the use of non-biodegradable microspheres is limited by the 
toxicity of polymeric materials remaining in the body for long periods and the associated 
difficulty in removing implanted systems. Recent research has focused on the development of 
biodegradable microspheres that require no surgical intervention for removal. In addition, 
release rates from non-biodegradable microspheres are not constant and therefore difficult to 
predict [395] warranting extensive investigations into the use of biodegradable systems. 
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Microspheres for parenteral use have mainly been prepared from PLGA [396-400], although 
other materials such as monomethoxypoly(ethylene glycol)-b-poly(DL-lactide) copolymer 
(PELA) have also been used [401]. Nanoparticles that have been investigated for the sustained 
release of proteins and peptides have also been prepared from PLGA [402] with 
copolymerisation with poly(γ-glutamic acid) (γ-PGA) and L-phenylalanine ethylester (L-PAE) 
[403] amongst other polymeric systems. 
 
Marketed examples of protein and peptide microsphere formulations include Lupron Depot®, a 
sustained release depot suspension of leuprolide acetate, Decapeptyl®, an injectable depot of 
triptorelin and Nutropin Depot®, a monthly subcutaneous preparation for administration of 
recombinant human growth hormone, which has subsequently been withdrawn from the market 
[404]. 
 
Major challenges in the use of microparticles for protein formulations include in vitro protein 
instability during encapsulation and instability in vivo during clinical use, resulting in 
unpredictable and unreliable release rates from formulations. Some studies have shown 
aggregation of the proteins during the encapsulation process for growth hormone [398], 
lysozyme [405], and ribonuclease [406]. In vivo instability was found to result in incomplete 
protein release for proteins such as insulin-like growth factor-I [399] and basic fibroblast growth 
factor [407]. As a result, encapsulation of the proteinaceous drug into microparticles must be 
carefully evaluated and optimised and the in vivo behaviour of the protein and peptide 
formulations prepared from such microspheres must be thoroughly investigated. The use of 
microspheres may also be disadvantageous in therapeutic applications since wide gauge needles 
are often required to administer the dosage form resulting in excessive pain at the injection site 
[408]. 
 
Another reported strategy for ensuring the sustained release of proteins includes the use of 
PLGA microspheres, which are porous when recombinant human growth hormone was loaded 
into the microspheres, but were made non-porous after protein loading resulting in the 
controlled and predictable release of the protein delivered using such systems [398]. The 
advantages of this drug delivery system include the method of preparation that allows for high 
encapsulation efficiency and high protein loading, without alteration to the protein structure. 
 
PLGA nanospheres were reported to release BSA in a sustained release manner [402]. Factors 
important in the optimisation of nanoparticle delivery systems were reported to be the method of 
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preparation, length of the polymer used for the preparation of the microspheres and the presence 
of surfactants in the microsphere composition for modulating protein release. The nanospheres 
that were produced were reported to produce an initial burst effect, followed by a sustained 
release profile for the model protein [402]. 
 
Ovalbumin was successfully loaded onto or into nanoparticles prepared by copolymerisation of 
poly(γ-glutamic acid) (γ-PGA) with L-phenylalanine ethylester (L-PAE) by surface 
immobilisation and encapsulation [403]. The results of the copolymerisation indicated that the 
nanoparticles that were produced could be preserved by freeze-drying without adverse effects 
on the integrity of the delivery systems. Furthermore, cytotoxicity testing indicated that no 
relevant cell damage was caused by the nanoparticles and thereby indicating the potential utility 
of these systems as protein delivery modules [403]. 
 
Sucrose acetate isobutyrate has been evaluated as an additive in the preparation of microspheres 
[409] and was found to increase protein encapsulation efficiency and to retard the release rate of 
lysozyme due to a reduction in the degradation of PLGA microspheres. Surfactants have also 
been evaluated as a means of improving the stability of microspheres [397] and a comparison of 
poloxamer 188, polysorbate 20, and sorbitan monooleate 80 showed that the surfactants reduced 
the effective diameter and the shape of the microspheres and the encapsulation efficiency of 
proteins was reduced. The release rate of insulin increased in the presence of surfactants as 
compared to when no surfactants were added. In addition, there were no short or long-term 
effects on the conformation of insulin observed in the study. Polysorbate 20 at a 3% w/v 
concentration was found to be the most appropriate surfactant for the formulation of insulin 
microspheres [397]. The addition of zinc carbonate to microspheres prepared from PLGA [399] 
was reported to reduce the burst effect that is often observed when microsphere preparations are 
used to deliver proteins. 
 
3.3.6.4 Liposomal Systems  
Liposomes are self-assembled phospholipid vesicles with colloidal dimensions [410]. 
Liposomal systems and modifications thereof have been investigated as drug carrier systems for 
the parenteral delivery of proteins and peptides [410,411]. Liposomes are made from natural 
non-toxic, non-immunogenic lipid molecules that form vesicles and are able to entrap drug 
molecules in their aqueous interior or the membrane structure of the liposome [410,412]. The 
primary advantage of using liposomal delivery systems for the delivery of proteins and peptides 
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is that liposomes have an aqueous environment in which the encapsulated proteins can be 
sequestered and protected from degradation by proteolytic enzymes [412]. 
 
Liposomes are amphiphilic, possessing both polar and non-polar segments, and are self-
aggregating forming different types of aggregates depending on temperature, molecular shape of 
the lipid segments and the conditions (concentration and ionic strength) of the aqueous/lipid 
environment to which they are exposed. The different types of aggregates that may be formed 
include micelles, inverse, prolate, inverse prolate and oblate micelles and unilamellar or 
multilamellar vesicles [410]. 
 
DepoFoam™ technology is comprised of multivesicular liposomes with multiple non-
concentric aqueous chambers that are surrounded by a lipid membrane network [413,414]. 
Formulations of proteins prepared using the DepoFoam™ technology have high loading 
capacity and encapsulation efficiency and minimal chemical/conformational changes in the 
loaded macromolecules were observed. In addition, the liposomes that were formed were found 
to have narrow size distribution and were primarily spherical particles. The utility of the 
technology was assessed by in vitro and in vivo release testing of liposomes containing 
macromolecules such as insulin, leuprolide and enkephalin. The compounds were released over 
a sustained period, varying from a few days to several weeks and sustained in vivo therapeutic 
effects were observed in the test animals [414]. 
 
A combination of polymeric and liposomal systems has resulted in optimised delivery systems 
designed to overcome the shortcomings of liposomes and polymeric systems as delivery 
vehicles for proteins and peptides. Individually, liposomal and polymeric systems are often 
unstable and have biocompatibility issues respectively. The combination systems are referred to 
as carrier-microencapsulated liposomal systems, where drug-containing liposomes are 
encapsulated into microparticles [415]. Polymers that have been used for these purposes include 
dextran [416], and alginate [415,417] and the polymeric systems protect liposomes from 
degradation and increase stability as well as drug loading and encapsulation efficiencies by up 
to 95%, compared to the use of microcapsules or liposomes individually [415]. There was little 
chemical change in BSA by the formulation process used to prepare liposome-encapsulated 
microcapsules. Furthermore, the potential of sustained release was demonstrated by the 
prolonged release of BSA over a period of two (2) weeks [415]. A similar technology for 
protein delivery has been described and uses a liposome-containing horseradish peroxidase 
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encapsulated with fibrin and demonstrated an increased stability of the protein within the system 
[412]. 
 
3.3.6.5 Hydrogel Systems 
Hydrogels are cross-linked hydrophilic polymers that form three-dimensional networks that are 
capable of absorbing large amounts of water or biological fluids [418]. Biocompatibility and 
limited toxicity, easy manipulation and solute permeability, are some of the key reasons for the 
application of hydrogel systems as drug delivery devices in controlled release technologies. 
Other advantages of hydrogels for drug delivery include the biodegradable nature of some 
hydrogels, high protein loading and encapsulation efficiency, easy scale up to produce large 
quantities of useful formulations, and their stability on storage [418]. In addition, hydrogels are 
easily injectable, with good drug diffusion properties, and may be designed to form in situ 
gelling systems for drug delivery. However, hydrogels are noted for their poor mechanical 
strength and difficulty in sterilisation and handling due to the fragile nature of some systems in 
addition to the difficulty in coordinating the release rates of drugs from hydrogel systems 
making it a challenge to produce reliable and predictable drug delivery systems [418]. 
 
Polymeric hydrogels have found application for the delivery of proteins and peptides especially 
for in situ forming depot systems, which have the advantages of ease of administration, are less 
invasive and painful in comparison to implants [419]. Localised or systemic drug delivery may 
be achieved and drug delivery may be tailored to specific therapeutic goals using such systems 
and generally, in situ forming hydrogels have relatively uncomplicated fabrication and 
manufacturing conditions and procedures [420]. 
 
In situ cross-linking of polymeric systems may be used for controlled diffusion of protein and 
peptide drugs, where the formation of cross-linked polymer systems is initiated in vivo 
following administration of the delivery system [420]. However, polymers for in situ cross-
linking devices must have double bonds and require free radical initiation of the cross-linking 
process and are damaging to living tissue, hence limiting the applicability of this method for 
sustaining or controlling protein delivery [420]. 
 
Hydrogel materials can be designed to respond to the external environment and those materials 
that are able to respond in this manner are called environmentally or stimuli sensitive hydrogels 
and may be referred to as smart gels. The environmentally sensitive nature of the materials is 
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due to the presence of thermodynamically active functional groups on the polymer chains that 
result in volume changes of the polymer with changes in the external environment [418].  
 
The use of responsive systems has relevance in biomedical and pharmaceutical applications, 
allowing for the development of drug delivery systems that can be tailored to release therapeutic 
agents with changes in the external environment. Environmental triggers that result in 
volumetric changes in responsive hydrogels include temperature, pH, pressure, electric fields, 
and glucose, amongst others [418,419]. Responsive systems can further be classified as 
externally regulated or self-regulated delivery systems, where externally regulated systems 
respond to external triggers for the pulsed delivery of drugs from a polymeric matrix such 
triggered by changes in magnetic fields, ultrasonic and/or thermal conditions. Conversely, self-
regulated systems allow for negative feedback control of drug release from a polymeric system. 
Drug release occurs when therapeutic intervention is required and is halted when drug effects 
are not necessary and triggers for release include, for example pH, enzyme substrate reactions, 
glucose levels and competitive binding [421]. 
 
3.3.6.5.1 Thermo-Sensitive Hydrogel Systems 
Thermo-responsive in situ forming hydrogels undergo changes in solubility with changes in the 
temperature of the environment to which the hydrogel is exposed [418,420]. The critical 
solution temperature of a thermo-responsive gel is the temperature at which the systems 
undergo a dramatic change in the solubility of the gel and exhibit such changes by swelling or 
shrinking. Thermo-sensitive hydrogels can be classified as positive or negative temperature-
sensitive systems. Positive thermo-sensitive hydrogels have an upper critical solution 
temperature (UCST) above which the aqueous solubility of hydrogel increases and they undergo 
swelling, but below which the solubility of the gel is low and the hydrogel shrinks. Conversely, 
negative thermo-sensitive hydrogels have a lower critical solution temperature (LCST), above 
which the solubility decreases and they undergo shrinking with increases in temperature above 
the LCST [422,423]. Examples of thermo-responsive hydrogels include poly(N-
isopropylacrylamide) (PNIPAAm), poly(N,N-diethylacrylamide) and poly(N-
isopropylacrylamide-co-butylmethacrylate) the chemical structures of which are shown in 
Figure 3.3. 
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Figure 3.3 Chemical structures of some temperature-sensitive polymers [424] 
 
Thermo-responsive gels are often characterised by the presence of many hydrophobic functional 
groups such as alkyl groups on the polymeric backbone [424]. PNIPAAm is the prototype 
thermo-responsive gels and has been the most extensively used and studied material. PNIPAAm 
has an LCST close to body temperatures and forms a stiff gel at approximately 32 °C, and 
therefore has potential to form depot delivery systems at body temperature. However, the 
biomedical use of this polymer for sustained release is limited due to the cytotoxicity and non-
biodegradable nature of the material necessitating surgical removal of dosage forms if this gel is 
used [420]. In addition, cross-linking agents and monomers used in synthesis of PNIPAAm and 
its derivatives are not biocompatible and therefore they have limited human use [424]. 
 
Copolymers are synthesised by the polymerisation of more than one type of monomer and block 
copolymers occur when the monomers used to synthesise the polymer occur as blocks of 
various lengths that are covalently bound together [425]. In a block copolymer, the blocks are 
arranged such that alternating hydrophobic and hydrophilic units occur in the backbone. Block 
copolymers made of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) possess 
reversible thermo-responsive behaviour, converting from sol to gel with increases in 
temperature [425,426]. PEO-PPO block copolymers have been investigated as drug delivery 
systems since high concentrations of PEO-PPO block copolymers exist as stiff gels at body 
temperatures, but are viscous fluids at low temperatures therefore having the potential for the 
formulation of depot systems for the sustained delivery of proteins or peptides. PEO-PPO block 
copolymers are commercially available as Pluronic® and Tetronic® [427]. Pluronic® copolymers 
have been approved by the Food and Drug Administration (FDA) for use in pharmaceutical 
products, including for parenteral dosage forms [428]. The molecular structures of these block 
copolymers are shown in Figure 3.4. 
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Figure 3.4 Polymer structures of several block copolymers:  
A, Pluronic®, B, Pluronic® R, C, Tetronic® and D, Tetronic® R [424] 
 
ReGel® is an ABA triblock copolymer comprised of poly(lactide-co-glycolide) A blocks, and 
poly(ethylene glycol), B blocks [429,430] that have a range of gelation temperatures depending 
on the ratio of PLGA and PEG in the copolymer, the molecular weight of the copolymer and 
concentration of the copolymer in solution. At low temperatures, the copolymers exist as 
viscous solutions, but on injection, a stiff gel is formed which has the potential for depot 
formation and sustained release of drugs formulated in the gel [429,430]. No chemical reaction 
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is required for the formation of the gel and conversion of the gel to the sol state is achieved by 
reducing the temperature of the system to below the transition temperature of the gel polymer 
[429,430]. 
 
Polymeric materials with a LCST undergo a decline in aqueous solubility with increasing 
temperatures and possess moderately hydrophobic functional groups or contain a mixture of 
hydrophilic and hydrophobic functional groups. At low temperatures, hydrogen bonding 
between the hydrophilic portion of the molecule and water molecules dominates and the 
polymer is hydrated and swollen. However, hydrogen bonding decreases with increasing 
temperatures and hydrophobic interactions between the polymer chains become more dominant 
resulting in a decrease in the aqueous solubility of the gel. Inter-chain interactions result in the 
polymer becoming more compact and the material shrinks in size [424] and therefore forms a 
potential depot for sustained drug release. This swelling behaviour is known as inverse or 
negative temperature dependence [424]. 
 
If the polymeric chains in a hydrogel system are not covalently cross-linked, then sol to gel 
transitions may be observed with increases in temperature instead of the swelling-shrinking 
transitions as previously described. Block copolymers such as the Pluronics® and ReGel® 
undergo such temperature-induced transitions [424]. 
 
PNIPAAm hydrogels have been evaluated for use as protein carriers including for BSA and 
insulin as model proteins [431]. It was observed that the rate of release was dependent on the 
type and concentration of cross-linker used in the system, thereby indicating the necessity for 
careful evaluation of hydrogel systems for the controlled release of protein molecules. In 
addition, the size of the protein was also found to be important in determining the rate and 
extent of release from the hydrogel matrix, where insulin which has a smaller molecular weight 
as compared to BSA showed a faster rate and more complete extent of release [431]. 
 
ReGel® has been evaluated for the in vitro and in vivo release of insulin [432] and the results of 
these studies indicated that no burst effect occurred and pharmacological effects were observed 
for a period of 15 days after which approximately 90% of the insulin in the delivery system had 
been released. 
 
Thermo-sensitive biodegradable hydrogels prepared by the polymerisation of Pluronic® triblock 
copolymers and ε-caprolactone were investigated as a sustained release carrier for insulin and 
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BSA [433]. It was reported that the resultant in vitro release rates were related to the molecular 
weight of the protein, with larger proteins being released at slower rates than the smaller sized 
proteins. From these studies, it was concluded that the hydrogel system investigated was 
suitable for use as a potential vehicle for the delivery of proteins and peptides. 
 
3.3.6.5.2 pH Sensitive Hydrogel Systems 
pH responsive hydrogels possess a large number of acidic (e.g. carboxylic and sulphonic acids) 
or basic functional groups (e.g. ammonium salts) that can accept or release hydrogen ions and 
are known as polyelectrolytes. Alteration of the pH of the environment in which the hydrogel is 
dispersed results in a change in the state of ionisation of the hydrogel resulting in the material 
either swelling or shrinking [328,424]. Swelling of pH responsive gels occurs because of 
ionisation of acidic or basic groups and as the degree of ionisation increases, there is an increase 
in the repulsion of the polymer chains resulting in swelling of the hydrogels [434,435]. 
Hydrogels with acidic functional groups tend to swell at pH values above the pKa of the 
polymer and basic polyelectrolytes swell at pH values below their pKb values [423]. Examples 
of pH-responsive polymers include poly(acrylic acid) and poly(N,N’-diethylaminoethyl 
methacrylate) and their molecular structure is shown in Figure 3.5, in addition to the ionisation 
reactions of the materials in acidic and basic media. 
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Figure 3.5 pH responsive ionisation of polyelectrolyte polymeric systems,  
A, poly (acrylic acid) B, poly (N, N’-diethylaminoethyl methacrylate [424] 
 
The ionisation of polyelectrolytes is more complex in comparison to that of monoacids or 
monobases as electrostatic forces exist between adjacent similarly charged functional groups 
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[424]. The use of pH responsive systems is often applied to oral delivery systems where the 
delivery system is exposed to a wide pH range following administration. 
 
3.3.6.6 Sterilisation 
Parenteral formulations must be sterilised prior to their use in vivo and sterilisation techniques 
that may be used for such purposes include membrane filtration, gamma irradiation, 
autoclaving, ethylene oxide sterilisation and high hydrostatic pressure sterilisation [436]. The 
selection of the most appropriate means of sterilisation for each of the different parenteral 
dosage forms developed is an important consideration during development studies in order to 
ensure that the integrity of a formulation is not compromised. 
 
Membrane filtration is a technique that physically removes contaminants from a pharmaceutical 
preparation by passing the formulation through a membrane [436]. Filtration has an advantage 
that it does not cause denaturation or alteration in the physicochemical and conformational 
properties of proteins and peptides in dosage forms. However, the use of this sterilisation 
method is limited when the dosage form is particulate in nature such as microparticles and 
nanoparticles > 200 nm in size and which will be retained on a filter [436]. Furthermore, 
proteins are surface active and can potentially be adsorbed onto membrane filter media resulting 
in a reduction in the effective concentration of the protein in solution [250,251]. 
 
Autoclaving at high temperatures (120 °C) is a very effective method of sterilisation of 
parenteral products [436]. However, high temperatures may cause degradation of proteins and 
may result in the instability of polymeric materials or other excipients used in formulation and 
preparation of dosage forms and it is thus important that the stability of API and excipients be 
investigated in autoclave studies conducted at relevant temperatures. 
 
Gamma irradiation is often used for the sterilisation of parenteral products with the advantage of 
a high penetration power and the isothermal nature of the process that allows for the sterilisation 
of heat sensitive materials such as proteins, without denaturation but with effective elimination 
of microorganisms [436]. In addition, gamma irradiation allows for the homogenous 
sterilisation of preparations that may also be sterilised in their packaging thereby preventing 
further contamination prior to use [436]. Despite the advantages of gamma irradiation as a 
sterilisation procedure it has been found to cause degradation of irradiated proteins by the 
formation of free radicals [437,438] and may compromise the integrity of excipients by 
initiating free radical induced chemical reactions in polymeric materials. To stabilise proteins 
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from degradation by ionising radiation, additives such as o-vanillin have been reported to 
prevent radiation-induced degradation of proteins such as porcine somatotropin [437]. 
 
An alternative method for the sterilisation of biopharmaceutical products is the use of 
supercritical carbon dioxide, which has the advantages of being non-reactive and is able to 
penetrate substances readily whilst maintaining protein conformations in pharmaceutical 
preparations. This method may also be used to sterilise protein/peptide formulations in their 
final packaging [439]. Furthermore, the application of supercritical carbon dioxide sterilisation 
rapidly inactivates bacterial endospores making this method both appealing and applicable to 
the sterilisation of parenteral biopharmaceutical products [439]. 
 
3.3.6.7 Syringeability and Injectability 
Syringeability refers to the characteristics of a parenteral formulation during the withdrawal of 
the formulation from its packaging and includes characteristics such as foaming potential, ease 
of withdrawal, and accuracy of dose measurement [367]. Injectability refers to the properties of 
a parenteral formulation during the actual administration of that formulation to a patient and 
includes the force required for the injection, qualities of aspiration, clogging and the nature of 
product fluid flow [367]. Parenteral delivery systems must be both syringeable and injectable to 
allow for the simple and reproducible administration of a drug product. 
 
3.3.6.8 Packaging 
Biopharmaceutical parenteral preparations are commonly presented as single-dose vials 
containing either a solution or a lyophilised cake intended for reconstitution prior to 
administration of the product [440]. 
 
The importance of an appropriate packaging configuration for biopharmaceutical products is 
obvious since the packaging must ensure that formulations are maintained in a stable state, 
protected from light, chemical contaminants and other potential sources of instability that may 
ultimately compromise the integrity of the formulation. The compatibility between a 
biopharmaceutical product and packaging must be established as packaging may introduce 
contaminants into formulations [440]. 
 
Packaging materials for pharmaceutical products may contain metal ions, plasticisers, and 
chemicals that may leach into a product contained therein. The conformation of proteins is 
important for biological safety and efficacy and the presence of these materials may result in 
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chemical and/or physical instability resulting in aggregation of proteins as discussed in § 
3.1.2.2. In addition, low concentrations of proteins and peptides are often in dosage forms and 
therefore, any chemical reactivity between the packaging and the biopharmaceutical product 
would result in a decrease in the effective concentration of the therapeutic agent in a product 
and therapeutic failure if that batch is used [440]. Moreover, proteins and peptides have a 
tendency to adsorb onto the surfaces of packaging materials, thereby further reducing the 
effective concentration of the proteins in the biopharmaceutical preparation [440]. Lyophilised 
proteins are also susceptible to instability reactions because of inappropriate packaging 
conditions and in cases, for example where a seal does not fit tightly to the primary package, 
moisture may enter the formulation resulting in deactivation of the protein. 
 
Silicone oil is a commonly lubricant for stoppers for parenteral vials, but often causes 
nucleation of proteins around the oil droplets resulting in deactivation of protein and peptide 
molecules [440]. It is therefore imperative that the design of biopharmaceutical dosage forms 
include compatibility assessments with potential packaging materials and these investigations 
must not be neglected and should be investigated over an extended period of time in order 
ensure the delivery of safe and effective protein and peptide formulations. 
 
3.4 CONCLUSION 
 
The successful formulation of proteins and peptides into sustained release dosage forms has the 
potential advantage of improving therapeutic outcomes for patients with less frequent painless 
administration of these agents. The importance of understanding the physicochemical and 
biopharmaceutical properties of proteins must not be neglected. These properties and factors 
have been discussed in Chapter 1, vide infra, for OT. Knowledge of the physicochemical 
stability of OT is important in formulation development to ensure that the molecule is not 
exposed to any factors that would otherwise result in degradation or aggregation of the protein. 
OT is unstable at pH extremes as described in § 1.3.2, exhibiting a maximum stability at a pH of 
between 3 and 5. In any formulation process, OT must not be exposed to any environment with 
pH values outside of this range, as this would result in degradation of OT. Furthermore, the final 
formulation developed for OT must also be buffered to within this pH range to ensure maximal 
stability of the molecule. 
 
The biopharmaceutical parameters of OT are important in designing an appropriate dosage form 
for the peptide, whilst ensuring that OT is delivered in a safe and effective manner. 
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Considerations about current clinical administration guidelines are important to ensure that the 
right dose of OT is delivered at the correct rate and these considerations have been discussed in 
§ 1.4.6. 
 
A review of literature regarding the current trends and technologies in delivery of protein and 
peptide macromolecules was critical in considering alternate routes of delivery and dosage 
forms for OT. The selection of an appropriate dosage form was based on the suitability of that 
method for OT delivery, ease of administration, and comfort for the patient, ease of manufacture 
and/or preparation of the dosage form. Ensuring that OT was retained in a stable form was a 
priority in the decision making process. Other important factors that were considered were the 
expense of the manufacturing process and assessment methods for the delivery system. These 
factors were deemed vital in the decision-making process, since medicines must be affordable 
and novel delivery systems must offer distinct advantages over currently available therapies. 
Each of the different routes of protein delivery discussed herein was considered as a potential 
method of delivery for OT. 
 
The oral route of administration would be the most ideal for administration of OT for the 
prevention of post-partum haemorrhage. However, OT is unstable and undergoes extensive 
degradation when exposed to gastric pH and enzymes in the GIT as documented in § 1.5.1 and 
therefore administration of OT in its native form, would be of no therapeutic use. Different 
strategies to improve OT stability were considered and one possible alternative was the 
modification of the hydrophilic peptide by conjugation with lipophilic groups, via an acylation 
reaction. Chemically, this is a relatively straightforward reaction, but modification of the 
molecule requires full identity characterisation, percent yield determinations and the exact 
positions of modification, which requires expensive instrumentation and can be labour, 
resource, and time intensive. Moreover, chemical modification may result in diminished 
biological efficacy of the molecule as modification may occur at a position that is necessary for 
molecule-receptor interaction and biological activity. 
 
Similarly, although modification with PEG offers distinct advantages to the pharmacokinetic 
stability of proteins and peptides following both parenteral and oral delivery as described in § 
3.1.2.3 and § 3.3.2.2, respectively, the challenges highlighted with the acylation of OT made 
this non-viable for OT formulation development. In addition, the attachment of PEG requires 
the reaction of PEG derivatives with reactive groups such as amino, sulphydryl and carboxyl 
groups on the molecule. The chemical structure of OT shown in Figure 1.2 reveals that the 
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peptide does not have a free carboxyl or sulphydryl group and that it has only a free amino 
terminal group that may be modified. However, the amino terminal functionality is from a 
cysteine residue that forms a disulphide bridge and therefore there is a likelihood of steric 
hindrance occurring during reactions with PEG derivatives and this may alter the conformation 
of OT and render it inactive. 
 
Site-directed delivery of OT into the colon using complexation hydrogels was considered, as 
metabolism of OT in this region of the GIT is not as extensive as that in the stomach and small 
intestine as discussed in § 1.5.1. However, the method of manufacture for complexation 
hydrogels is complex, diminishing the appeal of attempting to deliver OT via this route of 
administration. 
 
Transdermal delivery of OT was also considered and the use of a patch, such as Macroflux® 
described in § 3.3.4.2 was considered an attractive option and would be easily applied in the 
third stage of labour. However, the complication of optimising and characterising the in vitro 
and in vivo release of OT from these systems was a challenge. Microneedles were also 
disregarded for the same reasons and the use of iontophoresis for OT delivery for prevention of 
post partum haemorrhage was found to be impractical for this particular indication. 
 
Nasal delivery is a currently used technique for OT administration for promotion of lactation 
and the development of OT using this route of delivery has the advantage that pharmacokinetic 
parameters of OT using this route are well established. The use of a nasal solution of OT would 
be limited by the resultant short duration of action of the molecule, although modification by 
using colloidal carriers and bioadhesive polymers may overcome this limitation. However, the 
production of these systems requires a full characterisation of the particles used in the delivery 
system and therefore was not considered for OT delivery. 
 
Ocular delivery of OT has been demonstrated demonstrated [441], but was not considered as a 
practical alternative for OT administration due to the discomfort expected from instilling eye 
drops after labour and possible reduced efficacy because of lachrymation. 
 
The parenteral route was therefore considered the most feasible means of OT delivery. 
Nanoparticles and microparticles offer the advantage of extended release preparations that are 
capable of releasing drug for periods ranging from days to weeks. However, such a long 
duration of action was not desirable for use in the prevention of post partum haemorrhage using 
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OT. Liposomal systems offer an aqueous phase for the encapsulation of hydrophilic proteins 
and peptides that may reduce enzymatic degradation, but the inherent instability of liposomes, 
limits their potential usefulness in protein delivery. 
 
Hydrogels were considered as a possible carrier system for the administration of OT, with the 
primary advantage of being biocompatible. Although the low mechanical strength of most 
hydrogels may limit the duration and extent of release, this was considered as a positive factor 
as this would allow development of a dosage form that would release the drug over a relatively 
short period. Thermo-sensitive hydrogels were regarded as the best potential drug delivery 
matrices for OT as they permit the administration of a cold preparation via a needle, but forms a 
potential depot for sustained release in vivo. NPIAAm was considered for this application, 
although the usefulness is limited by the known cytotoxicity of the polymer.  
 
The Pluronic® block copolymers were evaluated as a potential delivery depot for OT. Some 
solutions of Pluronic® block copolymers are able to form gels as described and may be used for 
the sustained delivery of proteins and peptides. Furthermore, the FDA has approved Pluronic® 
block copolymers for parenteral use and therefore toxicity data has been evaluated making these 
polymers potentially useful for sustained drug delivery. Pluronic® block copolymers are also 
commercially available and therefore, little composition characterisation is required, as the 
copolymers must conform to international manufacturing standards. Pluronic® block 
copolymers were therefore characterised according to ultraviolet and infrared spectroscopy, 
critical micelle concentration, gelation temperatures and viscosity among other properties and 
these studies are fully described in Chapter 4, vide infra. 
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CHAPTER 4 
 
THE CHARACTERISATION OF PLURONIC® F127 AS A POTENTIAL 
VEHICLE FOR THE PARENTERAL DELIVERY OF OXYTOCIN 
  
4.1 INTRODUCTION 
 
The characterisation of Pluronic® F127 (PF-127) as a potential vehicle for the parenteral 
delivery of OT was performed as part of preliminary studies in the development of a delivery 
system for the peptide and to assess whether OT release from the dosage form was predictable. 
Information from characterisation studies would be valuable for predicting the behaviour of the 
vehicle during the manufacturing process, following storage as well as during administration of 
the dosage form in vivo. The impact of these processes on the integrity of the dosage form can 
be predicted from the data generated during preliminary studies. In addition, the polydisperse 
nature, possibility of homopolymer and diblock polymer impurities, as well as batch-to-batch 
variability characteristic of polymeric materials such as PF-127 warrants particular investigation 
of the batch to be used in the formulation of a dosage form [442,443]. 
 
4.2 PLURONIC® COPOLYMERS 
 
4.2.1 Introduction 
 
The non-proprietary name for the Pluronic® group of copolymers is poloxamer. They are also 
known commercially as Lutrol®, Monolan®, Supronic®, Synperonic® or as poloxalkol, 
poly(ethylene-propylene) glycol copolymers and poly(oxyethylene)-poly(oxypropylene) 
copolymers [428]. They are a series of commercially available high molecular weight synthetic 
block copolymers of ethylene oxide and propylene oxide [10,11,426]. The general formula for 
the poloxamer block copolymers is depicted in Figure 4.1. 
 
O C
H2
CH2
A
 
H O C
H
CH2
CH3 B
 
O C
H2
CH2
A
 
OH
 
Figure 4.1 The general formula for Pluronic® copolymers 
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They are known as ABA block copolymers where the poly(propylene oxide) (PPO) block (B) is 
sandwiched between two poly(ethylene oxide) (PEO) blocks (A). The PPO block is 
hydrophobic and the PEO block is hydrophilic, thereby creating amphililic poloxamers that 
possess surfactant properties and that are self-associating in melts and solutions [425]. 
 
Variations in the lengths and proportions of the PPO and PEO units generate a wide variety of 
poloxamers with different physicochemical properties and applications [425-427]. They are 
used primarily in pharmaceutical applications as solubilising or emulsifying agents for 
parenteral preparations of poorly soluble drugs and in the formation of fat emulsions. In syrups 
and elixirs, they are used for clarifying purposes and in suppositories and ointments; they may 
be used as wetting agents [428]. Poloxamers have been investigated as micro-containers for 
drugs where a drug is solubilised in micelles [444,445] and can increase the penetration of drugs 
through tissues such as the blood brain barrier [446]. In addition, they have been shown to 
potentiate the action of anticancer agents in cancerous cells [447]. There has also been a long-
standing interest in the use of poloxamers in the development of sustained release formulations 
for parenteral, topical, and oral delivery of drugs [448-454]. 
 
4.2.2 Synthesis 
 
The synthesis of poloxamer block copolymers is carried out under conditions of elevated 
temperature and pressure, with the use of a basic catalyst such as sodium or potassium 
hydroxide. A summary of the synthetic procedure for the production of these polymers is shown 
in Figure 4.2. Propylene oxide is slowly added to propylene glycol to produce a 
poly(oxypropylene glycol) derivative of the desired weight, depending on the specific 
poloxamer copolymer block required (Step 1). This produces the middle block of the copolymer 
(B as shown in Figure 4.1). Ethylene oxide is then added slowly to the polymer until the final 
molecular weight that is required, is obtained (Step 2). Finally, the catalyst is neutralised by the 
addition of phosphoric acid to produce a final pH of approximately 7 [426]. 
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Figure 4.2 The synthesis of Pluronic® copolymers [426] 
 
4.2.3 The Pluronic® Grid 
 
Different poloxamers of differing molecular weight and proportions of PEO and PPO can be 
produced using the synthetic procedure described Figure 4.2. As a result, polymers of different 
properties with regard to their physical state and nature at room temperatures and pressures are 
produced. This has resulted in the development of the Pluronic® grid, which characterises the 
different poloxamers with respect to their molecular weight and the ratio of PEO to PPO 
[425,426]. The Pluronic® grid is summarised in Figure 4.3. 
 
Copolymers shown in the Pluronic® grid that occur along vertical lines have the same PEO: 
PPO ratio and those shown along the same horizontal lines have the same PPO block lengths. 
The naming of the poloxamer polymeric materials is based on the Pluronic® grid. The use of a 
letter denotes the physical state of the polymer, viz., L for liquid, P for paste and F for flakes. 
The initial one (1) or two (2) digits indicate the molecular weight of the hydrophobic PPO block 
and the last digit denotes the proportion of PEO multiplied by 0.1 [425,426]. 
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Figure 4.3 Pluronic® grid adapted from [425,426] 
 
4.2.4 Gel Formation Properties of Poloxamers 
 
Some poloxamers are able to form gels depending on the molecular weight and proportion of 
PEO present in the copolymer. The lower molecular weight polymers are not able to form gels 
in aqueous media at any concentration, but as the molecular weight and proportions of PEO 
increase, there is an increased tendency of the polymer to form gels. Higher concentrations of 
the lower molecular weight copolymers are necessary for gel formation, for example, Pluronic® 
F88 (PF-88) forms a gel at 40% w/w and Pluronic® F108 (PF-108) forms a gel at 30% w/w, 
whereas PF-127 forms a gel at a concentration of only 20% w/w [426]. 
 
PF-127 exists as a viscous liquid at low temperatures (2 – 8 °C) and forms a stiff gel when 
warmed and the temperature at which this occurs depends on the concentration of gel former 
[425,426]. The thermo-gelling behaviour of PF-127 means that at low temperatures, the sample 
is free flowing, allowing relatively easy administration of a PF-127 based formulation using a 
syringe and a needle. The stiff gel that is formed at body temperatures would produce a 
potential depot for sustained delivery of drugs such proteins and peptides in situ; PF-127 is 
therefore a potentially useful copolymer for the development of a thermo-responsive parenteral 
delivery system. 
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4.3 PLURONIC® F127 
 
4.3.1 Physicochemical Properties 
 
PF-127 has a nominal molecular weight of approximately 12600, but the weight ranges between 
9840 – 14600 [10,11,428], with an approximate weight percent of PEO of 70%, (73.2+1.7%) 
[10]. PF-7 is free flowing with a melting point between 52 – 57 °C [428]. It is freely soluble in 
water, ethanol, and propan-2-ol and practically insoluble in light petroleum [11,428]. 
 
4.3.2 Toxicity 
 
The toxological properties of the poloxamer block copolymers have been studied [426]. 
Poloxamers are considered only slightly toxic and their toxicity decreases as the molecular 
weight and the proportion of PEO in the polymeric backbone increases. PF-127, which contains 
70% of PEO is considered to be non-toxic with a reported very high LD50 [426], the highest 
dose/concentration at which 50% of the test animals survive after the administration of a single 
dose of the copolymers. 
 
Chronic studies, where the poloxamers were administered to animals for a long period also 
indicated the non-toxic nature of these copolymers and no adverse effects were observed in 
tissues and organs. Three (3) generation toxicology studies, where the offspring of test animals 
dosed with PF-127 were observed and monitored for any adverse effects, showed that the block 
copolymers did not result in any adverse effects that could be attributed to the dose of the 
poloxamers received by the first generation test animals [426]. 
 
It is reported that the poloxamers, including PF-127 are considered safe, non-irritating, and non-
sensitising when applied in 5% and 10% w/v concentration to the eyes, gums, and skin [428]. 
Following intravenous administration for fourteen (14) days, of up to 0.5 g/kg/day of poloxamer 
in rabbits and dogs, no serious adverse effects were noted [428]. In a longer-term study, of up to 
two (2) years, rabbits were fed 3% or 5% w/w of poloxamer in food and the test animals did not 
show any obvious signs of toxicity, although at a dose of 7.5% w/w, there were indications of 
retardation in the growth rate of the animals [428]. Furthermore, poloxamers do not cause 
haemolysis after exposure of human blood cells for a period of eighteen (18) hours at 25 °C 
[428]. The non-toxic nature of PF-127 has resulted in its inclusion in the FDA Inactive 
Ingredients Guide, including for use in parenteral preparations [428]. 
 
 124 
The suitability of PF-127 as a vehicle for intramuscular use has been evaluated in rabbits [455] 
and the toxicity was evaluated by monitoring the morphology of muscle tissue and by 
monitoring creatine phosphokinase levels following single and multiple doses of the polymer. 
PF-127 administration causes a similar muscle irritability that is comparable to traditional 
parenteral vehicles such as peanut oil and Cremophor® EL, therefore making it a potentially 
viable vehicle for the parenteral administration of drugs [455]. 
 
Although PF-127 has generally been considered non-toxic, with no serious reported adverse 
effects, Wout et al. [456] showed that it can result in a sustained hypercholesterolamia and 
hypertrigylceridaemia over a period of four (4) days in rats, following intraperitoneal 
administration of a 30% w/w solution of PF-127 at a dose of 1.5 g/kg. These changes are related 
to alterations in the biological activity of lipid metabolising enzymes [456]. Blonder et al. [457] 
showed the dose dependant effects of PF-127 on hyperlipidaemia and after single injections of 
lower doses (< 27.5 mg/kg) in rabbits, there was no alteration in the lipid metabolism in those 
animals. Despite the induction of hyperlipidaemia following the use of PF-127, the use of the 
gel as a controlled delivery matrix for drugs would result in only low doses of poloxamer being 
administered, and as such would not result in these untoward effects [457]. 
 
4.4 EXPERIMENTAL 
 
4.4.1 Reagents and Materials 
 
PF-127 was donated by BASF (Ludwigshafen, Germany) and was used as received. Nujol® was 
obtained from UniLab (Redmont, WA, USA). Cobaltous nitrate was obtained from Merck 
Chemicals (Modderfontein, South Africa) and ammonium thiocyanate was purchased from 
Sigma-Aldrich (St Louis, MO, USA). Carbonyl free ethyl acetate and acetone were obtained 
from Burdick and Jackson (Muskegon, MI, USA) and Associated Chemical Enterprises (Pty) 
Ltd (Johannesburg, South Africa), respectively. Absolute ethanol was obtained from Saarchem-
Holpro Analytic (Pty) Ltd, (Krugersdorp, South Africa). All chemicals were used as received 
without further modification and were at least of analytical reagent grade. 
 
 125 
4.4.2 Methods 
 
4.4.2.1 Preparation of PF-127 Solutions 
The preparation of different solutions of PF-127 solutions was undertaken using the cold 
method as previously described by Schmolka [426]. The solutions of PF-127 were prepared by 
weight (% w/w) and commences by weighing appropriate amounts of PF-127 flakes into a 100 
ml beaker. The flakes were added to chilled HPLC-grade water (5 °C) slowly over a period of 
about 2 – 3 min with gentle stirring using a LabconTM MSH 10 model (Labmark, Maraisburg, 
South Africa) magnetic stirrer. The solution was then placed in a refrigerator for a period of 
approximately 24 hours or until all the PF-127 had dissolved and the solution was clear on 
visual inspection. Figure 4.4 summarises the cold method. 
 
PF-127 flakes weighed 
Dispersed slowly in chilled water
         using magnetic stirrer 
  Placed in a refrigerator for
until 24 hours or until solution 
   clear on visual inspection 
 
Figure 4.4 Cold method for PF-127 gel prepration 
 
4.4.2.2 Preparation of Stock Solutions 
A 1% w/v solution of PF-127 was prepared by accurately weighing 1 g of PF-127 flakes which 
were dispersed as described in Section 4.4.2.1 in approximately 70 ml of chilled HPLC-grade 
water in a 100 ml beaker and placed in a refrigerator until the solution was clear on visual 
inspection. The solution was then placed in a 100 ml A-grade volumetric flask and made up to 
volume with HPLC-grade water to obtain a final concentration of 1% w/v. The stock solution 
was used to prepare calibration standards, by serial dilution, of PF-127 with resultant 
concentrations of 0.01%, 0.025%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4% w/v using A-grade 
glassware.  
 
Approximately 10 g of PF-127 flakes were accurately weighed and dispersed in approximately 
70 ml of chilled HPLC grade water at 5 °C as described in § 4.4.2.1 and placed in the 
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refrigerator until the solution was clear on visual inspection. The solution was then placed in a 
100 ml A-grade volumetric flask and made up to volume with HPLC grade water to obtain a 
final concentration of 10% w/v. The 10% w/v stock solution was used to prepare standards with 
concentrations 0.00001%, 0.00002%, 0,00005%, 0.0001%, 0.0002%, 0.0005%, 0.001%, 
0.002%, 0.005%, 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 2% and 5% w/v, by serial 
dilution using A-grade glassware and ensuring that a minimum of 1 ml was used at each 
dilution. 
 
4.4.2.3 Ultraviolet Absorption Spectrum 
The ultraviolet absorption spectrum of a 0.5% w/v PF-127 solution and a combination of a 0.5% 
w/v PF-127 solution and 200 IU/ml OT were obtained using a GBC UV/VIS 916 
spectrophotometer (GBC Scientific Equipment Pty Ltd, Dandenong, VC, Australia). The 
spectrum was recorded in the wavelength range 200 – 600 nm, at a scan speed of 600 nm/min 
and data interval of 0.800 nm.  
 
4.4.2.4 Infrared Spectrum 
The infrared (IR) absorption spectrum of PF-127 and a mixture of PF-127 and OT, was obtained 
using a FT-IR Spectrometer Spectrum 2000 (Perkin Elmer Instruments LLC, Shelton, CT, 
USA) over the range 4000 – 400 cm-1, using Nujol® to suspend the poloxamer and the mixture. 
 
4.4.2.5 Validation of an Analytical Method for the Quantitation of PF-127 
An analytical method reported to be suitable for the quantitation of PF-127 [458] was validated 
by assessing linearity, accuracy, and precision. A stock solution of PF-127 and the calibration 
standards were prepared as described in § 4.4.2.2. 
 
In order to analyse the samples of PF-127, 3 g of cobaltous nitrate and 20 g of ammonium 
thiocyanate were dissolved in a 100 ml A-grade volumetric flask with HPLC-grade water to 
produce cobalt thiocyanate. 200 µl of the relevant Pluronic® standard, 100 µl of cobalt 
thiocynate, 200 µl of ethyl acetate and 80 µl of absolute ethanol were then added to a 1.5 ml 
microcentrifuge tube (Eppendorf AG, Hamburg, Germany) and centrifuged for 1 minute at 
14500 g in a Model 5414 Eppendorf Centrifuge (Eppendorf AG, Hamburg, Germany). After 
centrifuging, dark blue sediment formed at the bottom of the centrifuge tube and two (2) upper 
layers were formed above the sediment. Thereafter, the two (2) upper layers were carefully 
aspirated so as not to disturb the sediment. The sediment and tube were washed with 200 µl 
ethyl acetate until the ethyl acetate that was aspirated was colourless. The sediment was then 
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dissolved in 2 ml acetone and the absorbance measured at 328 nm using a Model 1240 UV-VIS 
Spectrophotometer (Shimadzu Scientific Instruments, Columbia, MD, USA) [458]. All 
determinations were performed in triplicate (n = 3). 
 
4.4.2.6 Measurement of Surface Tension 
The measurement of surface tension was achieved using the Du Noüy Tensiometer Version 2.0 
(Cambridge Instrument Co. Ltd, London and Cambridge, UK). The solutions for measurement 
were prepared by serial dilution of a stock solution of 10% w/w PF-127 and the solutions 
prepared for testing were prepared in the concentration range 10-5 – 10% w/v PF-127, as 
described in § 4.4.2.2. Surface tension measurements were carried out in triplicate (n = 3) in an 
ambient environmental temperature of 19 °C that was monitored using a mercury thermometer 
for the duration of the experiment.  
 
4.4.2.7 Determination of Transition Temperatures for PF-127 Solutions 
The measurement of the gelation or transition temperatures for various concentrations of PF-127 
solutions was conducted according to the method described by Gilbert et al. [459]. Aliquots (2.5 
ml) of PF-127 solution of concentrations 18%, 20%, 22.5%, 25%, 27.5%, 30% and 32.5% w/w 
were prepared as described in § 4.4.2.1 and placed into 10 X 75 mm Kimble Borosilicate Glass 
Culture tubes (Division of Owens-Illinois Perrysburg, OH, USA). The solutions were placed in 
a water bath at 5 °C and the temperature of the water bath was increased by 1 °C in incremental 
steps and the temperature was allowed to equilibrate for 15 min prior to the assessment of 
gelation. Gelation was considered to have occurred when the test tube was rotated by 90° and no 
movement of the meniscus occurred. A second transition temperature was considered to have 
occurred if the solutions became flowable at another temperature after the initial formation of 
the gel. The assessment of gelation was performed in triplicate (n = 3).  
 
4.4.2.8 Measurement of Viscosity 
Viscosity measurements were performed using a Brookfield Digital Viscometer Model DV-I+ 
(Brookfield Engineering Laboratories, Inc, Stoughton, MA, USA). The viscometer was 
calibrated using a 5000 cP viscosity standard (Brookfield Engineering Laboratories, Inc, 
Stoughton, MA, USA) in a 100 ml beaker and a correction factor was determined. PF-127 
solutions were placed in a water bath and allowed to equilibrate for at least 30 min before 
viscosity readings were taken at the different temperatures, viz 5, 10, 15, 20, 25, 30 and 37 °C. 
The viscosity of the relevant solution was measured in a 100 ml beaker with an internal 
diameter of 44.5 mm. Disc spindles were used to measure the viscosity before gelation occurred 
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and T-bars spindles were used to assess viscosity after gelation had commenced. In addition, a 
Helipath Stand (Brookfield Engineering Laboratories, Inc, Stoughton, MA, USA) was used to 
facilitate viscosity measurement after the gel had formed. Measurements were performed in 
triplicate (n = 3).  
 
4.4.2.9 Gravimetric Analysis of PF-127 Solutions of Different Concentrations 
Gravimetric analysis of three different concentrations of PF-127, viz. 20%, 25% and 30% w/w, 
solutions was performed by accurately weighing approximately 2 g of the previously 
manufactured gel solutions as described in § 4.4.2.1 into moulds with a single open end. The 
mould dimensions were 23.6 X 11.0 X 8.0 mm (LxWxD) and weighing was undertaken using a 
Mettler-Toledo Model AG135 electronic balance (Mettler-Toledo, Inc. Columbus, OH, USA). 
The gels were allowed to set at 37 °C in a convection oven for a period of 15 min prior to the 
dissolution test. The gels were then placed into a USP Apparatus 1 dissolution bath (Hanson 
Research Cooperation, Chatsworth, CA, USA) set at 25 rpm and a bath temperature of 37 + 0.5 
°C. Samples were removed from the basket at 30, 50, 90, 120, 180, 240, 300, 360, 420 and 480 
min, and weighed on a Mettler-Toledo AG135 electronic balance (Mettler-Toledo, Inc. 
Columbus, OH, USA) after gently blotting dry using filter paper, after which they were replaced 
and the test was continued. These studies were conducted in triplicate (n = 3).  
 
4.5 RESULTS AND DISCUSSION 
 
4.5.1 Ultraviolet Absorption 
 
The UV absorption spectra of a 0.5% w/v solution of PF-127 and of a combined solution of OT 
(100 IU/ml) and PF-127 (0.25% w/v) are shown in Figure 4.5. PF-127 has no significant 
absorbance in the specified region, as poloxamers do not contain chromophores (Figure 4.5a). 
The spectrum obtained for the combined solution of OT and PF-127 (Figure 4.5b) is similar to 
that reported in Figure 1.5 indicating that it is unlikely that an interaction exists between the 
drug and copolymer that may alter the chemical nature of the molecules and  OT biological 
activity, in vivo. 
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Figure 4.5 UV absorbance spectrum for PF-127 (0.5% w/v) solution (A) 
 and for PF-127 (0.5% w/v) combined with OT solution (200 IU/m)l (B) 
 
A 
 
B 
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4.5.2 Infrared Spectrum 
The IR spectrum of PF-127 is shown in Figure 4.6. Poloxamers are characterised by repeating 
units of ethylene oxide, with ether linkages between each of the units. Poloxamers also have C-
H bonds and a terminal hydroxyl group and the infrared spectrum indicates the presence of 
these functional groups. The medium intensity broad band at around 3500 cm-1 is attributed to 
the presence of a hydroxyl group and the broad intense peak that occurs between 3000 – 2850 
cm-1 is due to C-H bond frequencies, which are present in both the poloxamer molecule and 
liquid paraffin that was used to produce a sample for analysis. In addition, the wide bands of 
frequencies that occur between 1400 – 800 cm-1 are also due to the presence of C-H bond [29].  
 
The incidence or occurrence of an interaction between PF-127 and OT is considered minimal on 
investigation of the infrared spectra reported in Figure 4.6. An interaction between two 
compounds would be observed in the infrared spectrum by the appearance of frequencies 
different to those observed when considering IR spectra of pure OT or PF-127. The spectrum 
shown in Figure 4.6b reveals no incidence of new frequency bands when compared to both the 
spectra of OT and PF-127 shown in Figures 1.5 and 4.6a respectively, indicting no interactions 
between the compounds. 
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Figure 4.6 Infrared absorption spectra of PF-127 (A)  
and for PF-127 combined with OT (B) 
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4.5.3 Analytical Method for PF-127 
 
4.5.3.1 Introduction 
An analytical technique for the quantitation of dissolved poloxamer is valuable for establishing 
the mechanism(s) of drug release from gels [460]. The use of an accurate analytical tool was 
reported by Yang et al. [460] and that had been adapted from a method reported by Ghebeh et 
al. [458]. 
 
4.5.3.2 Poloxamer Assays 
A method for the approximation of the amount of PF-127 dissolved in a receptor medium has 
been described [450]. An aliquot of the receptor medium was removed at specific intervals, the 
aqueous component was evaporated and the amount of PF-127 dissolved at these times was 
determined gravimetrically from the residues that remained after ensuring that complete 
evaporation of the aqueous media had been achieved [450].  
 
Most commercial non-ionic surfactants such as PF-127 do not have chromophores that would be 
useful to enable quantitation by methods such as HPLC with UV or UV spectrophotometry 
[461] (See Figure 4.5a). The development of titrimetric and spectrophotometric analytical 
methods for poloxamers depends on the formation of complexes between polyether groups in 
the polymer and large cationic materials [461]. However, the main challenge with respect to 
assay development is the lack of reactivity of the polyether groups in poloxamers, which require 
vigorous reaction conditions to facilitate interaction [458]. 
 
Spectrophotometric techniques are used routinely for the quantitation of non-ionic surfactants 
such as poloxamers, despite sensitivity to interference [461]. The main challenge in the use of 
spectrophotometric assays for the quantitation of non-ionic surfactants include complicated 
calibration methods as the development of colour complexes depends on the molar 
concentration of the surfactant, length of the ethoxy chains and the particular hydrophobic 
component of a molecule [461]. In addition, the use of arbitrary standards for calibration may 
result in calibration errors, because a standard may not yield the same molar complex as a 
sample [461].  
 
Analytical methods described in the literature for the accurate quantitation of poloxamers are 
the Wickbold [462], potassium tetrakis (4-halophenyl) borate [463], iodine assay [464], and 
cobalt thiocyanate methods [458,465,466]. 
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The Wickbold method [462] results in the formation of a complex between the poloxamer and 
tetraiodobismuthate and the resultant precipitate is dissolved and titrated with pyrrolidone 
dithiocarbamate. The method requires the use of specially designed apparatus for concentrating 
samples [462]. The titration of poloxamer with potassium tetrakis (4-halophenyl) borate 
provides an alternate method of analysis in which the end point of the titration is determined by 
an indicator for excess tetrakis (4-halophenyl) borate [463]. Both these methods are described as 
tedious and time consuming, and were therefore not used for the quantitation of poloxamer in a 
reported study [458]. At an acidic pH, iodine reacts quantitatively with Pluronic F-68 giving a 
brown solution of which the optical density may be measured using spectrophotometric 
detection. This method however is non-specific and side reactions of the oxyethylene chain with 
other compounds may occur and the method is susceptible to interference from other 
compounds [464]. 
 
The cobalt thiocyanate method is the most commonly used method for the quantitation of non-
ionic surfactants [461]. The method has been used for the quantitation of poloxamers [465,466] 
and was optimised by Ghebeh et al. [458] to increase both the sensitivity and reproducibility of 
the method to allow the use of a smaller sample volume as compared to other methods. The 
method is based on the formation of a tetrathiocyanatocobaltate (II) complex with the polyether 
linkages in the polymer and which can be extracted from an aqueous phase into organic solvents 
[458,461]. The complex that is formed, precipitates after centrifuging and is soluble in acetone, 
which is used to dissolve the complex after washing [458] as described in § 4.4.5.7. The 
intensity of the colour that is developed is proportional to the poloxamer content of the system 
being tested [458]. The structure of the complex is postulated to be due to hydrogen (H+), 
ammonium (NH4+) or cobalt (M+) ions, which complex with the oxygen atoms in the ether 
linkages to form oxonium ions. These in turn are able to react with anionic entities such as 
thiocyanate ions (X-) [466], as shown in Figure 4.7. 
 
[ROCH2-(CH2OCH2)-(CHOCH2)-CH2OH]+.X-
M CH3
 
Figure 4.7 Structure of tetrathiocyanatocobaltate (II) complex with poloxamers [466] 
 
The coloured complex that is formed has an absorption spectrum in the UV region, with sharp 
absorption occurring at a wavelength of 328 nm [458,461] as shown in Figure 4.8, which shows 
the absorption spectrum of acetone baseline (A) and the complex (B). 
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Figure 4.8 UV spectrum of acetone solution (baseline) (A) and  
tetrathiocyanatocobaltate (II) complex with poloxamers (B)  
A 
 
B 
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The parameters investigated during validation studies included an assessment of linearity and 
range, precision (intraday and interday) and accuracy. The linearity was determined in order to 
ensure that the method used was indeed linear for the concentration range to be studied. The 
intra-day precision (repeatability) was determined to assess the degree of scatter among the 
individual sample points and inter-day precision was determined at three (3) levels within the 
concentration range to assess the reliability of the method on analyses carried out on different 
days. The limits of quantitation (LOQ) and detection (LOD) were not determined for these 
particular studies because the amount of gel former that would be present for the use of the 
analytical method is greater than what would be expected to be the LOQ and LOD.  
 
4.5.3.3 Linearity and Range 
The calibration curve for PF-127 in the concentration range 0.01 – 0.4 % w/v revealed that the 
analytical method was linear in the concentration range studied as observed from the coefficient 
of determination (r2 > 0.99) and the calibration curve is shown in Figure 4.9. 
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Figure 4.9 Calibration curve for PF-127 in the concentration range 0 – 0.40% w/v 
y = 5.790 + 0.1069, r2 = 0.9916 
 
4.5.3.4 Intra-assay Precision (Repeatability) 
The precision of an analytical method is a measure of the degree of scatter or agreement among 
individual data values, when the method is applied to multiple samples [232]. The repeatability 
data determined from the calibration curve shown in Figure 4.9, reported as the % RSD are 
summarised in Table 4.1.  
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Table 4.1 Intra-assay precision for PF-127 for the calibration curve (0 – 0.40% w/v) shown in Figure 4.9 
Concentration of PF-
127 (% w/v) 
Absorbance Standard deviation % RSD 
0.010 0.101 0.00195 1.92 
0.025 0.222 0.00083 0.38 
0.050 0.397 0.00356 0.90 
0.100 0.699 0.00231 0.33 
0.200 1.390 0.00327 0.24 
0.300 1.912 0.00644 0.34 
0.400 2.309 0.00879 0.38 
 
The precision of the method was considered very good, ranging between 1.92% for the lowest 
concentration and 0.23% for higher concentrations.  
 
4.5.3.5 Inter-day Precision (Intermediate Precision) 
The interday precision of the method was determined at three (3) levels viz., 0.075%, 0.15%, 
and 0.35% w/v over a period of three (3) days. The measurements were performed in triplicate 
(n = 3) and the results are summarised in Table 4.2. 
 
Table 4.2 Inter-day precision for PF-127 in the concentration range 0 – 0.40% w/v 
Day 1 Day 2 Day 3 Concentration 
(% w/v) Absorbance % RSD Absorbance % RSD Absorbance % RSD 
0.075 0.518 0.211 0.520 0.724 0.540 0.242 
0.150 1.071 0.304 1.039 0.690 0.998 0.719 
0.350 2.095 0.401 2.135 0.435 2.165 0.370 
 
The interday precision of the method was found to be very good with low % RSD less than 1% 
and thus the method can be considered to be reliable on a day-to-day basis.  
 
4.5.3.6 Accuracy 
The accuracy of the method was determined at three concentrations in the range 0 – 0.4% w/v, 
viz. 0.075%, 0.15%, and 0.35% w/v in triplicate. The results for the accuracy studies are 
summarised in Table 4.3. 
 
Table 4.3 Accuracy for PF-127 in the concentration range 0 – 0.40% w/v 
Concentration of 
PF-127 (% w/v) 
Absorbance % RSD Predicted concentration 
(% w/v) 
% Bias 
0.075 0.540 0.242 0.0748 0.309 
0.150 0.998 0.719 0.154 2.604 
0.350 2.165 0.370 0.355 2.571 
 
The analytical method for PF-127 was found to be accurate, yielding % Bias values below 5% 
at all levels. 
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4.5.4 The Critical Micelle Concentration of PF-127 
 
4.5.4.1 Introduction 
Block copolymers such as poloxamers possess surface and bulk activity and therefore may be 
considered to have surfactant properties [467]. At the surface of solutions, poloxamers have 
been shown to reduce surface tension [468,469] and can form micellar aggregates in the bulk 
solution. Furthermore, the formation of micelles by poloxamers has been established previously 
[470,471].  
 
PF-127 is composed of two dissimilar entities that result in the formation of aggregates in 
aqueous and organic media [468,472-474]. The micelles are composed of a hydrophobic core, 
largely comprised of PPO blocks surrounded by a hydrated corona of PEO blocks. There is 
however evidence to suggest that the hydrophobic core does not completely exclude PEO units 
and water when in solution [442,475]. 
 
The driving force for micellisation is provided by the hydrophobic PPO block component of the 
polymer. In comparison for alkyl surfactants, that also form micelles, the hydrophobic portion 
must be considerably larger than the alkyl chains of the alkyl surfactants to result in aggregation 
and formation of micelles [442]. The unimers and corresponding micelles of PF-127 and other 
poloxamers are therefore much larger than those formed by non-ionic alkyl surfactants. The 
radius of Pluronic® micelles is reported to be between 60 – 120 Å as compared to 20 – 30 Å of 
those formed by the alkyl surfactants [442]. 
 
The type of micellar aggregates that are formed depend on the molecular weight and size of the 
copolymer blocks, the composition of the solvent and the temperature of the environment in 
which the materials are used. A study of the phase behaviour of triblock copolymers has shown 
that the type of aggregates formed, depends on the temperature of the environment and the 
percentage composition of the polymer backbone [476].  
 
The formation of micelles is an important consideration when studying the behavioural 
characteristics of PF-127 gels. The formation of micelles determines the gel formation 
characteristics and the viscometric properties of the copolymer and therefore cannot be 
separated from these properties. 
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The critical micelle concentration (CMC) is the concentration at which amphiphilic entities such 
as surfactants start forming thermodynamically stable aggregates known as micelles in the bulk 
solution [467,477]. The formation of micelles by amphiphilic triblock copolymers is a more 
complex process than that which occurs when low molecular weight surfactants aggregate, 
forming micelles. In contrast to the low molecular weight surfactants, there is no distinct 
concentration at which the micellisation process commences and therefore a range may be used 
to define the CMC of these materials [425].  
 
Predictions with regard to the distribution and pharmaceutical availability of drugs and other 
excipients such as preservatives is important, and can be inferred from knowledge of the 
existence or absence of micellar aggregates in pharmaceutical preparations. The presence of 
micelles may also become important when formulating poorly soluble drugs, the solubility of 
which will be increased following solubilisation in the micelles [467]. 
 
A variety of different techniques can be used for the determination of micelles in block 
copolymer solutions and other surfactant systems. Such techniques include the measurement of 
changes in the equivalent conductivity, osmotic pressure, interfacial and surface tension, density 
change, and detergency of solution in which potential micelle forming excipients are 
incorporated [477]. The use of different techniques for determining the CMC for poloxamers 
has resulted in the reporting of conflicting results as different methods have different levels of 
sensitivity to the polydisperse nature of triblock copolymers. In addition, the presence of 
appreciable amounts of diblock copolymer impurities and free PPO chains, which are difficult 
to remove, have also contributed to the variability of these results [425,442]. Ultrasonic velocity 
and light scattering techniques [478-480] in addition to sound velocity [480] have been used to 
confirm the presence of micelles. Surface tension [469,473,479-481] and dye solubilisation 
[472,479,480] are however, the most commonly used methods to determine the CMC of 
poloxamers and have been found to have good correlation to each other [425].  
 
4.5.4.2 The Surface Activity of PF-127 
Surface-active substances are adsorbed at the air/water interface when in solution [467,477]. 
The hydrophilic portion of a surfactant is oriented towards the aqueous component of a system 
whereas the hydrophobic region projects out of the aqueous solution into the air. The presence 
of surfactants at the air/water interface affects the surface and interfacial tension of the vehicle 
[467,477] and typically an increase in the concentration of a surfactant results in a decline in the 
surface tension of a solution. This phenomenon shows an increase in the activity of the 
surfactant in solution under constant coverage of the air/water interface by a surfactant. A 
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continuous decrease in surface tension occurs as a result of the presence of surfactant materials 
until a plateau is reached, after which, further increases in the concentration of surfactant does 
not result in any changes in the surface tension. The concentration at which this occurs is known 
as the CMC [467,477,481]. Amphiphilic triblock copolymers are adsorbed at the air-water 
interface and show the ability to decrease the surface tension of water [481].  
 
The surface tension of PF-127 solutions was measured as described in § 4.4.2.6. A calibration 
factor was then calculated using Equation 4.1 from the surface tension of water at the 
temperature studied, 19 °C, 75.5 dynes/cm compared to the surface tension of water at 20 °C 
(72.75 dynes/cm). A calibration factor is important for the correction of the measurement of 
surface tension as surface tension varies with temperature [467].  
 
)/50.75(
)/75.72(
cmdyneswaterdistilledofreadingScale
cmdynesetemperaturambientatwateroftensionSurfaceC =   Equation 4.1 
 
Surface tension readings were multiplied by a correction factor to determine the true value. 
Figure 4.10 depicts the surface tension changes for PF-127 solutions (n = 3) over a 
concentration range of 0.00001 – 10% w/v of PF-127. The plot shows surface tension versus the 
logarithm of concentration of the polymer in solution and the % RSD for all calculated surface 
tension values ranged between 0.20 and 1.85 % RSD.  
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Figure 4.10 Semi logarithmic plot of PF-127 concentration versus surface tension of PF-127 solutions 
 
 140 
At low concentrations of PF-127 (10-5 – 10-3 %w/v), there is a decrease in the surface tension of 
the solution in a linear manner over several concentration decades. Thereafter a change in the 
slope of the line occurs at approximately 0.001% w/v PF-127, after which there is further 
decline in the surface tension as the concentration of PF-127 in solution increases, until the 
surface tension reaches a plateau at a concentration of 0.5% w/v of PF-127. The surface tension 
remains constant despite further increases in the concentration of the copolymer in solution. The 
results generated in these studies for PF-127 are in agreement with results for the same 
copolymer that have been studied and reported in the literature [468,469,481], where two 
changes the slope of the surface tension curve were observed. The final surface tension obtained 
was approximately 40 mN/m for PF-127 at 25 °C [468] and the first change in surface tension 
occurred at a concentration of approximately 0.001% w/v of the poloxamer [468,469,481]. The 
surface tension at the second change is also in agreement with the value obtained by Wanka et 
al. [468] who observed a second change in the slope at a concentration of approximately 0.4% 
w/v of PF-127.   
 
The presence of two changes in the slope of the surface tension readings has led to some 
confusion regarding the interpretation of the CMC and understanding of what occurs in the 
micellar systems that are formed. In a comprehensive study, Alexandridis et al. [481] examined 
the results obtained from their surface tension measurements and other related information in 
order to understand the conformation of the copolymers at the interface and their structure in the 
bulk solution, so as to elucidate the process of micelle formation and structure more clearly.  
 
Alexandridis et al. [481] proceeded to investigate the origin of the first change in the slope of 
the graph of logarithm of Pluronic® concentration versus surface tension. In earlier studies 
[482,483], this value was attributed to the CMC, but further analysis of the second change in the 
curve lead to the conclusion that the actual CMC occurred at the second change in the curve. It 
was thought that the first change in the slope was a result of the polydisperse nature of the 
poloxamer and the presence of synthetic and other hydrophobic impurities [425]. However, 
Alexandradis et al. [481] argued that the polydisperse nature of the copolymer would result in a 
poorly defined and obscure single decline in the surface tension and a decrease at the CMC 
value as shown by some earlier findings [484]. This is contrary to the surface tension behaviour 
changes observed for copolymers such as the poloxamers. In addition, the presence of 
impurities would result in a decrease at the CMC prior to the surface tension increasing slightly 
to reach a plateau [484]. Prasad et al. [469] proposed that the presence of the first change was 
due to the formation of monomolecular micelles, whereas Alexandridis et al. [481] argue that 
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the presence of monomolecular micelles is unlikely. This is because the concentration at which 
the first change occurs is very low and there is no apparent driving force to promote the 
formation of compact structures. 
 
A recent explanation in the surface behaviour of poloxamers is that the first change in the 
surface tension slope observed is due to a modification in the configuration of PF-127 at the 
air/water interface, occurring at low bulk concentrations of poloxamer. However, the 
concentration of PF-127 at the air/water interface is significant resulting in conformational 
changes of the poloxamer at the interface. At very low concentrations of < 10-6% w/v, the 
copolymers are adsorbed at the air/water interface in an extended configuration and the surface 
tension decreases with increasing poloxamer concentration. Concentrations in the region of 10-
6%  – 10-3% w/v result in constant coverage of the surface at the interface and the PEO-PPO-
PEO copolymers are adsorbed at the air/water interface as an inverted  U  and PEO chains at the 
air/water interface and hydrophobic PPO blocks projecting into the air. The surface tension 
continues to decrease as the concentration of the poloxamer at the air/water interface increases. 
At a bulk concentration of approximately 10-3% w/v of poloxamer, when the surface is fully 
covered with surfactant, there is a structural transition that occurs and the layer at the surface 
becomes more compact, expelling water and subsequently results in PEO segments projecting 
into the aqueous medium or folding around the PPO. Consequently, more PEO-PPO-PEO 
copolymers can fit onto the air/water interface and causes the adsorbed layer to become thicker 
and therefore the surface tension continually decreases, but at a slower rate than previously 
observed. At the CMC, micelles are formed in the bulk of the solution, the activity at the 
air/water interface remains the same, and there is no further decline in the surface tension as the 
concentration is increased, although there is an increase in the number of micelles that are 
formed in the bulk medium [481].  
 
The change in the surface tension curve at higher concentrations has been considered to be the 
CMC for poloxamer block copolymers. The reason for this phenomenon is that there is 
agreement between the value for the CMC that was obtained from dye solubilisation studies and 
the concentration at which the second change in the slope occurs [472]. Therefore, there is the 
presence of well-defined polymolecular micelles with a hydrophobic interior that are capable of 
solubilising hydrophobic molecules in these systems [472]. In addition, the CMC is considered 
to occur at the second change in surface tension because of the plateau in the profile that is 
observed after this concentration and which is characteristic at concentrations that are greater 
than the CMC. Surfactants typically behave in this manner and after the CMC, there is usually 
no further decline in the surface tension [467]. 
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4.5.5 The Sol-Gel-Sol Transition Temperatures of PF-127 
 
4.5.5.1 Introduction  
A thermodynamic study of the phase transitions of PF-127 was undertaken as the thermo-
reversible nature of PF-127 has been extensively reported in the literature [426,459,485,486]. 
PF-127 has the ability to undergo reverse thermal gelation [426] and this has led to interest in 
the use of this copolymer as a thermo-responsive controlled delivery system.   
 
4.5.5.2 The Transition Temperatures of PF-127 
The temperatures at which the transition from sol to gel occurs can be referred to as Tm1 and is 
dependent on the concentration of the copolymer used in the solution being tested. In addition, 
on further heating, the PF-127 gel state reverts to a sol state and the temperature at which this 
occurs can be referred to as Tm2 and which is dependent on the concentration of the polymer in 
solution [485]. As the temperature is increased, the copolymer solutions turn cloudy at a 
temperature referred to as the cloud point, which is a characteristic of the polymer [485]. The 
cloud point of PF-127 occurs at temperatures above 100 ˚C. The transition temperatures, viz., 
Tm1 and Tm2 of PF-127 solutions in the concentration range 18 – 32.5% w/w were determined 
using a method previously described in the literature [459] and in § 4.4.2.7. Figure 4.11 shows 
the sol to gel transition for PF-127 solutions in the concentration range studied.  
 
16 18 20 22 24 26 28 30 32 34
0
20
40
60
80
100
Tm1
Tm1
Concentration of PF-127 (w/w)
Tr
an
si
tio
n
 
te
m
pe
ra
tu
re
 
( °C
)
 
Figure 4.11 Tm1 and Tm2 transition temperatures for PF-127 aqueous 
solutions  in the concentration range 18 - 32.5 % w/w 
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As the concentration of PF-127 is increased, there is a decrease in the transition temperature, 
Tm1. A solution of 20% w/w PF-127 has a transition temperature of 23 ˚C whereas a solution of 
30% w/w forms a gel at only 12 ˚C. This is in agreement with other studies that show that there 
is a decrease in Tm1 with an increase in the concentration of PF-127 [487]. Furthermore, 
reported values that were determined for Tm1 for solutions of 20% w/w and 30% w/w were 21.5 
˚C and 10.9 ˚C, respectively. The results in this study are similar to those that have been 
reported, but because of batch-to-batch variability in the manufacture of copolymers, 
differences in the sol to gel transition properties can be expected [442,487]. Tm2 is also 
concentration dependent, and lower concentrations of gel former have lower transition 
temperatures. Solutions of PF-127 with concentrations of gel former greater than 25% w/w have 
transition temperatures greater than 100 °C, which cannot be determined using this method.   
 
The presence of micelles in the PEO-PPO-PEO block copolymers has been demonstrated by the 
surface tension study reported in § 4.5.4. Solutions of PF-127 with concentrations of polymer 
above 20% w/w have a tendency to form micelles when temperatures increase resulting in the 
formation of gels and an increased viscosity of the bulk solution. It has been proposed that 
conformational changes in the methyl groups of the hydrophobic PPO region of the micelles and 
the motion of hydrophilic components of the polymer result in dehydration of the micelles. 
Therefore, there is an increase in end chain friction and a resultant increase in the viscosity of 
the solution culminating in gel formation [471]. This proposition is in agreement with other 
studies [468,482,488] that show that as temperature increases there is an increase in the 
molecular weight of the micelles showing an increase in the aggregation number. However, 
there is no change in the hydrodynamic radius of the micelles indicating that the micelles have a 
more compact structure at higher temperatures due to dehydration of the micelles as the 
temperature is increased [488].  
 
Wanka et al. [468] described a mechanism for the gelation of PF-127 based on the DLVO-
theory and the concept of the dehydration. The overall interaction between aggregates or 
micelles was found to be repulsive in nature, although there is an attractive Van Der Waal’s 
interaction between such aggregates. The repulsive interaction between the aggregates is due to 
steric stabilisation of the PEO chains and the attractive interaction is more than likely due to the 
Van Der Waal’s forces present between the PPO chains. The dehydration of the interior PPO 
chains would result in greater Van Der Waal’s forces with a resultant increase in the attractive 
forces between the aggregates thereby promoting gelation [468]. The basis of this theory also 
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provides an explanation for gelation at increased temperatures following the dehydration of the 
core of the micellar structures.  
 
The kinetics of the sol to gel-transition are an important consideration with regard to the specific 
application of gel use in vivo. Wang and Johnston [487] studied the kinetics of poloxamers 
using a pulse shearometer. The rate of gelation was established for solutions of 20% and 30% 
w/w solutions of PF-127 and it was evident that the rate of gelation occurred at a faster rate 
when higher concentrations of copolymer were used in solution. This implies that the 
concentration of the gel would not only affect the overall release rate of a drug from these 
systems but would also affect the initial burst effect, if any exists. It may therefore be concluded 
that after an intramuscular injection of a solution of low PF-127 concentration the gelation 
process would be slower for these lower concentration solutions as compared to higher 
concentration solutions, thereby making the active principle immediately available. This 
phenomenon would result in a higher burst effect from the gel and might be an important 
consideration with regard to the clinical use of the specific therapeutic agents included in these 
novel delivery systems [487]. 
 
4.5.5.3 The Effect of Additives on the Transition Temperatures 
The effect of additives on the transition temperatures of PF-127 is an important consideration 
when developing formulations in which PF-127 is used as the rate-retarding polymer. For 
example, buffers salts may be added to formulations for several purposes, including but not 
limited, to a means of enhancing the stability and solubility of an API by maintaining a constant 
pH. The addition of sodium chloride may also be considered important for the formulation of 
parenteral products to produce a pharmaceutical preparation that has the desired state of 
tonicity. Excipients do not necessarily have biological activity but improve the performance of a 
formulation and are usually added to formulations. Evaluation of the impact of additives is also 
important to ascertain whether any factors that would influence the performance and the 
integrity of a dosage form exist. Three (3) different concentrations of PF-127 and the impact of 
addition of potential formulation additives were evaluated and the effect on transition 
temperatures monitored, and the results are depicted in Figure 4.12.  
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Figure 4.12 The effect of drug loading on Tm1 for three(3) concentrations of PF-127 
 
The addition of OT to PF-127 solutions also resulted in a decrease in the transition temperature 
as shown in Figure 4.12. At lower concentrations of the polymer, it was noted that the drug 
loading did not affect the extent of the decrease in the transition temperature, however at higher 
concentrations, such as 30% w/w PF-127, an increase in the drug loading resulted in a greater 
decrease in the transition temperature of the copolymer. 
 
The results illustrated in Figure 4.12 are in slight disagreement with those reported by Gilbert et 
al. [459] who studied the effects of adding preservatives such as benzoic acid and para-
hydroxybenzoate esters to solutions of PF-127. The increase in solute loading resulted in a large 
decrease in the transition temperature, but these results indicate that OT caused only a slight 
decrease in the transition temperature. Gilbert et al. [459] propose that the hydrophobic solutes 
bind to the chains of PF-127 and suggest that the para-hydroxybenzoate esters bind to the PEO 
chains, promoting dehydration and a consequent decrease in the gelation temperature. OT is a 
hydrophilic entity and does not affect the transition temperatures of PF-127 solutions 
significantly. It may be that the peptide does not bind appreciably to the polymer backbone and 
therefore does not interfere with the gelation process as described. However, at higher 
concentrations of the polymer, there is a possibility that the concentration of polymeric chains 
may result in steric interactions with the peptide thereby causing a decrease in the transition 
temperatures observed. Studies [485,486] have revealed that salts such as sodium chloride, 
sodium sulphate and calcium chloride that have salting-out effects also decrease the gelation 
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temperature of PF-127 gels. Peptides are known to have a salting-out effect, thereby reducing 
the effective water concentration in a system and would therefore be expected to cause a 
decrease in the gelation temperature of PF-127 systems [486]. 
 
The impact of additives on gel formation properties in PF-127 solutions was evaluated. The 
stability of OT is pH dependant as described in § 1.3.2 and therefore OT formulations are 
prepared with an acetate buffer to maintain the pH at approximately 4 [33]. Furthermore, 
parenteral formulations for intramuscular administration must be isotonic (0.9% w/v sodium 
chloride) or they would result in muscle irritation and sodium chloride may be added to OT 
formulations for this reason [33]. Finally, the formulation of parenteral formulations requires the 
use of a preservative and chlorbutol is used in OT commercial preparations [33]. The impact of 
these additives on the transition temperature of PF-127 solutions at three (3) concentrations, viz., 
20%, 25%, and 30% w/w was investigated and the results are shown in Figure 4.13.  
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Figure 4.13 The effect of selected additives on the transition temperatures of PF-127 solutions,  
where 1: 0.1 M Acetate buffer, 2: 0.5 % Chlorbutol and 3: 0.9 % Sodium chloride 
 
The addition of salts such as sodium acetate and sodium chloride resulted in a decrease in the 
transition temperatures for PF-127 whereas the presence of multivalent salts such as magnesium 
sulphate, aluminium sulphate and trisodium phosphate have been found to prevent gel formation 
of PF-127 formulations [485]. Sodium chloride and acetate buffer both reduces the transition 
temperature by a salting-out effect. Chlorbutol may result in a decrease in the transition 
temperature similar to that caused by para-hydroxybenzoate esters described above, as 
chlorbutol is also a hydrophobic molecule. 
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4.5.5.4 Thermodynamic Considerations 
The gelation of PF-127 can be described by use of thermodynamic relationships and equations. 
Vadnere et al. [486] performed a physico-chemical characterisation of PF-127. The gelation 
process of poloxamers can generally be described by use of an equation that shows the 
dependence of gelation on polymer concentration and this relationship has been described by 
Eldridge and Ferry [489]. According to the equation, an inverse linear relationship exists 
between the logarithm of the concentration of gel and the gel to sol transition temperature and 
the relationship shown in Equation 4.2 can be used to determine the enthalpy of the sol to gel 
transition for polymeric materials such as PF-127. 
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Where, 
c = concentration of the polymer 
∆H° = enthalpy for the sol-to-gel transition 
R = 8.3143 JK-1mole-1 
T = absolute temperature in Kelvin 
K = constant 
 
This relationship was applied to the experimentally determined transition temperatures obtained 
for PF-127 gels and revealed that a linear relationship exists as depicted in Figure 4.14.  
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Figure 4.14 Thermodynamic relationship between the transition temperature, Tm1  
and the concentration of the gel former in solution 
y = 3.015x – 7.1726, r2 = 0.9969 
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Enthalpy changes from a reaction process can be estimated from the gradient of the slope of a 
curve generated using Equation 4.2 [486,489]. The enthalpy change for these experiments was 
estimated to be 25.07 kJmol-1 or 5.99 kcalmol-1 and is in agreement with enthalpy change of 9.5 
kcalmol-1 reported in the literature for PF-127 gels by Vadnere et al. [486]. This small positive 
value for enthalpy is in contradiction with values reported for the gelation of gelatin, which 
occurs with a large negative enthalpy change ranging between -49 and -73 kcalmol-1 favouring 
the gelation process [489] and a small positive value would be indicative of system in which 
gelation of the copolymer is not favoured. 
 
Vadnere et al. [487] have proposed that the positive enthalpy is accompanied by an increase in 
the entropy of the system and therefore the gelation of the copolymer is favoured. They 
proposed a qualitative model to explain the observations with regard to the entropy and which is 
shown in Figure 4.15.  
 
Simulated structure
PEO units
PPO units 
Structured water molecules
Hydrophobic association 
Hot water 
Cold water 
Water molecules
 
Figure 4.15 Qualitative model for the gelation process of poloxamer copolymers (adapted from [486]) 
 
In solution, there is a higher order of water around the hydrophobic PPO unit of the copolymer 
that are structured between adjacent hydrophobic entities. As gelation occurs, the interaction 
between the hydrophobic units causes water expulsion from the ordered region between the 
chains, into the bulk solution of lower order. This results in an increase in the entropy of the 
system and thereby promotes the gelation process, even though a small positive enthalpy change 
exists in the system that would otherwise negatively influence the gelation process. Positive 
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entropy would therefore be a driving force for the association of the hydrophobic units. 
Furthermore, hydrophobic interactions are characterised by endothermic heat changes or 
positive enthalpy as observed in the gelation process for PF-127 [486]. 
 
Yu et al. [490] also used a similar relationship to characterise PF-127 gels and obtained an 
enthalpy value of 28 kJmol-1. A linear relationship was observed to exist between the logarithm 
of concentration of polymer and the inverse of the absolute temperature of the system. Positive 
enthalpy and entropy values were derived and these are in agreement with the results reported 
by Vadnere et al. [486]. 
 
A challenge with respect to the use of PF-127 systems is that the integrity of the gel structures 
tends to diminish on mixing with aqueous media [491]. This results in rapid dissolution and 
removal of the gel from the site of a potential depot injection thereby potentially limiting the use 
of the polymer for long duration sustained release formulations. However, for the application of 
developing a formulation of OT for prevention of post partum haemorrhage, this was not seen as 
a deterrent as the targeted duration of delivery from the dosage form was to be 8 hours. 
 
4.5.6 Viscosity of PF-127 Solutions 
 
4.5.6.1 Introduction 
The rheological behaviour of a vehicle is an important consideration for quality control 
purposes and with respect to predicting the release of a drug from a vehicle and ultimately its 
clinical use. In addition, packaging and storage conditions of the dosage form may be inferred 
by knowledge of the rheological properties of such systems. The viscosity of PF-127 solutions 
was studied as a function of the concentration of polymer and environmental temperature. 
 
4.5.6.2 Calibration of the Viscometer 
It is recommended that the measurement of viscosity using Brookfield viscometers be carried 
out using a vessel with an inside diameter of at least 83 mm. A 600 ml low form Griffin beaker 
is usually used for this purpose as the use of a smaller vessel will result in higher viscosity 
readings and falsified inflated readings [492]. If a smaller sample volume is to be used, then 
calibration of the system is necessary to obtain accurate viscosity readings. In these studies as a 
large sample volume would be required if a 600 ml beaker were used, a 100 ml beaker with an 
internal diameter of 44.5 mm was selected for use. The viscometer was calibrated prior to use 
by measuring the viscosity of a 5000 cP Silicone viscosity standard as described in § 4.4.2.8. 
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The viscosity was found to be 6880 + 10 cP and a calibration factor of 0.727 was calculated as 
recommended by Brookfield Engineering Laboratories [492]. 
 
4.5.6.3 Viscosity of PF-127 as a Function of the Concentration 
The viscosity of solutions of different concentrations was measured and the results are shown in 
Figure 4.16 in addition to the viscosity of PF-127 solutions determined at different 
temperatures. 
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Figure 4.16 Effect of increasing concentration of PF-127 on  
the viscosity of aqueous solutions at different temperatures 
 
As the concentration of PF-127 is increased, there is an increase in the viscosity of the system at 
all temperatures and these results are in agreement with previously reported studies [493,494]. 
This increase is more than likely due to the presence of micellar aggregates that are present in 
these systems. With increasing concentrations of polymer in solution, there is a corresponding  
increase in the number of micelles formed that are more closely packed, resulting in an increase 
in the viscosity of the solution [493,495]. 
 
A formulation with a lower viscosity would result in the administered formulation spreading 
extensively into the muscle fibres, resulting in a greater surface area for drug release and a 
corresponding increase in the rate of drug release, faster absorption into the systemic circulation 
and resultant device failure. This phenomenon would preclude or limit the use of the more dilute 
solutions of PF-127 for depot formulations from which sustained drug action is desired [487]. 
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Directly related to the viscosity of these systems is the syringeability and injectability of a 
product. The administration of viscous solutions with a needle can be difficult and therefore the 
final viscosity of a formulation to be injected should not be too high, although a high viscosity 
may be suitable for a long acting depot formulation compared to the lower viscosity 
formulations. A compromise between the intended duration of action and the impact of viscosity 
on practical application parameters is therefore necessary. The size of the syringe and needle 
must be considered in relation to the viscosity and duration of action that is intended to be built 
into a product and in relation to patient acceptability [496].  
 
4.5.6.4 Viscosity of PF-127 as Function of the Temperature 
The viscosity of PF-127 solutions is dependent on the temperature in which the solution is 
stored or used and therefore the relationship between temperature and viscosity was examined. 
Close inspection of the curves, for the concentration range 18 – 25% w/w F127 in the 
temperature range 5 – 20 °C shows an initial decrease in the bulk viscosity as the temperature in 
increased, after which the viscosity increases. Figure 4.17 shows the impact of the initial 
warming on the viscosity of PF-127 for a 20% w/w solution as an example of this phenomenon. 
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Figure 4.17 Relationship between the initial temperature increase 
 and the viscosity of a 20 % w/w solution of PF-127 
 
Lenaerts et al. [493] noted a similar phenomenon to that observed for the 20% w/w solution of 
PF-127 that is illustrated in Figure 4.17. The initial decrease in viscosity is most likely due to a 
rise in the activation energy of the system due to the increase in the temperature and was noted 
for solutions of PF-127 in the concentration range of 18 – 25% w/w where no gelation occurred 
at these temperatures. The slight decrease in viscosity as the temperature is increased has an 
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important implication for the clinical use of dosage forms manufactured from PF-127 polymers. 
Following removal of the ampoule/vial from a refrigerator, the dosage form can be allowed to 
warm slightly, thereby allowing a less viscous liquid to form and be administered conveniently. 
 
As the temperature is increased from 5 °C to approximately 25 °C, there is a small rise in 
viscosity for each solution tested, followed by a dramatic and rapid increase in the bulk 
viscosity of the system, depending on the concentration of PF-127 as shown in Figure 4.18. The 
rapid rise in viscosity occurs concurrently with visual observations of gelation.  
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Figure 4.18 Effect of increasing the temperature on the viscosity  
of different concentrations of PF-127 in solution 
 
It is clear on visual inspection of the curves shown in Figure 4.18 that the temperature at which 
the gelation occurs is dependent on the concentration of polymer in solution and in general 
occurs at lower temperatures for solutions of higher concentration of PF-127. These 
observations are in agreement with previously published work [493,494,497,498]. 
 
There is a rapid increase in the viscosity at Tm1 for the PF-127 systems studied and the increase 
in the viscosity is primarily due to the presence of micelles at the high concentrations of 
poloxamer. As the temperature is increased, the micelles undergo swelling and increase in size. 
Conformational changes that occur as the temperature is increased are due to de-solvatation of 
water from the micelles resulting in polymeric units and the different micelles being exposed to 
each other with a resultant increase in the bulk viscosity of the system as the temperature is 
increased. It is thought that pseudo-cross-linkages occur between the PF-127 units of different 
micelles that subsequently cause an increase in the viscosity [493].   
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4.5.7 Gravimetric Analysis 
 
4.5.7.1 Introduction 
Pluronic® copolymers undergo slow dissolution or erosion when exposed to aqueous media, a 
phenomenon that has been studied by several researchers [460,499-502]. Furthermore, it has 
been shown [500-502] that there is a strong correlation between the rate of erosion and the rate 
of drug release from poloxamer gels with resultant r2 values of > 0.99 obtained when modelling 
the relationship between the rates of gel dissolution and drug release. 
 
It has also been shown that the dissolution rate of the gel is dependent on the concentration of 
the gel former present in the dosage form and formulations with lower concentrations of PF-127 
resulting in a faster rate and extent of drug release [500,501]. This is expected since as PF-127 
concentrations increase there is an increase in the viscosity of the gels (§ 4.5.6) with a 
corresponding decrease in the rate of drug release [500-502].   
 
4.5.7.2 Gravimetric Analysis 
The rate of gel dissolution of PF-127 formulations of three (3) different concentrations was 
determined using the method described in § 4.4.2.9 and are summarised in Figure 4.19 and 
Table 4.4, which summarises the linearity curves for the dissolution of PF-127 under the 
specified conditions. The linearity curve for 20% w/w PF-127 gel was determined from t = 0 
min to t = 300 min after which 100% of the gel had dissolved. 
 
Table 4.4 Dissolution curve parameters summary (y = mx + c) for PF-127 gels 
Concentration of PF-127 (% w/w) Slope Intercept R2 
20 0.3747 2.4191 0.9934 
25 0.2055 2,2575 0.9975 
30 0.1459 2.5931 0.9978 
 
As expected, the rate and extent of dissolution of the gel decreased with an increase in PF-127 
concentration in the formulation. The rate of erosion was found to be zero order (r2 > 0.99) for 
all three (3)-gel formulations studied. Therefore, the rate of release of a drug included in such 
formulations would be expected to be zero order if dissolution of the polymer is the only 
mechanism by which drug is liberated from the polymer matrix. The mechanism of release will 
be discussed further in Chapter 5, vide infra, where mathematical models were used to assess 
the mechanism of drug release from these systems. 
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Figure 4.19 The influence of PF-127 concentration on percent  
gel dissolution in an aqueous medium 
 
4.6 CONCLUSION 
 
Preformulation studies of a primary excipient allow for appropriate formulation improvements 
and decisions to be made when developing dosage forms. This information generated in these 
studies provides a formulation scientist with invaluable information prior to optimisation of the 
dosage form, preventing a waste of valuable resources and time during early stage development 
projects. 
 
The data generated from spectral studies of PF-127, alone and in combination with OT gave 
preliminary information about the possibility of an interaction occurring between OT and the 
vehicle of choice that may have had an impact on the integrity and the performance of the final 
dosage form. From preliminary studies using UV and IR, it was concluded that the vehicle was 
suitable for use with OT because of the likelihood of minimal interaction.  
 
The use of an analytical method for PF-127 in solution was developed and validated by 
assessing linearity, accuracy, and precision parameters. This method will be invaluable in the 
formulation process and may be used to reveal information about the potential mechanism of 
drug release from the gel. The analytical method can be applied to the determination of the 
amount of gel that has dissolved at different time points during in vitro release testing and can 
therefore be used in conjunction with mathematical models and drug release rates in elucidating 
the mechanism of release of OT from PF-127 formulations [460].  
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The determination of the CMC of PF-127 was vital in the development of a dissolution method 
for the drug to develop an in vitro release test method in which micelle formation was avoided. 
The information is critical in assessing dosage forms where poorly soluble drug candidates 
and/or excipients such as preservatives may be solubilised thereby reducing the efficiency of the 
test method. The use of PF-127 as micelles as carriers for drugs has been evaluated by Kabanov 
et al. [443,444] and therefore the ability of PF-127 to solubilise API and other excipients is a 
possibility that must be considered during formulation and in vitro assessment of PF-127 
containing dosage forms. 
 
The thermodynamic properties of PF-127 were also characterised since the delivery system was 
intended to be a thermoresponsive system that exists as a flowable viscous liquid at low 
temperatures and forming a stiff gel at body temperature and a potential depot for sustained 
drug release. Knowledge of the transition temperatures is important in establishing storage 
conditions for the dosage form and for subsequent handling of that dosage form prior to clinical 
use. For example, the transition temperature for a formulation to be usable must preferably be 
above approximately 15 °C, to allow the formulation to remain in a syringeable form following 
removal of the product from the refrigerator. The formulation of products with solutions above 
approximately 25% w/w PF-127 is therefore limited because of the increased viscosity above 
this temperature. In addition, the low transition temperatures for higher concentrations (> 25% 
w/w) of PF-127 means that on slight warming (> 10 °C) they form stiff gels and can not be 
administered using a syringe and a needle. Furthermore, the second transition temperatures, Tm2 
for the concentration range 18 – 25% w/w PF-127 solutions were determined and the thermo-
reversible nature of the copolymer was confirmed. This information may be important in the 
formulation of the parenteral dosage form, indicating that heating the gel solutions, e.g. in 
sterilisation processes will not interfere with the integrity of the dosage form, and therefore this 
method can be used for sterilisation. The investigation of the effect of additives on the transition 
temperatures is also important as this allows the formulation scientist to consider the potential 
impact of these additives on product performance during formulation development. The 
potential additives that were investigated viz., sodium chloride, acetate buffer at pH = 4 and 
chlorbutol were found to decrease the transition temperatures, but not to any great extent 
although it is imperative that formulation optimisation must be performed in the presence of the 
additives. 
 
The assessment of the rheological properties of such systems is central in the development of 
sustained release dosage form as such properties are likely to impact on the release of API from 
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the dosage form following administration of the product. In addition, the behaviour of the 
viscosity as a function of temperature is of critical importance when establishing clinical use 
parameters of such systems. For example, it is necessary to answer questions such as to what 
extent does the viscosity change on warming to room temperature and can the dosage form still 
be administered using a syringe. Solutions of PF-127 containing lower concentrations of gel 
former, viz., 18 – 25% w/w when warmed from 5 °C to approximately 20 °C show a slight 
decrease in the viscosity and this is a potentially useful property for the use of PF-127 as a gel 
for sustained release as the reduced viscosity would allow the administration of the formulation 
with a needle. Higher viscosities for higher concentrations of PF-127 (> 25% w/w) solutions 
limit the clinical application of these gels compared to their more dilute counterparts. Although 
higher viscosity solutions of PF-127 have the potential of a more sustained release rate of API, 
the syringeability is limited. Another important consideration with respect to the viscosity is the 
clinical administration of the drug via a needle and the size of the syringe and needle assembly 
that would be necessary. Further evaluation that is recommended is an investigation of the flow 
properties of the drug and monitoring how the viscosity is affected by changes in the shear rate 
and the temperature. 
 
Gravimetric analysis was used to assess the impact of dissolution of the gel in an aqueous 
medium and was considered appropriate since the rate of polymer dissolution is likely to 
influence the rate and extent of drug release from such gels. Gravimetric analysis yields key 
information to the formulation scientists and allows strategies to be put in place to increase or 
reduce the rate of dissolution in order to design a formulation with a specific and desired rate of 
drug release. Strategies could involve the inclusion of additional polymers that can retard the 
rate of dissolution of the gel without influencing significantly on the viscosity or chemical 
modification of PF-127 [503,504], which has been performed in an attempt to increase gel 
viscosity. 
 
PF-127 was found to be a potentially useful vehicle for the formulation of a sustained release 
dosage form of OT, since it has no obvious potential for interaction with the drug. Furthermore, 
PF-127 gels have the potential to produce thermoresponsive delivery systems that undergo 
viscosity increases on warming, thereby proving suitable for the production of a depot injection 
for the prolonged release of OT release. Furthermore, the dosage form can dissolve in aqueous 
medium facilitating release of OT from the depot. 
 157 
CHAPTER 5 
 
THE DEVELOPMENT OF AN IN VITRO RELEASE TEST FOR THE 
ASSESSMENT OF OXYTOCIN RELEASE FROM PLURONIC® F127 GELS 
 
5.1 INTRODUCTION 
 
The value of in vitro drug dissolution and release testing in the pharmaceutical industry cannot 
be overlooked as information gained from such testing is used for quality control purposes, 
batch uniformity assessments, and homogeneity testing of dosage forms within a batch. 
Prediction of in vivo behaviour of dosage forms and assessments of the impact of formulation 
changes or method of manufacture on overall dosage form performance in vivo may be inferred 
from dissolution profiles [505]. In addition, in vitro release profiles generated during testing 
reveal information about the structure of disperse systems and behaviour of formulations at a 
molecular level, as well as possible interactions between a drug molecule and polymer matrices 
in which the molecule is contained. The mechanism of drug release may also be inferred from in 
vitro release profiles by the application of mathematical models to those profiles [506]. 
 
The intrinsic variability of in vitro release testing warrants careful development of methods in 
order for a test to reflect the true drug release characteristics from a drug delivery system. The 
type of drug and apparatus that are used must be carefully considered as these factors can 
influence the rate and extent of drug release obtained during in vitro release testing [507]. The 
selection of an in vitro release method and dissolution medium must consider the potential for 
an in vitro in vivo correlation of the method of choice, if possible [508]. 
 
There are no accepted compendial guidelines for in vitro testing to assess drug release for 
controlled and sustained release parenteral formulations, such as those made from PF-127. The 
USP [10] provides guidance for dissolution testing of oral and transdermal dosage forms, but no 
guidelines for assessing the in vitro release of an active ingredient from controlled release (CR) 
parenteral preparations are reported. 
 
The objective of these studies was to develop an appropriate discriminatory in vitro test for 
assessing formulation factors that may affect drug release during early formulation development 
studies for an OT formulation prepared from PF-127 as the gel-forming matrix. An appropriate 
release assessment method should be able to discriminate between the performance of different 
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formulation variants [496,509] and this was the primary criterion used for selection of an 
appropriate method during the in vitro release test method development process. Mathematical 
models and statistical tests were used to evaluate the discriminatory behaviour of different 
release test methods that were investigated in these studies and were also applied to drug release 
data generated using the different release test methods to assess the impact of the test method on 
possible mechanisms of OT release from the dosage form. 
 
5.2 METHODS FOR ASSESSING IN VITRO RELEASE OF PARENTERAL 
PRODUCTS 
 
5.2.1 Introduction 
 
The selection of an appropriate apparatus for in vitro release testing of CR parenteral systems, 
including microparticulate, nanoparticulate, hydrogel and liposomal dosage forms, has been the 
subject of several conferences and publications [496,508-511]. Important considerations for the 
evaluation of CR parenteral systems include the use of appropriate apparatus, dissolution media, 
sampling methods and total percent release attainable from an in vitro release test method [496]. 
Guidelines for the evaluation of novel delivery systems such as orally disintegrating and 
chewable tablets have been reported although recommendations for parenteral formulations 
have not yet been established. However, the use of compendial and modified flow-thorough cell 
apparatus has been applied with some success [509]. The most commonly used methods that 
have been used for in vitro release methods for CR parenteral systems can be classified into 
three broad classes, viz., sample and separate, continuous flow and dialysis methods [511]. 
 
5.2.2 USP Dissolution Apparatus 
 
Compendial apparatus recommended in the USP [10] for in vitro release testing have specific 
attributes that may result in each apparatus not being entirely suitable for in vitro release testing 
of CR parenteral preparations. USP Apparatus 1 (basket) and 2 (paddle) were designed for 
testing immediate and modified-release oral formulations and USP Apparatus 3 (reciprocating 
cylinder) and 4 (flow through cell) are appropriate for testing of extended release oral 
preparations. USP Apparatus 5 (paddle over disc), 6 (cylinder) and 7 (reciprocating holder) are 
recommended for in vitro testing of transdermal dosage forms. It has been reported that USP 
Apparatus 1 and 2 may not be entirely suitable for CR parenteral products but Apparatus 3 and 
4 may be useful with appropriate modifications [496]. 
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The use of the USP paddle apparatus is recommended for testing drug release from tablets, at a 
stirring speed of 50 rpm, while the USP basket apparatus is set at a speed of 100 rpm for 
pharmaceutical dosage forms that tend to float in dissolution media including capsules [512]. 
The USP basket and paddle apparatus contain a cylindrical vessel with a hemispherical bottom, 
which may be covered, a motor with a metallic drive shaft and a cylindrical basket or paddle, 
respectively. The vessel is placed in a water bath maintained at 37 + 0.5 °C. There is no source 
of agitation, motion, or vibration except that provided by the rotating stirring element connected 
to a cylindrical basket or paddle. A dosage form is then placed into the basket when using the 
USP Apparatus 1 or submerged at the bottom of the vessel when USP Apparatus 2 is utilised, 
prior to the commencement of the dissolution test [10]. Sampling of dissolution medium may be 
performed at predetermined intervals with or without replacement of the dissolution medium. 
 
One of the main disadvantages of using USP Apparatus 1 or 2 for the assessment of drug release 
from parenteral formulations is that a large volume of dissolution medium is used in the test 
procedure. Large volumes of test medium may not be relevant to small volume parenteral 
preparations for intramuscular and/or subcutaneous administration, as they are not exposed to 
such large volumes of plasma, in vivo [508]. Furthermore, the presence of a stationary 
dissolution medium limits the suitability of the basket and paddle apparatus for testing such 
products, as pharmaceutical preparations for parenteral use are exposed to dynamic body fluid 
compositions and volumes in vivo. Another disadvantage of the paddle apparatus is containment 
of the samples to be tested in the dissolution vessel, although modifications to in vitro release 
apparatus may be attempted to overcome the shortcomings of the apparatus for parenteral 
preparations. These include the use of a sinker to submerge a dosage form and the use of 
dialysis tubing for sample containment. Disadvantages in the use of sinker and dialysis tubing 
modifications are that resultant uneven dissolution of drug from the dosage forms being tested 
may produce unreliable and poorly reproducible results in the former, or aggregation of 
microspheres and prevention of gel dissolution and violation of sink conditions in the latter 
cases [508]. 
 
The USP Apparatus 3 or reciprocating cylinder apparatus is made up of rows and columns of 
outer flat bottom glass vessels, a set of inner glass reciprocating cylinders with inert fittings and 
screens that fit the tops and bottoms of the cylinders. A motor and drive assembly is attached to 
the cylinders, which results in reciprocation of the cylinders vertically inside outer glass vessels 
containing the dissolution test medium. The outer vessels are immersed in a water bath that is 
maintained at 37 + 0.5 °C and only the reciprocating action of the cylinders provides significant 
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agitation to the system. An evaporation cap is used for the duration of an in vitro release test to 
minimise dissolution fluid loss over extended test periods. Dosage forms to be tested are placed 
inside the reciprocating cylinders prior to the commencement of a dissolution test and during a 
test, the cylinders move through several rows of dissolution media in the outer vessels at 
predetermined intervals [10]. The amount of drug released from a dosage form during an in 
vitro release test is determined by analysing the contents of the dissolution vessels. 
Modifications of the apparatus may make it more relevant for the testing of parenteral CR 
preparations and may be achieved by using small samples vials and small vessels, with or 
without agitation [508]. 
 
The USP Apparatus 4 or flow-through apparatus is made up of a reservoir with a pump, a flow-
through cell that can be made of different sizes and a water bath, which is used to maintain the 
temperature of the reservoir at 37 + 0.5 °C. The pump forces dissolution medium upward 
through a flow cell at different flow rates viz., 4, 8 and 16 ml/min. A filter located at the top of 
the flow cell prevents the escape of undissolved drug particles and glass beads at the bottom of 
the cell protect the fluid entry probe. The tablet/dosage form to be tested is placed in the vessel 
prior to the commencement of the dissolution test [10]. The main advantages of the flow-
through apparatus are the flexibility in the volume, sample cell and flow rate, suggesting that 
this apparatus may be the most suitable for the assessment of in vitro release from parenteral CR 
formulations [508]. 
 
There is consensus that the use of USP Apparatus 5, 6 and 7 do not offer any advantages for the 
in vitro release assessment of parenteral CR preparations [508]. Further research is necessary in 
order to design an appropriate in vitro release test apparatus that considers the geometry, 
hydrodynamics, dissolution media, and acceptance criteria that are suitable for the assessment of 
in vitro drug release from CR parenteral dosage forms [496]. 
 
5.2.3 Sample and Separate Methods 
 
Sample and separate methods are the most extensively used techniques for assessing in vitro 
drug release from parenteral CR systems [513-519] and are extensively used for testing of 
microparticulate dosage forms, but have not found much use in the assessment of gel systems 
such as those manufactured using PF-127. Drug loaded microparticles are introduced into a 
media containing vessel and drug release is assessed over a specified time. The differences in 
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the reported techniques are variation in the size of the container, presence, or absence of 
agitation and sampling methods that are used in monitoring in vitro drug release. 
 
Tubes or vials may be used to contain the dissolution medium when small volumes of 
dissolution media are used or alternatively large bottles or Erlenmeyer flasks can be used for in 
vitro release tests that require larger volumes of fluid. Agitation may be constant, intermittent or 
absent and possible sources of agitation include the use of magnetic stirrers, rotating shakers or 
incubating water baths. Filtering or centrifuging of aliquots prior to quantitation may be 
necessary depending on the type of dosage form being tested and sink conditions can be 
maintained by replacing the medium after sampling [511]. Sample and separate methods are 
useful for dosage forms where the dispersed phase can be separated from the dissolution 
medium without influencing the overall in vitro release profile generated [506]. The main 
advantages of this test method are that it is relatively easy to set up, quick and accurate, 
although the aggregation of microparticles may present an analytical challenge [511]. The utility 
of sample and separate methods is also limited by the size and size distribution of the 
microparticles in a formulation, which may be difficult to filter or centrifuge if their particle size 
is too small [506]. 
 
5.2.4 Continuous Flow Methods 
 
Continuous flow methods describe modifications to the USP flow-through apparatus and other 
similar techniques where dissolution medium is circulated through a column/cell that contains a 
drug-loaded CR parenteral dosage form and the in vitro release characteristics of a drug are 
assessed over time. Variations in the medium, apparatus set-up, pumps and flow rates make 
each method specific for a dosage form [511]. Continuous flow methods that have been reported 
are varied and include placing a sample in a filtration cell and withdrawing samples at specified 
intervals from the cell and replacing fresh medium into the cell [520]. Modifications to this 
method include the use of jacketed column or water-bath to maintain the temperature at 37 °C 
[511]. An example of a custom made continuous flow system [521] is depicted in Figure 5.1 and 
that of a commercial continuous flow system is shown in Figure 5.2 [522]. 
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Figure 5.1 Apparatus for a continuous flow assessment method  
using a syringe pump (adapted from [521]) 
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Figure 5.2 Commercial apparatus for continuous flow assessment (adapted from [522]) 
 
Peristaltic pumps and syringes or HPLC pumps may be used to ensure a constant flow rate of 
the dissolution medium is maintained and modifications to the flow rate may be required to 
optimise in vitro release profiles for specific dosage forms. The use of low flow rates may result 
in incomplete release of a drug due to slow hydration and dissolution of a polymeric delivery 
system because polymer hydration may affect the rate of erosion of the polymer thereby 
affecting the overall rate of release rate of a drug from the delivery system [511]. 
 
The primary advantage of continuous flow methods for assessing in vitro release from CR 
parenteral formulations is that these systems attempt to simulate the in vivo environment by 
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providing a small dynamic volume of media that passes through a stationary depot of drug. In 
addition, these methods allow continuous sampling of the dissolution medium [511] and if the 
receptor medium is removed and replaced rapidly, the rate of release of a drug is proportional to 
the instantaneous release of the drug from the formulation, since there is no accumulation of 
drug in the receptor medium [506]. Limitations of continuous flow methods include variations 
in flow rate because of filters clogging when microparticulate systems are assessed. Using low 
flow rates may result in low release rates of drug, which may not be indicative of the in vivo 
performance characteristics of a delivery system. In addition, rapid replacement of buffer in the 
sampling procedure is quite difficult to achieve and may affect the resultant in vitro release 
profiles that are obtained [506,511]. 
 
5.2.5 Dialysis Methods 
 
In dialysis methods, the physical separation of a drug loaded CR system from the dissolution 
medium is achieved by use of a dialysis membrane. Dialysis techniques have been used 
extensively for assessment of in vitro release characteristics from different dosage forms 
including parenteral depot dosage forms of an oily nature, suppositories, liposomes, 
nanoparticles, implants, and micelles [511]. Dialysis methods have also been used extensively 
for in vitro drug release characterisation of CR parenteral dosage forms [523-527]. 
 
Dialysis techniques usually include placing a formulation in a dialysis bag, which is then placed 
in a vessel that contains the dissolution medium. The diffusion of drug through the membrane 
may be enhanced by the use of agitation and this may be achieved by use of a horizontal shaker 
or USP Apparatus 2. The assessment of quantity of drug released is performed by sampling the 
bulk media over time and analysing the samples with an appropriate analytical technique [511]. 
 
Several modifications can be made to dialysis methods for the assessment of in vitro drug 
release from dosage forms and such variations include the use of a tube with a dialysing 
membrane at one end as shown in Figure 5.3. The tube and membrane were placed in an 
appropriate dissolution medium thereby allowing for the diffusion of drug through the dialysis 
tube into the medium that was sampled at appropriate intervals [528]. 
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Figure 5.3 Dialysis method with a membrane on one side (adapted from [528]) 
 
The selection of membranes with specific molecular weight cut-offs (MWCO) may be arbitrary, 
but the MWCO must be sufficiently high to not limit diffusion of a drug entity from a dosage 
form into the dissolution medium [511]. The volume of medium in the dialysis bag must be at 
least 6 – 10-fold less than the volume of the bulk dissolution medium to ensure that sink 
conditions are maintained and that the driving force for drug transport-diffusion is unimpeded 
[511]. 
 
The advantages of using dialysis methods for the assessment of CR parenteral delivery systems 
include ease of sampling and medium replacement, as there is no interference of the dissolution 
medium by delivery systems. In addition, dialysis methods mimic in vivo conditions for 
subcutaneous and intramuscular administration, where a preparation is immobilised and permits 
only slow diffusion of a drug into the dissolution medium. However, the main disadvantage of 
dialysis systems is that sink conditions are not readily maintained, thereby limiting the utility 
and applicability of this type of method. The surface area of dialysis tube exposed to the 
dissolution medium affects the in vitro release profiles that are obtained since when a small 
surface area is exposed, the time taken for equilibration between the internal and external phases 
is increased with a subsequent decrease in the rate of release. Long equilibration times may limit 
the accurate analysis of drug release when a burst effect is present. Agitation may be used to 
minimise the effect of an unstirred water layer outside the membrane thereby reducing the time 
taken for equilibration, promoting of rapid release of drug from CR parenteral dosage forms 
[511]. 
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5.2.6 Methods Used for In Vitro Release Assessment of Hydrogels 
 
Hydrogels have been extensively explored as potential delivery systems for protein and peptide 
delivery systems, as was previously discussed in Chapter 3, vide infra and different methods 
have been used to assess the rate and extent of in vitro drug release from such systems. 
 
For methods that do not use agitation, hydrogels containing drug are placed in a relatively large 
volume of a dissolution medium and aliquots are removed for analysis at predetermined sample 
times. The sample medium may be replaced with an equivalent volume maintaining sink 
conditions in the test system [529-534]. A variation in this method is one in which the hydrogel 
formulation is exposed to a small volume of dissolution medium on a surface of the formulation 
and the fluid is removed and replaced by fresh buffer at specific sample times [449,535]. 
 
Methods that use agitation have also been used for assessing the in vitro release of drug from 
hydrogel systems. By way of example, drug loaded hydrogel pellets were placed in a phosphate 
buffer in a shaking water bath that was maintained at 37 °C and agitation was achieved using a 
reciprocating motion at 100 rpm. The dissolution medium was sampled periodically with 
replacement of fresh buffer [536]. Ruel-Garièpy et al. [537] placed a drug containing hydrogel 
in circular moulds and the hydrogel was allowed to set at 37 °C for 12 hours, after which the 
gels were removed from the moulds and placed in histology cassettes. These were then 
suspended in 500 ml of phosphate buffered saline (PBS) at pH 7.4 in which the surfactant, 
sodium dodecyl sulphate was used to increase the in vitro release rate. A shaking incubator set 
at 100 rpm maintained at 37 °C was used and samples were drawn periodically [537]. 
Alternatively, the entire dissolution medium could be removed at sampling intervals and 
replaced with fresh medium [538-541] or different rates of agitation may be used e.g. 150 rpm 
[541,542], 100 rpm [537], 70 rpm [538], and 50 rpm [541]. 
 
Kim et al. [543] used a dialysis tube for in vitro testing. A known amount of drug containing 
hydrogel was placed in a dialysis bag with 1 ml of PBS, the bag was positioned in 10 ml PBS 
maintained at 37 °C and stirred at 100 rpm, and the entire medium was removed and replaced at 
specific sample times. 
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5.2.7 In Vitro Testing of Drug Release from PF-127 Systems 
 
Several methods have been reported for the assessment of in vitro drug release from PF-127 
systems that were intended for parenteral use, membrane-less diffusion systems and/or 
modifications thereof have been utilised [450,460,499-501,544-546]. In summary, a drug 
containing PF-127 formulation is placed in a small vessel, which is then placed in a larger 
vessel, such as a beaker and the dissolution medium is gently poured directly above the delivery 
system and is in direct contact with the gel layer. The drug released is then analysed from 
samples of medium following removal of the receptor medium at predetermined time intervals. 
The system is usually maintained at 37 °C for the duration of the experiment, and gentle stirring 
can provide agitation in these systems.  
   
Anderson et al. [499] used a membrane-less diffusion system in which a petri dish fitted with a 
metal holding plate was placed in an inverted position in a beaker containing dissolution 
medium. Figure 5.4 depicts the apparatus that was placed in a beaker with the gel exposed to the 
dissolution medium. 
 
Steel holding plates
Petri dish with gel
(gel exposed)
Legs
 
Figure 5.4 Schematic diagram of the gel holder used by Anderson et al. (adapted from [499]) 
 
Membrane diffusion systems have also been used for the assessment of PF-127 formulations 
[452,547,548]. In these systems, the gel layer is separated from the dissolution or receptor 
media by means of a non-rate limiting membrane and the receptor fluid is sampled for analysis 
at specified times. The test system is usually maintained at 37 °C for the duration of the in vitro 
release test. 
 
A dialysis system has also been used for the assessment of in vitro drug release from PF-127 
formulations [451], where a drug containing cold PF-127 solution was placed in a cellulose 
dialysis tube that provided a cylindrical gel compartment. The gel was allowed to stiffen prior to 
commencement of the in vitro test and the preparation was then placed into a receptor medium 
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and maintained at 37 °C with agitation by a magnetic stirrer bar. The amount of drug release 
was assessed following sampling of the receptor phase at predetermined times. 
 
Paalova et al. [547] used a two compartment in vitro system depicted in Figure 5.5 to study drug 
release from PF-127 and other cellulose polymer gels. The donor compartment of the system 
was separated from the receptor fluid by a non-rate limiting membrane. The method was found 
to have a strong in vitro in vivo correlation since the amount of drug released and the 
pharmacological effect that was observed in vivo were directly related. 
 
Glass cylinder Plexiglass cover
Membrane
SInk solution
Stirring bar
Sampling port
(donor compartment)
 
Figure 5.5 A two-compartment dialysis method used to assess  
in vitro release from Pluronic® gels, (adapted from Paalova et al. [547]) 
 
Moore et al. [502] used USP Apparatus 2 to determine drug release from PF-127 gels. The gels 
were placed in containers with a diameter of 60 mm and a height of 15 mm and drug release 
was assessed at 37 °C. The speed of rotation of the paddle was varied between 20 and 80 rpm to 
determine the effect on release rates and to develop a mathematical model to evaluate the 
release of drugs from dissolving PF-127 gel systems. 
 
5.3 IN VITRO RELEASE TEST METHOD DEVELOPMENT 
 
New technologies and advances in the development of CR delivery systems have mandated the 
development of specific in vitro release test methods. Furthermore, modification of current 
compendial methods or the development of new procedures may be necessary in order to suit 
the specific needs for product assessment. An in-depth understanding of drug release 
mechanisms and the hydrodynamics of in vitro dissolution test apparatus on is necessary in 
order to develop discriminatory in vitro release methods that produce reliable and reproducible 
data that is also biorelevant [549]. 
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Biorelevance is an important consideration in the development of in vitro dissolution methods 
for CR parenteral products and where applicable, in vitro release tests should be developed for 
specific clinical outcomes. In order to achieve in vivo relevance, consideration of the 
physiological site of administration including body temperature, muscle pH, buffer capacity, 
and dosage form considerations such as volume and osmolarity of a product must be considered. 
Another important consideration is the duration over which the in vitro release test is conducted 
and sampling times and intervals in order to, where possible, mimic in vivo release 
characteristics and generate relevant drug release profiles [497,509,510]. For CR parenteral 
products, a multipoint drug release profile is recommended for the appropriate assessment of 
dosage form performance [509]. 
 
A recommended approach for in vitro release test method development has been described 
[496,508] as follows: 
i. Identification of appropriate dissolution medium/media and the conditions for ensuring 
reproducible release rates, 
ii. Preparation of different formulation compositions that are likely to result in changes in 
the performance of a dosage form, 
iii. Testing of different formulations both in vitro and in vivo and, 
iv. Modification of the in vitro test method to allow for discrimination between the 
different formulations that have different in vivo release profiles. 
 
The extent of drug release is a further consideration and for in vitro release assessment of CR 
parenteral delivery systems, a desirable outcome is that at least 80% be released as this is 
considered to be economical and safe, reducing costs and maintaining a low toxicity profile 
respectively [508]. In vitro release methods that are developed must also be able to identify 
burst release of the API and in cases where burst release occurs, the duration and extent of the 
burst release must be characterised as this may affect the toxicity of a dosage form and produce 
unwanted effects in vivo [508]. 
 
5.4 COMPARISON OF IN VITRO RELEASE PROFILES 
 
5.4.1 Introduction 
 
The comparison of in vitro release profiles can be achieved by the use of mathematical methods 
of analysis. Mathematical analysis for assessment of in vitro release profiles can be divided into 
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3 types viz, model-dependent (curve fitting), model-independent methods and statistical analysis 
[550]. 
 
5.4.2 Statistical Methods 
 
Statistical methods have been used for the evaluation and comparison of dissolution profiles 
following in vitro dissolution testing [551,552] and for development and optimisation of in vitro 
dissolution tests [553-555]. Statistical methods can be used to compare different formulations 
tested under the same experimental conditions as well as for the comparison of dissolution tests 
for the same formulation tested under different test conditions [550,553,554]. 
 
Analysis of variance methods can be distinguished into univariate or one-way analysis of 
variance (ANOVA) and multivariate analysis of variance (MANOVA). ANOVA tests may be 
used to assess the difference between means of two dissolution or drug release data sets in 
single time point dissolution tests and MANOVA analysis is useful for the evaluation of 
multiple time point dissolution tests [550]. It has been reported that ANOVA analysis is more 
informative and is easier to interpret compared to MANOVA analysis, which requires data 
transformation on repeated measures and makes interpretation of results difficult [552]. 
 
For the comparison of dissolution of in vitro release profiles a repeated measures design may be 
used, where the percent drug dissolved is the dependent variable and time is the repeated factor 
[552]. Univariate ANOVA analysis can be applied at each time point when comparing 
dissolution profiles to determine where differences, if any, exist between the dissolution profiles 
being compared [552]. Different post hoc tests can be used to determine the exact points of 
difference between dissolution profiles including the Least Significant Difference Test, Tukey’s 
Multiple Range Test, Scheffé Method, Newman-Keuls Test and Dunnett’s Test [556]. 
 
ANOVA based methods of analysis reveal information about differences in the shape and levels 
of different dissolution data sets that are being compared [552], although they have been 
criticised for being too discriminatory, showing statistical differences in dissolution profiles that 
may not necessarily reflect pharmaceutical differences [551]. 
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5.4.3 Model Independent Methods 
 
5.4.3.1 Introduction 
Model-independent methods make no assumptions about the shape of the curves being 
evaluated and are used to compare drug release profiles from different data sets. Model-
independent methods can be divided into ratio tests and pair-wise procedures. 
 
5.4.3.2 Ratio Test Procedures 
In ratio test procedures, the ratio between parameters derived from dissolution data from a test 
and reference product are compared at the same time point. The test procedures vary in 
complexity for the analysis of selected parameters. Ratio test procedures can include the 
evaluation of the ratio of percent released/dissolved (tx%) at a certain time point, area under the 
curve (AUC) or ratio of the mean dissolution time (MDT) [550,551]. The relationship that may 
be used to calculate the MDT, which is the sum of the individual times during which a specific 
fraction of the total dose in a dosage form is released is depicted in Equation 5.1 [550]. 
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    Equation 5.1 
Where, 
j = sample number 
n = number of dissolution sample times 
tj = time at midpoint between tj and tj-1 
∆M = additional amount of drug dissolved between tj and tj-1 
 
5.4.3.3 Pair-wise Procedures 
Examples of pair-wise test procedures include the Rescigno index [557] and the difference (f1) 
and similarity (f2) factors [558]. 
 
The bioequivalence index derived by Rescigno [557] was proposed as useful for the comparison 
of drug plasma levels as a function of time for a test and reference product. The same index may 
be applied to the comparison of in vitro dissolution profiles obtained when comparing drug 
release from a test and reference product. The expression used to calculate the Rescigno index 
for the comparison of dissolution profiles is depicted in Equation 5.2 [550,551]. 
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Where, 
  dR(t) = amount/percent of drug dissolved for reference product at time t 
  dT(t) = amount/percent of drug dissolved for test product at time t 
  i = any positive integer 
  t = time 
 
The Rescigno index is always a fraction between zero (0) and one (1). The index is zero (0) 
when the test and reference and products are identical and in cases where no drug is released 
from either the test or reference formulation, the index is equivalent to one (1) [557]. 
 
Moore and Flanner [558] proposed the use of difference and similarity factors, f1 and f2 
respectively, for the comparison of dissolution profiles and these factors are known as fit 
factors. The difference factor, f1 measures the percent error between dissolution profiles of a test 
and reference product at all time points. The percent error is zero (0) when the in vitro release 
profiles of the test and reference product are identical and this value increases proportionally as 
dissolution profiles become dissimilar [558]. The similarity factor, f2 is a logarithmic 
transformation of the sum-squared error of the differences between a test and reference product 
over all time points. The factor falls between 0 and 100 and a value of 100 indicates that the 
dissolution profiles of a test and reference product are identical. At least three (3) or four (4) 
dissolution time points are needed to calculate the similarity factor, f2 [558]. The difference and 
similarity factors can be calculated from Equations 5.3 and 5.4, respectively. 
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Where, 
  n = number of dissolution time points 
  Rt = percent of the reference product dissolved at time t 
  Tt = percent of the test product dissolved at time t 
  wt = an optional weight factor, usually set at 1 
 
In general, if the f1 value is lower than 15 and the f2 value falls between 50 and 100, then the two 
dissolution profiles being compared can be considered to be similar [558]. The Centre for Drug 
Evaluation and Research (FDA) [512,559] has adopted the use of the similarity factor, f2 as a 
valid criterion for the comparison of in vitro dissolution profiles between test and reference 
products. The guidance to industry [512,559] recommends that the similarity factor be used to 
compare in vitro dissolution profiles when at least 12 individual dosage units are used. 
 
Recommendations for the use of the f2 similarity factor include that the number of sample points 
included in the calculation should be limited to no more than one after more than 85% of the 
label claim of the product has been released, since the sensitivity of the test decreases after this 
point and fails to discriminate between measurements [560]. 
 
The main advantages of the use of the f1 and f2 difference and similarity factors are that they are 
easy to compute and each gives a single number that indicates the degree of closeness between 
the two in vitro dissolution profiles being compared [552]. However, limitations in the use of 
the similarity factor include failure to take into account the shape of the curve and unequal 
spacing between time points on in vitro release profiles. Furthermore, it is impossible to 
evaluate false positive and false negative values when the similarity factor is used and the 
similarity factor is often too liberal in concluding similarity between two dissolution profiles 
[550]. 
 
5.4.3.4 Other Model-Independent Methods 
A newer model-independent approach has been proposed by Gohel and Panchal [561] for the 
comparison of dissolution profiles of a test and reference product and this model uses a 
similarity factor, Sd for the comparison. The Gohel similarity factor can be calculated using 
Equation 5.5. [561]. 
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Where, 
n = number of data points collected during an in vitro release  test 
AUCRt = area under the curve of the reference product at time t 
AUCTt = area under the curve of the test product at time t 
 
Two dissolution profiles are considered similar when the Sd value is zero (0) or close to zero (0). 
The advantages of using the similarity factor for the comparison of dissolution profiles are that 
the method is simple and flexible as the data for dissolution profile comparison may be 
expressed as either amount or percent release/dissolved [561]. The calculation of the Sd value 
may be used to infer a percent difference between the formulations being tested and such 
differences have been reported and are summarised in Table 5.1 [561]. 
 
Table 5.1 Standard data for Gohel similarity factor, Sd 
Percent difference Sd 
0 0.0000 
5 0.0212 
10 0.0414 
15 0.0607 
20 0.0792 
25 0.0969 
30 0.1139 
 
The dissolution efficiency (DE) of a pharmaceutical dosage form is defined as the area under 
the dissolution curve up to a specific time, t, expressed as a percentage of the area of a rectangle 
representing 100% release following dissolution at the same time, t [562]. DE can be calculated 
using Equation 5.6. 
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Where, 
y = percent of drug released at time t 
t = time 
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5.4.4 Model-Dependent Methods 
 
5.4.4.1 Introduction 
Model-dependent methods make assumptions about the shape of the curve, fitting data using 
equations in which parameters defining the shape of the curve are optimised [563]. Commonly 
used model-dependent methods that have been used to characterise dissolution curves include 
zero order, first order, Higuchi, Hixson-Crowell, and the Korsmeyer-Peppas models [550]. The 
models can be used to evaluate the mechanism of drug release from delivery systems and are 
useful in understanding formulation factors that alter the in vitro release of an API from a 
dosage form, thereby optimising formulation development [564]. Furthermore, drug release 
from hydrogel systems can be characterised by the primary mechanism of release, which may 
be diffusion-controlled, chemically-controlled, and/or swelling controlled systems [423]. 
 
5.4.4.2 Zero Order Model 
The zero order model can be used to model drug release from dosage forms that do not 
disaggregate and that release the same amount of drug per unit time to obtain a predictable and 
sustained release of a medicinal agent [550]. The zero order model can be expressed using 
Equation 5.7. 
 
tKQQt 00 +=        Equation 5.7 
Where, 
  Qt = amount of drug released at time t 
  Q0 = initial amount of drug present in solution 
  K0 = zero order release constant 
t = time 
 
Diffusion controlled systems consist of a polymeric membrane which encapsulates an API 
within a core and the membrane separates the API from the external environment [423]. Drug 
release from encapsulated systems often follows a zero order model and is independent of time 
for planar, cylindrical and spherical geometries. The rate of release from a spherical diffusion 
controlled system may be determined by use of Equations 5.8 and 5.9. 
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Where,   
Mt = amount of drug released at time t 
dt
dM t
= rate of change of the amount of drug released per unit time 
Dip = diffusion coefficient of species i  
K = drug partition coefficient  
re = external radius of sphere 
ri = internal radius of sphere 
ci1 = drug concentration of species i inside polymer matrix 
ci2 = drug concentration of species i outside polymer matrix  
 
In reservoir diffusion systems as described, drug release is controlled by the geometry of the 
system [423]. 
 
5.4.4.3 First Order Model 
The application of a first order model to describe the in vitro release/dissolution kinetics of API 
was reported by Gibaldi and Feldman [565]. The first order release model may be expressed 
mathematically using Equation 5.10. 
 
tKQQt 10lnln +=       Equation 5.10 
Where,  
  Qt = amount of drug release in time t 
  Q0 = initial amount of drug present in solution  
  K1 = first order release constant  
  t = time 
 
Water-soluble drugs that are formulated into porous matrices are released according to first 
order kinetic principles [550,566] and that the rate of release is proportional to the amount of 
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drug remaining to be released from a matrix. The rate of release therefore declines with time as 
the amount of drug remaining in the dosage form diminishes over time. 
 
5.4.4.4 Higuchi Model 
The models for drug release developed by Higuchi [567,568] describe the mechanism of release 
of water-soluble and water-insoluble drugs that were homogeneously incorporated into non-
eroding semi-solid and/or solid matrices. A simplified version of the Higuchi model is depicted 
in Equation 5.11. 
 
2
1
tKQ Ht =     Equation 5.11 
Where,  
  Qt = amount of drug released at time t  
  KH = Higuchi dissolution constant  
  t = time  
 
The Higuchi model describes drug release based on Fick’s First Law of diffusion and release is 
considered to be diffusion controlled if the release of drug is square root time dependent [550]. 
 
5.4.4.5 Hixson-Crowell Model 
The Hixson-Crowell model describes drug release from systems that undergo a change in 
diameter and surface area with proceeding drug release. The model is applied to dosage forms 
where dissolution occurs in planes that are parallel to the surface of the dosage form and where 
the dimensions of the dosage form diminish in a proportional manner over time [550]. The 
Hixson-Crowell model can be described using Equation 5.12. 
 
tKQQ st =− 3
1
3
1
0    Equation 5.12 
Where,  
  Q0 = initial amount of drug in dosage form  
  Qt = amount of drug remaining in dosage form at time t  
  Ks = constant incorporating the surface/volume ratio  
  t = time 
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5.4.4.6 Korsmeyer-Peppas Model 
Korsmeyer et al. [569] proposed a semi-empirical comprehensive model known as the power 
law, to describe mechanism of release from different dosage forms and the power law may be 
described mathematically as shown in Equation 5.13 and Equation 5.14, which depicts the 
logarithmic transformation of the relationship. 
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Where,  
 
∞
M
M t
= fraction of released drug 
 k = constant incorporating geometric characteristics of dosage form    
n = release exponent indicating mechanism of release 
 t = time  
 
Drug release from hydrophilic matrices is controlled by the inward flux of solvent into the 
interior of the delivery system, which results in swelling of a polymer. In the initial stages of 
swelling of a hydrogel, two distinct phases are observed, viz., an inner glassy phase and outer 
swollen rubbery phase, from which drug molecules are able to diffuse [423]. The phenomenon 
of macromolecular relaxation occurs at the glassy-rubbery interface and the extent to which this 
affects the release of drug from the delivery system can be inferred from the exponent, n. 
 
The numerical value of the exponent, n, describes the mechanism of drug release from a dosage 
form [570]. For a slab, when n = 0.5 the mechanism of drug release in the system is governed 
by Fickian diffusion and is termed Case I transport. When n lies between 0.5 and 1.0 then mass 
transfer of drug from the matrix is reported to follow a non-Fickian model that corresponds to 
both drug diffusion and polymer relaxation. When the exponent n ≥ 1.0 the mechanism of drug 
release is considered to be swelling controlled or Case II transport. The interpretation of n also 
depends on the shape of the dosage form tested, and the limits for slab, cylinder, and sphere 
geometries are summarised in Table 5.2. 
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Table 5.2 Interpretation of release mechanism from polymeric films using the power law [550,570]. 
Geometry Case I  
Fickian diffusion  
Intermediate/ 
Anomalous 
Case II  
Swelling controlled  
Slab n = 0.50 0.50 < n < 1.0 n = 1.0 
Cylinder n = 0.45 0.45 < n < 0.89 n = 0.89 
Sphere n = 0.43 0.43 < n < 0.85 n = 0.85 
 
The Korsmeyer-Peppas power law is only valid for the first 60% of drug released from a dosage 
form, and must therefore be used accordingly to avoid misinterpretation of the mechanism of 
drug release. 
 
5.4.5 Mathematical Treatment of In Vitro Release Data 
 
The different test methods that were used for the assessment of OT release from PF-127 gels 
were evaluated for potential discriminatory behaviour using ANOVA analysis and model 
independent methods. In addition, the similarity of dissolution profiles for OT release from PF-
127 dosage forms containing different concentration of gel former was evaluated. Univariate 
ANOVA analysis was performed using GraphPad Prism software Version 4.00 for Windows 
(GraphPad Software, San Diego California USA, www.graphpad.com) to assess whether 
differences between each time point of in vitro dissolution profiles existed for each of the 
formulations tested. Tukey’s Multiple Range test was used as a post hoc test to assess which of 
the formulations were different for at the individual time points evaluated during in vitro 
dissolution tests.  
 
Model independent approaches that were used to assess the similarity and/or difference between 
in vitro dissolution profiles were the f1 and f2 difference and similarity factor and the Gohel 
similarity factor, Sd, approaches. Formulations were considered different if f1 > 15, f2 < 50 and 
an Sd value equivalent to a percent difference of at least 25% was considered to be similar. The 
model independent methods were used in an attempt to determine whether dissolution profiles 
and methods were discriminatory. In this study model independent approaches were used to 
evaluate the differences in release profiles that were generated for different concentrations of 
PF-127 in a formulation evaluated using a specific in vitro test method. The difference and 
similarity factors cannot be applied to the evaluation of the same formulation under different 
experimental conditions and fit factors have been reported to be of use during the development 
of an appropriate in vitro dissolution/release test [555,571].  
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Model dependent methods were used to assess differences, if any, on the mechanism of release 
of OT from PF-127 gels when different in vitro dissolution/release tests were used. The power 
law was used as the primary model to assess the mechanism of OT release from dosage forms. 
The zero order, first order, Higuchi and Hixson-Crowell models were also used to determine the 
mechanism of drug release from the gels produced in these studies. 
 
The determination of goodness of fit of data to the models was performed by assessing the 
adjusted coefficient of determination (R2adjusted). Other methods that may be used are the 
coefficient of determination (R2), correlation coefficient (R), sum of squares of residuals (SSR), 
mean square error (MSE) and the Akaike’s Information Criterion (AIC) [550]. The limitation of 
R2, despite its easy computation is that the value of R2 tends to increase as more model 
parameters are added, irrespective of the significance of the parameter added to a specific model 
[550]. The use of R2adjusted however is more meaningful to the interpretation of mathematical 
models as this value may increase or decrease when new parameters are added to a model.This 
indicates the impact of the added parameter on the performance of the model when used to 
assess the mechanism of drug release from a dosage form or formulation [550]. The R2adjusted 
may be calculated using Equation 5.15.  
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Where,  
  n = number of dissolution data points  
  p = number of parameters in the model  
  R2 = coefficient of determination 
 
To determine the most likely mechanism of release of OT from PF-127 gels based on the 
mathematical models described above a value of R2adjusted > 0.950 was considered acceptable. 
 
5.5 EXPERIMENTAL 
 
5.5.1 Dissolution Test Conditions 
 
OT containing PF-127 gels of concentration 20%, 25% and 30% w/w were prepared using the 
cold method as described in § 4.4.2.1 by addition of an appropriate amount of gel former to a 
previously cooled aqueous solution of OT (200 IU/ml). The solutions were assayed by HPLC 
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before use and the gels were set in moulds of dimensions 23.6 X 11.0 X 8.0 mm (L X W X D) 
and such that only one (1) surface of the gel was exposed to the dissolution medium. An 
appropriate amount of gel was weighed out such that each dosage unit contained approximately 
300 IU of OT and the gels were set in a convection oven (Weiss Gallenkamp, Loughborough, 
United Kingdom) at 37 °C prior to in vitro release testing. All in vitro release tests were 
performed with three dosage units (n = 3).  
 
The dissolution medium used in the initial stages of formulation development for all three 
formulations in each of the different test methods that were investigated was a 0.1 M phosphate 
buffer (pH = 7.2). The buffer was prepared by weighing 68 g of potassium dihydrogen 
phosphate and dissolving the salt in approximately 4 l of HPLC grade water in a beaker and 
adjusting the pH to the required value using sodium hydroxide pellets. The volume finally made 
up to 5 l in an A-grade volumetric flask using HPLC water.  
 
5.5.2 USP Apparatus 1 and 2 
 
In vitro dissolution/release testing using 500 ml of dissolution medium that was prepared as 
described in § 5.5.1, maintained at 37 + 0.5 °C for the basket (USP Apparatus 1) and paddle 
(USP Apparatus 2) apparatus was used. The dissolution tests were conducted using a fully 
automated Hanson Research SR 8 PLUS dissolution tester fitted with an AutoplusTM MultifillTM 
and Maximizer Syringe Fraction Collector (Hanson Research Cooperation, Chatsworth, CA, 
USA). The baskets (40-mesh) and the paddles were rotated at 25 rpm for the duration of the 
experiments. The gel retained in the moulds were placed in either the basket or placed at the 
bottom of a dissolution vessel when using USP Apparatus 1 or 2, respectively. The dissolution 
vessels were covered to minimise evaporation. Samples of 1.5 ml were withdrawn for analysis 
at 30, 60, 90, 120, 180, 240, 360, and 480 min and an equivalent amount (1.5 ml) of fresh 
dissolution medium was replaced automatically. The amount of drug released was quantitated 
using a validated HPLC method (Chapter 2). Dissolution profiles were generated by plotting the 
percent of OT released versus time and the resultant dissolution profiles were assessed by 
statistical methods and mathematical models as described in § 5.4.5. 
 
5.5.3 USP Apparatus 3 
 
A VanKel® Bio-Dis® dissolution tester (VanKel® industries, New Jersey, USA) was used for in 
vitro release assessment. A model VK 750D digitally controlled water circulation/heater 
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(VanKel® industries, New Jersey, USA) was used to maintain the temperature at 37 + 0.5 °C. A 
screen mesh of pore size of 177 µm and the dip speed of 5 dpm were used to retain the dosage 
form and provide agitation, respectively. The dosage form was moved through the different 
vessels at 30, 60, 120, 240, 360, and 480 min. The amount of drug released was determined 
using a validated HPLC method (Chapter 2) and appropriate the dissolution profiles that were 
generated were assessed by statistical methods and mathematical models as described in § 5.4.5. 
 
5.5.4 Dialysis Tubing Method 
 
Dialysis tubing cellulose membrane, 25 mm flat width (Sigma Aldrich, St Louis, MO, USA) 
was hydrated prior to use after which one end of the tube was tied and an appropriate amount of 
OT containing PF-127 gel was weighed out and placed in the dialysis tubing, such that there 
was approximately 300 IU in each dosage unit. The dialysis tube was then carefully tied at the 
other end. The gel was allowed to set in a convection oven (Weiss Gallenkamp, Loughborough, 
United Kingdom) at 37 °C prior to commencing the in vitro release test. USP Apparatus 2 set at 
50 rpm, with a dissolution medium comprised of a 0.1 M phosphate buffer that was prepared as 
previously described in § 5.5.1, was used to assess drug release and samples were harvested at 
60, 120, 180, 240, 360, and 480 min. The amount of drug released was determined using a 
validated HPLC method (Chapter 2). Dissolution profiles were generated and assessed by 
statistical methods and mathematical models as described in § 5.4.5.  
 
5.5.5 Membrane-less Diffusion System 
 
Appropriate amounts of gel (equivalent to 300 IU) (20%, 25% and 30%w/w) were weighed and 
placed in 5 ml test tubes. The gels were allowed to set in a water bath (Grant Instruments 
(Cambridge) Ltd, Cambridge, UK) maintained at 37 ˚C. 500 µl of dissolution medium 0.1 M 
phosphate buffer at pH 7.2  was prepared as described previously in § 5.5.1 and was carefully 
placed on the surface of the gel and the tubes were placed in the water bath for the duration of 
the study. At predetermined times of 30, 60, 90, 120, 180, 240, 360, and 480 min, the receptor 
fluid was completely removed and replaced with fresh receptor fluid. The sample that had been 
removed was diluted and analysed using a validated HPLC method (Chapter 2) and the resultant 
dissolution profiles were assessed by statistical methods and mathematical models as described 
in § 5.4.5. 
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5.5.6 Optimisation of In Vitro Release Test Method 
 
The in vitro dissolution test method that was selected as the most appropriate for the assessment 
of OT gels was then tested for further discriminating power by comparing drug release profiles 
obtained following testing a 25% w/w PF-127 formulation that had been manufactured to 
contain 25, 50, 100 and 200 IU of OT per dosage unit.  
 
The effect of dynamic pH was investigated to mimic in vivo conditions, where the pH of the 
muscle undergoes subtle changes as labour progresses. The formulation was exposed to a pH of 
6.85 for the first 30 min of the test and thereafter a pH of 7.2 was maintained for the duration of 
the in vitro dissolution test using USP Apparatus 3.  
 
5.6 RESULTS AND DISCUSSION 
 
5.6.1 The Discriminating Power of the Different In Vitro Release Test Methods 
 
5.6.1.1 In Vitro Release Profiles of OT from the different test methods 
The in vitro release profiles of OT from PF-127 gels using the different test methods described 
in § 5.5 are shown in Figures 5.6 – 5.10. 
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Figure 5.6 The extent of OT release from PF-127 gels using  
USP Apparatus 1(n = 3) for assessing in vitro release  
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Figure 5.7 The extent of OT release from PF-127 gels using 
 USP Apparatus 2 (n = 3) for assessing in vitro release  
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Figure 5.8 The extent of OT release from PF-127 gels using  
USP Apparatus 3 (n = 3) for assessing in vitro release 
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Figure 5.9 The extent of OT release from PF-127 gels using 
 the dialysis method (n = 3) for assessing in vitro release 
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Figure 5.10 The extent of OT release from PF-127 gels using the  
membrane-less diffusion method (n = 3) for assessing in vitro release 
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As expected, the rate of OT release from the different formulations tested was dependent on the 
concentration of PF-127 that was used in the formulation with the lower concentrations of gel 
former providing the fastest rate of release of the OT from the dosage forms. The trend was 
observed for all in vitro dissolution apparatus tested. Formulations with a low gel content have a 
lower viscosity in comparison to formulations with higher gel content (See § 4.5.6) and undergo 
faster gel dissolution (See § 4.5.7). These effects ultimately result in a faster rate of OT 
liberation and other studies have shown that the rate of release of drug from PF-127 systems is 
controlled by dissolution of the gel [500,502]. 
 
5.6.1.2 Analysis of Variance 
ANOVA analysis was used to compare the in vitro release profiles of OT from the different 
formulations when different in vitro release methods were used to assess which of the tests were 
discriminatory. The primary advantage of using ANOVA analysis for this purpose is that the 
statistical test allows for the detection of differences between in vitro release profiles at 
individual time points. Furthermore, the ANOVA analysis allows for careful monitoring of the 
profiles to determine if there are any changes in the discriminatory pattern of the test system as 
in vitro release testing proceeds. The results of the ANOVA analysis performed comparing in 
vitro release profiles for the different formulations with different PF-127 content are 
summarised in Tables 5.3 - 5.7.  
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Table 5.3 ANOVA analysis summary for in vitro release profiles generated using USP Apparatus 1 
95% Confidence interval to mean 
difference 
Time (min) Comparison  Mean difference 
Lower limit Upper limit  
P value  Summary  
30  20% vs. 25% 0.3021 -0.5800  1.184 P > 0.05 Not significant 
 20% vs. 30% 0.9569 0.07475 1.839 P < 0.05 Significant 
 25% vs. 30% 0.6548 -0.2274 1.537 P > 0.05 Not significant 
60 20% vs. 25% 1.665 0.2874 3.043 P < 0.05 Significant  
 20% vs. 30% 4.939 3.561 6.317 P < 0.01 Significant 
 25% vs. 30% 3.274 1.896 4.652 P < 0.01 Significant 
90 20% vs. 25% 2.961 1.734 4.189 P < 0.01 Significant 
 20% vs. 30% 8.594 7.367 4.189 P < 0.001 Significant 
 25% vs. 30% 8.594 4.406 6.860 P < 0.001 Significant 
120 20% vs. 25% 2.903 -1.890 7.696 P > 0.05 Not significant 
 20% vs. 30% 9.846 5.053 14.64 P < 0.01 Significant 
 25% vs. 30% 6.943 2.150 11.74 P < 0.05 Significant 
180 20% vs. 25% 4.612 -4.439 13.66 P > 0.05 Not significant 
 20% vs. 30% 14.15 5.098 23.20 P < 0.05 Significant 
 25% vs. 30% 9.537 0.4866 18.59 P < 0.05 Significant 
240 20% vs. 25% 2.146 -10.40 14.69 P > 0.05 Not significant 
 20% vs. 30% 15.37 2.822 27.91 P < 0.05 Significant 
 25% vs. 30% 13.22 0.6752 25.77 P < 0.05 Significant 
360 20% vs. 25% 2.983 -5.357 11.32 P > 0.05 Not significant 
 20% vs. 30% 20.31 11.97 28.65 P < 0.01 Significant 
 25% vs. 30% 17.33 8.987 25.67 P < 0.01 Significant 
480 20% vs. 25% 2.058  -3.278 7.394 P > 0.05 Not significant 
 20% vs. 30% 17.57 12.24 22.91 P < 0.01 Significant 
 25% vs. 30% 15.52 10.18 20.85 P < 0.01 Significant 
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Table 5.4 ANOVA analysis summary for in vitro release profiles generated using USP Apparatus 2 
95% Confidence interval to mean 
difference 
Time (min) Comparison  Mean difference 
Lower limit Upper limit  
P value  Summary 
30  20% vs. 25% -6.316 -13.41 0.7769 P > 0.05 Not significant 
 20% vs. 30% -1.612 -8.705 5.482 P > 0.05 Not significant 
 25% vs. 30% 4.705 -2.389 11.80 P > 0.05 Not significant 
60 20% vs. 25% -0.9969 -11.05 9.052 P > 0.05 Not significant 
 20% vs. 30% 5.052 -4.997 15.10 P > 0.05 Not significant 
 25% vs. 30% 6.049 -4.000 16.10 P > 0.05 Not significant 
90 20% vs. 25% 5.433 -5.343 16.21 P > 0.05 Not significant 
 20% vs. 30% 12.62 1.849 23.40 P < 0.05 Significant 
 25% vs. 30% 7.192 -3.584 17.97 P > 0.05 Not significant 
120 20% vs. 25% 7.014 -5.647 19.68 P > 0.05 Not significant 
 20% vs. 30% 15.42 2.758 28.08 P < 0.05 Significant 
 25% vs. 30% 8.404 -4.256 21.07 P > 0.05 Not significant 
180 20% vs. 25% 10.27 -14.96 35.50 P > 0.05 Not significant 
 20% vs. 30% 20.82 -4.411 46.05 P > 0.05 Not significant 
 25% vs. 30% 10.55 -14.68 35.78 P > 0.05 Not significant 
240 20% vs. 25% 6.988 -1.476 15.45 P > 0.05 Not significant 
 20% vs. 30% 15.15 6.688 23.62 P < 0.05 Significant 
 25% vs. 30% 8.164 -0.2997 16.63 P > 0.05 Not significant 
360 20% vs. 25% 1.631 -9.472 12.74 P > 0.05 Not significant 
 20% vs. 30% 5.443 -5.661 16.55 P > 0.05 Not significant 
 25% vs. 30% 3.812 -7.292 14.92 P > 0.05 Not significant 
480 20% vs. 25% -0.1106 -4.397 4.176 P > 0.05 Not significant 
 20% vs. 30% -1.956 -6.242 2.331 P > 0.05 Not significant 
 25% vs. 30% -1.845 -6.132 2.441 P > 0.05 Not significant 
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Table 5.5 ANOVA analysis summary for in vitro release profiles generated using USP Apparatus 3 
95% Confidence interval to mean 
difference 
Time (min) Comparison  Mean difference 
Lower limit Upper limit  
P value  Summary 
30  20% vs. 25% 6.236 4.620 7.852 P < 0.01 Significant 
 20% vs. 30% 11.93 10.32 13.55 P < 0.001 Significant 
 25% vs. 30% 5.699 4.083 7.314 P < 0.01 Significant 
60 20% vs. 25% 14.80 9.749 19.85 P < 0.01 Significant 
 20% vs. 30% 27.93 22.88 32.97 P < 0.001 Significant 
 25% vs. 30% 13.13 8.080 18.18 P < 0.01 Significant 
120 20% vs. 25% 7.502 5.617 9.387 P < 0.001 Significant 
 20% vs. 30% 31.77 29.88 33.65 P < 0.001 Significant 
 25% vs. 30% 24.26 22.38 26.15 P < 0.001 Significant 
240 20% vs. 25% -0.09111 -4.318 4.136 P > 0.05 Not significant 
 20% vs. 30% 8.688 4.461 12.91 P < 0.01 Significant 
 25% vs. 30% 8.779 4.552 13.01 P < 0.01 Significant 
360 20% vs. 25% -0.09111 -4.798 4.615 P > 0.05 Not significant 
 20% vs. 30% 5.892 1.186 10.60 P < 0.05 Significant 
 25% vs. 30% 5.984 1.277 10.69 P < 0.05 Significant 
480 20% vs. 25% -0.09111 -4.798 4.615 P > 0.05 Not significant 
 20% vs. 30% 5.892 1.186 10.60 P < 0.05 Significant 
 25% vs. 30% 5.984 1.277 10.69 P < 0.05 Significant 
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Table 5.6 ANOVA analysis summary for in vitro release profiles generated using the dialysis method 
95% Confidence interval to mean 
difference 
Time (min) Comparison  Mean difference 
Lower limit Upper limit  
P value  Summary 
60 20% vs. 25% 1.893 -0.2980 4.085 P > 0.05 Not significant 
 20% vs. 30% 2.464 0.2730 4.656 P < 0.05 Significant 
 25% vs. 30% 0.5710 -1.620 2.762 P > 0.05 Not significant 
120 20% vs. 25% 1.872 -1.215 4.958 P > 0.05 Not significant 
 20% vs. 30% 3.586 0.4989 6.673 P < 0.05 Significant 
 25% vs. 30% 1.714 -1.373 4.801 P > 0.05 Not significant 
180 20% vs. 25% 2.755 0.8885 4.621 P < 0.05 Significant 
 20% vs. 30% 5.244 3.378 7.111 P < 0.01 Significant 
 25% vs. 30% 2.489 0.6228 4.356 P < 0.05 Significant 
240 20% vs. 25% 2.731 -0.9598 6.422 P > 0.05 Not significant 
 20% vs. 30% 5.921 2.230 9.612 P < 0.05 Significant 
 25% vs. 30% 3.190 -0.5006 6.881 P > 0.05 Not significant 
360 20% vs. 25% 2.695 -3.338 8.728 P > 0.05 Not significant 
 20% vs. 30% 6.457 0.4245 12.49 P < 0.05 Significant 
 25% vs. 30% 3.762 -2.271 9.795 P > 0.05 Not significant 
480 20% vs. 25% 4.949 -0.4982 10.40 P > 0.05 Not significant 
 20% vs. 30% 9.107 3.660 14.55 P < 0.05 Significant 
 25% vs. 30% 4.158 -1.289 9.605 P > 0.05 Not significant 
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Table 5.7 ANOVA analysis summary for in vitro release profiles generated using the membrane-less diffusion method 
95% Confidence interval to mean 
difference 
Time (min) Comparison  Mean difference 
Lower limit Upper limit  
P value Summary 
30  20% vs. 25% 0.3581 -0. 1599 0.8762 P > 0.05 Not significant 
 20% vs. 30% 0.8357 0.3177 1.354 P < 0.01 Significant  
 25% vs. 30% 0.4776 -0.04045 0.9957 P > 0.05 Not significant 
60 20% vs. 25% 0.8112 0.2285 1.394 P < 0.05 Significant 
 20% vs. 30% 1.884 1.302 2.467 P < 0.001 Significant 
 25% vs. 30% 1.073 0.4904 1.656 P < 0.01 Significant 
90 20% vs. 25% 1.446 0.6220 2.269 P < 0.01 Significant 
 20% vs. 30% 3.085 2.261 3.909 P < 0.001 Significant 
 25% vs. 30% 1.639 0.8155 2.463 P < 0.01 Significant 
120 20% vs. 25% 1.922 1.066 2.778 P < 0.01 Significant 
 20% vs. 30% 4.049 3.192 4.905 P < 0.001 Significant 
 25% vs. 30% 2.127 1.271 2.983 P < 0.001 Significant 
180 20% vs. 25% 2.348 1.315 3.381 P < 0.01 Significant 
 20% vs. 30% 5.238 4.205 6.272 P < 0.001 Significant 
 25% vs. 30% 2.890 1.857 3.924 P < 0.001 Significant 
240 20% vs. 25% 2.783 1.711 3.854 P < 0.001 Significant 
 20% vs. 30% 6.233 5.162 7.305 P < 0.001 Significant 
 25% vs. 30% 3.451 2.379 4.522 P < 0.001 Significant 
360 20% vs. 25% 3.500 1.969 5.030 P < 0.01 Significant 
 20% vs. 30% 7.464 5.933 8.994 P < 0.001 Significant 
 25% vs. 30% 3.964 2.434 5.495 P < 0.001 Significant 
480 20% vs. 25% 4.211 2.738 5.684 P < 0.001 Significant 
 20% vs. 30% 8.839 7.366 10.31 P < 0.001 Significant 
 25% vs. 30% 4.627 3.154 6.100 P < 0.001 Significant 
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ANOVA analysis of data generated using  USP Apparatus 1 and summarised in Table 5.3 reveal 
that for the initial 30 min of the dissolution test, there was no discrimination between the 25% 
w/w PF-127 formulation with both the 20% and 30% w/w PF-127 formulations, although 
discrimination was observed between the extremes of gel concentration that were used. 
However, between 60 and 120 min into the in vitro release test, it can be observed from the 
summarised ANOVA results Table 5.3 and on visual inspection of the graph, that the three 
curves corresponding to the different concentrations of PF-127 are separated from each other. In 
the later stages dissolution testing using USP Apparatus 1, the ANOVA results indicate that 
there were no significant differences between the in vitro release profiles that were obtained 
from the 20% and 25% w/w PF-127 formulations, although the 30% w/w PF-127 formulation 
can be discriminated from both the lower and intermediate PF-127 formulations.   
 
The ANOVA analysis data presented in Table 5.4 reveal that the use of USP Apparatus 2 does 
not allow for discrimination between the formulations tested and that no significant differences 
exist between the dissolution profiles. Visual inspection of Figure 5.7 clearly shows that the 
early and late segments of the in vitro release profiles are very close together. However, 
according to the ANOVA analysis, the in vitro release profiles show differences between the 
20% and the 30% w/w PF-127 formulations at times points in between the early and late sample 
points and that there was no discrimination between the 25% w/w PF-127 formulation and the 
20% ww and 30% w/w formulations. The lack of discrimination using the USP apparatus 2 may 
also be observed from visual inspection of Figure 5.7, as the dissolution profile for the 25% w/w 
PF-127 formulation appears to fall midway between the two formulations in which low and 
high concentrations of PF-127 were used.  
 
A summary of the ANOVA results for comparison of the in vitro release profiles generated 
using USP Apparatus 3 is reported in Table 5.5 and the data indicate that significant differences 
exist between the percent OT dissolved at different time points in the early stages of test 
procedure, specifically between 0 min and 240 min. Thereafter, a plateau is reached for the 20% 
and 25% w/w PF-127 formulations and no significant differences were observed between the 
OT release profiles. Thereafter, discrimination between the 20% and 25% w/w concentrations of 
PF-127 is not achieved as these systems reached a plateau at the same time and level. 
 
The dialysis method for in vitro release testing of OT from PF-127 gels indicates that there are 
no significant differences between the 25% and both the 20% and 30% w/w PF-127 
formulations for the majority of the time points tested and the data are summarised in Table 5.6. 
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The lack of discrimination can also be observed by visual inspection of Figure 5.9 as the 25% 
w/w PF -127 formulation in vitro release profile for OT falls approximately midway between 
the two (2) formulations in which 20% w/w and 30% w/w PF-127 were used. However, 
discrimination was achieved between the 20% and 30% w/w PF-127 formulations for all time 
points using this dissolution or in vitro release method. 
 
The use of membrane-less diffusion indicates that the in vitro release profiles are different for 
the majority of all time points tested and that significant differences between the means were 
observed according to the ANOVA analysis performed and summarised in Table 5.7. Visual 
inspection of the dissolution profiles generated and shown in Figure 5.10 confirm these 
observations as the in vitro release profiles for the   different formulations are clearly well 
distinguished from each other.  
 
5.6.1.3 Model Independent Methods 
The f1 and f2 difference and similarity factors and the Gohel similarity factor, Sd were used to 
compare the in vitro release profiles generated for OT using the different in vitro release test 
methods, from PF-127 gels of different concentration. For the purposes of assessing the 
discriminatory behaviour of the in vitro release tests evaluated, the 25% w/w formulation was 
used as the reference product and the results of these analyses are summarised in Table 5.8.  
 
Table 5.8 f1, f2 and Sd values for the different formulations, using the 25% w/w formulation as the 
reference and shaded areas indicates discriminatory behaviour 
20% w/w PF-127 30% w/w PF-127 In vitro release test 
f1  f2 Sd f1 f2 Sd 
USP apparatus 1 9.9 72.8 0.0452 31.1 49.1 0.129 
USP apparatus 2 13.7 72.6 0.0944 15.7 66.6 0.147 
USP apparatus 3 23.3 49.4 0.0899 26.1 41.9 0.155 
Dialysis tube 21.9 75.7 0.0883 19.4 81.6 0.0677 
Membrane-less diffusion 36.6 81.4 0.134 43.2 78.9 0.258 
 
On consideration of the difference factor, f1 , both USP Apparatus 1 and 2 were not able to 
discriminate between the dissolution profiles generated for the 20% and 25% w/w formulation 
as the f1 factors that were calculated were < 15 for these comparisons. The similarity factor, f2, 
for the comparison of the 20% and 25% w/w formulations indicate that the in vitro release 
profiles are similar and therefore it may be concluded that both the USP Apparatus 1 and 2 are 
unable to produce data in which discrimination between different formulations is achieved. The 
Gohel Sd values that were calculated for the comparison of the 20% and 25% w/w PF-127 
containing formulations using USP Apparatus 1 and 2 indicate that differences that are detected 
are approximately 10% and between 20% and 25%, respectively, indicating similarity in the in 
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vitro release profiles that were generated. However, the use of f1 for the comparison of the 25% 
and the 30% w/w formulation indicated that discrimination is achieved (f1 > 15) for both USP 
Apparatus 1 and 2. However this is not the case on consideration of f2 for the profiles generated 
using USP Apparatus 2 (f2 = 66.6) which indicates similarity between the in vitro release 
profiles but the test indicates that for the f2 calculated for profiles generated using USP 
Apparatus 1 (f2 = 49.1), discrimination is achieved. The Sd values that were obtained when the 
25% and 30% w/w PF-127 OT containing gels were compared indicate percent differences that 
are greater than 30% for both USP Apparatus 1 and 2 indicating that the profiles are different. 
 
Data generated using USP Apparatus 3 show that the use of this apparatus is able to 
discriminate between different formulations since f1 > 15 and f2 < 50 in all cases, indicating that 
differences were detected when the 25% w/w PF-127 formulation was compared to the 20% and 
30% w/w gel formulations. Furthermore, the Sd factors that were calculated for the comparison 
of the 25% w/w PF-127 gel concentration with both the 20% and 30% w/w PF-127 produced Sd 
values with equivalent percent differences greater than 30%, indicating differences in the 
formulations do exist.  
 
The use of a dialysis bag with the paddle apparatus and the membrane-less diffusion system did 
not allow for discrimination between all formulations tested as f2 values that were calculated 
from the relevant in vitro release profiles were greater than 50, although values of greater than 
15 were obtained for some of the f1 factors calculated. The use of Sd for the comparison of 
dialysis membrane test method indicated that there was a percent difference of between 20% 
and 25% when the in vitro release profiles of OT of the 20% and 25% w/w PF-127 gels were 
compared. An Sd value equivalent to approximately 20% difference was obtained when in vitro 
release profiles of the 25% w/w PF-127 was compared to that obtained when a 30% w/w gel 
was used. These results indicate that according to the criterion to determine similarity using 
Gohel’s Sd factor, the dialysis in vitro release test method is unable to discriminate between 
formulation variants. However, the values for Sd, indicate that membrane-less diffusion system 
studied resulted in differences of greater than 30% when the 25% w/w PF-127 formulation was 
compared to the 20% and 30% w/w formulation suggesting a potentially discriminatory test 
procedure may exist.  
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5.6.1.4 Conclusion 
The three tests that were used to assess the discriminatory power of the dissolution methods 
produce some conflicting results although there is also some consensus between the tests and 
the results are summarised in Tables 5.9 and 5.10. 
 
Table 5.9 Summary of comparison of the mathematical models used to compare the 20% vs. 25% 
 ANOVA f1 f2 Sd 
USP apparatus 1 X X X X 
USP apparatus 2 X X X X 
USP apparatus 3    X 
Dialysis tube X  X X 
Membrane-less diffusion   X  
 indicates discriminatory behaviour and X indicates failure to discriminate 
 
Table 5.10 Summary of comparison of the mathematical models used to compare the 25% vs. 30% 
 ANOVA f1 f2 Sd 
USP apparatus 1     
USP apparatus 2 X  X  
USP apparatus 3     
Dialysis tube X  X X 
Membrane-less diffusion   X  
 indicates discriminatory behaviour and X indicates failure to discriminate 
 
A comparison of the different mathematical tools used to assess the similarity/difference of the 
dissolution profiles generated using different apparatus indicate that there is some consensus 
between the data obtained for comparison of the in vitro release test methods. Consensus in the 
results can be observed in Tables 5.9 and 5.10, which show that the different methods for 
comparison yield the same conclusions for USP Apparatus 1 and 2 in Table 5.9 and for USP 
Apparatus 1 and 3 in Table 5.10.  
 
The different sensitivities of the methods to assess discrimination between dissolution profiles is 
evident on comparison of the f1 and f2 fit factors when they are used for the dialysis tube and the 
membrane-less diffusion methods, which yield conflicting results. Specifically, the f1 test 
indicates a difference between the in vitro release profiles whereas the f2 factor indicates that the 
in vitro release profiles are similar. This is due to the sensitivity of the method when comparing 
dosage forms with a relatively low percent release from the dosage forms and results in 
insensitivity of the methods that was not observed when a large amount of OT was released 
using compendial apparatus. Although the use of ANOVA analysis has been deemed too 
discriminatory for comparison of in vitro release profiles between a test and reference product, 
these studies indicate that there is a general consensus between data generated using ANOVA 
and that generated using the other comparison techniques that were applied. Although the use of 
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the f2 fit factor for the membrane-less diffusion system indicated that there were no differences 
between the formulation variants, the use of ANOVA and Sd which are based on the differences 
between means and AUC respectively indicate that there are differences. The f2 factor is based 
on the differences between the percent released which is relatively low and the data are close 
together and therefore the tool fails to distinguish between the dissolution profiles for the 
different formulations tested, despite the mean amount released and the AUC being evaluated as 
different.  
 
The selection of the appropriate dissolution method for use from the different methods 
evaluated was based on the ease of use of the method and the ability of the method to 
discriminate between formulations. In addition to the fact that the use of USP Apparatus 3 
permits discrimination between formulations, the system is automated and therefore convenient 
to use. Furthermore, the use of USP Apparatus 3 permits further optimisation of an in vitro 
dissolution test method by allowing for changes in pH and other in vivo conditions to be 
mimicked as drug is released. In addition, the system allows for the assessment of whether such 
changes will affect the release kinetics of OT from the gel.  
 
5.6.2 The Impact of the Type of Apparatus on the In Vitro Release 
 
5.6.2.1 OT release rate 
The different compendial apparatus result in different hydrodynamic conditions in vitro and as a 
result drug release profiles show fundamental differences that can be understood by considering 
the type of dosage form (swelling, eroding, non-eroding etc) and the hydrodynamic effects 
present when using the different apparatus [554,571]. 
 
The in vitro release profiles generated for OT release from a 25% w/w PF-127 gel using the 
different dissolution methods were compared and are shown in Figure 5.11. 
 
 The rates (IU/min) of release of OT determined from samples tested in all apparatus for the 
25% w/w formulation were compared, using the total amount of OT that was released at the end 
of the test period or the time taken to reach a plateau and the results are summarised in Table 
5.11.  
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Figure 5.11 Comparison of the rate and extent of OT release 
 from a 25% w/w PF-127 gel using different dissolution test methods 
 
Table 5.11 Rate of release of OT from the 25% w/w formulation for the different test methods 
In vitro release test Rate of OT release (IU/min) 
USP Apparatus 1 0.361 
USP Apparatus 2 0.489 
USP Apparatus 3 0.964 
Dialysis tube method 0.129 
Membrane-less diffusion  method 0.077 
 
A comparison of the rate of release of OT from the 25% w/w PF-127 gel using the three 
compendial apparatus reveals that the overall release rate and pattern of release is such that USP 
3 > USP 2 > USP 1 which may observed when comparing the profiles in Figure 5.11 and the 
data summarised in Table 5.11. This is in agreement with observations from another study 
comparing the three compendial methods that noted the same pattern of release [571]. The rate 
of OT liberation from the paddle apparatus was faster than that from the basket apparatus 
because of the greater efficiency of the paddle to create agitation in a dissolution test compared 
to a basket rotating at the same speed of 50 rpm [553]. The faster rate of release observed when 
using the paddle apparatus has been proposed to be due to the difference in the hydrodynamic 
properties of the medium with the paddle resulting in increased agitation of the medium [507] 
and therefore a faster erosion/dissolution of the matrix in the system, resulting in faster drug 
release.  
 
The finding that the basket apparatus results in slower release rates is not conclusive but is 
found to depend on the nature of the dosage form and the drug candidate [507]. It has been 
reported that the dissolution rate of cetirizine and pseudoephedrine from a dosage form tested 
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using a basket and paddle apparatus did not differ significantly for the two apparatus [555]. The 
importance of selecting an appropriate dissolution test apparatus considering formulation factors 
and drug properties has been emphasised by Fernandes et al. [554], who showed that for one of 
the formulations of lamivudine tested, the basket apparatus resulted in faster dissolution of the 
drug. However, for some other formulations the dissolution rate of lamivudine was independent 
of the medium, the apparatus used and the time over which the test was conducted. 
 
The hydrodynamics of a test system describe the flow of fluid within the dissolution vessel and 
considerations about how fluid flow is likely to impact on in vitro release of a drug must be 
taken into account. The velocity of the fluid within a basket apparatus and at the bottom of the 
vessel when using the paddle apparatus has been compared using computational fluid dynamics 
[572]. The velocity of fluid for the basket ranges between 0.5 – 57.4 X 10-3 ms-1 at 50 rpm and 
the velocity at the bottom of the vessel at the same speed ranges between 0.003 – 3.5 X 10-3 ms-
1
. At 50 rpm, the velocity at the bottom of the vessel of the paddle apparatus ranges between 0.8 
– 79.6 X 10-3 ms-1. The comparison of the velocities indicates that there is a possibility that the 
rates of dissolution for a dosage form may be similar as the velocity ranges that are attainable in 
both Apparatus overlap. For a non-disintegrating dosage form, where diffusion controls drug 
release the similar velocities within the basket apparatus and at the bottom of the paddle 
apparatus means that comparable dissolution rates can be achieved [572]. However, for a 
delivery system such as those manufactured using PF-127, which undergoes dissolution 
[500,502], slightly higher in vitro release rates can be expected from the paddle apparatus 
compared to the basket apparatus. This occurs due to the higher velocity of the dissolution 
medium in the USP paddle apparatus vessel, resulting in faster dissolution of the gel and hence 
faster drug release. 
 
Dissolution profiles generated using USP Apparatus 3 show the fastest rates of release as 
compared to the other four methods evaluated and these findings are in agreement with other 
observations for an eroding matrix system [571]. The oscillating movement of the inner cylinder 
within the outer cylinder results in full exposure of all surfaces of a dosage form to the 
dissolution medium in which it is reciprocating, resulting in a higher degree of erosion [571]. In 
addition, the oscillating movements of the cylinder cause more vigorous hydrodynamics 
compared to the other two systems, intensifying the erosion of a matrix and increase in the rate 
of in vitro release compared to the basket and paddle apparatus [571]. 
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The dialysis method of dissolution rate testing reveals a slower rate of release as compared to 
that generated using the three compendial apparatus. The gel was separated from the aqueous 
dissolution medium by a physical barrier that prevents the dissolution of the gel matrix and 
hence OT molecules must therefore diffuse from the interior of the gel into the dissolution 
medium in order for release to occur. Drug release that occurs as result of diffusion from a 
matrix system is slower as compared to systems in which dissolution of the matrix may play an 
important role in drug release rates. The release of drug candidates from PF-127 matrices has 
been found to be diffusion controlled when a membrane is used to separate the gel from the 
dissolution medium [448,573] and such release has been shown to follow Higuchi release 
kinetics [567,568]. It was noted for the dialysis test system that the rate of release was faster in 
the initial stages of the dissolution test as the gradient of the release profile is steeper but this 
decreases as the in vitro release test proceeds over time. The reduction in release rate may be 
attributed to changes in the concentration gradient that controls diffusion and where during the 
initial stages of the test there is a steep concentration gradient and faster diffusion of the drug 
from the dialysis bag into the dissolution medium. As more drug is released into the dissolution 
medium, so the release rate slows down due to a change in the concentration gradient. In 
addition, as the drug diffuses out of the gel the distance over which OT diffuses from the inner 
regions of the dialysis bag is increased during the later stages of the test when compared to the 
initial stages of release and therefore the release rate is slower as the in vitro release test 
proceeds. The extent of release for the dialysis system is also low which can be attributed to the 
attainment of equilibrium for OT in the dissolution media and the gel. As a result, there is no 
more OT diffusing out of the gel and this may be because in this system, there is the physical 
separation of the gel from the dissolution medium which prevents dissolution of the gel, which 
is important in the release of drug from the PF-127 matrices [500,502]. 
 
The membrane-less diffusion method revealed the slowest rate of release (0.077 IU/min) of OT 
from the gels. In the membrane-less diffusion method the test gel is in direct contact with the 
dissolution medium at only interface of the gel and the dissolution medium and since there is no 
agitation of the dissolution medium during the in vitro release test, dissolution of the gel is 
slower compared to the other in vitro release test methods. This results in slower liberation of 
OT as dissolution of the gel matrix has been determined to control the rate of release of drugs 
from PF-127 matrices [500,502].  
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5.6.2.2 Application of the Korsmeyer-Peppas Model 
Drug release from polymeric systems can be a complex process that is primarily dependent on 
the nature of a drug and the physico-chemical characteristics of a hydrogel and the interaction of 
the system with an aqueous dissolution medium. Drug release from polymeric systems can be 
generally attributed to occur by one or a combination of three basic mechanisms, viz., diffusion 
controlled, swelling controlled, and erosion CR [564]. 
 
Diffusion controlled polymeric systems describe release mechanisms that are limited by the rate 
of diffusion of a drug through the polymer in which the drug is contained and include reservoir 
systems and matrix systems, in which the drug is surrounded by a polymeric membrane or may 
be either be dissolved or dispersed within the polymer, respectively [564]. However, polymeric 
systems are often swelling-controlled and show non-Fickian or anomalous diffusional behaviour 
and this is reported to be due to the interaction between water molecules and polymeric chains, 
which often rearrange to accommodate water molecules [564]. Extremes of anomalous diffusion 
behaviour have been termed Case I and Case II transport [574], where Case I transport refers to 
the condition in which solvent mobility is lower than the segmental relaxation rate of the 
polymeric chains and this describes diffusion controlled systems. Conversely, Case II transport 
describes mechanisms in which solvent mobility is higher than the relaxation rate of the 
polymer, which are swelling controlled systems with anomalous diffusional characteristics. 
Often, however release of a drug from a polymeric matrix often exhibits attributes intermediary 
to Case I and Case II transport [564]. 
 
The Korsmeyer-Peppas power law is one of the most comprehensive mathematical models that 
may be used to infer the mechanism of drug release from a polymeric dosage form, such as 
those prepared from PF-127 gels. The power law was applied to in vitro release profiles of OT 
from a 25% w/w PF-127 gel concentration that were analysed using the different in vitro 
dissolution methods described in § 5.5. A summary of Korsmeyer-Peppas parameters that were 
obtained following modelling of the  in vitro release profiles generated using the different in 
vitro release tests to the power law are summarised in Table 5.12. 
 
Table 5.12 Summary of Korsmeyer-Peppas best-fit parameters. 
In vitro release test Mt/M∞ (max) N k (%/minn) R2adjusted 
USP Apparatus 1 0.5783 0.8190 0.004127 0.9937 
USP Apparatus 2 0.5296 0.6855 0.012503 0.9992 
USP Apparatus 3 0.6102 0.9904 0.006139 0.9983 
Dialysis membrane  0.2067 0.5055 0.009066 0.9996 
Membrane-less diffusion 0.1224 0.8472 0.000759 0.9809 
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The geometry of the dosage forms was assumed to be that of a slab as only one flat surface was 
exposed to the dissolution medium during in vitro release testing performed using compendial 
and membrane-less diffusion systems and a cylindrical geometry was assumed for the dialysis 
membrane system. 
 
The predominant mechanism of release of OT from PF-127 gels following modelling of data 
generated using all test apparatus was determined to occur by anomalous transport. Therefore 
drug release is characterised by both diffusion and swelling control as n values are between 0.5 
and 1 for the slab geometries and for the cylinder assumed for the dialysis membrane an n value 
of > 0.45 was obtained. However, the main differences in the mechanisms of release as 
indicated by the numerical value of the exponent is the extent to which the transport processes 
are governed by swelling and diffusion in the systems. The different hydrodynamics described 
in § 5.6.2.1 are likely factors that influence the type of release that is observed from these 
polymeric systems. 
 
For the assumed slab geometries, USP Apparatus 2 has the lowest numerical value of the 
exponent, n indicating that diffusion in an important contributing factor when this in vitro 
release test is used to generate in vitro release profiles. Mixed transport mechanisms are 
observed when USP Apparatus 1 and 3 and the membrane-less diffusion method were used. The 
results that were obtained from the Korsmeyer-Peppas model are in close agreement with the 
work of Anderson et al. [499], who derived a mathematical model to describe the mechanism of 
drug release form poloxamer gels. Anderson et al. reported that whilst dissolution of the gel was 
important for the liberation of drug from the gels, diffusion of a drug through the polymeric 
system also contributed to the mechanism of release. The dissolution of the gel in poloxamer 
systems may be considered to be due to the interaction of polymeric micelles, described in § 
4.5.5 for gel systems, with water molecules causing dissociation of micellar aggregates from the 
gel surface into the bulk dissolution medium. 
 
The use of a dialysis bag for dissolution profile generation is a slightly different system to those 
described for the compendial apparatus and for the membrane-less diffusion system. The impact 
of the release test on the mechanism of release differs due to the assumption that a cylindrical 
geometry is necessary and that there is physical separation of the gel phase from the dissolution 
media. The results that were obtained from the Korsmeyer-Peppas model indicate that the 
exponent that was obtained had an n of 0.5055, which is Case I transport for cylindrical 
geometry, indicating that diffusion is an important mechanism of release of OT from the 
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dialysis system. Nonetheless, the impact of swelling CR cannot be neglected as dialysis tubing 
is permeable to water molecules and this allows interaction of polymeric micellar aggregates 
with water, causing relaxation of the micelles, although these are contained within the dialysis 
bag. 
 
The Korsmeyer-Peppas model is an attractive mathematical model for use for understanding the 
mechanism of drug release from polymeric systems. The exponent is relatively easy to compute 
using appropriate mathematical tools and is easy to interpret, assuming that correct assumptions 
are made about the geometry of the dosage form being tested. However, limitations to the use of 
the power law are that release from CR devices must be carefully applied as certain assumptions 
to the power law may not be completely applicable to CR devices being test. These include 
assumption about constant diffusivities of a drug with a polymer, constant dimensions of a 
device during an in vitro release test, one-dimensional diffusional behaviour, and perfect sink 
conditions in an in vitro release test [564]. 
 
5.6.2.3 Other Mathematical Models 
Zero and first order models, Higuchi and Hixson-Crowell models were also used to further 
elucidate the mechanism of release of OT from the dosage forms manufactured using PF-127 
gels from profiles generated using different in vitro release test methods. The suitability of each 
model to describe the mechanism of OT liberation was based on the calculation of the R2adjusted 
for the formulations. The model parameters and the values of R2adjusted are summarised in Table 
5.13. 
 
Table 5.13 Summary of other mathematical model parameters 
Zero Order  First Order Higuchi Hixson-Crowell In vitro release 
test K0 R2adjusted K1 R2adjusted KH R2adjusted Ks R2adjusted 
USP Apparatus 1 0.3688 0.9663 0.0044 0.8108 8.7029 0.9656 -0.0061 0.8833 
USP Apparatus 2 0.6369 0.9690 0.0063 0.9103 10.46 0.9779 -0.0093 0.9466 
USP Apparatus 3 1.7342 0.9990 0.0146 0.9476 18.424 0.9143 -0.0234 0.9729 
Dialysis 
membrane 
0.1165 0.9088 0.0023 0.9200 2.8244 0.9998 -0.0027 0.9476 
Membrane-less 
diffusion 
0.0768 0.9554 0.0044 0.7622 1.8273 0.9707 -0.0036 0.8465 
 
The application of the zero order model may be considered as suitable for describing the 
mechanism of release of OT from PF-127 gels as the R2adjusted values that were obtained were 
greater than 0.950 for all systems except for the dialysis membrane method. Drug release from 
PF-127 gels has been determined to be controlled by dissolution of the gel in an aqueous 
medium and as described in § 4.5.7, where gel dissolution is a zero order process. The 
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correlation that exists between gel dissolution and drug release has been noted in earlier studies 
[500-502] and therefore the mechanism of release of a drug is zero order. Due to the absence of 
dissolution when using the dialysis membrane method a similar mechanism of release as 
described for the other systems is not observed. Generally, zero order models are useful in 
describing mechanisms of drug release if the dosage forms being tested do not disaggregate 
during the course of an in vitro release test. However, PF-127 undergoes dissolution in aqueous 
media as was observed in § 4.5.7 and therefore the zero order model may not be entirely 
suitable to describe the mechanism of OT release from PF-127 gels. 
 
On inspection of the R2adjusted values that were obtained following modelling of OT release data 
with a first order model indicated that the mechanism of release was not first order and was 
unable to describe OT liberation from PF-127 gels. In general, water-soluble drugs that are 
incorporated into porous matrices are released according to first order kinetics and the PF-127 
gel matrix is made up of micellar aggregates that do not form a porous structure to enable 
liberation of OT by this mechanism. 
 
The Higuchi model may be useful in explaining the in vitro release mechanism of OT when the 
USP Apparatuses 1 and 2, the dialysis bag and the membrane-less diffusion methods are used to 
assess OT dissolution rates. The Higuchi model explains the role of diffusion in liberation of 
drug from a matrix and these results are in agreement with those presented in Table 5.12, where 
anomalous transport mechanisms were observed for the four (4) in vitro release tests that 
exhibited Higuchi kinetics, indicating the role of diffusion in the release of OT from these 
systems. However, the in vitro release profile for OT generated when using USP Apparatus 3 
produced a value for n very close to one (1), which indicated very little diffusion in the system 
and on application of Higuchi kinetics, diffusion was not determined to be an important 
mechanism of OT release from PF-127 dosage forms when tested using this apparatus. 
 
The Hixson-Crowell model was not particularly useful for the description of OT liberation from 
PF-127 systems as the R2adjusted values that were obtained were generally less than 0.950 except 
for data generated using USP Apparatus 3. The Hixson-Crowell model describes drug release 
from systems that experience a change in diameter and surface area of particles with proceeding 
drug release. When USP Apparatus 3 is used vigorous hydrodynamics are produced in the 
system compared to other in vitro release tests and may therefore cause more significant 
changes in the shape of the dosage form compared to the other in vitro release test methods that 
were assessed.  
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5.6.3 The Impact of Drug Loading on the In Vitro Release of OT 
 
The amount of OT that was initially used in the comparison of the dissolution profiles is in 
excess of the amount of OT that would normally be used for therapeutic purposes. Dosages of 5 
– 20 IU are normally used in clinical practice [9,14], but due to the large sample volume 
required when using the USP Apparatus 1 and 2, a larger dose was used  to facilitate analysis of 
samples using the HPLC method described in  Chapter 2. However, the dissolution fluid volume 
for USP Apparatus 3 is smaller than that for USP Apparatus 1 and 2 and therefore the 
formulations could be optimised with regard to dose strength to produce dosage forms that were 
clinically relevant. 
 
The impact of drug loading was studied for 200 IU, 100 IU, 50 IU and 25 IU dosage strengths in 
a 25% w/w PF-127 formulation and the resultant profiles are shown in Figure 5.12. 
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Figure 5.12 Impact of drug loading on the in vitro release profile of OT from the USP apparatus 3 
 
Table 5.14 summarises the percent OT released at 120 min and the calculated rate of release as a 
percent/minute for each of the dosage strengths tested. 
 
Table 5.14 The rate of release of OT for the different dosage strengths 
Dosage strength (IU) Percent release at 120 min (%) Percent release /min (%/min) 
25 95.31 0.794 
50 100.68 0.839 
100 101.79 0.848 
200 100.47 0.837 
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It was observed that the rate of the release of OT was similar for the higher dosage strengths, 
but this is slightly lower for the lowest dosage strength. These observations indicate that 
diffusion of the drug through the matrix may also play a role in the mechanism of drug release 
as described in § 5.6.2.2 and § 5.6.2.3. Although the dissolution rate of the gel is the same for 
the PF-127 gels in the formulations and is likely to be the most important factor controlling the 
release of the drug, the role of diffusion can not be neglected. 
 
The ANOVA analysis results for the comparison of the different dosage strengths of OT that 
were tested using USP apparatus 3 are summarised in Table 5.15. 
 
The ANOVA results that were generated indicate that the extent of OT release is dependent on 
the amount of OT that is used in the formulation. It was noted that significant differences 
between the individual time points for the formulations were observed for example between the 
25 IU/dosage form and the other concentrations that were investigated, although there was no 
discrimination between the higher strength dosage forms. The significant differences between 
the 25 IU/dosage unit and the higher dosage strengths may be a result of the differences in 
diffusion rates of OT from the dosage form. Although diffusion was concluded not to be a 
primary mechanism for OT release when USP Apparatus 3 is used for in vitro release testing 
(See § 5.6.2.2), the role of diffusion is still a contributing factor at higher concentrations. This is 
likely to be due to steeper concentration gradients existing when higher concentrations of OT 
are used, resulting in faster release of OT from these dosage forms. The difference in 
concentration may not be as apparent as the amount of OT per dosage unit increases, but this is 
evident when very low amounts of drug are used.  
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Table 5.15 ANOVA analysis summary for in vitro release profiles generated for different dosage strengths of OT. 
95% Confidence interval to mean 
difference 
Time (min) Comparison  Mean difference 
Lower Limit Upper Limit 
P value Summary 
30 25 IU vs. 50 IU -16.91 -19.40 -14.41 P < 0.001 Significant  
 25 IU vs. 100 IU -15.09 -17.58 -12.60 P < 0.001 Significant  
 25 IU vs. 200 IU -17.92 -20.41 -15.43 P < 0.001 Significant  
 50 IU vs. 100 IU 1.818 -0.6733 4.310 P > 0.05 Not significant 
 50 IU vs. 200 IU -1.015 -3.506 1.477 P > 0.05 Not significant 
 100 IU vs. 200 IU -2.833 -5.325 -0.3415 P < 0.05 Not significant 
60 25 IU vs. 50 IU -38.74 -45.83 -31.64 P < 0.001 Significant  
 25 IU vs. 100 IU -36.20  -45.41 -29.10 P < 0.001 Significant  
 25 IU vs. 200 IU -38.31 -43.30 -31.21 P < 0.001 Significant  
 50 IU vs. 100 IU 2.539 -4.557 7.523 P > 0.05 Not significant 
 50 IU vs. 200 IU 0.4274 -6.669 9.635 P > 0.05 Not significant 
 100 IU vs. 200 IU -2.112 -9.208 4.984 P > 0.05 Not significant 
120 25 IU vs. 50 IU -5.509 -11.34 0.3187 P > 0.05 Not significant 
 25 IU vs. 100 IU -6.622 -12.45 -0.7941 P > 0.05 Not significant 
 25 IU vs. 200 IU -5.297 -11.12 0.5310 P > 0.05 Not significant 
 50 IU vs. 100 IU -1.113 -6.940 4.715 P > 0.05 Not significant 
 50 IU vs. 200 IU 0.2122 -5.615 6.040 P > 0.05 Not significant 
 100 IU vs. 200 IU 1.325 -4.502 7.153 P > 0.05 Not significant 
240 25 IU vs. 50 IU -0.2007 -4.605 4.204 P > 0.05 Not significant 
 25 IU vs. 100 IU -1.314 -5.718 3.091 P > 0.05 Not significant 
 25 IU vs. 200 IU 0.01160 -4.393 4.416 P > 0.05 Not significant 
 50 IU vs. 100 IU -1.113 -5.517 3.291 P > 0.05 Not significant 
 50 IU vs. 200 IU 0.2122 -4.192 4.617 P > 0.05 Not significant 
 100 IU vs. 200 IU 1.325 -3.079 5.729 P > 0.05 Not significant 
360 25 IU vs. 50 IU -0.2007 -4.605 4.204 P > 0.05 Not significant 
 25 IU vs. 100 IU -1.314 -5.718 3.091 P > 0.05 Not significant 
 25 IU vs. 200 IU 0.01160 -4.393 4.416 P > 0.05 Not significant 
 50 IU vs. 100 IU -1.113 -5.517 3.291 P > 0.05 Not significant 
 50 IU vs. 200 IU 0.2122 -4.192 4.617 P > 0.05 Not significant 
 100 IU vs. 200 IU 1.325 -3.079 5.729 P > 0.05 Not significant 
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5.6.4 The Impact of a Dynamic pH on OT Release 
 
During labour the reduction in blood flow in uterine muscles occurs which is known to impact 
metabolic activity in the uterus. Effects that occur in vivo include stimulation of anaerobic 
metabolism, alteration of adenosine-5’-triphosphate (ATP) and a decrease in the pH [575]. 
Larcombe-McDouall et al. [575] investigated the impact of occlusion (reducing blood flow) 
in the rat uterus on certain metabolites and pH. From their studies, the pH at rest was 
determined to be 7.23 + 0.01 and with occlusion, there was a decrease in the pH that was 
related to the extent of occlusion and the pH ranged from 7.20 to 6.88 with maximal occlusion 
[575]. However, the recovery of pH following occlusion was very rapid, returning to normal 
levels within 10 min of allowing the return of blood flow to the muscle tissues. These results 
have important implications with regard to studying the effect of pH on the release kinetics of 
OT from the PF-127 dosage forms. If the dosage form is to be administered after labour 
muscle pH would be expected to be lower than that of resting muscle but the body recovers 
rapidly and therefore muscle pH would return to normal after a relatively short period. The 
impact of pH on the release of the OT was studied and these data are shown in Figure 5.13. 
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Figure 5.13 The impact of dynamic pH on the rate and extent of OT release. 
 
It is evident that pH does not have any impact on the rate and extent of release of OT from 
this dosage form. The release rates are very similar and computation of the f1 and f2 difference 
and similarity factors (f1 = 3.5 and f2 = 81.8) reflects this observation. The impact of pH on the 
release of API from PF-127 systems has been studied [501] and the similar results were 
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observed. PF-127 is a non-ionic block copolymer [427] and is therefore unlikely to be 
affected when exposed to media of different pH and therefore pH should not impact the rate 
and extent of drug release from these systems. However, OT is an ionisable peptide with an 
isoelectric point at pH = 7.7 and the increase in pH towards this value means that a greater 
proportion of OT molecules exist in the unionised state. However, the change in the 
proportion of unionised/ionised OT molecules is unlikely to impact on the rate of OT 
liberation from the dosage form because the interaction with the non-ionic poloxamer is 
unlikely to be altered to any significant extent.  
 
5.7 CONCLUSION 
 
The development of a discriminatory in vitro dissolution test is necessary in early formulation 
studies in order to develop an effective and safe dosage form. A novel in vitro release test for 
the assessment of parenteral dosage form of OT extemporaneously prepared using PF-127 as 
the gel former was developed.  
 
Mathematical models are important in assessing the mechanism of drug release from a dosage 
form. The use of models has the primary advantage of facilitating the optimisation of drug 
release characteristics from a delivery system and for dosage form performance evaluation 
and the impact of excipients on the mechanism of drug release. However, for the purposes of 
this study model dependent mathematical models were used to enhance the understanding of 
the impact of the apparatus and in vitro release test methodology on the liberation of OT from 
a matrix formulation. This is important in the development of in vitro release test methods in 
cases where the mechanism of drug release may be known or in cases where a specific 
mechanism of release is desirable in vivo. In such cases, an in vitro release test may be 
optimised based on the specific mechanistic requirements for drug release. The optimisation 
of an in vitro release test method is essential in assessing whether an in vitro in vivo 
correlation exists for a specific in vitro release method and establishing a correlation is a 
logical next step in the development and optimisation of in vitro release tests as described in § 
5.3. 
 
Following an evaluation of five (5) different test methods using the f1 and f2 difference and 
similarity factors, the Gohel similarity factor, Sd and ANOVA analysis, USP Apparatus 3 was 
found to be the most discriminatory method and therefore the most suitable tool for further 
optimisation. Furthermore, the extent of drug release from this test method was higher in 
comparison to other in vitro release test methods that were assessed (See § 5.6.2.1 and § 
5.6.2.2) and therefore the method was found to be suitable to assess the release of OT from 
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test formulations that were developed for optimisation. The smaller volume that is required 
for when using USP Apparatus 3 as compared to USP Apparatus 1 and 2, (180 ml compared 
to 500 ml) also allowed for the formulation to be further optimised with respect to drug 
loading, permitting lower amounts of drug to be used in accordance with the relevant doses 
used in clinical practice. In addition, an assessment of the impact that drug loading on the 
release of the drug from the dosage form was undertaken. The impact of variation in pH on 
drug delivery can also be easily assessed using USP Apparatus 3. Although the pH was found 
not to impact on the rate and extent of drug release from PF-127 gels, it was decided that the 
dynamic pH be used as the desired in vitro release method. This is because excipients and 
additives that can be used to modify release of OT from the formulation as well as to optimise 
a delivery system of OT may be affected by pH and therefore impact on the mechanism of 
release. The optimal release test developed for the assessment of OT from parenteral dosage 
forms prepared from PF-127 gels is summarised in Table 5.16.  
 
Table 5.16 Optimal in vitro release test conditions for assessing OT release from PF-127 gels 
Aspect Specifications 
In vitro release test apparatus  USP apparatus 3 
Dissolution medium  0.1 M phosphate buffer, pH = 6.85 for 30 min, then 0.1 M 
phosphate buffer pH = 7.2 for 7 hours 30 min 
Sampling intervals 30, 60, 120, 240, 360 and 480 min 
Speed 5 dips/minute 
Temperature  37 + 0.5 °C 
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CHAPTER 6 
 
 
CONCLUSION 
 
OT is an endogenous peptide with a diverse pharmacological profile in vivo, although the 
primary use of OT is for the induction of labour and promotion of lactation. Therapeutically 
OT is used for labour induction, treatment, and prevention of post partum haemorrhage and 
for the promotion of lactation. For the purposes of preventing post partum haemorrhage, OT 
is often administered as an intramuscular dose, which has a short duration of action. 
Therefore, the use of a long acting parenteral preparation for treatment and prevention of post 
partum haemorrhage may be necessary and appropriate to provide sustained tone to the 
uterus, thereby preventing excessive bleeding. 
 
A sensitive, selective, accurate, and precise stability indicating HPLC method for the 
quantitation of OT in pharmaceutical dosage was developed and validated according to ICH 
guidelines. The analytical method was found to be specific and therefore selective for OT in 
the presence of degradation products and the preservative, chlorbutol. The method was further 
optimised for the quantitation of in vitro release rate of OT from extemporaneously prepared 
PF-127 dosage forms. The HPLC method was found to be linear over a concentration range of 
0 – 0.50 IU/ml and precise with % RSD values that were < 5% RSD. The method was also 
found to be accurate with a % Bias that was determined to be < 5%. 
 
Current trends in protein and peptide delivery systems were reported and an alternative route 
or dosage form for sustained OT delivery was proposed. Various alternatives including 
covalent modification of OT by attachment of fatty acids (lipidisation) or PEG (PEGylation), 
nasal and transdermal delivery were reviewed and considered. Parenteral delivery of OT 
using liposomes, hydrogels and particulate systems were evaluated as viable means of OT 
delivery. However the selection of an appropriate delivery system require an appropriate 
pharmacokinetic profile of OT, ease of manufacture and scale up of the dosage form and the 
biocompatibility and toxicity of delivery system components. Thermo-sensitive hydrogel 
systems which exist as flowing viscous liquids at low temperatures, but that stiffen on 
warming to body temperature thereby forming a potential depot were considered as a viable 
and appropriate means to deliver OT. Pluronic® copolymers are commercially available 
polyethylene glycol polypropylene glycol block copolymers that behave in this manner and 
have been investigated for use for the sustained delivery of drug molecules. Furthermore, 
Pluronic® block copolymers have been approved by the FDA for inclusion in parenteral 
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formulations, therefore the toxicity profile and biocompatibility of these molecules is well 
established. 
 
Investigation into the types of Pluronic® block copolymers revealed that PF-127 was an 
appropriate and potentially useful polymer for the sustained release of OT. PF-127 was 
characterised in order to determine the properties of the copolymer that may be important in 
developing and optimising a pharmaceutical dosage form as well as to assess whether the 
release of a molecule may be predicted from the behaviour of PF-127 with changes in 
concentration of PF-127 in a formulation and temperature. UV and IR absorption spectra of 
OT and PF-127 combinations revealed that a potential interaction between OT and PF-127 
was unlikely. The CMC of PF-127 was determined to be 0.5% w/v in aqueous solution. An 
analytical method for quantifying PF-127 in solution was developed and validated with 
respect to linearity, accuracy and precision, where the method yielded % RSD values < 2% in 
the range 0.01 – 0.4% w/v. The onset of gelation was found to be dependent on the 
concentration of gel former in the solution, and higher concentrations underwent gelation at 
lower temperatures compared to lower concentrations of PF-127. For example, a 30% w/w 
solution of PF-127 formed a stiff gel at only 12 °C and a 20% w/w solution formed a gel at 23 
°C. The viscosity of PF-127 solutions was found to be dependent on the temperature and 
concentration of gel former that was used, where an increase in viscosity was generally 
observed with increases in both temperature and concentration of PF-127. Furthermore, there 
was a dramatic change in viscosity of the solution that occurred simultaneously with the onset 
of gelation. Gravimetric analysis of PF-127 dissolution at 37 °C revealed that dissolution of 
PF-127 is a zero order process that depends on the concentration of gel that is in a 
formulation, where higher concentrations of gel dissolve at slower rates compared to lower 
concentrations. 
 
The lack of compendial or official guidelines for the development of in vitro release test 
methods for controlled release parenteral preparations is a challenge for the development of 
such dosage forms. Five different in vitro test systems were evaluated as possible tools for the 
assessment of OT release from PF-127 gel systems prepared using the cold method. The 
amount of PF-127 that was used to prepare dosage forms of OT that contained 300 IU of 
active were 20%, 25% and 30% w/w. The release rate of OT from these formulations was 
evaluated using USP Apparatus 1, 2 and 3, a dialysis bag in USP Apparatus 2 and a 
membrane-less diffusion system. The different test methods were assessed for their 
discriminatory capacity using ANOVA analysis, the f1 and f2, difference and similarity 
factors, and the Gohel (Sd) similarity factor as model independent methods using the 25% w/w 
formulation as the reference product. The results indicated that the USP Apparatus 1 and 2 
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failed to discriminate adequately between the 20% and 25% w/w formulations, although 
discrimination was observed between the 25% and 30% w/w formulations. USP Apparatus 3 
showed adequate discrimination between the different formulation compositions that were 
tested. The results indicate that, in general the dialysis bag method showed poor 
discrimination between the formulations and although the f1 and f2 tests indicated that the 
membrane-less diffusion system was unable to discriminate between formulations, ANOVA 
analysis and the Sd factor showed that discrimination was achieved. USP Apparatus 3 was 
found to be the most appropriate apparatus for the assessment of PF-127 OT formulations. 
 
The Korsmeyer-Peppas power law was the primary model dependent method that was used to 
elucidate the mechanism of OT release from the different formulations tested using the 
different in vitro release tests. It was observed that the release of OT from the dosage forms 
generally showed anomalous transport mechanisms suggesting that drug release is a 
consequence of both Fickian diffusion and swelling controlled transport mechanisms. 
However, the extent to which these mechanisms contribute to drug release differ according to 
the apparatus used to generate dissolution profiles and it was noted that the dialysis bag 
method displayed release kinetics that were predominantly diffusion controlled whereas the 
USP Apparatus 3 method revealed that swelling controlled transport mechanisms were 
prevalent. The application of zero order, first order, Higuchi, and Hixson-Crowell models to 
assess the kinetics of drug release indicated that the first order and Hixson-Crowell models 
were not generally applicable to describing the mechanism of OT release from PF-127 gels 
using the apparatus described. However, the application of zero order and the Higuchi models 
indicated the importance of zero order dissolution of the PF-127 gel as a release controlling 
mechanism and diffusion as a control element in liberating drug from the gel matrix, 
respectively. 
 
In vitro release testing using USP Apparatus 3 was conducted to optimise the amount of OT 
in each dosage form and the impact of pH of the release media on OT release was assessed. It 
was observed that dosage forms that contain 25 IU can be tested using the USP Apparatus 3 
and that although pH changes may occur in the muscle during labour, these changes did not 
influence the liberation of OT from OF-127 dosage forms. 
 
The studies conducted and reported in this thesis represent the early stages in the development 
and optimisation of an OT parenteral dosage form. Further studies that would be necessary for 
progression of the project would be the in vivo optimisation of drug release and establishing 
whether an in vitro in vivo correlation exists for this system. An established in vitro in vivo 
correlation would ensure the clinical applicability of the in vitro release test and allow 
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strategic decisions to be made during product development that would allow quality control 
tests to predict in vivo behaviour of the product. The dosage form that is developed must 
therefore be administered to test animals in order to achieve a realistic rate of OT delivery in 
vivo and then further optimisation of the in vitro release test method. 
 
In order to produce an optimal delivery system for OT, the desired rate of OT release must be 
evaluated and compared to intravenous infusion rates that are used to administer OT in a 
clinical setting for the prevention of post partum haemorrhage. The desired rate of OT release 
from an optimised dosage form for a period of 8 hours was calculated and a dose of 9.6 – 19.2 
IU is administered when OT is infused at a rate of 20 – 40 mU/min [9]. This would ensure 
delivery of pharmaceutically relevant doses of OT to a patient from a parenteral sustained 
release delivery system. 
 
The project therefore looks at some important aspects that are vital in the development of 
pharmaceutical dosage forms. Literature review of not only current trends in drug delivery, 
but also of drug properties are highlighted as important in the pharmaceutical development 
stages in order to ensure that practical solutions to drug delivery challenges are addressed. An 
accurate, precise and sensitive analytical method is a key element in successful dosage form 
design as this permits the optimisation of delivery systems. Preformulation studies to assess 
drug and matrix properties, including stability, excipient behaviour with changing 
environmental conditions and compatibility are important, especially if no such data has been 
published. In vitro release tests are important in the development of dosage forms in order to 
ensure that optimal drug delivery devices are produced.  
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APPENDIX I 
BATCH RECORD REPORTS 
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Rhodes University 
Faculty of Pharmacy, Department of Pharmaceutics 
Grahamstown 6140 
 
BATCH RECORD SUMMARY 
 
Formulator     Faith Chaibva  
Product  300 IU Oxytocin acetate in 20 %w/w  
Pluronic® F127  
Date of Manufacture    11 August 2006 
 
Formula: 
Name  Original formula Working formula  Rhodes Batch Number 
Pluronic® F127  20 %w/w 20 g RM000175 
200 IU/ml Oxytocin 
solution  
80 %w/w 80 ml  RM000174 
 
Methodology 
20 g of Pluronic® F127 was weighed and dispersed in 80 ml of a 200 IU/ml solution of OT using 
a magnetic stirrer over a period of 2 – 3 min. This was placed in the refrigerator for at least 24 
hours or until complete dissolution had occurred and a clear viscous solution obtained. 
 
Tests performed 
Assay     154.12 IU/g 
Weight used (300 IU)   1.97 + 0.02 g 
Gel transition temperature  21 °C 
Viscosity     5 °C  73.33 + 2.08    
      25 °C  648 000 + 2200 
      37 °C  1 068 000 + 30 500 
 
IN VITRO RELEASE AND COMMENTS 
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• A clear gel viscous gel was 
produced  
• The gel that was placed in casts set 
forming a stiff gel after placing the 
gel in a convection oven at 37 °C  
• The surface of the gel was smooth 
and had no bubbles  
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Rhodes University 
Faculty of Pharmacy, Department of Pharmaceutics 
Grahamstown 6140 
 
BATCH RECORD SUMMARY 
 
Formulator     Faith Chaibva  
Product  300 IU Oxytocin acetate in 25 %w/w  
Pluronic® F127  
Date of Manufacture    11 August 2006 
 
Formula: 
Name  Original formula Working formula  Rhodes Batch Number 
Pluronic® F127  25 %w/w 25 g RM000175 
200 IU/ml Oxytocin 
solution  
75 %w/w 75ml  RM000174 
 
Methodology 
25 g of Pluronic® F127 was weighed and dispersed in 75 ml of a 200 IU/ml solution of OT using 
a magnetic stirrer over a period of 2 – 3 min. This was placed in the refrigerator for at least 24 
hours or until complete dissolution had occurred and a clear viscous solution obtained. 
 
Tests performed 
Assay     147.12 IU/g  
Weight used (300 IU)   2.08 + 0.05 g 
Gel transition temperature  15 °C 
Viscosity     5 °C  106.33 + 3.51    
     25 °C  1 270 000 + 15 000 
     37 °C  1 480 000 + 20 000 
 
IN VITRO RELEASE AND COMMENTS 
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• A clear gel viscous gel was 
produced  
• The gel that was placed in casts set 
forming a stiff gel after placing the 
gel in a convection oven at 37 °C  
• The surface of the gel was smooth 
and had no bubbles  
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Rhodes University 
Faculty of Pharmacy, Department of Pharmaceutics 
Grahamstown 6140 
 
BATCH RECORD SUMMARY 
 
Formulator     Faith Chaibva  
Product  300 IU Oxytocin acetate in 30 %w/w  
Pluronic® F127  
Date of Manufacture    13 August 2006 
 
Formula 
Name  Original formula Working formula  Rhodes Batch Number 
Pluronic® F127  30 %w/w 30 g RM000175 
200 IU/ml Oxytocin 
solution  
70 %w/w 70 ml  RM000174 
 
Methodology 
30 g of Pluronic® F127 was weighed and dispersed in 70 ml of a 200 IU/ml solution of OT using 
a magnetic stirrer over a period of 2 – 3 min. This was placed in the refrigerator for at least 24 
hours or until complete dissolution had occurred and a clear viscous solution obtained. 
 
Tests performed 
Assay     137.57 IU/g  
Weight used (300 IU)   2.20 + 0.03 g 
Gel transition temperature  11 °C  
Viscosity     5 °C  198.21 + 2.00    
     25 °C  1 500 000 + 20 000 
     37 °C  1 800 000 + 19 000 
      
IN VITRO RELEASE AND COMMENTS 
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• A clear gel viscous gel was 
produced  
• The gel that was placed in casts set 
forming a stiff gel after placing the 
gel in a convection oven at 37 °C  
• The surface of the gel was smooth 
and had no bubbles  
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Rhodes University 
Faculty of Pharmacy, Department of Pharmaceutics 
Grahamstown 6140 
 
BATCH RECORD SUMMARY 
 
Formulator     Faith Chaibva  
Product 200 IU Oxytocin acetate in 25 %w/w  
Pluronic® F127  
Date of Manufacture   21 August 2006  
 
Formula 
Name  Original formula Working formula  Rhodes Batch Number 
Pluronic® F127  25 %w/w 3.33 g RM000175 
150 IU/ml Oxytocin 
solution  
75 %w/w 10.00 ml RM000174 
 
Methodology 
3.33 g of Pluronic® F127 was weighed and dispersed in 10 ml of a 150 IU/ml solution of OT 
using a magnetic stirrer over a period of 2 – 3 min. This was placed in the refrigerator for at least 
24 hours or until complete dissolution had occurred and a clear viscous solution obtained. 
 
Tests performed 
Assay     105.66 IU/g 
Weight used (200 IU)   1.89 + 0.03 g   
 
IN VITRO RELEASE AND COMMENTS 
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• A clear gel viscous gel was 
produced  
• The gel that was placed in casts set 
forming a stiff gel after placing the 
gel in a convection oven at 37 °C  
• The surface of the gel was smooth 
and had no bubbles  
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Rhodes University 
Faculty of Pharmacy, Department of Pharmaceutics 
Grahamstown 6140 
 
BATCH RECORD SUMMARY 
 
Formulator     Faith Chaibva  
Product 100 IU Oxytocin acetate in 25 %w/w  
Pluronic® F127  
Date of Manufacture   21 August 2006  
 
Formula 
Name  Original formula Working formula  Rhodes Batch Number 
Pluronic® F127  25 %w/w 3.33 g RM000175 
100 IU/ml Oxytocin 
solution  
75 %w/w 10.00 ml RM000174 
 
Methodology 
3.33 g of Pluronic® F127 was weighed and dispersed in 10 ml of a 200 IU/ml solution of OT 
using a magnetic stirrer over a period of 2 – 3 min. This was placed in the refrigerator for at least 
24 hours or until complete dissolution had occurred and a clear viscous solution obtained. 
 
Tests performed 
Assay     65.78 IU/g 
Weight used (100 IU)   1.52 + 0.02 g   
 
IN VITRO RELEASE AND COMMENTS 
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• A clear gel viscous gel was 
produced  
• The gel that was placed in casts set 
forming a stiff gel after placing the 
gel in a convection oven at 37 °C  
• The surface of the gel was smooth 
and had no bubbles  
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Rhodes University 
Faculty of Pharmacy, Department of Pharmaceutics 
Grahamstown 6140 
 
BATCH RECORD SUMMARY 
 
Formulator     Faith Chaibva  
Product     50 IU Oxytocin acetate in 25 %w/w  
Pluronic® F127  
Date of Manufacture    21 August 2006  
 
Formula 
Name  Original formula Working formula  Rhodes Batch Number 
Pluronic® F127  25 %w/w 3.33 g  RM000175 
50 IU/ml Oxytocin 
solution  
75 %w/w 10.00 ml  RM000174 
 
Methodology 
3.33 g of Pluronic® F127 was weighed and dispersed in 10 ml of a 200 IU/ml solution of OT 
using a magnetic stirrer over a period of 2 – 3 min. This was placed in the refrigerator for at least 
24 hours or until complete dissolution had occurred and a clear viscous solution obtained. 
 
Tests performed 
Assay     35.02 IU/g 
Weight used (50 IU)   1.43 + 0.02 g 
 
IN VITRO RELEASE AND COMMENTS 
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• A clear gel viscous gel was 
produced  
• The gel that was placed in casts set 
forming a stiff gel after placing the 
gel in a convection oven at 37 °C  
• The surface of the gel was smooth 
and had no bubbles  
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Rhodes University 
Faculty of Pharmacy, Department of Pharmaceutics 
Grahamstown 6140 
 
BATCH RECORD SUMMARY 
 
Formulator     Faith Chaibva  
Product     25 IU Oxytocin acetate in 25 %w/w  
Pluronic® F127  
Date of Manufacture    24 August 2006  
 
Formula 
Name  Original formula Working formula  Rhodes Batch Number 
Pluronic® F127  25 %w/w 3.33 g  RM000175 
20 IU/ml Oxytocin 
solution  
75 %w/w 10.00 ml  RM000174 
 
Methodology 
3.33 g of Pluronic® F127 was weighed and dispersed in 10 ml of a 200 IU/ml solution of OT 
using a magnetic stirrer over a period of 2 – 3 min. This was placed in the refrigerator for at least 
24 hours or until complete dissolution had occurred and a clear viscous solution obtained. 
 
Tests performed 
Assay     19.51 IU/g 
Weight used (25 IU)   1.28 + 0.03 g   
 
IN VITRO RELEASE AND COMMENTS 
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• A clear gel viscous gel was 
produced  
• The gel that was placed in casts set 
forming a stiff gel after placing the 
gel in a convection oven at 37 °C  
• The surface of the gel was smooth 
and had no bubbles  
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ANOVA SUMMARY TABLES 
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Table A1 ANOVA summary statistics of the in vitro release of OT from USP apparatus 1 comparing the means of percent OT released at different time points for 
20%, 25% and 30% w/w PF-127 formulations 
Time (min) R squared  F  P value Are means significantly 
different?  
(p < 0.05) 
30 0.8774 10.74 0.0429 Yes  
60 0.9873 116.2 0.0014 Yes 
90 0.9966 442.0 0.0002 Yes 
120 0.9629 38.92 0.0071 Yes 
180 0.9367 22.20 0.0159 Yes 
240 0.9111 15.37 0.0265 Yes 
360 0.9758 60.40 0.0038 Yes 
480 0.9869 113.2 0.0015 Yes 
 
Table A2 ANOVA summary statistics of the in vitro release of OT from USP apparatus 2 comparing the means of percent OT released at different time points for 
20%, 25% and 30% w/w PF-127 formulations 
Time (min) R squared  F  P value Are means significantly 
different?  
(p < 0.05) 
30 0.8329 7.477 0.0683 No 
60 0.7081 3.638 0.1577 No 
90 0.8894 12.06 0.0368 Yes 
120 0.8964 12.99 0.0333 Yes 
180 0.7985 5.946 0.0904 No 
240 0.9492 28.04 0.0114 Yes 
360 0.5957  2.210 0.2570 No 
480 0.6047 2.295 0.2485 No 
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Table A3 ANOVA summary statistics of the in vitro release of OT from USP apparatus 3 comparing the means of percent OT released at different time points for 
20%, 25% and 30% w/w PF-127 formulations 
Time (min) R squared  F  P value Are means significantly 
different?  
(p < 0.05) 
30 0.9969 476.8 0.0002 Yes 
60 0.9944 267.5 0.0004 Yes 
120 0.9994 2710 P<0.0001 Yes 
240 0.9707  49.71 0.0050 Yes 
360 0.9251 18.54 0.0205 Yes 
480 0.9251 18.54 0.0205 Yes 
 
Table A4 ANOVA summary statistics of the in vitro release of OT from dialysis tubing in USP apparatus 2 comparing the means of percent OT released at 
different time points for 20%, 25% and 30% w/w PF-127 formulations 
Time (min) R squared  F  P value Are means significantly 
different?  
(p < 0.05) 
60 0.8897 12.10 0.0366 Yes 
120 0.8871 11.79 0.0379 Yes 
180 0.9787 68.99 0.0031 Yes 
240 0.9375 22.52 0.0156 Yes 
360 0.8706 10.10 0.0465 Yes 
480 0.9422   24.47 0.0139 Yes 
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Table A5 ANOVA summary statistics of the in vitro release of OT from the membrane-less diffusion system comparing the means of percent OT released at 
different time points for 20%, 25% and 30% w/w PF-127 formulations 
Time (min) R squared  F  P value Are means significantly 
different?  
(p < 0.05) 
30 0.8043 12.33 0.0075 Yes 
60 0.9429 49.53 0.0002 Yes 
90 0.9566 66.10 P<0.0001 Yes 
120 0.9723 105.3 P<0.0001 Yes 
180 0.9759 121.4 P<0.0001 Yes 
240 0.9816 159.9 P<0.0001 Yes 
360 0.9739 112.1 P<0.0001 Yes 
480 0.9826  169.6 P<0.0001 Yes 
 
Table A6 ANOVA summary statistics of the in vitro release of OT from USP apparatus 3 using different amounts of OT per dosage unit, viz., 25, 50, 100 and 200 
IU per dosage unit 
Time (min) R squared  F  P value Are means significantly 
different?  
(p < 0.05) 
30 0.9965 376.8 P<0.0001 Yes 
60 0.9944 235.3 P<0.0001 Yes 
120 0.8653 8.563 0.0325 Yes 
240 0.3391 0.6842 0.6068 No 
360 0.3391 0.6842 0.6068 No 
480 0.3391 0.6842 0.6068 No 
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